<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Antibiotics (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Antibiotics (Basel)</journal-id><journal-id journal-id-type="publisher-id">antibiotics</journal-id><journal-title-group><journal-title>Antibiotics</journal-title></journal-title-group><issn pub-type="epub">2079-6382</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6963833</article-id><article-id pub-id-type="doi">10.3390/antibiotics8040157</article-id><article-id pub-id-type="publisher-id">antibiotics-08-00157</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Actinomycete-Derived Polyketides as a Source of Antibiotics and Lead Structures for the Development of New Antimicrobial Drugs</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Robertsen</surname><given-names>Helene L.</given-names></name></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-3538-5142</contrib-id><name><surname>Musiol-Kroll</surname><given-names>Ewa M.</given-names></name><xref rid="c1-antibiotics-08-00157" ref-type="corresp">*</xref></contrib></contrib-group><aff id="af1-antibiotics-08-00157">Interfakult&#x000e4;res Institut f&#x000fc;r Mikrobiologie und Infektionsmedizin, Eberhard Karls Universit&#x000e4;t T&#x000fc;bingen, Auf der Morgenstelle 28, 72076 T&#x000fc;bingen, Germany; <email>helene.robertsen@biotech.uni-tuebingen.de</email></aff><author-notes><corresp id="c1-antibiotics-08-00157"><label>*</label>Correspondence: <email>ewa.musiol@biotech.uni-tuebingen.de</email></corresp></author-notes><pub-date pub-type="epub"><day>20</day><month>9</month><year>2019</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2019</year></pub-date><volume>8</volume><issue>4</issue><elocation-id>157</elocation-id><history><date date-type="received"><day>27</day><month>8</month><year>2019</year></date><date date-type="accepted"><day>10</day><month>9</month><year>2019</year></date></history><permissions><copyright-statement>&#x000a9; 2019 by the authors.</copyright-statement><copyright-year>2019</copyright-year><license license-type="open-access"><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Actinomycetes are remarkable producers of compounds essential for human and veterinary medicine as well as for agriculture. The genomes of those microorganisms possess several sets of genes (biosynthetic gene cluster (BGC)) encoding pathways for the production of the valuable secondary metabolites. A significant proportion of the identified BGCs in actinomycetes encode pathways for the biosynthesis of polyketide compounds, nonribosomal peptides, or hybrid products resulting from the combination of both polyketide synthases (PKSs) and nonribosomal peptide synthetases (NRPSs). The potency of these molecules, in terms of bioactivity, was recognized in the 1940s, and started the &#x0201c;Golden Age&#x0201d; of antimicrobial drug discovery. Since then, several valuable polyketide drugs, such as erythromycin A, tylosin, monensin A, rifamycin, tetracyclines, amphotericin B, and many others were isolated from actinomycetes. This review covers the most relevant actinomycetes-derived polyketide drugs with antimicrobial activity, including anti-fungal agents. We provide an overview of the source of the compounds, structure of the molecules, the biosynthetic principle, bioactivity and mechanisms of action, and the current stage of development. This review emphasizes the importance of actinomycetes-derived antimicrobial polyketides and should serve as a &#x0201c;lexicon&#x0201d;, not only to scientists from the Natural Products field, but also to clinicians and others interested in this topic.</p></abstract><kwd-group><kwd>actinomycetes</kwd><kwd>bioactivity</kwd><kwd>antimicrobials</kwd><kwd>polyketides</kwd><kwd>polyketide synthases</kwd><kwd>biosynthesis</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-antibiotics-08-00157"><title>1. Introduction</title><p>More than 70 years has passed since the discovery of the first antibiotics from actinomycetes. Although some of the high G+C (bacteria with high guanine- (G) and cytosine- (C) content in their genomes) [<xref rid="B1-antibiotics-08-00157" ref-type="bibr">1</xref>,<xref rid="B2-antibiotics-08-00157" ref-type="bibr">2</xref>], Gram-positive bacteria of the order <italic>Actinomycetales</italic> and their products have been studied in depth, they remain one of the most important sources of secondary metabolites, including the naturally-derived antimicrobial drugs (e.g., &#x003b2;-lactams, tetracyclines, rifamycins, macrolides, aminoglycosides, and glycopeptides). In the past, the producers of valuable bioactive compounds were mainly isolated from soil samples and either directly or indirectly, using culture filtrates or extracts, subjected to susceptibility testing (diffusion method) (<xref ref-type="fig" rid="antibiotics-08-00157-f001">Figure 1</xref>). Recent advances in different disciplines of science, such as robotics [<xref rid="B3-antibiotics-08-00157" ref-type="bibr">3</xref>], biology [<xref rid="B4-antibiotics-08-00157" ref-type="bibr">4</xref>], chemistry [<xref rid="B5-antibiotics-08-00157" ref-type="bibr">5</xref>,<xref rid="B6-antibiotics-08-00157" ref-type="bibr">6</xref>,<xref rid="B7-antibiotics-08-00157" ref-type="bibr">7</xref>], genetics [<xref rid="B8-antibiotics-08-00157" ref-type="bibr">8</xref>], and/or bioinformatics [<xref rid="B9-antibiotics-08-00157" ref-type="bibr">9</xref>] has extended the spectrum of methodology applied to the isolation and identification of actinomycetes and the produced metabolites. In addition to technical innovations which, for example, enable sampling of unexplored and difficult to access environments, Next Generation Sequencing Technologies (NGST) and genome mining facilitate accurate and cost-effective sequencing of actinomycetes genomes and a fast identification of genes encoding the proteins of the secondary metabolite biosynthetic machineries (biosynthetic gene clusters, BGCs). In the past two decades, hundreds of actinomycetes genomes have been sequenced and many of them have been fully annotated. The analysis of the data has demonstrated that a significant portion of the BGCs are associated with polyketide synthase (PKS) and nonribosomal peptide synthetase (NRPS) pathways, indicating that polyketides, nonribosomal peptides, and their hybrid compounds are the major secondary metabolites of actinomycetes [<xref rid="B10-antibiotics-08-00157" ref-type="bibr">10</xref>,<xref rid="B11-antibiotics-08-00157" ref-type="bibr">11</xref>]. The biosynthesis of both, polyketides and nonribosomal peptides, involves multifunctional megaenzymes referred as PKSs and NRPSs, respectively (<xref ref-type="sec" rid="sec2-antibiotics-08-00157">Section 2</xref>). Despite the fact that polyketides are assembled according to a similar biosynthetic principle, a wide variety of chemical structures are found in the producer strains. This structural diversity is mainly accomplished through the different architecture and specificity of the PKSs, variation of the building blocks for the polyketide chain biosynthesis, and post-PKS modification reaction. Consequently, it is expected that the chemical arsenal provided by polyketide pathways encompasses molecules targeting various cellular compartments or interacting with distinct sites of the same target. Indeed, polyketide drugs such as erythromycins and rifamycins have a different mode of action. The antimicrobial drug-target interactions and their effects are well described [<xref rid="B12-antibiotics-08-00157" ref-type="bibr">12</xref>,<xref rid="B13-antibiotics-08-00157" ref-type="bibr">13</xref>,<xref rid="B14-antibiotics-08-00157" ref-type="bibr">14</xref>]. In general, the four major mode of actions (MOAs) include interference with cell wall synthesis (e.g., penicillins), interference with nucleic acid synthesis (e.g., rifamycins), inhibition of metabolic pathways (e.g., sulfonamides), and inhibition of protein synthesis (e.g., erythromycins) [<xref rid="B15-antibiotics-08-00157" ref-type="bibr">15</xref>,<xref rid="B16-antibiotics-08-00157" ref-type="bibr">16</xref>]. A fifth MOA has been identified for the polymyxins and colistin, which disrupts the bacterial cell membranes by increasing membrane permeability [<xref rid="B17-antibiotics-08-00157" ref-type="bibr">17</xref>].</p><p>Based on the success of antimicrobial drugs during the &#x0201c;Golden Age&#x0201d; of antibiotic discovery (1940s&#x02013;1960s) some experts were confident that &#x0201c;the tide had turned&#x0201d; in the war against pathogens causing severe infections. However, microbes develop the ability to resist the effects of an antibiotic whenever the dose of the drug is too low to eliminate the whole population of the pathogen (minimum bactericidal concentration (MBC)) and thus, antibiotic resistance developed shortly after the drugs were applied [<xref rid="B18-antibiotics-08-00157" ref-type="bibr">18</xref>,<xref rid="B19-antibiotics-08-00157" ref-type="bibr">19</xref>,<xref rid="B20-antibiotics-08-00157" ref-type="bibr">20</xref>,<xref rid="B21-antibiotics-08-00157" ref-type="bibr">21</xref>,<xref rid="B22-antibiotics-08-00157" ref-type="bibr">22</xref>,<xref rid="B23-antibiotics-08-00157" ref-type="bibr">23</xref>,<xref rid="B24-antibiotics-08-00157" ref-type="bibr">24</xref>]. Resistance to antibiotics arises from chromosomal mutations or acquisition of genetic elements encoding resistance genes (horizontal gene transfer). Several resistance mechanisms have been reported [<xref rid="B25-antibiotics-08-00157" ref-type="bibr">25</xref>,<xref rid="B26-antibiotics-08-00157" ref-type="bibr">26</xref>,<xref rid="B27-antibiotics-08-00157" ref-type="bibr">27</xref>]. The most frequent resistance mechanisms are exported through the efflux pumps, degradation or inactivation of an antibiotic, and modification or alteration of the cellular target of the antibiotic [<xref rid="B15-antibiotics-08-00157" ref-type="bibr">15</xref>,<xref rid="B28-antibiotics-08-00157" ref-type="bibr">28</xref>]. Furthermore, the overuse and misuse of antimicrobial drugs have promoted and accelerated the spreading of antibiotic resistance (e.g., methicillin-resistant <italic>Staphylococcus aureus</italic> (MRSA) and vancomycin-resistant <italic>enterococci</italic> (VRE)). New resistance mechanisms are constantly being reported, and transmission elements are identified on a regular basis [<xref rid="B29-antibiotics-08-00157" ref-type="bibr">29</xref>]. According to the World Health Organisation (WHO), antimicrobial resistance is widely regarded as one of the greatest global challenges to humanity (estimated 10 million lives a year by 2050) [<xref rid="B30-antibiotics-08-00157" ref-type="bibr">30</xref>]. Thus, guidelines and initiatives are being put forward in order to limit the further spread of antimicrobial resistance [<xref rid="B31-antibiotics-08-00157" ref-type="bibr">31</xref>]. Some of these initiatives include the development of vaccines, faster diagnostic tests to ensure appropriate antibiotic administration, and immune-based therapies [<xref rid="B32-antibiotics-08-00157" ref-type="bibr">32</xref>]. These measures could provide promising solutions for prevention of infections however, once infection occurs in a human host, antibiotics remain the choice of treatment for bacterial and fungal infections. Therefore, the need for new antibiotic classes and improvement of the old compounds remain more important than ever. Unfortunately, discovery of novel antibiotic classes is halted by the low return on investment, forcing companies to abandon their discovery platforms. According to an issue brief of The Pew Charitable Trusts from March 2019 [<xref rid="B33-antibiotics-08-00157" ref-type="bibr">33</xref>], out of the roughly 38 companies currently invested in antibiotic clinical development, only four of these are multinational pharmaceutical companies. Furthermore, 90% of the current products in development are studied by small pharmaceutical or biotech companies, which are ill-equipped to deal with the expense of possible setbacks, delays or even rejections, which are often faced in clinical trials [<xref rid="B34-antibiotics-08-00157" ref-type="bibr">34</xref>]. </p><p>Since polyketide-derived antimicrobials have had a historical significance in human therapy, this group of compounds remain important for continuation of research aiming at: the identification of new structures and activities, the biosynthesis and/or chemical semi-synthesis for discovery of novel derivatisation routes, and finally, at understanding of resistance mechanisms to overcome this obstacle. </p><p>In this review, we focus on the therapeutically relevant polyketide drugs which were derived from actinomycetes. We describe compounds active against microbial pathogens, including pathogenic fungi and bacteria, their biosynthesis in the natural producer, and the most recent results on production optimization and derivatisation attempts. This review should serve as a &#x0201c;lexicon&#x0201d; of actinomycetes-derived antimicrobial polyketides, not only to scientists from the Natural Products field, but also to clinicians and others interested in this topic.</p></sec><sec id="sec2-antibiotics-08-00157"><title>2. The Biosynthetic Assembly Lines</title><p>The biosynthesis of polyketides and nonribosomal peptides requires the PKS and NRPS enzymatic machineries. PKSs are grouped into type I, II, and III, and can be iterative (type I, II, III) or modular (type I) [<xref rid="B35-antibiotics-08-00157" ref-type="bibr">35</xref>,<xref rid="B36-antibiotics-08-00157" ref-type="bibr">36</xref>,<xref rid="B37-antibiotics-08-00157" ref-type="bibr">37</xref>,<xref rid="B38-antibiotics-08-00157" ref-type="bibr">38</xref>,<xref rid="B39-antibiotics-08-00157" ref-type="bibr">39</xref>]. The diverse polyketide assembly lines have been previously reviewed [<xref rid="B7-antibiotics-08-00157" ref-type="bibr">7</xref>,<xref rid="B40-antibiotics-08-00157" ref-type="bibr">40</xref>,<xref rid="B41-antibiotics-08-00157" ref-type="bibr">41</xref>,<xref rid="B42-antibiotics-08-00157" ref-type="bibr">42</xref>,<xref rid="B43-antibiotics-08-00157" ref-type="bibr">43</xref>]. Here, we introduce types of PKSs that are represented in this review. </p><p>The modular type I PKSs can give rise to large, complex polyketides. A &#x0201c;minimal PKS module&#x0201d; is composed of three essential domains; the acyltransferase (AT), the ketosynthase (KS), and the acyl carrier protein (ACP). The AT domain selects and loads the building blocks onto the activated ACPs, while the KS domain catalyses the decarboxylative Claisen-like condensation of the newly loaded unit and the already existing polyketide chain. The &#x003b2;-keto-processing of the generated chain is accomplished by optional domains, such as the ketoreductase (KRs), the dehydratases (DHs) and/or the enoyl reductases (ERs). The final chain termination and release of the polyketide intermediate from the PKS is facilitated by the thioesterase (TE) domain, often found as the &#x0201c;last domain&#x0201d; in the multimodular PKS.</p><p>Type II iterative PKSs are responsible for the biosynthesis of aromatic polyketides [<xref rid="B44-antibiotics-08-00157" ref-type="bibr">44</xref>,<xref rid="B45-antibiotics-08-00157" ref-type="bibr">45</xref>,<xref rid="B46-antibiotics-08-00157" ref-type="bibr">46</xref>]. The overall architecture of this type of PKSs appears simpler than the one of complex modular PKSs, as they only require the presence of three enzymes, the KS<sub>&#x003b1;</sub>, KS<sub>&#x003b2;</sub> (also referred to as chain elongation factor (CLF)), and an ACP. During elongation, a thioester is bound to the ACP while the KS<sub>&#x003b1;</sub>KS<sub>&#x003b2;</sub> complex orchestrates chain extension with malonyl-CoA units exclusively. The BGCs of type II PKSs often contain additional genes encoding cyclases (CYCs) and KRs, which act as chaperones and reductive enzymes to ensure the correct cyclisation of the polyketide precursor, respectively. Finally, the presence of aromatases (AROs) leads to the biosynthesis of aromatic ring systems. The iterative type I PKS [<xref rid="B47-antibiotics-08-00157" ref-type="bibr">47</xref>,<xref rid="B48-antibiotics-08-00157" ref-type="bibr">48</xref>] work in a similar fashion as the iterative type II PKSs [<xref rid="B44-antibiotics-08-00157" ref-type="bibr">44</xref>]. However, the bacterial iterative type I PKSs only facilitate the biosynthesis of small aromatic polyketides [<xref rid="B35-antibiotics-08-00157" ref-type="bibr">35</xref>,<xref rid="B49-antibiotics-08-00157" ref-type="bibr">49</xref>]. </p><p>NRPSs display a similar architecture to modular type I PKSs and function in an analogous manner [<xref rid="B39-antibiotics-08-00157" ref-type="bibr">39</xref>,<xref rid="B50-antibiotics-08-00157" ref-type="bibr">50</xref>]. The selection and loading of the building blocks (proteinogenic or non-proteinogenic amino acids) onto peptidyl carrier proteins (PCPs) of NRPSs is catalysed by an adenylation (A) domain, resulting in an amino acid&#x02013;PCP&#x02013;thioester. A condensation (C) domain attaches the amino acid to the so-far synthesised peptide (chain elongation). Modifications, such as epimerisation or N-methylation at the peptide chain may occur due to the activity of the optional epimerisation (E) and methyltransferase (MT) domain, respectively. The peptide chain is released from the NRPS by a TE domain. In the case of hybrid PKS/NRPS structures [<xref rid="B51-antibiotics-08-00157" ref-type="bibr">51</xref>], the transfer of the growing precursor chain between the different megaenzymes might require additional enzymes. However, this remains speculative and requires deeper investigation.</p></sec><sec id="sec3-antibiotics-08-00157"><title>3. Clinically-Relevant Polyketide Derived Antibiotics</title><sec id="sec3dot1-antibiotics-08-00157"><title>3.1. Erythromycin and Derivatives</title><p>The history of the macrolide erythromycin began in 1949 with a soil sample, collected in Iloilo City, (Iloilo, Philippine Islands) by Dr. Abelardo Aguilar, who sent the sample to Lilly Research Laboratories, where the soil-dwelling bacterium <italic>Saccharopolyspora erythraea</italic> (formerly known as <italic>Streptomyces erythreus</italic>) and the antibiotic erythromycin were isolated [<xref rid="B52-antibiotics-08-00157" ref-type="bibr">52</xref>]. Inspired by the name of the place from which the soil sample was collected, erythromycin was launched by Eli Lilly Co. in 1952 as Ilosone (also Ilotycin) (<xref rid="antibiotics-08-00157-t001" ref-type="table">Table 1</xref>) for treatment of respiratory tract infections, skin infections, and Legionnaire&#x02019;s disease. </p><p>The antibiotic erythromycin is composed of a 14-membered lactone, erythronolide B, to which two deoxysugars <sc>l</sc>-mycarose and &#x003b1;-<sc>d</sc>-desosamine are attached [<xref rid="B53-antibiotics-08-00157" ref-type="bibr">53</xref>,<xref rid="B54-antibiotics-08-00157" ref-type="bibr">54</xref>] (<xref ref-type="fig" rid="antibiotics-08-00157-f002">Figure 2</xref>). The BGC of erythromycin remains one of the most-studied in terms of the type I PKS [<xref rid="B55-antibiotics-08-00157" ref-type="bibr">55</xref>,<xref rid="B56-antibiotics-08-00157" ref-type="bibr">56</xref>,<xref rid="B57-antibiotics-08-00157" ref-type="bibr">57</xref>,<xref rid="B58-antibiotics-08-00157" ref-type="bibr">58</xref>]. The precursor erythronolide B is generated by the modular type I deoxyerythronolide B synthase (DEBS), composed of the three enzymes DEBS 1&#x02013;3, encoded by the genes <italic>eryAI&#x02013;eryAIII</italic> (<xref ref-type="app" rid="app1-antibiotics-08-00157">Figure S1</xref>). The PKS complex contains six modules, which are responsible for the initial loading of propionyl-CoA, the six steps of chain elongation with methylmalonyl-CoA as extender units, modification of the growing polyketide chain by reductive domains, and finally chain release and cyclization by the TE domain in DEBS 3 [<xref rid="B57-antibiotics-08-00157" ref-type="bibr">57</xref>,<xref rid="B59-antibiotics-08-00157" ref-type="bibr">59</xref>,<xref rid="B60-antibiotics-08-00157" ref-type="bibr">60</xref>]. The hydroxylation of the released aglycone is catalysed by the cytochrome P450 enzyme EryF, resulting in the intermediate erythronolide B. The glycosyltransferases EryBV and EryCII/EryCIII attach the sugar structures, derived from thymidine diphosphate (TDP)-<sc>l</sc>-mycarose and TDP-<sc>d</sc>-desosamine, which leads to the production of erythromycin D. Erythromycin D is further converted to erythromycin B or C, which are the substrates for erythromycin A. Erythromycin B is formed whenever the methyltransferase EryG is acting on erythromycin D. In the case where the molecule erythromycin D is modified by the monooxygenase EryK, erythromycin C is produced as an intermediate. </p><p>Although the strain produces a mixture of erythromycins, erythromycin A was the most abundant and biologically active compound [<xref rid="B61-antibiotics-08-00157" ref-type="bibr">61</xref>]. Erythromycin shows activity against many Gram-positive and some Gram-negative bacteria, including <italic>Haemophilus influenzae</italic>, <italic>S. aureus</italic>, <italic>Streptococcus pyogenes</italic>, <italic>Streptococcus pneumoniae</italic>, <italic>Legionella pneumophila</italic>, <italic>Neisseria gonorrhoeae,</italic> and <italic>Mycoplasma pneumonia</italic> [<xref rid="B61-antibiotics-08-00157" ref-type="bibr">61</xref>,<xref rid="B62-antibiotics-08-00157" ref-type="bibr">62</xref>]. The antibiotic interacts with the large 50S subunit of the prokaryotic ribosomes and inhibits the protein biosynthesis [<xref rid="B63-antibiotics-08-00157" ref-type="bibr">63</xref>,<xref rid="B64-antibiotics-08-00157" ref-type="bibr">64</xref>]. More specifically, the antibiotic binds to the exit tunnel and blocks its large subunit whereby the elongation of the nascent peptide chain is stalled. This stalling leads to the premature dissociation of the peptidyl-transfer RNA (tRNA) from the ribosome [<xref rid="B64-antibiotics-08-00157" ref-type="bibr">64</xref>,<xref rid="B65-antibiotics-08-00157" ref-type="bibr">65</xref>]. As the inhibition occurs directly after initiation of protein synthesis, the nascent polypeptide chain remains short, however, the length size is determined by binding of the macrolide structure to the complex. Consequently, the size and conformation of erythromycin play a crucial role in the bioactivity of the molecule [<xref rid="B66-antibiotics-08-00157" ref-type="bibr">66</xref>]. In case of erythromycin A, binding to the 50S subunit leads to dissociation and accumulation of peptidyl-tRNAs with six, seven, or eight amino acid residues. This accumulation causes depletion of the free tRNA pool, whereby protein biosynthesis is inhibited [<xref rid="B65-antibiotics-08-00157" ref-type="bibr">65</xref>]. </p><p>In order to improve the chemical, microbiological, and pharmacokinetic properties of macrolides, a lot of effort was put into the production of semi-synthetic and synthetic derivatives [<xref rid="B63-antibiotics-08-00157" ref-type="bibr">63</xref>,<xref rid="B170-antibiotics-08-00157" ref-type="bibr">170</xref>,<xref rid="B171-antibiotics-08-00157" ref-type="bibr">171</xref>]. Some of the most successful semi-synthetic derivatives produced from erythromycin include the 14-membered clarithromycin and roxithromycin and the nitrogen-containing 15-membered azithromycin (<xref ref-type="fig" rid="antibiotics-08-00157-f002">Figure 2</xref>) [<xref rid="B73-antibiotics-08-00157" ref-type="bibr">73</xref>,<xref rid="B74-antibiotics-08-00157" ref-type="bibr">74</xref>]. Clarithromycin (trade name: Biaxin, <xref rid="antibiotics-08-00157-t001" ref-type="table">Table 1</xref>) and roxithromycin (not commercially available, <xref rid="antibiotics-08-00157-t001" ref-type="table">Table 1</xref>) were discovered in the 1980s in screening programs aiming at identification of erythromycin A variants with improved acidic stability and oral availability [<xref rid="B74-antibiotics-08-00157" ref-type="bibr">74</xref>,<xref rid="B75-antibiotics-08-00157" ref-type="bibr">75</xref>,<xref rid="B172-antibiotics-08-00157" ref-type="bibr">172</xref>]. The pharmacokinetic profiles of erythromycin A and clarithromycin (6-<italic>O</italic>-methylerythromycin A derivative, Taisho Pharmaceutical Co.) are similar however, due to the methylation in clarithromycin, the antibiotic displays an increased and more stable absorption [<xref rid="B62-antibiotics-08-00157" ref-type="bibr">62</xref>]. At a Croatian pharmaceutical company PLIVA, chemists succeeded in producing a range of novel erythromycin derivatives based on chemical modification of an erythromycin A oxime. One of the analogues was roxithromycin which contains a N-oxime side chain on the macrolactone ring [<xref rid="B76-antibiotics-08-00157" ref-type="bibr">76</xref>,<xref rid="B77-antibiotics-08-00157" ref-type="bibr">77</xref>,<xref rid="B172-antibiotics-08-00157" ref-type="bibr">172</xref>]. However, since the general pharmacokinetic properties of roxithromycin are similar to those of erythromycin A, the search for more active and stable derivatives continued and ultimately, azithromycin (trade name: Zithromax, <xref rid="antibiotics-08-00157-t001" ref-type="table">Table 1</xref>), which was the first azalide, was discovered [<xref rid="B172-antibiotics-08-00157" ref-type="bibr">172</xref>,<xref rid="B173-antibiotics-08-00157" ref-type="bibr">173</xref>]. Azithromycin (also CP 62,993 or XZ-450) differed from the other erythromycin derivatives due to its nitrogen-containing macrolactone ring [<xref rid="B78-antibiotics-08-00157" ref-type="bibr">78</xref>,<xref rid="B172-antibiotics-08-00157" ref-type="bibr">172</xref>,<xref rid="B173-antibiotics-08-00157" ref-type="bibr">173</xref>]. In addition to its high stability and sustained tissue concentrations, azithromycin also had an extended activity spectrum, covering both Gram-positive and Gram-negative bacteria associated with respiratory tract infections [<xref rid="B62-antibiotics-08-00157" ref-type="bibr">62</xref>,<xref rid="B78-antibiotics-08-00157" ref-type="bibr">78</xref>,<xref rid="B79-antibiotics-08-00157" ref-type="bibr">79</xref>,<xref rid="B172-antibiotics-08-00157" ref-type="bibr">172</xref>]. Interestingly, azithromycin was the first derivative identified with a MOA different to that of erythromycin. Similar to other macrolides, azithromycin binds to the 50S ribosomal subunit. However, instead of one molecule, as it is the case for example for erythromycin, two molecules of azithromycin bind simultaneously to the 50S ribosomal subunit [<xref rid="B174-antibiotics-08-00157" ref-type="bibr">174</xref>]. </p><p>Another class of interesting semi-synthetic erythromycin A derivatives are the ketolides, which were developed as a part of a rational drug design approach [<xref rid="B80-antibiotics-08-00157" ref-type="bibr">80</xref>,<xref rid="B81-antibiotics-08-00157" ref-type="bibr">81</xref>,<xref rid="B175-antibiotics-08-00157" ref-type="bibr">175</xref>]. Telithromycin (also HMR 3647) (<xref ref-type="fig" rid="antibiotics-08-00157-f002">Figure 2</xref>, <xref rid="antibiotics-08-00157-t001" ref-type="table">Table 1</xref>), with the trade name Ketek, was the first ketolide introduced into clinical practice. The main difference between ketolides and other semi-synthetic erythromycin A derivatives is the exchange of the mycarose sugar moiety with a 3-keto group. Furthermore, telithromycin contains a large aromatic N-substituted carbamate side chain to which an imidazo-pyridyl group is attached at position C11/C12 of the aglycone structure [<xref rid="B175-antibiotics-08-00157" ref-type="bibr">175</xref>]. Telithromycin was not only more stable than some of the other semi-synthetic erythromycin A derivatives under acidic conditions, the ketolide also retained activity against erythromycin resistance isolates of <italic>S. aureus</italic> and <italic>S. pneumonia</italic> [<xref rid="B80-antibiotics-08-00157" ref-type="bibr">80</xref>]. It was suggested that the exchange of the sugar with a 3-keto group is the reason for the lack of macrolide&#x02013;lincosamide&#x02013;streptogramin B (MLS<sub>B</sub>) resistance against ketolides [<xref rid="B176-antibiotics-08-00157" ref-type="bibr">176</xref>]. Furthermore, telithromycin binds to prokaryote ribosomes with ten-times higher affinity than erythromycin A [<xref rid="B177-antibiotics-08-00157" ref-type="bibr">177</xref>]. Unfortunately, shortly after its introduction into the clinics, severe side effects were reported (&#x0201c;Ketek effects&#x0201d;). These included visual disturbance and hepatic failure [<xref rid="B82-antibiotics-08-00157" ref-type="bibr">82</xref>]. As the reports of fatal liver failures in patients receiving Ketek increased, the US Food and Drug Administration (FDA) withdrew the approval of the drug for simple infections in 2007 [<xref rid="B73-antibiotics-08-00157" ref-type="bibr">73</xref>]. </p><p>Since many pharmaceutical companies were in possession of large macrolide and ketolide libraries, screening for novel macrolide drug candidates continued. Two novel ketolides, solithromycin (trade names: CEM-101 and T-4288) and nafithromycin (trade name: WCK 4873) were identified and used for treatment of community-acquired bacterial pneumonia (CABP) (<xref ref-type="fig" rid="antibiotics-08-00157-f002">Figure 2</xref>, <xref rid="antibiotics-08-00157-t001" ref-type="table">Table 1</xref>) [<xref rid="B73-antibiotics-08-00157" ref-type="bibr">73</xref>,<xref rid="B83-antibiotics-08-00157" ref-type="bibr">83</xref>,<xref rid="B84-antibiotics-08-00157" ref-type="bibr">84</xref>]. Solithromycin is metabolically stable and shows potency against CABP-associated bacteria and the Gram-negative pathogen <italic>N. gonorrhoeae</italic>, which is the causative agent of gonorrhea. However, the future of solithromycin is currently less certain. Despite promising phase III study results, the US FDA rejected the approval of the drug for treatment of CABP in 2016, stating their concerns for the lack of sufficient safety studies addressing the risk of hepatotoxicity [<xref rid="B34-antibiotics-08-00157" ref-type="bibr">34</xref>]. </p><p>At present, nafithromycin is the only ketolide in global clinical development [<xref rid="B85-antibiotics-08-00157" ref-type="bibr">85</xref>]. The compound has been enrolled in a phase II clinical study for treatment of CABP. The structure of nafithromycin (<xref ref-type="fig" rid="antibiotics-08-00157-f002">Figure 2</xref>) differs from other ketolides. Instead of a carbamate at position C11/C12, nafithromycin contains a lactone group. In addition, the backbone of the side chain is differentiated by amino group and methyl group substituents. Finally, the side chain is attached at another position of the pyridine [<xref rid="B73-antibiotics-08-00157" ref-type="bibr">73</xref>]. </p><p>Erythromycin remains one of the best-studied 14-membered macrolides however, other naturally occurring macrolide antibiotics have been reported. These include oleandomycin (<italic>Streptomyces antibioticus</italic>, 1954), megalomicin (<italic>Micromonospora megalomicea</italic>, 1968), and pikromycin (<italic>Streptomyces venezuelae</italic>, 1951) [<xref rid="B67-antibiotics-08-00157" ref-type="bibr">67</xref>,<xref rid="B178-antibiotics-08-00157" ref-type="bibr">178</xref>,<xref rid="B179-antibiotics-08-00157" ref-type="bibr">179</xref>], of which only oleandomycin made it into the clinics. Oleandomycin displays lower in vitro activity against <italic>S. aureus</italic> and <italic>Streptococcus</italic> spp. than erythromycin A [<xref rid="B180-antibiotics-08-00157" ref-type="bibr">180</xref>]. However, scientists working at Charles Pfizer and Company claimed that the derivative sigmamycin (<xref rid="antibiotics-08-00157-t001" ref-type="table">Table 1</xref>), a 2:1 mixture of tetracycline and oleandomycin, showed synergic effect on 22 <italic>S. aureus</italic> isolates, which were otherwise resistant to the two individual antibiotics [<xref rid="B68-antibiotics-08-00157" ref-type="bibr">68</xref>]. Since other groups failed to reproduce the original findings, sigmamycin was removed from the market in the early 1970s [<xref rid="B69-antibiotics-08-00157" ref-type="bibr">69</xref>].</p><p>Another naturally occurring macrolide is the 16-membered spiramycin (trade name: Rovamycin) (<xref ref-type="fig" rid="antibiotics-08-00157-f002">Figure 2</xref>, <xref rid="antibiotics-08-00157-t001" ref-type="table">Table 1</xref>), which was discovered in 1954 from culture of <italic>Streptomyces ambofaciens</italic>, [<xref rid="B70-antibiotics-08-00157" ref-type="bibr">70</xref>,<xref rid="B71-antibiotics-08-00157" ref-type="bibr">71</xref>,<xref rid="B181-antibiotics-08-00157" ref-type="bibr">181</xref>]. This was just two years after the discovery of erythromycin and due to a number of studies reporting better in vitro antimicrobial activity of erythromycin A compared to spiramycin, the latter never made it to clinical development in the US [<xref rid="B72-antibiotics-08-00157" ref-type="bibr">72</xref>]. Although spiramycin is not commercially available in the US, pregnant women, suspecting an infection with the protozoan parasite <italic>Toxoplasma gondii</italic>, can request spiramycin for free from the US FDA after a consultation. The details are described in other comprehensive reviews [<xref rid="B182-antibiotics-08-00157" ref-type="bibr">182</xref>,<xref rid="B183-antibiotics-08-00157" ref-type="bibr">183</xref>].</p><p>Macrolide antibiotics such as erythromycin and its derivatives remain some of the most successful antibiotics in human therapy [<xref rid="B73-antibiotics-08-00157" ref-type="bibr">73</xref>]. In addition to their application in treatment of common respiratory, genital, and skin infections, the overall properties of erythromycin and its derivatives still favour their use. These properties include, but are not limited to, good oral availability, narrow spectrum of activity, and a strong safety profile [<xref rid="B73-antibiotics-08-00157" ref-type="bibr">73</xref>]. Furthermore, this compound class represents a safe and efficient alternative to patients suffering from allergies to penicillins [<xref rid="B184-antibiotics-08-00157" ref-type="bibr">184</xref>]. </p></sec><sec id="sec3dot2-antibiotics-08-00157"><title>3.2. Tylosin</title><p>The antibiotic tylosin (<xref ref-type="fig" rid="antibiotics-08-00157-f003">Figure 3</xref>, <xref rid="antibiotics-08-00157-t001" ref-type="table">Table 1</xref>) was discovered in a preliminary screening by Denny and Bohrer in 1959 (Washington Research Laboratory, Washington, DC, USA) and later produced by Eli Lilly and Company in Indianapolis, Indiana (trade names: Tylocine, Tylan, tylosin tartrate) [<xref rid="B86-antibiotics-08-00157" ref-type="bibr">86</xref>,<xref rid="B185-antibiotics-08-00157" ref-type="bibr">185</xref>,<xref rid="B186-antibiotics-08-00157" ref-type="bibr">186</xref>,<xref rid="B187-antibiotics-08-00157" ref-type="bibr">187</xref>,<xref rid="B188-antibiotics-08-00157" ref-type="bibr">188</xref>]. Tylosin was obtained from a fermentation culture of <italic>Streptomyces fradiae</italic> which was originally isolated from a soil sample collected in Thailand [<xref rid="B86-antibiotics-08-00157" ref-type="bibr">86</xref>,<xref rid="B189-antibiotics-08-00157" ref-type="bibr">189</xref>]. The compound is also produced by other streptomycetes strains such as <italic>Streptomyces rimosus</italic> [<xref rid="B190-antibiotics-08-00157" ref-type="bibr">190</xref>] and <italic>Streptomyces hygroscopicus</italic> [<xref rid="B191-antibiotics-08-00157" ref-type="bibr">191</xref>], however, <italic>S. fradiae</italic> remains the preferred choice for industrial fermentation of tylosin.</p><p>The naturally-derived tylosin is a mixture of the four 16-membered macrolide antibiotics tylosin A, B, C, and D [<xref rid="B86-antibiotics-08-00157" ref-type="bibr">86</xref>,<xref rid="B188-antibiotics-08-00157" ref-type="bibr">188</xref>,<xref rid="B192-antibiotics-08-00157" ref-type="bibr">192</xref>,<xref rid="B193-antibiotics-08-00157" ref-type="bibr">193</xref>,<xref rid="B194-antibiotics-08-00157" ref-type="bibr">194</xref>,<xref rid="B195-antibiotics-08-00157" ref-type="bibr">195</xref>]. Although tylosin A is found in highest concentration in the mixture (80&#x02013;90%), tylosin B (desmycosin), tylosin C (macrocin), and tylosin D (relomycin) are also believed to contribute to the overall bioactivity of tylosin [<xref rid="B195-antibiotics-08-00157" ref-type="bibr">195</xref>]. The structure of tylosin A (<xref ref-type="fig" rid="antibiotics-08-00157-f003">Figure 3</xref>) is a 16-atom polyketide lactone with the three deoxyhexose sugars <sc>d</sc>-mycaminose, mycinose (6-deoxy-<sc>d</sc>-allose), and <sc>l</sc>-mycarose attached [<xref rid="B87-antibiotics-08-00157" ref-type="bibr">87</xref>].</p><p>The biosynthetic pathway of tylosin has been studied in detail [<xref rid="B87-antibiotics-08-00157" ref-type="bibr">87</xref>,<xref rid="B196-antibiotics-08-00157" ref-type="bibr">196</xref>,<xref rid="B197-antibiotics-08-00157" ref-type="bibr">197</xref>,<xref rid="B198-antibiotics-08-00157" ref-type="bibr">198</xref>,<xref rid="B199-antibiotics-08-00157" ref-type="bibr">199</xref>,<xref rid="B200-antibiotics-08-00157" ref-type="bibr">200</xref>]. With a size of ~85 kb, the tylosin (<italic>tyl</italic>) gene cluster occupies 1% of the entire genome of <italic>S. fradiae</italic>. Sequencing of the <italic>tyl</italic> gene cluster has revealed 13 genetic loci, <italic>tylA</italic> through <italic>tylM</italic>. These genes encode the PKS megaenzyme complex (TylGI&#x02013;TylGV) for the assembly and cyclization of the precursor tylactone (<xref ref-type="app" rid="app1-antibiotics-08-00157">Figure S2</xref>), proteins responsible for the biosynthesis of mycaminose, mycarose, and mycinose, hydroxylases, a methyltransferase, a reductase, and finally proteins involved in resistance and regulation. The biosynthesis of the tylosin polyketide chain is initiated by the loading of methylmalonyl-CoA to the first module in TylGI. The polyketide chain is extended by the attachment of four methylmalonyl-CoA, two malonyl-CoA, and one ethylmalonyl-CoA [<xref rid="B88-antibiotics-08-00157" ref-type="bibr">88</xref>,<xref rid="B201-antibiotics-08-00157" ref-type="bibr">201</xref>,<xref rid="B202-antibiotics-08-00157" ref-type="bibr">202</xref>,<xref rid="B203-antibiotics-08-00157" ref-type="bibr">203</xref>,<xref rid="B204-antibiotics-08-00157" ref-type="bibr">204</xref>]. The TE-catalysed release of the aglycone and cyclisation of the structure yields the 16-atom tylactone, which is further modified at C20 and C23 by the two cytochrome P450 hydroxylases TylI and TylHI, respectively. The resulting intermediate tylonolide is then glycosylated through the attachment of the deoxyhexose sugars <sc>d</sc>-mycaminose, mycinose, and <sc>l</sc>-mycarose by TylMII, TylN, and TylCV, respectively [<xref rid="B87-antibiotics-08-00157" ref-type="bibr">87</xref>,<xref rid="B199-antibiotics-08-00157" ref-type="bibr">199</xref>,<xref rid="B200-antibiotics-08-00157" ref-type="bibr">200</xref>,<xref rid="B205-antibiotics-08-00157" ref-type="bibr">205</xref>] (<xref ref-type="app" rid="app1-antibiotics-08-00157">Figure S2</xref>). Finally, to yield tylosin A, TylE and TylF modify the mycinose through the <italic>O</italic>-methylation of the C2&#x02034; and C3&#x02034; positions in the sugar. The remaining genes found in the <italic>tyl</italic> gene clusters encode ancillary proteins (crotonyl-CoA carboxylase/reductase (CCR), MetK, and, MetF), regulators (TylP, TylS, TylQ, TylU, TylR (TylT)), and proteins involved in resistance (TlrB&#x02013;TlrD) [<xref rid="B87-antibiotics-08-00157" ref-type="bibr">87</xref>]. </p><p>Similar to other macrolides, tylosin inhibits protein biosynthesis in prokaryotes by binding to the large 50S subunit [<xref rid="B88-antibiotics-08-00157" ref-type="bibr">88</xref>,<xref rid="B89-antibiotics-08-00157" ref-type="bibr">89</xref>,<xref rid="B185-antibiotics-08-00157" ref-type="bibr">185</xref>]. Poulsen et al. have shown that the disaccharide <sc>d</sc>-mycaminosyl-<sc>l</sc>-mycarose at the C5-atom in tylosin affects the binding of the molecule to the ribosome complex [<xref rid="B206-antibiotics-08-00157" ref-type="bibr">206</xref>]. As opposed to erythromycin A (<xref ref-type="fig" rid="antibiotics-08-00157-f002">Figure 2</xref>), in which tri- and tetrapeptides are still released from the ribosome upon binding of the macrolide, for tylosin the C5-disaccharide extends binding of the macrolide to the ribosome, only allowing formation of dipeptides [<xref rid="B206-antibiotics-08-00157" ref-type="bibr">206</xref>,<xref rid="B207-antibiotics-08-00157" ref-type="bibr">207</xref>]. </p><p>The antibiotic tylosin is approved exclusively for veterinary use. It is applied to treat leptospirosis, mycoplasmosis, and respiratory tract infection, caused by Gram-positive bacteria, including <italic>Streptococcus</italic> spp., <italic>Staphylococcus</italic> spp., <italic>Clostridium perfringens</italic>, and <italic>Mycoplasma</italic> spp. [<xref rid="B208-antibiotics-08-00157" ref-type="bibr">208</xref>]. Historically, tylosin has been used as feed additive for cattle to prevent the development of liver abscesses and for swine as a growth promoter.</p><p>Tylosin remains a valuable antibiotic for use in veterinary medicine. However, derivatives of the native compound have been introduced in clinical practice as well. One such molecule is the semi-synthetic derivative tilmicosin, which has an extended antimicrobial spectrum compared to tylosin [<xref rid="B90-antibiotics-08-00157" ref-type="bibr">90</xref>,<xref rid="B91-antibiotics-08-00157" ref-type="bibr">91</xref>]. Tilmicosin displayed activity against <italic>Pasteurella multocida</italic> and <italic>Pasteurella haemolytica</italic>, and is important for treatment of bacterial pneumonia in young cattle. In addition, tilmicosin has shown improved activity against <italic>P. multocida</italic> in chickens. Tilmicosin is available under different trade names (<xref rid="antibiotics-08-00157-t001" ref-type="table">Table 1</xref>), including Pulmotil and Micotil (Elanco Animal Health (<uri xlink:href="https://www.elanco.com/">https://www.elanco.com/</uri>), previously owned by Eli Lilly Company) and as Tilmovet (Huvepharma (<uri xlink:href="https://www.huvepharma.com/">https://www.huvepharma.com/</uri>)). Other semi-synthetic tylosin derivatives, which have been approved for treatment of respiratory diseases in animal production, include the 16-membered macrolide tildipirosin (trade name: Zuprevo) and the two 15-membered macrolides, tulathromycin (trade name: Draxxin), as well as gamithromycin (trade name: Zactran) (<xref ref-type="fig" rid="antibiotics-08-00157-f003">Figure 3</xref>, <xref rid="antibiotics-08-00157-t001" ref-type="table">Table 1</xref>) [<xref rid="B92-antibiotics-08-00157" ref-type="bibr">92</xref>,<xref rid="B93-antibiotics-08-00157" ref-type="bibr">93</xref>,<xref rid="B94-antibiotics-08-00157" ref-type="bibr">94</xref>,<xref rid="B95-antibiotics-08-00157" ref-type="bibr">95</xref>]. </p><p>In most cases, the 16-membered macrolides have less in vivo efficacy than the 14- and 15-membered macrolides. This is due to the fact that the side chains are metabolised and the generated products have a decreased activity compared to 14- and 15-membered macrolides.</p></sec><sec id="sec3dot3-antibiotics-08-00157"><title>3.3. Monensins</title><p>The polyether ionophore monensin A (<xref ref-type="fig" rid="antibiotics-08-00157-f004">Figure 4</xref>, <xref rid="antibiotics-08-00157-t001" ref-type="table">Table 1</xref>) (trade names: Coban, Rumensin, and Monensin) is another example of antibiotics being particularly important for veterinary medicine. The compound was identified in fermentation cultures of <italic>Streptomyces cinnamonensis</italic> and reported for the first time in 1967 as monensic acid by the Lilly Research Laboratories and the Department of Biochemistry of Indiana University School of Medicine [<xref rid="B96-antibiotics-08-00157" ref-type="bibr">96</xref>,<xref rid="B209-antibiotics-08-00157" ref-type="bibr">209</xref>]. In the natural producer, a mixture of monensin-like agents (monensin A, B and C) is synthesised, however, monensin A is the main constituent of this product (<xref ref-type="fig" rid="antibiotics-08-00157-f004">Figure 4</xref>). Monensin A is composed of five rings to which seven methyl, one ethyl, one carboxyl, and one hydroxyl group are attached [<xref rid="B96-antibiotics-08-00157" ref-type="bibr">96</xref>]. Monensin B and C vary from monensin A by their side groups. In monensin B, the ethyl group on C16 is replaced by a methyl group, whereas in monensin C the methyl group at C2 is replaced by an ethyl group [<xref rid="B210-antibiotics-08-00157" ref-type="bibr">210</xref>,<xref rid="B211-antibiotics-08-00157" ref-type="bibr">211</xref>,<xref rid="B212-antibiotics-08-00157" ref-type="bibr">212</xref>]. The carboxyl and hydroxyl groups can interact through hydrogen bonds, whereby a pseudocyclic conformation of monensin is formed (<xref ref-type="fig" rid="antibiotics-08-00157-f004">Figure 4</xref>). This results in an oxygen-containing center, which is selective for cations. Due to these conformational changes of monensin, an exterior composed of alkyl groups, which render the molecule hydrophobic and capable of passing the lipid bilayer of cell membranes, is built. The ionophore monensin A is able to bind monovalent metal cations such as Li<sup>+</sup>, Na<sup>+</sup>, K<sup>+</sup>, Rb<sup>+</sup>, Cs<sup>+</sup>, and Ag<sup>+</sup>. However, the compound prefers sodium cations for the formation of the ion&#x02013;ionophore complex, which facilitates cation transport across cell membranes. This disturbs the natural Na<sup>+</sup>/K<sup>+</sup> concentration gradient in Gram-positive bacteria causing death of the cell [<xref rid="B97-antibiotics-08-00157" ref-type="bibr">97</xref>,<xref rid="B210-antibiotics-08-00157" ref-type="bibr">210</xref>,<xref rid="B213-antibiotics-08-00157" ref-type="bibr">213</xref>,<xref rid="B214-antibiotics-08-00157" ref-type="bibr">214</xref>,<xref rid="B215-antibiotics-08-00157" ref-type="bibr">215</xref>,<xref rid="B216-antibiotics-08-00157" ref-type="bibr">216</xref>].</p><p>The genome sequencing of the producer and understanding the biosynthetic pathway of monensin have been crucial for optimizing the production of monensin in <italic>S. cinnamonensis</italic>. Sequence analysis of the 97 kb BGC of monensin (<italic>mon</italic>) has revealed a modular type I PKS, encoded by the genes <italic>monAI&#x02013;monAVIII</italic> [<xref rid="B98-antibiotics-08-00157" ref-type="bibr">98</xref>,<xref rid="B217-antibiotics-08-00157" ref-type="bibr">217</xref>] (<xref ref-type="app" rid="app1-antibiotics-08-00157">Figure S3</xref>). The first step in the assembly of the polyketide backbone is the loading of the &#x0201c;initiation module&#x0201d; of MonAI with malonate, which is derived from a malonyl-CoA starter unit. Twelve &#x0201c;downstream&#x0201d; extension modules in the PKS complex MonAI&#x02013;AVIII catalyse the loading and condensation of additional four acetate, one butyrate, and seven propionate molecules, leading to the biosynthesis of the monensin polyketide chain. Since no TE domain is present in MonAVII, the release of the monensin intermediate must be facilitated by TEs acting in <italic>trans</italic>. Originally, it was assumed that either MonAIX and/or MonAX, which show homology to TEs involved in rifamycin, tylosin, and erythromycin biosynthesis [<xref rid="B98-antibiotics-08-00157" ref-type="bibr">98</xref>], catalyse this reaction. Later, the enzyme MonCII, previously assigned as an epoxide hydrolase, was proposed as a putative novel TE, which might be responsible for the release of the monensin polyketide chain from the PKS assembly line [<xref rid="B218-antibiotics-08-00157" ref-type="bibr">218</xref>]. The additional genes found in the <italic>mon</italic> gene cluster encode enzymes involved in isomerisation, epoxidation (MonCI), hydroxylation (MonBI, MonBII, and MonD), and methylation (MonE) of the structure to the final product monensin A [<xref rid="B98-antibiotics-08-00157" ref-type="bibr">98</xref>,<xref rid="B219-antibiotics-08-00157" ref-type="bibr">219</xref>]. Finally, the <italic>mon</italic> gene cluster includes three regulator genes, <italic>monH</italic>, <italic>monRI</italic>, and <italic>monRII</italic>, and the gene <italic>monT</italic>, which encodes an efflux protein, believed to confer self-resistance to the host [<xref rid="B98-antibiotics-08-00157" ref-type="bibr">98</xref>,<xref rid="B217-antibiotics-08-00157" ref-type="bibr">217</xref>,<xref rid="B220-antibiotics-08-00157" ref-type="bibr">220</xref>,<xref rid="B221-antibiotics-08-00157" ref-type="bibr">221</xref>]. </p><p>Monensin A is used as a coccidiostat (inhibitor of coccidiosis) in poultry and as a non-hormonal growth promoter for cattle in the beef and dairy industry [<xref rid="B97-antibiotics-08-00157" ref-type="bibr">97</xref>,<xref rid="B210-antibiotics-08-00157" ref-type="bibr">210</xref>]. In addition, it was suggested that monensin A might also improve food metabolism in ruminants. Therefore, the feed additive Rumensin, which contains 6.6% monensin, was introduced for cattle to improve the composition of the intestinal bovine microbiota, reducing lactic acid formation, and ultimately leading to faster growth of cattle [<xref rid="B99-antibiotics-08-00157" ref-type="bibr">99</xref>]. </p><p>In 1971, monensin A was the first ionophore to be approved as a veterinary medicine. Two additional ionophore antibiotics lasalocid and salinomycin have subsequently been approved. Lasalocid, originally identified from fermentation broth of <italic>Streptomyces lasaliensis</italic>, was introduced in 1977 as a coccidiostat for poultry (trade name: Avatec) and later in 1982 as growth promoter for cattle (trade name: Bovatec). Salinomycin (trade name: Bio-Cox), produced by <italic>Streptomyces albus</italic>, received its approval as a coccidiostat for chickens in 1983 [<xref rid="B210-antibiotics-08-00157" ref-type="bibr">210</xref>,<xref rid="B222-antibiotics-08-00157" ref-type="bibr">222</xref>,<xref rid="B223-antibiotics-08-00157" ref-type="bibr">223</xref>,<xref rid="B224-antibiotics-08-00157" ref-type="bibr">224</xref>].</p><p>Given the nature of their applications, ionophore antibiotics have been subjected to increased concerns with regards to the association between their misuse as feed additives and development of resistance. However, studies on ionophore resistance in ruminal bacteria indicate that instead of resistance occurring as a result of mutations or horizontal gene transfer, it is more a matter of physiological selection [<xref rid="B225-antibiotics-08-00157" ref-type="bibr">225</xref>]. Since ionophore antibiotics are restricted to only a few animal species and have never been used in human medicine, it appears that the risk of cross-resistance is rather low. Little is known about resistance development in bacteria subjected to ionophores. Based on in vitro and in vivo experiments several ionophore resistance mechanisms have been suggested. Those include the hypothesis of a proton-translocating enzyme which might counteract ionophore-dependent ion flux [<xref rid="B226-antibiotics-08-00157" ref-type="bibr">226</xref>,<xref rid="B227-antibiotics-08-00157" ref-type="bibr">227</xref>], the cell wall model of ionophore resistance [<xref rid="B228-antibiotics-08-00157" ref-type="bibr">228</xref>,<xref rid="B229-antibiotics-08-00157" ref-type="bibr">229</xref>,<xref rid="B230-antibiotics-08-00157" ref-type="bibr">230</xref>], and the theory of extracellular polysaccharides (biofilm) [<xref rid="B225-antibiotics-08-00157" ref-type="bibr">225</xref>], such as glycocalyx produced by ruminal bacteria. As no clear indications of resistance development and spreading have been reported, it is likely that the use of ionophore antibiotics as feed additives will continue [<xref rid="B225-antibiotics-08-00157" ref-type="bibr">225</xref>]. </p></sec><sec id="sec3dot4-antibiotics-08-00157"><title>3.4. Tiacumicin</title><p>In the 1980s, scientists working at Abbott Laboratories were screening soil samples for novel microbes with antimicrobial activities. In a soil sample from Hamden, Connecticut, USA, the novel Gram-positive bacterium <italic>Dactylosporangium aurantiacum</italic> subsp. <italic>hamdenensis</italic> subsp. Nov. AB718C-41 (NRRL 18085) was isolated based on its activity against MRSA. After scaling up the production, six novel compounds were isolated known collectively as the tiacumicins [<xref rid="B100-antibiotics-08-00157" ref-type="bibr">100</xref>,<xref rid="B231-antibiotics-08-00157" ref-type="bibr">231</xref>]. Structure elucidation of the tiacumicins further revealed a shared 18-membered macrolactone, which differed between the analogues based on the types of modification to the macrocyclic ring and the number and esterification pattern of the sugar groups attached. Out of the six compounds produced, tiacumicin B (<xref ref-type="fig" rid="antibiotics-08-00157-f005">Figure 5</xref>) was found in largest quantities [<xref rid="B100-antibiotics-08-00157" ref-type="bibr">100</xref>].</p><p>The tiacumicin (<italic>tia</italic>) biosynthetic gene cluster of the original producer strains <italic>D. aurantiacum</italic> subsp. <italic>hamdenensis</italic> NRRL 18,085 was elucidated by Xiao and co-workers in 2011 based on sequence analysis and gene knockout studies [<xref rid="B101-antibiotics-08-00157" ref-type="bibr">101</xref>]. The data revealed the presence of 50 open reading frames (ORFs) spanning an 110,663 bp DNA region. Additional sequence analysis has shown that 31 of the originally identified 50 ORFs are directly involved in tiacumicin biosynthesis. The remaining 83 kb DNA region includes genes encoding enzymes responsible for polyketide backbone assembly, sugar biosynthesis, glycosylation, halogenation, methylation, hydroxylation, epoxidation, and resistance determinants. The four genes <italic>tiaA1</italic> through <italic>tiaA4</italic> encode the multimodular type I PKS responsible for the assembly of the central aglycone tiacumicinone (<xref ref-type="app" rid="app1-antibiotics-08-00157">Figure S4</xref>) [<xref rid="B101-antibiotics-08-00157" ref-type="bibr">101</xref>,<xref rid="B232-antibiotics-08-00157" ref-type="bibr">232</xref>]. After loading of the starter unit propionate, additional three malonates, four methylmalonates, and one ethylmalonate are condensed to the polyketide chain. Several genes are encoded in the <italic>tia</italic> BGC, which could provide the precursors for the polyketide. The synthesis of isobutyryl-CoA, propionyl-CoA, and acyl-CoA might be catalysed by TiaC and TiaD. Furthermore, the propionyl-CoA carboxylase encoded by <italic>tiaL</italic> might catalyse the formation of methylmalonyl-CoA from propionyl-CoA, and the CCR encoded by <italic>tiaK</italic> could be responsible for provision of the ethylmalonyl-CoA subunit [<xref rid="B233-antibiotics-08-00157" ref-type="bibr">233</xref>]. Upon reaching the TE domain in module eight of TiaA4, the polyketide chain is released and cyclised, yielding the tiacumicinone precursor (<xref ref-type="app" rid="app1-antibiotics-08-00157">Figure S4</xref>). An additional TE TiaE, which shows homology to the type II TE NysE involved in nystatin biosynthesis, is found in the <italic>tia</italic> BGC. Since these type II TEs are believed to act as repair enzymes, removing aberrant PKS precursors, TiaE has been hypothesized to have a similar role in <italic>tia</italic> biosynthesis [<xref rid="B101-antibiotics-08-00157" ref-type="bibr">101</xref>,<xref rid="B234-antibiotics-08-00157" ref-type="bibr">234</xref>]. Tiacumicinone undergoes several modifications including C18 and C20 hydroxylations, which are catalysed by the two cytochrome P450 enzymes TiaP1 and TiaP2, respectively, and the attachment of the rhamnose sugars at position C11 and C20, catalysed by the two glycosyltransferases TiaG1 and TiaG2 (<xref ref-type="app" rid="app1-antibiotics-08-00157">Figure S4</xref>). The sugars are further modified. First, to yield the final 4-<italic>O</italic>-isobutyryl-5-methyl-&#x003b2;-rhamnose at position C11, the sugar C-methyltransferase TiaS2 and O-acyltransferase TiaS6 incorporate the methyl and isobutyryl moieties, respectively. The sugar at C20 also undergoes several modifications. The synthesis of the homo-orsellinic moiety is believed to be catalysed by an iterative type I PKS TiaB based on a propionyl-CoA starter unit and three malonyl-CoA extender units [<xref rid="B101-antibiotics-08-00157" ref-type="bibr">101</xref>]. The transfer of the aromatic moiety to the C20 sugar could then be facilitated by the acyltransferase encoded by <italic>tiaF</italic> (<xref ref-type="app" rid="app1-antibiotics-08-00157">Figure S4</xref>). Further modifications to the sugar are achieved by the actions of TiaS5, responsible for the 2&#x02032;-<italic>O</italic>-methyltransferase reaction leading to 2-<italic>O</italic>-methyl-&#x003b2;-rhamnose and, finally, the dihalogenase TiaM, which is responsible for attachment of two chlorine atoms to the homo-orsellinic acid. Within the <italic>tia</italic> cluster, genes encoding proteins putatively involved in regulation and resistance are also found. This includes the putative LuxR class regulator TiaR1 and the putative ArsR family transcriptional regulator TiaR2, of which only the function of TiaR2 has been experimentally verified [<xref rid="B101-antibiotics-08-00157" ref-type="bibr">101</xref>]. Since the &#x00394;<italic>tiaR2</italic> mutant strain produced slightly higher levels of tiacumicin than the wild type strain, the regulator might act as negative regulator in <italic>tia</italic> biosynthesis. TiaT1 through TiaT4 show homology to membrane proteins and ATP-binding cassette (ABC) transporter and therefore, have been hypothesized to be involved in export of tiacumicin. However, genetic and biochemical studies are necessary to clarify their role in the biosynthesis of tiacumicin [<xref rid="B101-antibiotics-08-00157" ref-type="bibr">101</xref>].</p><p>Coincidentally, in the same year as the tiacumicins were discovered and reported, a Japanese group, led by Satoshi Omura, reported the discovery of the antibiotics clostomicins, produced by <italic>Micromonospora echinospora</italic> subsp. <italic>armenica</italic> subsp. Nov [<xref rid="B235-antibiotics-08-00157" ref-type="bibr">235</xref>]. Structure comparisons not only revealed tiacumicin B and clostomicin B<sub>1</sub> to be identical, but also that a third antibiotic, lipiarmycin A3, discovered in 1975 from culture of <italic>Actinoplanes deccanensis</italic> A/10655, shared the same structure [<xref rid="B231-antibiotics-08-00157" ref-type="bibr">231</xref>,<xref rid="B236-antibiotics-08-00157" ref-type="bibr">236</xref>]. Ultimately, only tiacumicin B went through to further clinical studies. Although originally identified for its activity against MRSA, promising in vivo potency against <italic>Clostridioides</italic> (formerly <italic>Clostridium</italic>) <italic>difficile</italic> in animal models directed the development of tiacumicin B towards a narrow spectrum antibiotic for treatment of clostridia [<xref rid="B233-antibiotics-08-00157" ref-type="bibr">233</xref>]. The antibiotic was approved by FDA in 2011 under the generic name fidaxomicin and trade name Dificid (<xref rid="antibiotics-08-00157-t001" ref-type="table">Table 1</xref>) for treatment of <italic>C. difficile</italic> infections (CDI), which remains one of the main causes of hospital-acquired diarrhoea [<xref rid="B233-antibiotics-08-00157" ref-type="bibr">233</xref>]. At the time, Dificid was regarded as an alternative to vancomycin, which was used to treat CDI. One of the major drawbacks of vancomycin is its broad-spectrum and bacteriostatic activity which promote reoccurrence of CDI. In contrast, fidaxomicin is a bactericidal, narrow-spectrum antibiotic and has been found to not only reduce recurrence of CDI but also promote survival of commensal gut microbes and prevent the development of colitis [<xref rid="B102-antibiotics-08-00157" ref-type="bibr">102</xref>,<xref rid="B237-antibiotics-08-00157" ref-type="bibr">237</xref>]. In addition, fidaxomicin is administered orally with no reports of resistance development in <italic>C. difficile</italic> isolates. In a recent US-based national survey, 1889 <italic>C. difficile</italic> isolates were collected from the stool of patients infected with the pathogen over the period of 2013 to 2016. The isolates were screened for susceptibility against fidaxomicin and showed that fidaxomicin MIC<sub>50</sub> (maximum inhibitory concentration of an antibiotic, at which 50% of the isolates are inhibited) and MIC90 (maximum inhibitory concentration of an antibiotic, at which 90% of the isolates are inhibited) values toward <italic>C. difficile</italic> had not changed over the time period [<xref rid="B238-antibiotics-08-00157" ref-type="bibr">238</xref>]. However, the fact that fidaxomicin was only recently introduced to the clinics stresses the need for continuous surveillance [<xref rid="B238-antibiotics-08-00157" ref-type="bibr">238</xref>]. </p><p>Recently, the MOA of tiacumicin B has been further clarified based on the cryogenic electron microscopy (cryo-EM) structure of <italic>Mycobacterium tuberculosis</italic> RNA polymerase (RNAP) holoenzyme in complex with lipiarmycin A3 [<xref rid="B103-antibiotics-08-00157" ref-type="bibr">103</xref>]. Although the target of fidaxomicin was already known to be the bacterial RNAP [<xref rid="B239-antibiotics-08-00157" ref-type="bibr">239</xref>], the recent findings could show the binding of the antibiotic to be specific for the RNAP clamp. Upon binding of fidaxomicin, the RNAP is trapped in an open-clamp conformation, which prevents the simultaneous engagement of the &#x02212;10 and &#x02212;35 elements needed for transcription initiation. Furthermore, since the binding sites of fidaxomicin do not overlap with those of other known RNAP inhibitors, including rifamycin and sorangicin, the risk of cross-resistance is lowered [<xref rid="B103-antibiotics-08-00157" ref-type="bibr">103</xref>].</p><p>At the moment, fidaxomicin is the only substance approved for human therapy within the tiacumicin-like compounds. However, the advanced information on the structure activity relationship (SAR) of fidaxomicin might trigger a more rational structure-based design of drug analogues in the future [<xref rid="B103-antibiotics-08-00157" ref-type="bibr">103</xref>]. </p><p>The knowledge obtained from studies on the <italic>tia</italic> gene cluster aided the design of a dihalogenase-deficient &#x00394;<italic>tiaM</italic> mutant strain, which produced 14 tiacumicin congeners of which 11 were novel derivatives [<xref rid="B240-antibiotics-08-00157" ref-type="bibr">240</xref>]. Based on minimum inhibitory concentration (MIC) tests, tiacumicin congener 3 displayed higher potency against <italic>Bacillus thuringiensis</italic> (MIC = 0.5 &#x003bc;g/mL), <italic>Micrococcus luteus</italic> (MIC = 1 &#x003bc;g/mL), and <italic>Enterococcus faecelis</italic> (MIC = 4 &#x003bc;g/mL) compared to all other congeners and the parent compound tiacumicin B. Interestingly, in addition to its lack of chlorine atoms, congener 3 contained a propyl group on the aromatic ring. The four-fold antibacterial activity increase of congener 3 compared to tiacumicin B was putatively assigned to the structural change in the aromatic ring. In the future, this knowledge could provide the foundation for further gene manipulations, which would result in generation of novel tiacumicin derivatives with improved antibacterial activities [<xref rid="B240-antibiotics-08-00157" ref-type="bibr">240</xref>]. Furthermore, these derivatives might also provide more cost-effective alternatives to fidaxomicin, the price of which remains a major point of criticism [<xref rid="B241-antibiotics-08-00157" ref-type="bibr">241</xref>].</p></sec><sec id="sec3dot5-antibiotics-08-00157"><title>3.5. Rifamycin and Derivatives</title><p>Rifamycins (<xref ref-type="fig" rid="antibiotics-08-00157-f006">Figure 6</xref>) belong to the class of ansamycin antibiotics. This group of compounds is distinguished by a cyclic structure bridged at two nonadjacent positions by an aliphatic chain [<xref rid="B104-antibiotics-08-00157" ref-type="bibr">104</xref>,<xref rid="B105-antibiotics-08-00157" ref-type="bibr">105</xref>]. This basket or handle-like architecture gave rise to the naming ansamycins (Latin: ansa = handle). Ansamycins comprise a range of different substances. In the following, we cover rifamycin and its derivatives, which collectively belong to the group of naphtalenes-ansamycins. </p><p>The history of this class of compounds started in 1959 with the isolation of the naturally-derived rifamycins, a complex mixture of several congeners produced by <italic>Streptomyces mediterranei</italic> [<xref rid="B106-antibiotics-08-00157" ref-type="bibr">106</xref>]. More detailed studies on morphology, cell wall composition, and phage susceptibility resulted in re-classification of the strain, first as <italic>Nocardia mediterranei</italic>, and later as <italic>Amycolatopsis mediterranei</italic> [<xref rid="B105-antibiotics-08-00157" ref-type="bibr">105</xref>,<xref rid="B242-antibiotics-08-00157" ref-type="bibr">242</xref>]. Structure elucidation has revealed common architectures of the complex of rifamycins, which include a 17-membered aliphatic chain and a C&#x02013;O bond linking the benzene ring to the chain [<xref rid="B243-antibiotics-08-00157" ref-type="bibr">243</xref>] (<xref ref-type="fig" rid="antibiotics-08-00157-f006">Figure 6</xref>). In the initial attempts to separate and isolate each of the congeners from the fermentation broth of <italic>A. mediterranei</italic>, only rifamycin B, which constitutes 5&#x02013;10% of the mixture, could be purified [<xref rid="B244-antibiotics-08-00157" ref-type="bibr">244</xref>]. Since the substance was the least active congeners in the mixture, further studies were necessary to identify the more potent substances. One of the breakthroughs came with the elucidation of four additional rifamycin intermediates, including rifamycin S, L, O, and SV [<xref rid="B105-antibiotics-08-00157" ref-type="bibr">105</xref>,<xref rid="B245-antibiotics-08-00157" ref-type="bibr">245</xref>,<xref rid="B246-antibiotics-08-00157" ref-type="bibr">246</xref>]. </p><p>Using the sequence encoding RifK (3-amino-5-hydroxy benzoic acid synthase (AHBA synthase)) in the natural producer as a probe, the BGC of rifamycin was isolated from a cosmid library of <italic>A. mediterranei</italic> [<xref rid="B107-antibiotics-08-00157" ref-type="bibr">107</xref>]. The gene cluster stretches over a 95 kb DNA region and contains 34 genes encoding all structural, modification, resistance, export, and regulatory elements. The assembly of the polyketide chain is governed by the modular type I PKS, encoded by the five genes <italic>rifA</italic> through <italic>rifE</italic> (<xref ref-type="app" rid="app1-antibiotics-08-00157">Figure S5</xref>). Since the loading module within RifA contains domains with homology to A and T domains of NRPSs, the rifamycin assembly line is a hybrid PKS/NRPS [<xref rid="B247-antibiotics-08-00157" ref-type="bibr">247</xref>]. The starter and extender units involved in the formation of the polyketide has been identified [<xref rid="B248-antibiotics-08-00157" ref-type="bibr">248</xref>]. This includes the atypical starter unit AHBA, of which biosynthesis is orchestrated by enzymes encoded by <italic>rifG</italic> through <italic>rifN</italic>. The shikimate-related pathway of aromatic biosynthesis leading to the formation of AHBA was elucidated based on gene inactivation and heterologous expression [<xref rid="B248-antibiotics-08-00157" ref-type="bibr">248</xref>]. Upon loading of AHBA, the polyketide chain is further elongated by the ten extender modules, which facilitate the addition of eight acetate and two propionate extender units [<xref rid="B107-antibiotics-08-00157" ref-type="bibr">107</xref>,<xref rid="B108-antibiotics-08-00157" ref-type="bibr">108</xref>]. The rifamycin PKS does not encode a typical TE domain. Instead, downstream of <italic>rifE</italic>, the gene <italic>rifF</italic> which shares homology to an arylamine <italic>N</italic>-acetyl-transferase is located. The role of RifF in chain release and macrolactam ring closure has been confirmed through an in-frame deletion, in which the &#x00394;<italic>rifF</italic> mutant lost its ability to produce rifamycin B and instead accumulated shorter open-chain ketides [<xref rid="B249-antibiotics-08-00157" ref-type="bibr">249</xref>]. An additional TE encoded by <italic>rifR</italic> has been identified in the rifamycin gene cluster [<xref rid="B250-antibiotics-08-00157" ref-type="bibr">250</xref>]. However, since the &#x00394;<italic>rifR</italic> and &#x00394;<italic>rifF</italic>+&#x00394;<italic>rifR</italic> mutants showed identical production profile, in which the same aberrant open-chain polyketides were detected, it was concluded that RifR is directly involved in the release of polyketide precursors from the assembly line. Furthermore, closer examinations of the PKS intermediates produced by the &#x00394;<italic>rifF</italic> mutant revealed that while the tetraketide contained an unmodified aromatic chromophore, the pentaketide through the decaketide contained the bicyclic naphthoquinone moiety [<xref rid="B251-antibiotics-08-00157" ref-type="bibr">251</xref>]. This indicated that naphthoquinone ring closure must occur while the polyketide chain is still attached to the PKS. This hypothesis was later confirmed based on the genetic studies of <italic>rif19</italic>, which encodes a 3-(3-hydroxyphenyl)propionate hydroxylase-like protein [<xref rid="B252-antibiotics-08-00157" ref-type="bibr">252</xref>]. It was concluded that Rif19 catalyses the naphthoquinone ring closure, which occurs between module three in RifA and module four in RifB (<xref ref-type="app" rid="app1-antibiotics-08-00157">Figure S5</xref>). Upon its release from the PKS, the polyketide precursor undergoes a series of post-modifications, including dehydrogenation at the C8 and hydroxylation of the C34, which results in the formation of one of the early intermediates in the post-modification pathway, namely rifamycin W [<xref rid="B252-antibiotics-08-00157" ref-type="bibr">252</xref>,<xref rid="B253-antibiotics-08-00157" ref-type="bibr">253</xref>]. The conversion of rifamycin W to rifamycin B involves the formation of the intermediate rifamycin SV (<xref ref-type="app" rid="app1-antibiotics-08-00157">Figure S5</xref>) [<xref rid="B105-antibiotics-08-00157" ref-type="bibr">105</xref>,<xref rid="B252-antibiotics-08-00157" ref-type="bibr">252</xref>]. The final steps in the conversion of rifamycin SV to rifamycin B, through the intermediates rifamycin S, L, and O, have only recently been elucidated based on in vitro assays with the cytochrome P450 enzyme Rif16 and the two-subunit transketolase Rif15 (<xref ref-type="app" rid="app1-antibiotics-08-00157">Figure S5</xref>) [<xref rid="B254-antibiotics-08-00157" ref-type="bibr">254</xref>].</p><p>Additional genes encoding enzymes involved in regulation, export, and self-resistance have been identified in the rifamycin BGC. This includes the LuxR family regulator RifZ, which acts as an activator, and the TetR-family transcriptional regulator RifQ, which is a repressor of rifamycin biosynthesis in <italic>A. mediterranei</italic> [<xref rid="B255-antibiotics-08-00157" ref-type="bibr">255</xref>,<xref rid="B256-antibiotics-08-00157" ref-type="bibr">256</xref>,<xref rid="B257-antibiotics-08-00157" ref-type="bibr">257</xref>]. The repressor RifQ is feedback-regulated by rifamycin B, the product of the rifamycin gene cluster in <italic>A. mediterranei</italic>. When a threshold concentration of rifamycin B is reached intracellularly, the substance interferes with the binding of RifQ to the promoter region of <italic>rifP</italic>, which encodes a membrane protein, whereby export of the antibiotic is initiated [<xref rid="B258-antibiotics-08-00157" ref-type="bibr">258</xref>]. </p><p>The importance of the rifamycins in human therapy is evident from their strong activities against a wide range of Gram-positive bacteria and to a lesser extent, some Gram-negatives. The reason for the higher MIC of Gram-negatives is most likely due to a reduced penetration of the rifamycins through the outer membranes of Gram-negatives [<xref rid="B258-antibiotics-08-00157" ref-type="bibr">258</xref>]. The rifamycins remain the first-line treatment of tuberculosis (TB) caused by <italic>M. tuberculosis</italic> and for treatment of non-tuberculous mycobacterial infections [<xref rid="B105-antibiotics-08-00157" ref-type="bibr">105</xref>,<xref rid="B119-antibiotics-08-00157" ref-type="bibr">119</xref>,<xref rid="B244-antibiotics-08-00157" ref-type="bibr">244</xref>]. Collectively, the rifamycins interact with the bacterial DNA-dependent RNAP whereby transcription is blocked. </p><p>As previously mentioned, rifamycin B itself displays modest bioactivity and therefore, the need for derivatisation of the scaffold is necessary to produce rifamycin analogues with improved activity and availability. In fact, from the naturally derived rifamycins, only rifamycin SV has been introduced in human therapy. With a strong bioactivity against Gram-positives, including <italic>M. tuberculosis</italic>, and moderate activity against some Gram-negatives [<xref rid="B244-antibiotics-08-00157" ref-type="bibr">244</xref>], rifamycin SV was introduced into the clinic in 1963 as a topical and parental agent. Extensive semi-synthesis efforts on rifamycins delivered several clinically relevant compounds. Using information gained from SAR studies, the first series of rifamycin analogous were generated based on substitutions at the C3/C4 positions in the aromatic moiety of the intermediate 3-formyl rifamycin SV. One of the resulting substances, 3-(4-methyl-piperazinyl-iminomethyl) rifamycin SV, coined rifampicin (<xref ref-type="fig" rid="antibiotics-08-00157-f006">Figure 6</xref>), displayed strong bioactivity against Gram-positive bacteria, including <italic>M. tuberculosis</italic> and <italic>Neisseria</italic> species, and modest activity against Gram-negatives [<xref rid="B105-antibiotics-08-00157" ref-type="bibr">105</xref>,<xref rid="B110-antibiotics-08-00157" ref-type="bibr">110</xref>]. Just as importantly, rifampicin was fat-soluble and could be administered orally. Ultimately, rifampicin (trade names: Rifadin and Rimactane) (<xref rid="antibiotics-08-00157-t001" ref-type="table">Table 1</xref>) was introduced for human therapy in 1968 in Italy and in 1971 in the US, and has since then been an important agent in treatment of TB, leprosy, and other mycobacterial infections [<xref rid="B243-antibiotics-08-00157" ref-type="bibr">243</xref>]. Additionally, rifampicin has also been an important substance for determining the MOA of rifamycins. Based on the 3.3 &#x000c5; crystal structure of the RNAP core of <italic>Thermus aquaticus</italic> complexed with rifampicin, Campbell and co-workers determined the binding of the antibiotic to the &#x003b2; subunit within the DNA/RNA channel. This binding resulted in the physical blockage of the channel for the elongating RNA, when the transcripts reach a size of two to three nucleotides in length [<xref rid="B111-antibiotics-08-00157" ref-type="bibr">111</xref>]. Determining the MOA of rifampicin also aided in understanding the high frequency of resistance development in rifamycin sensitive microorganism. Since pathogens can develop resistance to rifampicin with a rate of 10<sup>&#x02212;8</sup> to 10<sup>&#x02212;9</sup> per cell division, the application of the antibiotic is restricted to combination therapy, in which the antimycobacterial agent isoniazid is often used together with rifampicin, or used only in severe cases of TB infection [<xref rid="B105-antibiotics-08-00157" ref-type="bibr">105</xref>]. The high rate of resistance is most commonly associated with the acquisition of mutations in the <italic>rpoB</italic> gene, which encodes the &#x003b2; subunit in the RNAP, whereby the binding affinity of the enzyme to the antibiotic is lowered. The <italic>rpoB</italic> gene is highly conserved in prokaryotes, however, pathogens acquire different levels of mutations in their respective <italic>rpoB</italic> genes, and consequently the level of resistance also can vary amongst isolates. For clinical isolates of <italic>M. tuberculosis</italic>, the three amino acids S411, H406, and D396 (<italic>T. aquaticus</italic> numbering) are most often mutated. Mutations at these positions in the RNAP core influence the hydrogen bonds formed between the hydroxyl groups on C8 and C21 of rifampicin, which interact with S411 and with H406 and D396, respectively [<xref rid="B105-antibiotics-08-00157" ref-type="bibr">105</xref>,<xref rid="B111-antibiotics-08-00157" ref-type="bibr">111</xref>]. </p><p>Additional rifamycin analogues obtained through the derivatisation efforts on rifamycin SV have made it through to the clinics (<xref ref-type="fig" rid="antibiotics-08-00157-f006">Figure 6</xref>). One of these analogues is the 3-(((4-cyclopentyl-1-piperazinyl) imino) methyl) rifamycin S, also known as rifapentine (trade name: Priftin) (<xref rid="antibiotics-08-00157-t001" ref-type="table">Table 1</xref>). Rifapentine was discovered during the initial derivatisation efforts on the C3/C4 aromatic moiety in rifamycin SV. The analogue was approved for treatment of TB in 1998 and similar to rifampicin can be administered orally [<xref rid="B115-antibiotics-08-00157" ref-type="bibr">115</xref>,<xref rid="B259-antibiotics-08-00157" ref-type="bibr">259</xref>]. Unfortunately, isolates which are resistant to rifampicin display cross-resistance to rifapentine, which has limited the application of the antibiotic.</p><p>The two rifamycin analogues rifabutin (trade name: Mycobutin) and rifaximin (trade names: Normix, Rifacol, Xifaxan) were approved for human therapy in 1992 and 2004, respectively (<xref rid="antibiotics-08-00157-t001" ref-type="table">Table 1</xref>) [<xref rid="B243-antibiotics-08-00157" ref-type="bibr">243</xref>]. Rifamixin ((4-deoxy-4)-methylpyrido [1),2)-1,2]imidazo-[5,4-c]rifamycin SV) is non-systemic and can reach high concentrations in the gastrointestinal (GI) tract, enabling its application for treatment of traveller&#x02019;s diarrhoea caused by enteropathogens, including <italic>Escherichia coli</italic> [<xref rid="B116-antibiotics-08-00157" ref-type="bibr">116</xref>]. More recently, rifaximin has been further implicated in the treatment and prevention of various GI diseases, including inflammatory bowel diseases such as Crohn&#x02019;s disease and ulcerative colitis. Although the continuous administration of rifaximin has raised concerns for selection of resistance and undesirable disruption of the gut microbiota, several studies have shown that rifaximin may promote a healthy gut microbiota [<xref rid="B117-antibiotics-08-00157" ref-type="bibr">117</xref>,<xref rid="B260-antibiotics-08-00157" ref-type="bibr">260</xref>,<xref rid="B261-antibiotics-08-00157" ref-type="bibr">261</xref>]. The beneficial effects of the antibiotic are lost quickly after the treatment with rifaximin was terminated which probably limits its application as a preventive agent for GI-associated diseases [<xref rid="B118-antibiotics-08-00157" ref-type="bibr">118</xref>]. Only recently, an alternative antibiotic combination has been approved by the US FDA for the treatment of traveller&#x02019;s diarrhoea. The oral formulation developed at Cosmo Pharmaceuticals N.V. (Ireland) is based on the unique combination of rifamycin SV together with the MultiMatrix (MMX<sup>&#x000ae;</sup>) technology, which ensures colonic delivery of the antibiotic [<xref rid="B109-antibiotics-08-00157" ref-type="bibr">109</xref>]. Based on in vitro studies, rifamycin SV MMX<sup>&#x000ae;</sup> (trade names: Aemcolo and Relafalk) (<xref rid="antibiotics-08-00157-t001" ref-type="table">Table 1</xref>) was found to exhibit antibacterial activity against most enteropathogens associated with traveller&#x02019;s diarrhoea. Moreover, in later phase III clinical studies, the oral substance was well-tolerated in patients undergoing treatment and could shorten the duration of non-dysenteric traveller&#x02019;s diarrhoea [<xref rid="B109-antibiotics-08-00157" ref-type="bibr">109</xref>].</p><p>The semi-synthetic derivative rifabutin (4-<italic>N</italic>-isobutylspiropiperidylrifamycin S) was approved for human therapy due to its inhibitory activity against a number of rifampicin-resistant <italic>M. tuberculosis</italic> clinical isolates in addition to its well-documented activity against <italic>Mycobacterium avium</italic> and <italic>M. intracellulare</italic> (also referred to as <italic>Mycobacterium avium-intracellulare</italic> complex (MAC)) [<xref rid="B112-antibiotics-08-00157" ref-type="bibr">112</xref>,<xref rid="B113-antibiotics-08-00157" ref-type="bibr">113</xref>]. MAC infection frequently occurs in patients with acquired immunodeficiency syndrome (AIDS) and when administered prophylactically as a 300 mg daily dose, rifabutin significantly reduces the incidence of MAC bacteraemia. However, due to the risk of cross-resistance between rifampicin and rifabutin in <italic>M. tuberculosis</italic> isolates, rifabutin is restricted to MAC patients and for newly diagnosed and multidrug-resistant TB in Europe [<xref rid="B114-antibiotics-08-00157" ref-type="bibr">114</xref>].</p><p>During the derivatisation of rifamycins, modifications to the ansa bridge often led to compounds with lowered activities [<xref rid="B262-antibiotics-08-00157" ref-type="bibr">262</xref>]. Recently, the natural ansamycin antibiotic kanglemycin A, which has an altered ansa chain, was found to maintain potency against rifampicin-resistant bacterial isolates, including multidrug-resistant <italic>M. tuberculosis</italic> (<xref ref-type="fig" rid="antibiotics-08-00157-f006">Figure 6</xref>). Kanglemycin A was originally isolated from <italic>Nocardia mediterranei</italic> var. <italic>kanglensis</italic> 1741-64 in 1988, however, the MOA of the compound was only recently elucidated. Based on the crystal structure of the RNAP-promoter complex of <italic>Thermus thermophiles</italic> with kanglemycin A, it became evident that the sugar (&#x003b2;-<italic>O</italic>-3,4-<italic>O</italic>,<italic>O</italic>&#x02032;-methylene digitoxose) and acid (2,2-dimethyl succinic acid) moieties on the ansa bridge in the molecule increase the binding surface of the antibiotic with the RNAP. Furthermore, the additional interaction of the sugar group of kanglemycin A was hypothesized to limit the frequency of resistance development as this would require two simultaneous mutations in the binding pocket of the RNAP [<xref rid="B119-antibiotics-08-00157" ref-type="bibr">119</xref>,<xref rid="B120-antibiotics-08-00157" ref-type="bibr">120</xref>]. Although kanglemycin A (<xref rid="antibiotics-08-00157-t001" ref-type="table">Table 1</xref>) itself has not been introduced to the clinics, its discovery might open up for future structural derivatisation efforts in which the ansa bridge might prove to be a valuable &#x0201c;target&#x0201d; for generating new synthetic ansamycin antibiotics with improved bioactivities.</p></sec><sec id="sec3dot6-antibiotics-08-00157"><title>3.6. Tetracyclines</title><p>The tetracycline group of antibiotics covers a variety of natural and semi-synthetic compounds. There are three naturally derived tetracyclines that have been described in detail and have formed the basis for 2nd and 3rd generation tetracycline derivatives. The three natural substances include chlortetracycline (trade names: Aureomycin, <xref rid="antibiotics-08-00157-t001" ref-type="table">Table 1</xref>) discovered from the fermentation broth of <italic>Streptomyces aureofaciens</italic> in 1948 [<xref rid="B125-antibiotics-08-00157" ref-type="bibr">125</xref>], oxytetracycline (trade name: Terracycline, <xref rid="antibiotics-08-00157-t001" ref-type="table">Table 1</xref>) found in the broth of <italic>Streptomyces rimosus</italic> in 1950 [<xref rid="B121-antibiotics-08-00157" ref-type="bibr">121</xref>], and finally tetracycline, which was discovered as a fermentation product of <italic>Streptomyces viridofaciens</italic> and the two aforementioned strains [<xref rid="B263-antibiotics-08-00157" ref-type="bibr">263</xref>] (<xref ref-type="fig" rid="antibiotics-08-00157-f007">Figure 7</xref>). Based on the structural elucidation of the three compounds, which revealed a characteristic DCBA naphthacene tetra-cyclic core (<xref ref-type="fig" rid="antibiotics-08-00157-f007">Figure 7</xref>), the agents later became descriptively known as the tetracyclines [<xref rid="B264-antibiotics-08-00157" ref-type="bibr">264</xref>]. Within the group of tetracyclines, tetracycline represents the simplest of the structures, whereas chlortetracycline and oxytetracycline contain modifications at the core cyclic structure. While chlortetracycline contains a chlorine atom at the C7 atom in ring D, oxytetracycline instead harbours a hydroxyl group at the C5 position in ring B.</p><p>The biosynthesis of chlortetracycline and oxytetracycline follows a similar logic and in the following, we focus on the biosynthetic principle of the latter compound. The BGC of oxytetracycline covers a 21.2 kb DNA region in <italic>S. rimosus</italic> and contains 21 ORFs encoding structural, modification, resistance, and regulatory elements [<xref rid="B265-antibiotics-08-00157" ref-type="bibr">265</xref>]. The biosynthesis of oxytetracycline starts with the assembly of the polyketide precursor by the type II minimal PKS encoded by the genes <italic>oxyA</italic> through <italic>oxyC</italic> (<xref ref-type="app" rid="app1-antibiotics-08-00157">Figure S6</xref>). More specifically, the KS<sub>&#x003b1;</sub> (OxyA) and KS<sub>&#x003b2;</sub> (OxyB) form the heterodimer responsible for chain elongation, while the ACP (OxyC) provides the extender units. An interesting feature of the natural tetracyclines is the unusual starter unit, malonamate, giving rise to the amide group on ring A in the naphthacene core [<xref rid="B122-antibiotics-08-00157" ref-type="bibr">122</xref>,<xref rid="B265-antibiotics-08-00157" ref-type="bibr">265</xref>]. The gene encoding the enzyme responsible for the provision of this starter unit has been identified as <italic>oxyD</italic>, which is located immediately downstream of the minimal PKS-encoding genes <italic>oxyA</italic> through <italic>oxyC</italic> in the oxytetracycline gene cluster in <italic>S. rimosus</italic>. The protein sequence of OxyD shows homology to the ATP-dependent class II asparagine synthases and it is believed to catalyse the transamination of malonate to yield malonamate [<xref rid="B266-antibiotics-08-00157" ref-type="bibr">266</xref>]. Once attached to the minimal PKS, the malonamate is condensed with eight additional malonates, giving rise to the amidated decaketide backbone, which is released from the megaenzyme and further processed by AROs and CYCs encoded by genes in the oxytetracycline gene cluster (<xref ref-type="app" rid="app1-antibiotics-08-00157">Figure S6</xref>). Based on the heterologous expression of the extended minimal PKS of oxytetracycline (OxyABCD) in <italic>Streptomyces coelicolor</italic> CH999, three enzymes have been identified and assumed to play a role in the correct cyclisation of the polyketide precursor [<xref rid="B267-antibiotics-08-00157" ref-type="bibr">267</xref>]. This includes the NADPH-dependent KR OxyJ, which catalyses the C9 reduction in ring D, the two-component CYC/ARO OxyK which is responsible for closing the first ring (ring D), and the CYC OxyN, catalysing the ring closure of the second ring (ring C). An additional putative CYC, encoded by <italic>oxyI</italic>, has been identified in the oxytetracycline gene cluster, however, since the heterologous expression of OxyABCDJKNI displayed a profile similar to that of OxyABCDJKN, it was concluded that OxyI is not directly involved in cyclisation of the third or fourth ring (ring B and A, respectively). Instead, closing of these two rings is believed to occur spontaneously [<xref rid="B268-antibiotics-08-00157" ref-type="bibr">268</xref>].</p><p>Upon ring closure, the stable intermediate pretetramid is formed, which undergoes a series of modification reactions, of which the actual sequence remains to be clarified [<xref rid="B269-antibiotics-08-00157" ref-type="bibr">269</xref>] (<xref ref-type="app" rid="app1-antibiotics-08-00157">Figure S6</xref>). The modification of pretetramid involves a C6 methylation in ring C, which is catalysed by the S-adenosyl methionine (SAM)-dependent methyltransferase OxyF, yielding the intermediate 6-methylpretetramide. In the next step, the dihydroxylation of C4 and C12a in ring A, yielding the substance 4-keto-anhydrotetracycline, is catalysed by the two oxygenases OxyL and OxyE. While OxyL can give rise to both hydroxylations, OxyE only catalyses the addition of the hydroxyl group at the C4 position. The reason for the extra function of OxyE seems to be a matter of increasing the rate of the enzymatic reaction [<xref rid="B268-antibiotics-08-00157" ref-type="bibr">268</xref>]. The further conversion of 4-keto-anhydrotetracycline is achieved first by the actions of the aminotransferase OxyQ, yielding the intermediate 4-amino-anhydrotetracycline, which then serves as a substrate for the SAM-dependent methyltransferase OxyT, catalysing a <italic>N</italic>, <italic>N</italic>-dimethylation that gives rise to anhydrotetracycline. The final enzymatic reactions leading to formation of oxytetracycline from anhydrotetracycline was recently elucidated by Wang and co-workers (<xref ref-type="app" rid="app1-antibiotics-08-00157">Figure S6</xref>) [<xref rid="B270-antibiotics-08-00157" ref-type="bibr">270</xref>]. In this study, OxyS was confirmed to catalyse the two sequential hydroxylations of C6 and C5 in ring C and B, respectively. Furthermore, OxyR was shown to act as a F<sub>420</sub>-dependent reductase, which is responsible for the final C5a&#x02212;C11a reduction affording oxytetracycline (<xref ref-type="app" rid="app1-antibiotics-08-00157">Figure S6</xref>). In the case of chlortetracycline, an additional gene, <italic>ctcP</italic>, encoding a flavin-dependent halogenase, has been identified in the chlortetracycline BGC in <italic>S. aureofaciens</italic> [<xref rid="B126-antibiotics-08-00157" ref-type="bibr">126</xref>]. CtcP yields the final product chlortetracycline based on the halogenation at position C7 in ring D (<xref ref-type="app" rid="app1-antibiotics-08-00157">Figure S6</xref>). In addition to structural and tailoring genes, the BGCs of chlortetracycline and oxytetracycline include additional genes involved in resistance (<italic>otrA</italic> and <italic>otrB</italic>) and regulation (<italic>otcG</italic> and <italic>otcR</italic>). In the case of the oxytetracycline BGC, the two genes <italic>otrA</italic> and <italic>otrB</italic>, which encode proteins responsible for host resistance, are found at the flanking regions of the actual gene cluster. Based on sequence similarity, OtrA shows homology to TetM and is believed to provide resistance to <italic>S. rimosus</italic> by binding the ribosome and competing with the produced oxytetracycline. OtrB encodes a membrane protein and ensures the efflux of oxytetracycline from the cell [<xref rid="B269-antibiotics-08-00157" ref-type="bibr">269</xref>,<xref rid="B271-antibiotics-08-00157" ref-type="bibr">271</xref>]. The genes for the regulators OtcG and OtcR are also present in the flanking regions of the oxytetracycline BGC in <italic>S. rimosus</italic> [<xref rid="B269-antibiotics-08-00157" ref-type="bibr">269</xref>,<xref rid="B272-antibiotics-08-00157" ref-type="bibr">272</xref>,<xref rid="B273-antibiotics-08-00157" ref-type="bibr">273</xref>]. OtcG, is a LuxR family transcriptional activator which was shown to provide positive regulation of oxytetracycline biosynthesis since an inactivation of <italic>otcG</italic> resulted in a mutant strain producing 40% less oxytetracycline than the wild type strain <italic>S. rimosus</italic> [<xref rid="B272-antibiotics-08-00157" ref-type="bibr">272</xref>]. The overexpression of <italic>otcG</italic> did not yield a significant increase in production of oxytetracycline. OtcR was assigned to a <italic>Streptomyces</italic> antibiotic regulatory protein (SARP) activator of the oxytetracycline in <italic>S. rimosus</italic> [<xref rid="B273-antibiotics-08-00157" ref-type="bibr">273</xref>]. Since a deletion of <italic>otcR</italic> completely abolished oxytetracycline production in the producer strain, the authors tested whether its overexpression would result in increased yields of the antibiotic. Indeed, the introduction two additional copies of <italic>otcR</italic>, under the control of a SF14 promoter, in <italic>S. rimosus</italic> increased the yields of oxytetracycline to 6.24 g/L (6.49 times higher than the yields of the parental strain) [<xref rid="B273-antibiotics-08-00157" ref-type="bibr">273</xref>].</p><p>Tetracyclines are broad-spectrum antibiotics with activities against a range of microorganisms, including Gram-positive and Gram-negative bacteria, chlamydiae, mycoplasmas, and protozoan parasites [<xref rid="B123-antibiotics-08-00157" ref-type="bibr">123</xref>]. They act as bacteriostatic drugs by binding to the 30S subunit of the prokaryote ribosome in a reversible fashion whereby protein synthesis is inhibited [<xref rid="B132-antibiotics-08-00157" ref-type="bibr">132</xref>]. Furthermore, crystal structures of tetracycline in complex with both, the 30S subunit and 70S ribosome of <italic>Thermus thermophiles</italic>, have expanded the knowledge of the MOA of tetracyclines [<xref rid="B124-antibiotics-08-00157" ref-type="bibr">124</xref>,<xref rid="B274-antibiotics-08-00157" ref-type="bibr">274</xref>]. Based on the first X-ray structure of Brodersen et al., the primary binding site of tetracycline (Tet1) was found to be located between the head and shoulder of the 30S subunit, just above the transfer RNA (tRNA) binding site. When binding the A site, tetracycline act as a physical barrier for aminoacyl-tRNA so that the peptide chain cannot be elongated and protein synthesis is stalled [<xref rid="B123-antibiotics-08-00157" ref-type="bibr">123</xref>,<xref rid="B274-antibiotics-08-00157" ref-type="bibr">274</xref>]. Furthermore, the oxidised hydrophilic part of the tetracyclines appear to provide the main chemical interactions with the 16S ribosomal RNA (rRNA) and therefore, they are most important for the binding [<xref rid="B275-antibiotics-08-00157" ref-type="bibr">275</xref>]. Another interesting property of the tetracyclines is their ability to chelate ions (Mg<sup>2+</sup>). In addition to the hydrogen bond interactions between the hydrophilic side of tetracycline and the nucleotides on the 16s rRNA, the Mg<sup>2+</sup> ions, coordinated by ring A of tetracycline, seem to further strengthen the binding to the ribosome [<xref rid="B274-antibiotics-08-00157" ref-type="bibr">274</xref>]. The ion chelating properties of tetracyclines also explain their broad spectrum, including activity against Gram-negatives. In order to enter the periplasm of Gram-negatives, tetracycline forms a complex with Mg<sup>2+</sup> allowing the antibiotic to pass through the porins of the outer membrane. To diffuse through the cytoplasmic membrane, tetracycline dissociates from Mg<sup>2+</sup> enabling its passage through to the cytosol. The chelating complex is restored inside the cytosol [<xref rid="B132-antibiotics-08-00157" ref-type="bibr">132</xref>].</p><p>The emergence of tetracycline resistance in clinical isolates has led to many studies to clarify the driving forces behind it. To date, four mechanisms by which bacteria acquire resistance to tetracyclines have been identified. These include active efflux of the antibiotic, ribosomal protection proteins, antibiotic modification, and alteration of the antibiotic target site, i.e., the ribosome. More information on the basis behind these individual resistance mechanisms can be found elsewhere [<xref rid="B123-antibiotics-08-00157" ref-type="bibr">123</xref>,<xref rid="B127-antibiotics-08-00157" ref-type="bibr">127</xref>,<xref rid="B132-antibiotics-08-00157" ref-type="bibr">132</xref>].</p><p>The discovery of the naturally derived tetracyclines immediately triggered studies on improving the overall performance of the antibiotics. This resulted in the so-called 2nd generation tetracyclines, two of which, doxycycline and minocycline (<xref ref-type="fig" rid="antibiotics-08-00157-f007">Figure 7</xref>), were marketed in 1967 and 1972, respectively [<xref rid="B123-antibiotics-08-00157" ref-type="bibr">123</xref>]. The discovery of doxycycline was based on the structural observations that the C6 hydroxyl group of tetracyclines greatly impact the stability of the molecules while antibacterial properties are not affected [<xref rid="B128-antibiotics-08-00157" ref-type="bibr">128</xref>]. Consequently, derivatisation at this site of the molecule was conducted. The first attempt to alter the functional group at the C6 position in oxytetracycline gave rise to 6-methylene-5-hydroxytetracycline (methacycline), which was further modified to 6-deoxy-5-hydroxytetracycline, later named doxycycline (trade name: Vibramycin, <xref rid="antibiotics-08-00157-t001" ref-type="table">Table 1</xref>). On the other hand, minocycline was the result of studies on biogenesis mutants of <italic>S. aureofaciens</italic>, the producer of chlortetracycline [<xref rid="B129-antibiotics-08-00157" ref-type="bibr">129</xref>]. Here, scientists working at the former Lederle Laboratories succeeded in isolating the precursor C6-demethyl-C7-chlorotetracycline (demeclocycline), which gave rise to the C6-demethyl-C6-deoxytetracycline (sancycline) precursor, that ultimately was converted to the final substance 7-dimethylamino-6-demethyl-6-deoxytetracycline (minocycline, trade name: Minocin, <xref rid="antibiotics-08-00157-t001" ref-type="table">Table 1</xref>) [<xref rid="B130-antibiotics-08-00157" ref-type="bibr">130</xref>,<xref rid="B131-antibiotics-08-00157" ref-type="bibr">131</xref>]. Both doxycycline and minocycline are lipophilic molecules, which allow for oral absorption and thereby extend their applicability in the human therapy. Furthermore, they display improved antibacterial activities compared to tetracycline, including potent activities against Gram-negative bacteria such as <italic>E. coli</italic> and <italic>Pseudomonas aeruginosa</italic> and against the Gram-positive bacteria <italic>S. aureus</italic> and <italic>E. faecalis</italic> [<xref rid="B127-antibiotics-08-00157" ref-type="bibr">127</xref>]. The importance of their introduction in human therapy was further strengthened by their activities against tetracycline-resistant isolates.</p><p>To ensure the continuous potential of the tetracyclines, a second round of derivatisation efforts, aiming at discovering novel tetracycline analogues with activities against both susceptible and tetracycline-resistant isolates, was initiated in the 1990s [<xref rid="B123-antibiotics-08-00157" ref-type="bibr">123</xref>]. These efforts gave rise to the so-called glycylcyclines, also referred to as the 3rd generation tetracyclines, including tigecycline, omadacycline, and sarecycline (<xref ref-type="fig" rid="antibiotics-08-00157-f007">Figure 7</xref>) [<xref rid="B127-antibiotics-08-00157" ref-type="bibr">127</xref>,<xref rid="B133-antibiotics-08-00157" ref-type="bibr">133</xref>]. Tigecycline (trade name: Tygacil) was the first of the 3rd generation tetracyclines and was the result of the derivatisation of minocycline (<xref rid="antibiotics-08-00157-t001" ref-type="table">Table 1</xref>) [<xref rid="B134-antibiotics-08-00157" ref-type="bibr">134</xref>]. Compared to its precursor, tigecycline contains a <italic>N</italic>-alkyl-glycylamido group at position C9 in ring D. This structural modification resulted in a ~10&#x02013;100-fold improved binding of tigecycline to the ribosome when compared to tetracycline [<xref rid="B127-antibiotics-08-00157" ref-type="bibr">127</xref>,<xref rid="B134-antibiotics-08-00157" ref-type="bibr">134</xref>]. Based on the crystal structure of <italic>T. thermophilus</italic> 70S ribosome bound to tigecycline, it has been shown that while the derivative binds the 30S subunit in the same manner as tetracycline, the interaction of tigecycline with the ribosome is greatly improved based on its additional <italic>tert</italic>-butylglycylamido group [<xref rid="B274-antibiotics-08-00157" ref-type="bibr">274</xref>]. In cell-free translation assays tigecycline was capable of retaining its binding to the ribosome in the presence of the two resistance determinants TetM and TetO, confirming the activity of the derivative against tetracycline-resistant clinical isolates, which had acquired resistance based on ribosome protection proteins [<xref rid="B135-antibiotics-08-00157" ref-type="bibr">135</xref>]. Tigecycline was approved by the US FDA in 2005 [<xref rid="B132-antibiotics-08-00157" ref-type="bibr">132</xref>]. The current major limitation of tigecycline is its poor oral bioavailability and consequently the antibiotic is administered intravenously, giving rise to nausea and vomiting in the majority of patients [<xref rid="B276-antibiotics-08-00157" ref-type="bibr">276</xref>].</p><p>Three additional 3rd generation tetracycline analogues have been approved by the US FDA for various applications in human therapy. Two of these, omadacycline (trade name: Nuzyra) and eravacycline (trade name: Xerava), bear a C9 substitution on ring D and have been licensed as broad-spectrum antibiotics, while the third, sarecycline (trade name: Seysara), was developed specifically as a narrow-spectrum tetracycline antibiotic for treatment of acne (<xref rid="antibiotics-08-00157-t001" ref-type="table">Table 1</xref>). Omadacycline is an aminomethylcycline derivative of minocycline, which was isolated based on its superior activity against tetracycline-susceptible and -resistant bacteria, lack of toxicity, and the oral bioavailability [<xref rid="B136-antibiotics-08-00157" ref-type="bibr">136</xref>,<xref rid="B137-antibiotics-08-00157" ref-type="bibr">137</xref>,<xref rid="B264-antibiotics-08-00157" ref-type="bibr">264</xref>]. Additionally, omadacycline shows improved activity against Gram-positive isolates compared to tigecycline and superior activity against Gram-negatives compared to eravacycline. This improved activity is believed to be a consequence of the C7 dimethylamino group and the C9 aminomethyl moiety in ring D of the molecule, since these modifications allow the antibiotic to evade the most common resistant determinants of efflux and ribosome protection [<xref rid="B276-antibiotics-08-00157" ref-type="bibr">276</xref>]. The antibiotic was approved by the US FDA in October 2018 for the treatment of acute bacterial skin/skin structure infections, caused by a variety of bacteria, including methicillin-susceptible and -resistant strains of <italic>S. aureus</italic>, and for treatment of CABP, caused by <italic>S. pneumonia</italic> and methicillin-susceptible <italic>S. aureus</italic> [<xref rid="B138-antibiotics-08-00157" ref-type="bibr">138</xref>]. Furthermore, omadacycline is currently undergoing safety and efficacy studies for its use in treatment of uncomplicated urinary tract infections. Eravacycline, developed at Tetraphase Pharmaceuticals, Inc., varies from the other clinical available 3rd generation tetracycline analogues with its fluorine atom at the C7 position and a pyrrolidinoacetamido group on the C9 of ring D (<xref ref-type="fig" rid="antibiotics-08-00157-f007">Figure 7</xref>) [<xref rid="B139-antibiotics-08-00157" ref-type="bibr">139</xref>,<xref rid="B140-antibiotics-08-00157" ref-type="bibr">140</xref>]. It displays activity against both Gram-positives and Gram-negatives and has been approved by the US FDA for treatment of infections caused by multidrug-resistant microorganisms, including carbapenem-resistant <italic>Enterobacteriaceae</italic>, MRSA, VREs, and extended spectrum &#x003b2;-lactamase (ESBL)-producing <italic>Enterobacteriaceae</italic> [<xref rid="B141-antibiotics-08-00157" ref-type="bibr">141</xref>]. Following the same logic as for tigecycline and omadacycline, the altered functional groups on this fully synthetic tetracycline derivative was designed to evade tetracycline resistance determinants, which is evident from the retained activity of eravacycline against TetM-protected <italic>E. coli</italic> cells tested in an in vitro transcription/translation assay [<xref rid="B140-antibiotics-08-00157" ref-type="bibr">140</xref>]. An additional fully synthetic tetracycline derivative, named TP-271 (<xref rid="antibiotics-08-00157-t001" ref-type="table">Table 1</xref>), is currently being investigated by Tetraphase Pharmaceuticals, Inc. for its activity against pathogens causing CABP, anthrax, tularemia, and bubonic plague [<xref rid="B143-antibiotics-08-00157" ref-type="bibr">143</xref>,<xref rid="B144-antibiotics-08-00157" ref-type="bibr">144</xref>]. Similar to eravacycline, TP-271 is TetM-insensitive and can be used as an agent for bacterial isolates with this type of acquired resistance [<xref rid="B143-antibiotics-08-00157" ref-type="bibr">143</xref>]. According to the pipeline of Tetraphase Pharmaceuticals, TP-271 is currently in phase I clinical testing [<xref rid="B145-antibiotics-08-00157" ref-type="bibr">145</xref>]. The latest 3rd generation tetracycline to be approved by the US FDA, is the sarecycline, an aminomethylcycline with the unique and stable methoxy(methyl)aminomethyl modification at position C7 in ring D. Unlike the other tetracyclines, sarecycline has been approved as a narrow-spectrum antibacterial agent for the treatment of moderate to severe acne vulgaris caused by <italic>Cutibacterium acnes</italic> (formerly <italic>Propionibacterium acnes</italic>). Sarecycline was developed to meet the need for a safe treatment regime against acnes vulgaris, while simultaneously limiting resistance development of <italic>C. acnes</italic> [<xref rid="B142-antibiotics-08-00157" ref-type="bibr">142</xref>].</p></sec><sec id="sec3dot7-antibiotics-08-00157"><title>3.7. Streptogramins</title><p>The group of streptogramins is an important class of antibiotics given their chemical complexity and potent antibacterial activity. They are composed of a mixture of two chemically unrelated substances, known as type A and type B streptrogramins, which are produced by the same host in a 70:30 ratio, respectively [<xref rid="B277-antibiotics-08-00157" ref-type="bibr">277</xref>,<xref rid="B278-antibiotics-08-00157" ref-type="bibr">278</xref>]. Streptogramin A and B, produced by <italic>Streptomyces graminofaciens</italic>, were the first in the group of streptogramin antibiotics to be discovered and provided the name for the substance class [<xref rid="B279-antibiotics-08-00157" ref-type="bibr">279</xref>]. Following their discovery in 1953, several additional streptogramins were identified, some of which include mikamycin from <italic>Streptomyces mitakaensis</italic> [<xref rid="B280-antibiotics-08-00157" ref-type="bibr">280</xref>,<xref rid="B281-antibiotics-08-00157" ref-type="bibr">281</xref>], griseoviridin and viridogrisein from <italic>Streptomyces griseoviridis</italic> [<xref rid="B282-antibiotics-08-00157" ref-type="bibr">282</xref>], as well as virginiamycin from <italic>Streptomyces virginiae</italic> [<xref rid="B283-antibiotics-08-00157" ref-type="bibr">283</xref>]. Out of these substances, virginiamycin has had significant impact on veterinary medicine. Since its discovery, virginiamycin (trade names: Staphylomycin and Stafac) has been used all over the world in animal production as a disease control agent and feed additive for swine, poultry, and cattle. However, due to scientific concerns of resistance transmission between animals and humans, the use of drugs containing virginiamycin as a feed additive in Europe has been forbidden since 1999 [<xref rid="B284-antibiotics-08-00157" ref-type="bibr">284</xref>]. Pristinamycin (<xref ref-type="fig" rid="antibiotics-08-00157-f008">Figure 8</xref>) is a close structural relative to virginiamycin. The antibiotic was first isolated from <italic>Streptomyces pristinaespiralis</italic>, which produces the two substances pristinamycin II<sub>A</sub> and pristinamycin I<sub>A</sub> in the ratio 70:30 [<xref rid="B146-antibiotics-08-00157" ref-type="bibr">146</xref>,<xref rid="B147-antibiotics-08-00157" ref-type="bibr">147</xref>]. Within the group of streptogramins, the two natural substances virginiamycin and pristinamycin and the semi-synthetic quinupristin&#x02013;dalfopristin substance mixture (trade name: Synercid) (<xref ref-type="fig" rid="antibiotics-08-00157-f008">Figure 8</xref>, <xref rid="antibiotics-08-00157-t001" ref-type="table">Table 1</xref>) have been subject to the most studies and will be the focus of this section. Since virginiamycin and pristinamycin share a common biosynthetic logic (<xref ref-type="app" rid="app1-antibiotics-08-00157">Figure S7</xref>), only pristinamycin with its significant role in human medicine will be described.</p><p>The biosynthetic gene cluster of pristinamycin remains one of the largest bacterial antibiotic clusters identified, covering a DNA region of 210 kb [<xref rid="B148-antibiotics-08-00157" ref-type="bibr">148</xref>]. Within this region, 45 genes, covering a 120 kb region, are involved in the biosynthesis, regulation, and resistance of pristinamycin. Pristinamycin II is synthesised by a hybrid PKS/NRPS complex responsible for the assembly of the starter unit isobutyryl-CoA with six malonyl-CoA extender units and the amino acids glycine, serine, and proline (<xref ref-type="app" rid="app1-antibiotics-08-00157">Figure S7</xref>). The assembly starts at SnaE1, which ensures the successful loading of isobuturyl-CoA followed by its extension with two malonyl-CoA and glycine. The following four modules in SnaE2 and SnaE3 attach additional four malonyl-CoA extender units to the growing chain. In between the genes for the two megaenzymes SnaE2 and SnaE3, <italic>snaG</italic> through <italic>snaL</italic> are located. Together their respective enzymes are believed to be responsible for the C12 methyl group in pristinamycin II [<xref rid="B148-antibiotics-08-00157" ref-type="bibr">148</xref>]. Downstream of <italic>snaL</italic>, the gene for the hybrid PKS/NRPS SnaE4 is located that is responsible for attachment of serine before transferring the precursor chain to the final module. The last NRPS module of SnaD, including the TE domain is responsible for the attachment of proline to the polyketide-hybrid chain and the release and cyclisation of the precursor chain. An interesting feature of the PKS is its lack of AT domains. Sequence analysis of the BGC and phylogenetic analysis of discrete ATs suggested that similar to the <italic>trans</italic>-AT KirCI, which is involved in kirromycin biosynthesis [<xref rid="B285-antibiotics-08-00157" ref-type="bibr">285</xref>], SnaM also groups in the clade of discrete ATs of <italic>trans</italic>-AT-PKSs [<xref rid="B148-antibiotics-08-00157" ref-type="bibr">148</xref>,<xref rid="B286-antibiotics-08-00157" ref-type="bibr">286</xref>]. This indicates that SnaM might be responsible for an <italic>in trans</italic> loading of malonate units to assemble the pristinamycin II polyketide chain.</p><p>Pristinamycin I is synthesised from the NRPS encoded by genes <italic>snbA</italic>, <italic>snbC</italic>, and <italic>snbDE</italic>, which ensures the successful condensation of the four non-proteinogenic amino acids 3-hydroxypicolinic acid, <sc>l</sc>-aminobutyric acid, 4-<italic>N</italic>, <italic>N</italic>-dimethylamino-<italic>N</italic>-methyl-<sc>l</sc>-phenylalanine (DMAPA), 4-oxo-<sc>l</sc>-pipecolic acid, <sc>l</sc>-phenylglycine, and the two proteinogenic amino acids <sc>l</sc>-threonine and <sc>l</sc>-proline (<xref ref-type="app" rid="app1-antibiotics-08-00157">Figure S7</xref>). Through the actions of the TE domain in the C-terminal of SnbDE, the precursor is released from the NRPS and cyclised. Additionally, 12 genes are involved in pristinamycin I biosynthesis through their synthesis of the amino acid precursors. This includes <italic>hpaA</italic> for 3-hydroxypicolinic acid, <italic>pipA</italic> and <italic>snbF</italic> for 4-oxo-<sc>l</sc>-pipecolic acid, and <italic>papA/B/C/M</italic> for DMAPA biosynthesis. For the non-proteinogenic amino acids, sequence analyses identified <italic>pglA</italic> through <italic>pglE</italic> to be involved in their biosynthesis [<xref rid="B148-antibiotics-08-00157" ref-type="bibr">148</xref>]. Furthermore, within the 210 kb DNA region, several genes encoding regulatory elements have been identified [<xref rid="B287-antibiotics-08-00157" ref-type="bibr">287</xref>,<xref rid="B288-antibiotics-08-00157" ref-type="bibr">288</xref>]. Knowledge of the complex regulatory network behind pristinamycin I and II biosynthesis have fed metabolic engineering approaches in order to improve yields in the natural host [<xref rid="B289-antibiotics-08-00157" ref-type="bibr">289</xref>,<xref rid="B290-antibiotics-08-00157" ref-type="bibr">290</xref>]. In the study of Li and co-workers, the team systematically manipulated the cluster-situated genes <italic>spbR</italic> and <italic>papR1</italic> through <italic>papR6</italic> and found the best production enhancement of pristinamycin II<sub>A</sub> when deleting either <italic>papR3</italic> or <italic>papR5</italic> and overexpressing both <italic>papR4</italic> and <italic>papR6</italic>. Surprisingly, strains overexpressing the major SARP activator PapR2 resulted in lowered pristinamycin production which could indicate a maximum threshold concentration of pristinamycin II<sub>A</sub> in <italic>S. pristinaespiralis</italic> [<xref rid="B290-antibiotics-08-00157" ref-type="bibr">290</xref>].</p><p>When applied separately as therapeutics, the type A and B streptogramins only provide a bacteriostatic effect. In combination, the two antibiotics act in a synergetic manner leading to a bactericidal activity against susceptible pathogens. Streptogramin antibiotics are active against a range of Gram-positive bacteria, including the severely resistant pathogens MRSA, vancomycin-resistant <italic>S. aureus</italic> (VRSA), <italic>E. faecium</italic> strains, and drug-resistant <italic>S. pneumonia</italic>. Activity against Gram-negative bacteria is mostly restricted to pathogens causing upper respiratory tract infection, including <italic>H. influenza</italic>, <italic>Haemophilus parainfluenzae</italic>, <italic>M. pneumonia</italic>, and <italic>Moraxella catarrhalis</italic> [<xref rid="B150-antibiotics-08-00157" ref-type="bibr">150</xref>,<xref rid="B277-antibiotics-08-00157" ref-type="bibr">277</xref>,<xref rid="B278-antibiotics-08-00157" ref-type="bibr">278</xref>]. The synergistic activity of the type A and B streptogramins can be explained from the unique MOA, in that both antibiotics bind to the prokaryotic 50S ribosomal subunit however, at separate sites. The type A substances inhibit the early phase of protein elongation through their binding to the A and P sites on the 23S rRNA, thereby preventing the attachment of tRNA at each site [<xref rid="B149-antibiotics-08-00157" ref-type="bibr">149</xref>,<xref rid="B278-antibiotics-08-00157" ref-type="bibr">278</xref>]. Type B streptogramins also bind to the P site on the ribosome however, inhibit the late stage of polypeptide chain elongation by binding the exit tunnel of the ribosome. As a result, elongation of the nascent polypeptide chain is prevented and incomplete peptide chains are released from the complex. While the MOA of type B streptogramins is similar to that of erythromycin and related macrolides, the MOA for the type A streptogramins is similar to that of chloramphenicol. Furthermore, it has been shown that the binding of group A streptogramins to the P site leads to conformational changes in the subunit, which increases the affinity to the ribosome of the type B streptogramins. Even upon dissociation of the type A substances from the ribosome, the increase of ribosome affinity for type B streptogramins remains, explaining the synergetic effect of the mixture [<xref rid="B291-antibiotics-08-00157" ref-type="bibr">291</xref>]. Recently, the crystal structure of the 50S ribosomal subunit from <italic>Deinococcus radiodurans</italic> in complex with Synercid (quinupristin/dalfopristin, <xref ref-type="fig" rid="antibiotics-08-00157-f008">Figure 8</xref>) has expanded our knowledge on the binding of streptogramins antibiotics to the ribosome [<xref rid="B151-antibiotics-08-00157" ref-type="bibr">151</xref>]. Firstly, the two streptogramins share direct contact with a single nucleotide A2062 (<italic>E. coli</italic> numbering) through hydrophobic interactions and hydrogen bonds. This leads to conformational changes at A2062 whereby the binding of both antibiotics is strengthened. Secondly, an additional conformational change occurs when dalfopristin (type A) binds to the peptidyl transferase center (PTC) in that the universally conserved nucleotide U2585 is rotated to point away from the tunnel of the PTC. The altered conformation of U2585 in the PTC is stabilised by hydrogen bonds and might explain the post-antibiotic effect of streptogramin A antibiotics, in which protein synthesis is still inhibited after treatment with the antibiotic has been terminated [<xref rid="B151-antibiotics-08-00157" ref-type="bibr">151</xref>].</p><p>To date, several resistance mechanisms against streptogramin antibiotics have been proposed. Some of these include target modification, drug inactivation, drug efflux, and impermeability [<xref rid="B278-antibiotics-08-00157" ref-type="bibr">278</xref>,<xref rid="B292-antibiotics-08-00157" ref-type="bibr">292</xref>]. Excellent reviews exist detailing the mode of drug resistance [<xref rid="B292-antibiotics-08-00157" ref-type="bibr">292</xref>,<xref rid="B293-antibiotics-08-00157" ref-type="bibr">293</xref>,<xref rid="B294-antibiotics-08-00157" ref-type="bibr">294</xref>]. Briefly, a common resistance mechanism developed towards macrolide antibiotics is ribosomal target modification. This antibiotic resistance is encoded by the erythromycin-resistance methylase (<italic>erm</italic>) genes, which can mono- or dimethylate an adenosine residue of the 23S rRNA of the ribosomal 50S subunit [<xref rid="B295-antibiotics-08-00157" ref-type="bibr">295</xref>]. Methylation changes the conformation of the ribosome and collectively causes resistance towards antibiotics of the MLS<sub>B</sub> group. Additionally, the pathogen can develop resistance by drug inactivation through acetyltransferases (targets type A) and hydrolases (targets type B) or by drug efflux, encoded by genes such as <italic>msrA</italic>/<italic>B</italic>, <italic>mefA</italic>, <italic>lsa</italic>, and <italic>vga</italic> [<xref rid="B294-antibiotics-08-00157" ref-type="bibr">294</xref>,<xref rid="B296-antibiotics-08-00157" ref-type="bibr">296</xref>,<xref rid="B297-antibiotics-08-00157" ref-type="bibr">297</xref>]. Resistance against streptogramins depends on the substance type. Type B streptogramins, which shares properties with erythromycin, are classified as MLS<sub>B</sub> antibiotics, which suffer from cross-resistance between each other. Type A streptogramins instead show cross-resistance with lincosamides and pleuromutilins and group in the lincosamide&#x02013;streptogramin A&#x02013;pleuromutilin (LS<sub>A</sub>P) antibiotics. Since bacterial isolates with lowered susceptibility towards the synergetic mixture have already been isolated, it is evident that caution should be taken when administering these drugs. In order to reduce the risk of resistance towards this important class of compounds, streptogramins are classified as drugs of last resort [<xref rid="B278-antibiotics-08-00157" ref-type="bibr">278</xref>].</p><p>Due to its hydrophobic nature, pristinamycin (<xref rid="antibiotics-08-00157-t001" ref-type="table">Table 1</xref>) is administered orally, which limits its use in paediatrics and intensive care [<xref rid="B152-antibiotics-08-00157" ref-type="bibr">152</xref>,<xref rid="B278-antibiotics-08-00157" ref-type="bibr">278</xref>]. To solve the issue of bioavailability, medicinal chemists employed by the French chemical and pharmaceutical company Rh&#x000f4;ne-Poulenc Rorer worked on synthesising novel pristinamycin derivatives with improved water solubility. Their attempts proved successful and in 1999 the US FDA approved the antibiotic Synercid (<xref rid="antibiotics-08-00157-t001" ref-type="table">Table 1</xref>), which is a 70:30 mixture of the two semi-synthetic derivatives dalfopristin (type A) and quinupristin (type B), for treatment of bacteraemia caused by VRE and skin/skin structure infections caused by methicillin-susceptible <italic>S. aureus</italic> and <italic>S. pyogenes</italic> [<xref rid="B152-antibiotics-08-00157" ref-type="bibr">152</xref>,<xref rid="B153-antibiotics-08-00157" ref-type="bibr">153</xref>,<xref rid="B278-antibiotics-08-00157" ref-type="bibr">278</xref>]. Information on the synthesis of dalfopristin and quinupristin (<xref ref-type="fig" rid="antibiotics-08-00157-f008">Figure 8</xref>) remain scarce. From the published structures, it is known that quinupristin is the result of derivatisation of pristinamycin I<sub>A</sub> at position five of the 4-oxo pipicolic acid residue and that dalfopristin is generated based on the substitution of pristinamycin II<sub>A</sub> with a 2-diethylaminoethane thiol [<xref rid="B292-antibiotics-08-00157" ref-type="bibr">292</xref>].</p><p>Synercid suffers from its own limitations, including a high treatment price and the risk of infusion site thrombosis in addition to myalgias and arthralgias [<xref rid="B154-antibiotics-08-00157" ref-type="bibr">154</xref>]. A more recent example of a semi-synthetic pristinamycin derivative is NXL-103 (<xref rid="antibiotics-08-00157-t001" ref-type="table">Table 1</xref>), which is a 70:30 mixture of flopristin (type A) and linopristin (type B) [<xref rid="B154-antibiotics-08-00157" ref-type="bibr">154</xref>,<xref rid="B155-antibiotics-08-00157" ref-type="bibr">155</xref>]. As opposed to Synercid, NXL-103 is administered orally thereby avoiding the complication associated with intravenous therapy. Additionally, NXL-103 has been shown to possess an improved activity against multiple Gram-positive isolates when compared to Synercid [<xref rid="B155-antibiotics-08-00157" ref-type="bibr">155</xref>]. With its expanded activity against clinical Gram-positive isolates such as MRSA, methicillin-resistant <italic>Staphylococcus epidermidis</italic>, and VRE, NXL-103 could provide an additional treatment option to the current drugs on the market. However, since the report of phase II clinical trials in 2010, to the best of our knowledge, no new information on NXL-103 exists and the drug made no progress towards its introduction into the market [<xref rid="B154-antibiotics-08-00157" ref-type="bibr">154</xref>].</p></sec></sec><sec id="sec4-antibiotics-08-00157"><title>4. Other Clinically Relevant Polyketide-Derived Antimicrobials</title><sec id="sec4dot1-antibiotics-08-00157"><title>4.1. Nystatin A1</title><p>The antifungal polyene macrolides are characterised by a large macrolactone ring containing 20 to 40 carbon atoms connected by a series of conjugated double bonds, an exocyclic carboxyl group, and a mycosamine sugar. Several compounds belonging to this group have been studied in detail, including candicidin, nystatin, amphotericin, and pimaricin (also referred to as natamycin) [<xref rid="B298-antibiotics-08-00157" ref-type="bibr">298</xref>,<xref rid="B299-antibiotics-08-00157" ref-type="bibr">299</xref>] (<xref ref-type="fig" rid="antibiotics-08-00157-f009">Figure 9</xref>). In this review, we focus on nystatin A1, amphotericin B, and pimaricin/natamycin, since these are the drugs still used in the clinic.</p><p>The first polyene macrolide was discovered in 1950 by E.L. Hazen and R.F. Brown from the New York State Department of Health and was the initially named fungicidin [<xref rid="B156-antibiotics-08-00157" ref-type="bibr">156</xref>,<xref rid="B300-antibiotics-08-00157" ref-type="bibr">300</xref>]. The compound was discovered from <italic>Streptomyces</italic> No. 48240 isolated from a soil sample collected at a farm owned by H. Nourse. Later, the strain was renamed <italic>S. noursei</italic> and the compound name changed from fungicidin to nystatin [<xref rid="B157-antibiotics-08-00157" ref-type="bibr">157</xref>]. With the advances in analytical separation techniques it became evident that nystatin was a mixture of three components, namely nystatin A1, A2, and A3. Nystatin A1 was the major component in the fermentation mixture [<xref rid="B301-antibiotics-08-00157" ref-type="bibr">301</xref>]. So far, <italic>S. noursei</italic> remains the commercial strain for production of nystatin, however, other strains, including <italic>Streptomyces fungicidicus</italic> ATCC 27,432 [<xref rid="B302-antibiotics-08-00157" ref-type="bibr">302</xref>] and <italic>Streptomyces albulus</italic> ATCC 12,757 [<xref rid="B303-antibiotics-08-00157" ref-type="bibr">303</xref>], have also been identified as nystatin producers.</p><p>Nystatin A1 (brand names: Mycostatin and Nystop) (<xref rid="antibiotics-08-00157-t001" ref-type="table">Table 1</xref>) is composed of a 38-membered macrolactone ring which includes sets of two and four conjugated double bonds separated by one saturated bond (<xref ref-type="fig" rid="antibiotics-08-00157-f009">Figure 9</xref>). Similar to other polyene macrolides, nystatin contains a mycosamine sugar attached to the aglycone ring in addition to an exocyclic carboxyl group (<xref ref-type="fig" rid="antibiotics-08-00157-f009">Figure 9</xref>) [<xref rid="B299-antibiotics-08-00157" ref-type="bibr">299</xref>,<xref rid="B304-antibiotics-08-00157" ref-type="bibr">304</xref>].</p><p>The aglycone macrolide of nystatin (<xref ref-type="fig" rid="antibiotics-08-00157-f009">Figure 9</xref>) is assembled from one acetyl-CoA starter unit and further extended through condensation with three methylmalonyl-CoA and 15 malonyl-CoA extender units (<xref ref-type="app" rid="app1-antibiotics-08-00157">Figure S8</xref>). The assembly of the nystatin precursor is governed by a type I PKS, composed of a total of one loading and 18 extender modules, which are all encoded in the six genes <italic>nysA, nysB, nysC, nysI, nysJ</italic>, and <italic>nysK</italic> [<xref rid="B158-antibiotics-08-00157" ref-type="bibr">158</xref>]. The TE domain found at the C-terminal of module 18 in NysK is responsible for chain termination and cyclisation, forming the aglycone precursor of nystatin. Immediately downstream of <italic>nysC</italic>, the gene <italic>nysE</italic> is located. NysE displays protein similarity to TEs found in <italic>Streptomyces venezuelae</italic> and <italic>Streptomyces fradiae</italic>, however, the role of the enzyme has not been experimentally verified. It is postulated that this additional TE enzyme, like in the case of erythromycin and tylosin biosynthesis, acts as a &#x0201c;proof-reading&#x0201d; enzyme to avoid stalling at the PKS. Additional genes found in the nystatin gene cluster include the two P450 monooxygenases, encoded by <italic>nysL</italic> and <italic>nysN</italic>, which are responsible for the C10 hydroxylation and C16 methyl group oxidation, respectively. The role of NysN has been confirmed based on genetic inactivation. The &#x00394;<italic>nysN</italic> mutant lost the ability to produce nystatin A1, and instead the analogue 16-decarboxy-16-methyl nystatin was isolated from the culture broth [<xref rid="B160-antibiotics-08-00157" ref-type="bibr">160</xref>].</p><p>The biosynthesis and transfer of the mycosamine sugar to the aglycone of nystatin are carried out by three enzymes encoded by <italic>nysDI</italic>, <italic>nysDII</italic>, and <italic>nysDIII</italic> [<xref rid="B158-antibiotics-08-00157" ref-type="bibr">158</xref>]. Specifically, the biosynthesis of the sugar is believed to be facilitated by the aminotransferase NysDII and the guanosine diphosphate (GDP)-mannose-4,6-dehydratase NysDIII, while the attachment of mycosamine at C19 of the nystatin aglycone is thought to be catalysed by the glycosyltransferase NysDI. Furthermore, it has been postulated that mycosamine is synthesised from a GDP-mannose instead of deoxythymidine diphosphate (dTDP)-glucose [<xref rid="B298-antibiotics-08-00157" ref-type="bibr">298</xref>].</p><p>Two ATP-binding cassette (ABC) transporter-encoding genes <italic>nysG</italic> and <italic>nysH</italic> are located at the border of the nystatin gene cluster [<xref rid="B305-antibiotics-08-00157" ref-type="bibr">305</xref>]. Since mutants in either of the two genes displayed similar phenotypes, NysG&#x02013;NysH is thought to be part of the same transporter. Furthermore, four genes <italic>nysRI</italic> through <italic>nysRIV</italic> encoding regulator proteins have been identified and their role clarified in the nystatin gene cluster [<xref rid="B299-antibiotics-08-00157" ref-type="bibr">299</xref>,<xref rid="B306-antibiotics-08-00157" ref-type="bibr">306</xref>]. NysRIV is most likely directly controlling the expression of nystatin biosynthesis genes. More information on the regulation governing nystatin biosynthesis in <italic>S. noursei</italic> can be found elsewhere [<xref rid="B299-antibiotics-08-00157" ref-type="bibr">299</xref>,<xref rid="B306-antibiotics-08-00157" ref-type="bibr">306</xref>].</p><p>Nystatin A1 is primarily used as a topical agent e.g., in treatment of mucous membrane candidiasis caused by members of the yeast-like family <italic>Candida</italic> [<xref rid="B307-antibiotics-08-00157" ref-type="bibr">307</xref>]. As it is the case for most polyenes, nystatin has a low water solubility and shows detectable toxicity, which restricts its application in human therapy. The explanation for the toxicity is found in the MOA shared among the polyenes. In general, the MOA of polyenes is based on their interaction with sterols in eukaryotic cell membranes, resulting in pores and increase membrane permeability for ions and small molecules, which is usually lethal for the cell [<xref rid="B159-antibiotics-08-00157" ref-type="bibr">159</xref>]. Although nystatin displays a higher selectivity toward the ergosterol found in fungal cell membranes, it can also interact with the cholesterol of mammalian cells membranes, which is limiting its use for human therapy. Taken together, due to its undesired toxicity, low solubility, and lower antifungal potency than that of amphotericin B, the application of nystatin as human medicine remains restricted [<xref rid="B160-antibiotics-08-00157" ref-type="bibr">160</xref>,<xref rid="B308-antibiotics-08-00157" ref-type="bibr">308</xref>].</p><p>With the elucidation of the gene cluster responsible for the biosynthesis of the polyene macrolides candicidin, pimaricin, amphotericin, and nystatin it has become evident that the overall organisation of these cluster is highly similar [<xref rid="B298-antibiotics-08-00157" ref-type="bibr">298</xref>]. This logic was utilised to design a polyene-specific polymerase chain reaction (PCR)-guided genome screening approach to screen for novel polyene-producing actinomycetes [<xref rid="B309-antibiotics-08-00157" ref-type="bibr">309</xref>]. Using the sequence of a cytochrome P450 hydroxylase gene, which is similar between polyenes, the authors could identify and later confirm the presence of a Nystatin-like <italic>Pseudonocardia</italic> Polyene (NPP) gene cluster in the rare actinomycete <italic>Pseudonocardia autotrophica</italic> [<xref rid="B310-antibiotics-08-00157" ref-type="bibr">310</xref>]. Structural analysis of NPP revealed an aglycone identical to that of nystatin however, with a modified sugar residue (a unique disaccharide moiety; mycosaminyl-(&#x003b1;1-4)-<italic>N</italic>-acetyl-glucosamine) [<xref rid="B311-antibiotics-08-00157" ref-type="bibr">311</xref>]. Compared to nystatin A1, NPP A1 displayed a 300-fold increase in water solubility, 10-fold reduced hemolytic activity, but also ~50% lower antifungal activity against <italic>Candida albicans</italic>. The issue of lowered bioactivity was later solved through the manipulation of the ER domain in module five (ER5) of the NPP biosynthetic cluster [<xref rid="B312-antibiotics-08-00157" ref-type="bibr">312</xref>]. Deleting this gene disables the reduction at the C28&#x02013;C29 unsaturated bond in the aglycone of NPP A1 hence, generating a heptaene instead of the original tetraene. The new derivative NPP B1 displayed in vitro and in vivo activity against <italic>C. albicans</italic> and improved hemolytic activity compared to amphotericin B. However, the production yields of NPP B1 in the pathway-engineered strain (<italic>P. autotrophica</italic> ER5 mutant) were extremely low. In an attempt to solve this issue, the <italic>P. autotrophica</italic> ER5 mutant strain was subjected to <italic>N</italic>-methyl-<italic>N</italic>&#x02032;-nitro-<italic>N</italic>-nitrosoguanidine (NTG) iterative random mutagenesis [<xref rid="B312-antibiotics-08-00157" ref-type="bibr">312</xref>]. The resulting mutants were screened in zone-of-inhibition agar plug assays in which the mutant strain 3R-42 produced the largest inhibition zone. The transcriptional analysis further revealed a general up-regulation of the NPP biosynthetic genes in the 3R-42 mutant compared to the original ER5 mutant. Based on this observation, the authors introduced a second copy of each putative regulatory gene into the chromosome of the 3R-42 mutant strain and could determine a final NPP B1 production of 31.6 mg/L [<xref rid="B312-antibiotics-08-00157" ref-type="bibr">312</xref>], which was a substantial increase in comparison to the 0.77 mg/L NPP B1 produced by the original ER5 mutant.</p><p>Additionally, studies on the biosynthesis of nystatin itself also open up for the discovery of novel derivatives with improved properties. In fact, based on genetic engineering of the nystatin gene cluster, Brautaset and colleagues obtained seven nystatin derivatives with altered exocyclic carboxy groups and polyol regions [<xref rid="B160-antibiotics-08-00157" ref-type="bibr">160</xref>]. The mutational studies were based on the already obtained <italic>S. noursei</italic> mutant strain GG5073SP, in which the ER5 was deleted. This mutant produced a heptaene nystatin analogue, named S44HP. The introduction of a CL346AS mutation in the <italic>nysN</italic> of GG5073SP resulted in the mutant BSM1 and the isolation of a novel compound. Its structure was confirmed as 16-decarboxy-16-methyl-28,29-didehydro-nystatin (BSG005) by nuclear magnetic resonance (NMR) analysis. The authors also succeeded in generating a mutant strain, BSM3, which in addition to the mutation in <italic>nysN</italic> also was disrupted in the dehydratase (DH) domain in module 15, located in NysJ. The mutant strain BSM3 produced the analogue 5-oxo-5-deoxy-16-decarboxy-16-methyl-28,29-didehydro nystatin (BSG020). Both BSG005 and BSG020 display improved toxicities and comparable antifungal activities against disseminated candidiasis in a mouse model when compared to amphotericin B and thus, represent promising candidates for the development of new antifungal drugs [<xref rid="B160-antibiotics-08-00157" ref-type="bibr">160</xref>]. The derivatives have not yet been introduced for human therapy however, based on information obtained from the homepage of the Swedish biotech company Biosergen AS, the company has selected the BSG005 candidate for further preclinical and clinical tests (<xref rid="antibiotics-08-00157-t001" ref-type="table">Table 1</xref>) [<xref rid="B161-antibiotics-08-00157" ref-type="bibr">161</xref>].</p></sec><sec id="sec4dot2-antibiotics-08-00157"><title>4.2. Amphotericin B</title><p>The antifungal polyene macrolide amphotericin B (trade names: Fungizone and Amphocin) was first discovered together with amphotericin A in the 1950s in the fermentation broth of soil-derived <italic>Streptomyces nodosus</italic> [<xref rid="B162-antibiotics-08-00157" ref-type="bibr">162</xref>]. While amphotericin A contains a tetraene chromophore, amphotericin B possesses a heptaene (<xref ref-type="fig" rid="antibiotics-08-00157-f009">Figure 9</xref>).</p><p>The BGC of amphotericin B has been fully sequenced. The sequence analysis revealed that the cluster organisation is similar to the BGC of nystatin [<xref rid="B313-antibiotics-08-00157" ref-type="bibr">313</xref>]. The polyketide chain is biosynthesised by an assembly line involving one loading (encoded by <italic>amphA</italic>) and 18 extension modules (encoded by the five genes <italic>amphB</italic>, <italic>amphC</italic>, and <italic>amphI</italic> through <italic>amphK</italic>) (<xref ref-type="app" rid="app1-antibiotics-08-00157">Figure S8</xref>). Assembly of the precursor on the amphotericin PKS is initiated by the loading of a malonyl-CoA starter unit which is further elongated by additional 15 acetate and nine propionate extender units (<xref ref-type="app" rid="app1-antibiotics-08-00157">Figure S8</xref>) [<xref rid="B163-antibiotics-08-00157" ref-type="bibr">163</xref>]. In the last module, encoded by <italic>amphK</italic>, a TE domain is responsible for chain termination and release from the PKS. Two putative cytochrome P450 enzymes AmphL and AmphN are possibly involved in the modification of the amphotericin B structure. While AmphL most likely catalyses the C8 hydroxylation in the macrolactone, AmphN may facilitate the oxidation of the methyl group on C16 to yield a carboxyl group. Targeted deletion of <italic>amphN</italic> resulted in a <italic>S. nodosus</italic> mutant strain producing a amphotericin analogue in which the exocyclic methyl group is retained [<xref rid="B314-antibiotics-08-00157" ref-type="bibr">314</xref>]. The fact that the antifungal activity of this analogue was unchanged, and the haemolytic activity reduced compared to amphotericin B, makes the derivative an interesting candidate for clinical studies.</p><p>Additional modification of amphotericin is facilitated by the glycosyltransferase, encoded by <italic>amphDI</italic>, which is responsible for the attachment of the mycosamine to the aglycone core of amphotericin [<xref rid="B313-antibiotics-08-00157" ref-type="bibr">313</xref>,<xref rid="B314-antibiotics-08-00157" ref-type="bibr">314</xref>]. The biosynthesis of the mycosamine is believed to be catalysed by a GDP-mannose-4,6-dehydratase encoded by <italic>amphDIII</italic>, which uses GDP-mannose derived from primary metabolism as substrate [<xref rid="B298-antibiotics-08-00157" ref-type="bibr">298</xref>]. The product of the AmphDIII-catalysed dehydratase reaction is GDP-4-keto-6-deoxy-<sc>d</sc>-mannose and not GDP-3-keto-6-deoxy-<sc>d</sc>-mannose, which is the substrate recognised by the transaminase AmphDII. So far, no GDP-4-keto-6-deoxy-<sc>d</sc>-mannose-3,4-isomerase has been identified in any of the polyene gene clusters and it is hypothesised that the ketoisomerisation reaction is the result of a spontaneous, non-enzymatic reaction [<xref rid="B298-antibiotics-08-00157" ref-type="bibr">298</xref>].</p><p>Export of amphotericin B has been hypothesised to be facilitated by two putative ABC transporters, encoded by <italic>amphG</italic> and <italic>amphH</italic>. The reason why two transporters are present in the gene cluster remains unknown. It has been speculated that ABC transporters can confer self-resistance of the producing host [<xref rid="B313-antibiotics-08-00157" ref-type="bibr">313</xref>]. Based on the high degree of sequence similarity between nystatin and amphotericin PKS genes, it has been postulated that the genes <italic>amphRI</italic> through <italic>amphRIV</italic> are homologues of the genes <italic>nysRI&#x02013;nysRIV</italic> in nystatin and encode regulatory proteins, which act in a very similar fashion [<xref rid="B298-antibiotics-08-00157" ref-type="bibr">298</xref>,<xref rid="B315-antibiotics-08-00157" ref-type="bibr">315</xref>].</p><p>Since its marketing in 1957, amphotericin B (<xref rid="antibiotics-08-00157-t001" ref-type="table">Table 1</xref>) has been used as the &#x0201c;gold standard&#x0201d; for treatment of the most severe dimorphic fungal and yeast infections, caused by <italic>Blastomyces</italic>, <italic>Candida</italic>, <italic>Cryptococcus</italic>, and <italic>Histoplasma</italic> spp. [<xref rid="B307-antibiotics-08-00157" ref-type="bibr">307</xref>]. The MOA of amphotericin B is identical to that of nystatin. Despite its preference for ergosterol found in fungal cellular membranes, amphotericin B also interacts to a lesser extend with the cholesterol found in mammalian cell membranes [<xref rid="B164-antibiotics-08-00157" ref-type="bibr">164</xref>]. This and the side effects, including nephrotoxicity present a major limitation to the application of amphotericin B as an antibiotic for human therapy. In addition to its antifungal properties, amphotericin has also been implemented in delaying onset of prion disease in cultured cells with human immunodeficiency virus (HIV) and in inhibition of the protozoal parasite <italic>Leishmania</italic> [<xref rid="B313-antibiotics-08-00157" ref-type="bibr">313</xref>].</p><p>Although amphotericin B shows a promising spectrum of activity and potential applications, the compound is poorly soluble in water and displays certain toxicity, which restricts its use in intravenous therapy. Consequently, only life-threatening fungal infections are treated with amphotericin B. Interestingly, despite its use as an antifungal drug for more than 40 years, reports of mycological resistance development in clinical fungi isolates against amphotericin B remain relatively scarce [<xref rid="B316-antibiotics-08-00157" ref-type="bibr">316</xref>]. Nonetheless, resistance occurs, as it was demonstrated by the isolation of resistant <italic>Candida</italic> spp., <italic>Fusarium</italic> spp., and <italic>Scedosporium apiospermum</italic> [<xref rid="B317-antibiotics-08-00157" ref-type="bibr">317</xref>]. In these fungi, drug resistance is most likely conferred by either the production of alternative ergosterols to which the amphotericin B is less efficient or simply by decreasing the ergosterol level in the fungal cell membranes. Both mechanisms reduce the potency of the antifungal drug [<xref rid="B316-antibiotics-08-00157" ref-type="bibr">316</xref>].</p><p>The promising features of amphotericin B, such as broad-spectrum activity and low resistance against the compound were encouraging for numerous engineering attempts in order to improve the properties of the antifungal drug. A great improvement in the solubility of the amphotericin B was already achieved in the case of Fungizone, which is a mixture of amphotericin B and the bile acid deoxycholate [<xref rid="B165-antibiotics-08-00157" ref-type="bibr">165</xref>]. Additionally, reduction in the overall toxicity of amphotericin B was further achieved through liposome encapsulation, which has resulted in the three formulations; Amphotec, AmBisome, and Abelcet [<xref rid="B165-antibiotics-08-00157" ref-type="bibr">165</xref>]. Unfortunately, the reduced toxicity of the liposome-packed amphotericin B seems to come at a cost in antifungal efficiency.</p><p>The extensive investigations on amphotericin and polyene biosynthesis are of advantage for targeted engineering to increase production yields and to generate new derivatives with improved therapeutic properties. Furthermore, it should be noted that great efforts have been made in the field of semi-synthesis and several amphotericin B analogues with improved solubility and toxicity have been generated using different chemical approaches. Many of these have already been reviewed elsewhere [<xref rid="B318-antibiotics-08-00157" ref-type="bibr">318</xref>]. Despite the many advances in both semi-synthesis and genetic engineering for obtaining amphotericin B analogues with improved properties, the yields of the derivatives are often very low, and to date, none of the reported amphotericin B analogues have made it through to the market. Consequently, the actinomycetes-derived substance amphotericin B remains one of the most important polyketides in the sparse portfolio of antifungal drugs. This urges the need for improved production titers in the natural producer strain. Recently, Zhang and co-workers set out to improve yields of amphotericin B in a newly isolated strain <italic>Streptomyces</italic> spp. ZJB 2013082, which produced the antifungal substance in low yields [<xref rid="B319-antibiotics-08-00157" ref-type="bibr">319</xref>]. Using a combination of ultraviolet (UV) and NTG mutagenesis, the mutant strain N3 was isolated, which produced 1735 mg/L, a substantially increased amount of the product compared to the 56.2 mg/L obtained from the parent strain ZJB 2013082. Additionally, the N3 mutant accumulated less amphotericin A than the parent strain ZJB 2013082. This could be of industrial importance, since substance A is only allowed to account for more than five percent in the amphotericin mixture. The genome sequence of the N3 mutant is not yet published however, identification of the genomic architecture in the N3 mutant could help guide future engineering efforts to obtain a stable production host for amphotericin B.</p></sec><sec id="sec4dot3-antibiotics-08-00157"><title>4.3. Pimaricin/Natamycin</title><p>Pimaricin (later renamed natamycin, trade names: Natacyn and E235) (<xref ref-type="fig" rid="antibiotics-08-00157-f009">Figure 9</xref>, <xref rid="antibiotics-08-00157-t001" ref-type="table">Table 1</xref>) was first discovered in the 1950s as the product of soil-derived <italic>Streptomyces natalensis</italic> isolated from the South African region of Natal [<xref rid="B166-antibiotics-08-00157" ref-type="bibr">166</xref>,<xref rid="B320-antibiotics-08-00157" ref-type="bibr">320</xref>]. Additional producer strains have been identified, including <italic>Streptomyces chattanoogensis</italic> [<xref rid="B321-antibiotics-08-00157" ref-type="bibr">321</xref>,<xref rid="B322-antibiotics-08-00157" ref-type="bibr">322</xref>] and <italic>Streptomyces lydicus</italic> [<xref rid="B323-antibiotics-08-00157" ref-type="bibr">323</xref>].</p><p>The structure of pimaricin varies slightly from those of amphotericin B and nystatin A1 (<xref ref-type="sec" rid="sec4dot1-antibiotics-08-00157">Section 4.1</xref>) owing to the smaller size of the macrolactone (<xref ref-type="fig" rid="antibiotics-08-00157-f009">Figure 9</xref>). Pimaricin is composed of a 26-membered aglycone, containing four conjugated double bonds, to which the characteristic mycosamine sugar is attached at the C15 atom. The tetraene polyene further contains an exocyclic carboxyl group at C12, a functionally interestingly epoxide at C4/C5, and an internal hemiketal ring, which originates from a spontaneous cyclisation of the C9 keto group with a hydroxyl group on C13 [<xref rid="B167-antibiotics-08-00157" ref-type="bibr">167</xref>].</p><p>The elucidation of pimaricin biosynthesis has relied primarily on genome sequencing and genetic studies of the two pimaricin-producer strains <italic>S. chattanoogensis</italic> and <italic>S. natalensis</italic> [<xref rid="B320-antibiotics-08-00157" ref-type="bibr">320</xref>]. In the case of <italic>S. natalensis</italic>, an 85 kb-large genomic region containing 16 ORFs was identified from a cosmid library as the pimaricin gene cluster [<xref rid="B167-antibiotics-08-00157" ref-type="bibr">167</xref>]. Pimaricin biosynthesis follows a logic, which is highly similar to that governing amphotericin B and nystatin biosynthesis. Since the gene clusters identified from <italic>S. chattanoogensis</italic> and <italic>S. natalensis</italic> are nearly identical, the following subsection will describe the studies on <italic>S. natalensis</italic>.</p><p>The assembly of the 26-membered lactone, termed pimaricinolide, is catalysed by a type I PKS composed of 13 (one starter and 12 extender) modules, encoded by the genes <italic>pimS0&#x02013;pimS4</italic> (<xref ref-type="app" rid="app1-antibiotics-08-00157">Figure S9</xref>). Chain initiation starts at PimS0 with the loading of a malonyl-CoA. Further elongation, catalysed by PimS1 through PimS4, leads to the condensation of additional 12 acetate units and one propionate unit to the growing polyketide precursor. In PimS4, the last domain, a TE, is responsible for the release and cyclisation of pimaricinolide [<xref rid="B167-antibiotics-08-00157" ref-type="bibr">167</xref>]. Further examination of the pimaricin gene cluster has revealed an additional gene <italic>pimI</italic>, which encodes an enzyme with homology to the TE found in the candicidin gene cluster in <italic>S. griseus</italic> and to the TylO in the tylosin gene cluster in <italic>S. fradiae</italic>. It has been postulated that the additional TE in the pimaricin gene cluster helps to remove aberrant precursors from the PKS, ensuring continuous biosynthesis [<xref rid="B167-antibiotics-08-00157" ref-type="bibr">167</xref>,<xref rid="B204-antibiotics-08-00157" ref-type="bibr">204</xref>]. Upon its release from the PKS, pimaricinolide undergoes oxidation of the methyl group on C12 resulting in the formation of a carboxylic acid. This is catalysed by PimG, a cytochrome P450 enzyme. The resulting 12-carboxy-pimaricinolide is then glycosylated at the C15 hydroxyl group through the attachment of a mycosamine by the actions of the glycosyltransferase PimK. The final modification of the pimaricin precursor involves another cytochrome P450 (encoded by the gene <italic>pimD</italic>) which catalyse the oxidation leading to the spontaneous formation of an epoxy group between C4 and C5.</p><p>Sugar biosynthesis is believed to involve only two enzymes; PimJ, a GDP-mannose-4,6-dehydratase responsible for the conversion of GDP-mannose (from primary metabolism) to GDP-4-keto-6-deoxymannose, and PimC, a GDP-3-keto-6-deoxymannose aminotransferase, which synthesises GDP-mycosamine from GDP-3-keto-6-deoxymannose. Similar to what has been described for mycosamine biosynthesis in amphotericin B and nystatin, no gene encoding an enzyme responsible for the 3,4-isomerisation required for the conversion of GDP-4-keto-6-deoxymannose to GDP-3-keto-6-deoxymannose was found in the pimaricin gene cluster, and the reaction is believed to occur spontaneously [<xref rid="B298-antibiotics-08-00157" ref-type="bibr">298</xref>,<xref rid="B320-antibiotics-08-00157" ref-type="bibr">320</xref>].</p><p>The three gene products of <italic>pimA</italic>, <italic>pimB</italic>, and <italic>pimH</italic> have been putatively assigned to proteins ensuring the export of pimaricin in <italic>S. natalensis</italic>. While PimA and PimB group in the family of ABC transporters, PimH might encode an efflux pump [<xref rid="B320-antibiotics-08-00157" ref-type="bibr">320</xref>,<xref rid="B324-antibiotics-08-00157" ref-type="bibr">324</xref>]. The functions of PimA and PimB remain to be experimentally verified. For the homologues of PimA and PimB (ScnA and ScnB) in <italic>S. chattanoogensis</italic>, it was reported that they are involved in primary exporters of natamycin [<xref rid="B324-antibiotics-08-00157" ref-type="bibr">324</xref>]. With amino acid sequence similarities of above 95% for ScnA/ScnB and PimA/PimB, it is likely that the later enzymes have a similar function and also act as primary transporters of pimaricin.</p><p>The regulatory mechanisms governing pimaricin biosynthesis has been studied in <italic>S. natalensis</italic> and <italic>S. chattanoogensis</italic>. Two transcriptional regulators PimM and PimR play an important role in pimaricin production in <italic>S. natalensis</italic> [<xref rid="B325-antibiotics-08-00157" ref-type="bibr">325</xref>,<xref rid="B326-antibiotics-08-00157" ref-type="bibr">326</xref>]. Furthermore, the amino acid exporter PimT and the putative cholesterol oxidase PimE add an extra layer of regulation to the pimaricin biosynthesis. While PimT was found to play a role in export of quorum-sensing pimaricin-inducer (PI) factor [<xref rid="B327-antibiotics-08-00157" ref-type="bibr">327</xref>], PimE could act as a signalling molecule, triggering production of pimaricin in the producer in the presence of fungi [<xref rid="B328-antibiotics-08-00157" ref-type="bibr">328</xref>,<xref rid="B329-antibiotics-08-00157" ref-type="bibr">329</xref>]. The complex regulation cascade contains potential &#x0201c;targets&#x0201d; for engineering of the producer and increasing the production of the antifungal compound. Some of the most successful examples include overexpression of the regulator-encoding gene <italic>scnRII</italic> (homologue to <italic>pimM</italic>) in <italic>S. chattanoogensis</italic>, deletion of <italic>sngR</italic>, a &#x003b3;-butyrolactone receptor-encoding gene, in <italic>S. natalensis</italic>, and chromosomal integration of the <italic>Vitreoscilla</italic> haemoglobin <italic>vgb</italic> gene in <italic>S. gilvosporeus</italic>, resulting in 460%, 460%, and 407% increase in pimaricin yields, respectively, in the mutant strains compared to wild types [<xref rid="B320-antibiotics-08-00157" ref-type="bibr">320</xref>,<xref rid="B330-antibiotics-08-00157" ref-type="bibr">330</xref>,<xref rid="B331-antibiotics-08-00157" ref-type="bibr">331</xref>,<xref rid="B332-antibiotics-08-00157" ref-type="bibr">332</xref>].</p><p>More than 40 years after the introduction of pimaricin to the market, it remains an important antifungal agent and it is still used in the treatment of fungal keratitis, an infection of the cornea caused primarily by filamentous fungi <italic>Fusarium</italic> and <italic>Aspergillus</italic>, and yeast-like <italic>Candida</italic> [<xref rid="B168-antibiotics-08-00157" ref-type="bibr">168</xref>]. Due to its low water solubility and limited oral absorption, pimaricin is mainly available as a topical agent in human medicine. Recently, an antiprotozoan activity of pimaricin was detected which makes the compound attractive for potential treatment of keratitis caused by <italic>Acanthamoeba</italic>.</p><p>The MOA of pimaricin differs from that of nystatin and amphotericin B. While the main target of the pimaricin is ergosterol, which is the major sterol found in fungal cells membranes, pimaricin only binds to the lipid receptor. The interaction between pimaricin and ergosterol has been examined in <italic>Aspergillus niger</italic>, showing that upon its binding, pimaricin blocks transport of amino acids and glucose across the fungal plasma membrane, which leads to cell death [<xref rid="B169-antibiotics-08-00157" ref-type="bibr">169</xref>]. Due to its specific interaction with ergosterol, the development of microbial resistance towards pimaricin is seen as posing only a minor risk [<xref rid="B320-antibiotics-08-00157" ref-type="bibr">320</xref>]. This, combined with its low oral absorption, has paved the way for pimaricin as a food preservative. Sold under the label E235, pimaricin is approved as a protecting agent against yeast and mould and is used for surface treatment of hard, semi-hard, and semi-soft cheeses, and of dried, cured sausage in Europe. Other applications of pimaricin are summarised in the review by Aparicio and co-workers [<xref rid="B320-antibiotics-08-00157" ref-type="bibr">320</xref>]. Additionally, pimaricin is the only antifungal agent to date, which has gained the generally regarded as safe (GRAS) status.</p><p>While pimaricin itself remains an important agent for treatment of fungal keratitis and as a food preservative, efforts to engineer strains which produce novel pimaricin analogues with improved solubility and toxicity have been undertaken. These efforts have been greatly aided by the complete genome sequencing of <italic>S. natalensis</italic> and <italic>S. chattanoogensis</italic>, both harbouring the BGC of pimaricin. Recently, Qi and co-workers could identify three novel pimaricin analogues based on a single mutation of the gene <italic>scnG</italic> in <italic>S. chattanoogensis</italic> (<italic>pimG</italic> in <italic>S. natalensis</italic>) [<xref rid="B333-antibiotics-08-00157" ref-type="bibr">333</xref>], which encodes the cytochrome P450 enzyme responsible for the formation of carboxyl group at the C12 in pimaricin. Out of the three identified derivatives, 12-decarboxy-12-methyl pimaricin and 4,5-desepoxy-12-decarboxy-12-methyl pimaricin, both displayed reduced cytotoxicity compared to pimaricin. Additionally, 12-decarboxy-12-methyl pimaricin showed a two-fold increase in antifungal activity against <italic>C. albicans</italic> ATCC 14,053 compared to pimaricin. Through further biochemical and genetic analyses, 4,5-desepoxy-12-decarboxy-12-methyl pimaricin was found to be the precursor of 12-decarboxy-12-methyl pimaricin in the reaction catalysed by the C4/C5 epoxidase encoded by <italic>scnD</italic> (<italic>pimD</italic>). Therefore, to ensure the complete conversion of 4,5-desepoxy-12-decarboxy-12-methyl pimaricin into 12-decarboxy-12-methyl pimaricin, <italic>scnD</italic> was overexpressed in the &#x00394;<italic>scnG</italic> mutant, which led to a 20% increase in production of the latter derivative. However, with an overall yield of 268 &#x000b1; 10 mg/L for 12-decarboxy-12-methyl pimaricin in the best performing mutant, the needs for further engineering to optimise yields are necessary. In this case, the pathway-specific regulators PimM and PimR or the PI-factor could be the next targets for improving pimaricin derivative production [<xref rid="B333-antibiotics-08-00157" ref-type="bibr">333</xref>].</p></sec></sec><sec id="sec5-antibiotics-08-00157"><title>5. Strategies and Tools for the Discovery of Natural Products</title><p>The emergence of antibiotic resistant microbes is alarming and underlines the urgent need for new drugs to combat the pathogens. However, the discovery and approval of new antibiotics is more difficult than expected [<xref rid="B334-antibiotics-08-00157" ref-type="bibr">334</xref>,<xref rid="B335-antibiotics-08-00157" ref-type="bibr">335</xref>,<xref rid="B336-antibiotics-08-00157" ref-type="bibr">336</xref>]. Therefore, the question arises: how to improve the chances for finding new antimicrobial compounds? Recently, new approaches and advances of the existing technologies within the early stage of drug discovery and development were reported.</p><p>For natural product-derived antimicrobial compounds, the &#x0201c;journey&#x0201d; starts with the identification of the source (e.g., producer organism) and/or the bioactive molecule, responsible for the inhibition or killing of a pathogen. Already at this stage, the re-discovery rate of known structures might be reduced by taking samples and isolation of potential producers or compounds from undiscovered environments [<xref rid="B337-antibiotics-08-00157" ref-type="bibr">337</xref>,<xref rid="B338-antibiotics-08-00157" ref-type="bibr">338</xref>,<xref rid="B339-antibiotics-08-00157" ref-type="bibr">339</xref>,<xref rid="B340-antibiotics-08-00157" ref-type="bibr">340</xref>,<xref rid="B341-antibiotics-08-00157" ref-type="bibr">341</xref>,<xref rid="B342-antibiotics-08-00157" ref-type="bibr">342</xref>,<xref rid="B343-antibiotics-08-00157" ref-type="bibr">343</xref>]. This is often limited by the fact that organisms originating from &#x0201c;extreme&#x0201d; habitats require special cultivation conditions and thus, many strategies were developed to overcome this barrier (e.g., co-cultivation [<xref rid="B344-antibiotics-08-00157" ref-type="bibr">344</xref>,<xref rid="B345-antibiotics-08-00157" ref-type="bibr">345</xref>,<xref rid="B346-antibiotics-08-00157" ref-type="bibr">346</xref>], iChip [<xref rid="B347-antibiotics-08-00157" ref-type="bibr">347</xref>,<xref rid="B348-antibiotics-08-00157" ref-type="bibr">348</xref>,<xref rid="B349-antibiotics-08-00157" ref-type="bibr">349</xref>,<xref rid="B350-antibiotics-08-00157" ref-type="bibr">350</xref>,<xref rid="B351-antibiotics-08-00157" ref-type="bibr">351</xref>,<xref rid="B352-antibiotics-08-00157" ref-type="bibr">352</xref>], or combination of both [<xref rid="B353-antibiotics-08-00157" ref-type="bibr">353</xref>]).</p><p>Confirmed or potential producers of new antimicrobial agents are further analysed by diverse &#x0201c;omics&#x0201d; approaches [<xref rid="B342-antibiotics-08-00157" ref-type="bibr">342</xref>,<xref rid="B354-antibiotics-08-00157" ref-type="bibr">354</xref>,<xref rid="B355-antibiotics-08-00157" ref-type="bibr">355</xref>,<xref rid="B356-antibiotics-08-00157" ref-type="bibr">356</xref>,<xref rid="B357-antibiotics-08-00157" ref-type="bibr">357</xref>]. The downstream evaluation of the collected data sets using bioinformatics tools enables for example the identification of the BGC for the product of interest and/or provides an overview on the overall biosynthetic potential of target strain (genome mining) [<xref rid="B9-antibiotics-08-00157" ref-type="bibr">9</xref>,<xref rid="B358-antibiotics-08-00157" ref-type="bibr">358</xref>,<xref rid="B359-antibiotics-08-00157" ref-type="bibr">359</xref>,<xref rid="B360-antibiotics-08-00157" ref-type="bibr">360</xref>]. In cases where promising BGCs were identified, however, no products were found with the available fermentation and analytic methods [<xref rid="B361-antibiotics-08-00157" ref-type="bibr">361</xref>,<xref rid="B362-antibiotics-08-00157" ref-type="bibr">362</xref>,<xref rid="B363-antibiotics-08-00157" ref-type="bibr">363</xref>,<xref rid="B364-antibiotics-08-00157" ref-type="bibr">364</xref>], the expression of the clusters and production of the respective metabolite might be achieved by addition of elicitors [<xref rid="B341-antibiotics-08-00157" ref-type="bibr">341</xref>,<xref rid="B342-antibiotics-08-00157" ref-type="bibr">342</xref>,<xref rid="B365-antibiotics-08-00157" ref-type="bibr">365</xref>,<xref rid="B366-antibiotics-08-00157" ref-type="bibr">366</xref>,<xref rid="B367-antibiotics-08-00157" ref-type="bibr">367</xref>,<xref rid="B368-antibiotics-08-00157" ref-type="bibr">368</xref>,<xref rid="B369-antibiotics-08-00157" ref-type="bibr">369</xref>] or the heterologous expression of the BGC in optimized hosts [<xref rid="B370-antibiotics-08-00157" ref-type="bibr">370</xref>,<xref rid="B371-antibiotics-08-00157" ref-type="bibr">371</xref>,<xref rid="B372-antibiotics-08-00157" ref-type="bibr">372</xref>,<xref rid="B373-antibiotics-08-00157" ref-type="bibr">373</xref>,<xref rid="B374-antibiotics-08-00157" ref-type="bibr">374</xref>,<xref rid="B375-antibiotics-08-00157" ref-type="bibr">375</xref>].</p><p>In order to improve the production of relevant products, including polyketides, molecular biology tools and methods (e.g., vectors, plasmids, recombinases, CRISPR-Cas9, promoters, and other synthetic parts as well as methods for their delivery (conjugation, protoplast transformation, and direct transformation)) are used. They play an important role for engineering of both, the natural producer and heterologous hosts. Challenges and new opportunities for the genetic manipulation of actinomycetes were recently reviewed [<xref rid="B376-antibiotics-08-00157" ref-type="bibr">376</xref>,<xref rid="B377-antibiotics-08-00157" ref-type="bibr">377</xref>,<xref rid="B378-antibiotics-08-00157" ref-type="bibr">378</xref>,<xref rid="B379-antibiotics-08-00157" ref-type="bibr">379</xref>,<xref rid="B380-antibiotics-08-00157" ref-type="bibr">380</xref>,<xref rid="B381-antibiotics-08-00157" ref-type="bibr">381</xref>].</p><p>Although each one of these cutting-edge technologies and approaches already contributed to the identification of new compounds, the interplay of the different disciplines will grant a better access to novel natural products with valuable bioactivities.</p></sec><sec sec-type="conclusions" id="sec6-antibiotics-08-00157"><title>6. Conclusions and Outlook</title><p>Actinomycetes are one of the most prolific sources of biologically active secondary metabolites, including polyketides. In the past decades, numerous polyketide compounds were isolated and developed to highly potent antimicrobial drugs, which have saved millions of lives. However, rapid emergence of multidrug resistant pathogens is occurring worldwide which poses a severe threat to human health. This calls for the discovery and development of new antibiotics and antimicrobial strategies. Unlike drugs used in case of chronic diseases (e.g., diabetes, cardiovascular disease, cancer, arthritis, asthma), antibiotics are taken for a short period of time and thus, they are non-profitable and economically unattractive. This and several other obstacles such as high costs of the research and development and insufficient investment from stakeholders has prompted the big pharmaceutical companies to terminate the development of new antibiotics. Currently, it seems that the screening and development of new lead structures for novel antimicrobial agents is mainly conduced at public research and non-profit institutions.</p><p>The fact that many habitats around the globe are unexplored and poorly investigated for the presence of antibiotic-producing microbes, such as actinomycetes, motived researchers to collect samples from these environments and isolate the diverse producers of potentially new bioactive compounds. The valuable knowledge obtained from the investigation of the biosynthesis, regulation and natural resistance in the natural host of the old drugs as well as the recent developments within screening and isolation methods, sequencing and genome mining, and analytics potentiate the platforms for drug discovery. For example, the analysis of a relatively underexplored genus of <italic>Actinoallomurus</italic> led to the discovery of two new spirotetronate polyketide antibiotics NAI414-A and NAI414-B [<xref rid="B382-antibiotics-08-00157" ref-type="bibr">382</xref>].</p><p>As exemplified in this review (<xref ref-type="sec" rid="sec3dot1-antibiotics-08-00157">Section 3.1</xref>), the success in derivatisation and combination of existing compound classes has enabled the continuous efficient treatment of otherwise resistant clinical isolates. In particular, the knowledge gained from detailed MOA and SAR studies of the antimicrobials have paved the way for the development of drugs with improved pharmacokinetic properties and expanded spectrum of bioactivity, compared to the original substance. In the future, semi-synthesis will continue to play an important role in drug development, of both, old and new drug candidates.</p><p>Last, but not least, support from governments and cooperation across the world e.g., public research institutions as well as United Nations organisations, the WHO, the Food and Agriculture Organization, and the inter-governmental World Organisation for Animal Health, combined with strategies offering long-term incentive for the pharmaceutical companies to reinvigorate their antimicrobial drug discovery platforms are an important political aspect that has been gaining more attention these days. The option of the US FDA to gain a fast-track approval of drug leads which can be used to treat serious or life-threatening conditions might further enhance the chances of taking on the expenses associated with drug discovery by pharmaceutical companies. The combination of all these efforts may give a competitive advantage in the never-ending race between the discovery of antimicrobials and the rise of drug resistance in pathogens.</p></sec></body><back><app-group><app id="app1-antibiotics-08-00157"><title>Supplementary Materials</title><p>The following are available online at <uri xlink:href="https://www.mdpi.com/2079-6382/8/4/157/s1">https://www.mdpi.com/2079-6382/8/4/157/s1</uri>, Figure S1: The erythromycin biosynthetic pathway, Figure S2: The tylosin biosynthetic pathway, Figure S3: The monensin biosynthetic pathway, Figure S4: The biosynthetic pathway of tiacumicin, Figure S5: The biosynthetic pathway of rifamycin, Figure S6: The biosynthetic pathway of oxytetracycline and chlortetracycline, Figure S7: The biosynthetic pathways of pristinamycin II and pristinamycin I, Figure S8: The biosynthetic pathways of nystatin and amphotericin B, Figure S9: The biosynthetic pathway of pimaricin. </p><supplementary-material content-type="local-data" id="antibiotics-08-00157-s001"><media xlink:href="antibiotics-08-00157-s001.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>The review was written and edited by the authors H.R. and E.M.-K.</p></notes><notes><title>Funding</title><p>The authors and work in their laboratory are supported by the Eberhard Karls Universit&#x000e4;t T&#x000fc;bingen, the Deutsche Forschungsgemeinschaft (DFG), the Bundesministeriums f&#x000fc;r Bildung und Forschung (BMBF) (FKZ 031L 0018A, ERASysApp), the German Center for Infection Research (DZIF) (TTU 09.912), and Biovet (Sofia, Bulgaria).</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><glossary><title>Abbreviations</title><array orientation="portrait"><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">A</td><td align="left" valign="top" rowspan="1" colspan="1">adenylation domain</td><td align="left" valign="top" rowspan="1" colspan="1">MBC</td><td align="left" valign="top" rowspan="1" colspan="1">minimum bactericidal concentration</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ABC</td><td align="left" valign="top" rowspan="1" colspan="1">ATP-binding cassette</td><td align="left" valign="top" rowspan="1" colspan="1">MIC</td><td align="left" valign="top" rowspan="1" colspan="1">minimum inhibitory concentration</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ACP</td><td align="left" valign="top" rowspan="1" colspan="1">acyl carrier protein</td><td align="left" valign="top" rowspan="1" colspan="1">MLS<sub>B</sub></td><td align="left" valign="top" rowspan="1" colspan="1">macrolide&#x02013;lincosamide&#x02013;streptogramin B</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">AHBA</td><td align="left" valign="top" rowspan="1" colspan="1">3-amino 5-hydroxybenzoic acid</td><td align="left" valign="top" rowspan="1" colspan="1">MOA</td><td align="left" valign="top" rowspan="1" colspan="1">mode of action</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ARO</td><td align="left" valign="top" rowspan="1" colspan="1">aromatase</td><td align="left" valign="top" rowspan="1" colspan="1">MRSA</td><td align="left" valign="top" rowspan="1" colspan="1">methicillin-resistant <italic>Staphylococcus aureus</italic></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">AT</td><td align="left" valign="top" rowspan="1" colspan="1">acyltransferase</td><td align="left" valign="top" rowspan="1" colspan="1">MT</td><td align="left" valign="top" rowspan="1" colspan="1">methyltransferase domain</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">BGC</td><td align="left" valign="middle" rowspan="1" colspan="1">biosynthetic gene cluster</td><td align="left" valign="middle" rowspan="1" colspan="1">NADPH</td><td align="left" valign="middle" rowspan="1" colspan="1">nicotinamide adenine dinucleotide phosphate</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">C</td><td align="left" valign="top" rowspan="1" colspan="1">condensation domain</td><td align="left" valign="top" rowspan="1" colspan="1">NGST</td><td align="left" valign="top" rowspan="1" colspan="1">Next Generation Sequencing Technologies</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CABP</td><td align="left" valign="top" rowspan="1" colspan="1">community-acquired bacterial pneumonia</td><td align="left" valign="top" rowspan="1" colspan="1">NMR</td><td align="left" valign="top" rowspan="1" colspan="1">nuclear magnetic resonance</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CCR</td><td align="left" valign="top" rowspan="1" colspan="1">crotonyl-CoA carboxylase/reductase</td><td align="left" valign="top" rowspan="1" colspan="1">NRPS</td><td align="left" valign="top" rowspan="1" colspan="1">nonribosomal peptide synthetase</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CDI</td><td align="left" valign="top" rowspan="1" colspan="1"><italic>Clostridioides difficile</italic> infection</td><td align="left" valign="top" rowspan="1" colspan="1">NTG</td><td align="left" valign="top" rowspan="1" colspan="1"><italic>N</italic>-methyl-<italic>N</italic>&#x02032;-nitro-<italic>N</italic>-nitrosoguanidine</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CLF</td><td align="left" valign="top" rowspan="1" colspan="1">chain elongation factor</td><td align="left" valign="top" rowspan="1" colspan="1">ORF</td><td align="left" valign="top" rowspan="1" colspan="1">open reading frame</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CoA</td><td align="left" valign="top" rowspan="1" colspan="1">coenzyme A</td><td align="left" valign="top" rowspan="1" colspan="1">PCP</td><td align="left" valign="top" rowspan="1" colspan="1">peptidyl carrier protein</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">cryo EM</td><td align="left" valign="top" rowspan="1" colspan="1">cryogenic electron microscopy</td><td align="left" valign="top" rowspan="1" colspan="1">PCR</td><td align="left" valign="top" rowspan="1" colspan="1">polymerase chain reaction</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CYC</td><td align="left" valign="top" rowspan="1" colspan="1">cyclase</td><td align="left" valign="top" rowspan="1" colspan="1">PKS</td><td align="left" valign="top" rowspan="1" colspan="1">polyketide synthase</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DEBS</td><td align="left" valign="top" rowspan="1" colspan="1">deoxyerythronolide B synthase</td><td align="left" valign="top" rowspan="1" colspan="1">PTC</td><td align="left" valign="top" rowspan="1" colspan="1">peptidyl transferase center</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DH</td><td align="left" valign="top" rowspan="1" colspan="1">dehydratase</td><td align="left" valign="top" rowspan="1" colspan="1">RNA</td><td align="left" valign="top" rowspan="1" colspan="1">ribonucleic acid</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DNA</td><td align="left" valign="top" rowspan="1" colspan="1">deoxyribonucleic acid</td><td align="left" valign="top" rowspan="1" colspan="1">RNAP</td><td align="left" valign="top" rowspan="1" colspan="1">RNA polymerase</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">dTDP</td><td align="left" valign="top" rowspan="1" colspan="1">deoxythymidine diphosphate</td><td align="left" valign="top" rowspan="1" colspan="1">rRNA</td><td align="left" valign="top" rowspan="1" colspan="1">ribosomal RNA</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">E</td><td align="left" valign="top" rowspan="1" colspan="1">epimerisation domain</td><td align="left" valign="top" rowspan="1" colspan="1">SAM</td><td align="left" valign="top" rowspan="1" colspan="1">S-adenosyl methionine</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ER</td><td align="left" valign="top" rowspan="1" colspan="1">enoyl reductase</td><td align="left" valign="top" rowspan="1" colspan="1">SAR</td><td align="left" valign="top" rowspan="1" colspan="1">structure activity relationship</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ESBL</td><td align="left" valign="top" rowspan="1" colspan="1">extended spectrum &#x003b2;-lactamase</td><td align="left" valign="top" rowspan="1" colspan="1">SARP</td><td align="left" valign="top" rowspan="1" colspan="1"><italic>Streptomyces</italic> antibiotic regulatory protein</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">FDA</td><td align="left" valign="top" rowspan="1" colspan="1">Food and Drug Administration</td><td align="left" valign="top" rowspan="1" colspan="1">Spp.</td><td align="left" valign="top" rowspan="1" colspan="1">Species</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">GDP</td><td align="left" valign="top" rowspan="1" colspan="1">guanosine diphosphate</td><td align="left" valign="top" rowspan="1" colspan="1">TB</td><td align="left" valign="top" rowspan="1" colspan="1">Tuberculosis</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">GI</td><td align="left" valign="top" rowspan="1" colspan="1">gastrointestinal</td><td align="left" valign="top" rowspan="1" colspan="1">TDP</td><td align="left" valign="top" rowspan="1" colspan="1">thymidine diphosphate</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Kb</td><td align="left" valign="top" rowspan="1" colspan="1">kilobase</td><td align="left" valign="top" rowspan="1" colspan="1">TE</td><td align="left" valign="top" rowspan="1" colspan="1">Thioesterase</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">KR</td><td align="left" valign="top" rowspan="1" colspan="1">ketoreductase</td><td align="left" valign="top" rowspan="1" colspan="1">tRNA</td><td align="left" valign="top" rowspan="1" colspan="1">transfer RNA</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">KS</td><td align="left" valign="top" rowspan="1" colspan="1">ketosynthase</td><td align="left" valign="top" rowspan="1" colspan="1">VRE</td><td align="left" valign="top" rowspan="1" colspan="1">vancomycin-resistant <italic>Enterococci</italic></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">LS<sub>A</sub>P</td><td align="left" valign="top" rowspan="1" colspan="1">Lincosamide&#x02013;streptogramin A&#x02013;pleuromutilin</td><td align="left" valign="top" rowspan="1" colspan="1">VRSA</td><td align="left" valign="top" rowspan="1" colspan="1">vancomycin-resistant <italic>Staphylococcus aureus</italic></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MAC</td><td align="left" valign="top" rowspan="1" colspan="1"><italic>Mycobacterium avium-intracellulare</italic> complex</td><td align="left" valign="top" rowspan="1" colspan="1">WHO</td><td align="left" valign="top" rowspan="1" colspan="1">World Health Organisation</td></tr></tbody></array></glossary><ref-list><title>References</title><ref id="B1-antibiotics-08-00157"><label>1.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Mohammadipanah</surname><given-names>F.</given-names></name><name><surname>Dehhaghi</surname><given-names>M.</given-names></name></person-group><article-title>Classification and taxonomy of actinobacteria</article-title><source>Biology and Biotechnology of Actinobacteria</source><person-group person-group-type="editor"><name><surname>Wink</surname><given-names>J.</given-names></name><name><surname>Mohammadipanah</surname><given-names>F.</given-names></name><name><surname>Hamedi</surname><given-names>J.</given-names></name></person-group><publisher-name>Springer</publisher-name><publisher-loc>Berlin/Heidelberg, Germany</publisher-loc><year>2017</year><fpage>51</fpage><lpage>77</lpage></element-citation></ref><ref id="B2-antibiotics-08-00157"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barka</surname><given-names>E.A.</given-names></name><name><surname>Vatsa</surname><given-names>P.</given-names></name><name><surname>Sanchez</surname><given-names>L.</given-names></name><name><surname>Gaveau-Vaillant</surname><given-names>N.</given-names></name><name><surname>Jacquard</surname><given-names>C.</given-names></name><name><surname>Klenk</surname><given-names>H.P.</given-names></name><name><surname>Cl&#x000e9;ment</surname><given-names>C.</given-names></name><name><surname>Ouhdouch</surname><given-names>Y.</given-names></name><name><surname>van Wezel</surname><given-names>G.P.</given-names></name></person-group><article-title>Taxonomy, physiology, and natural products of Actinobacteria</article-title><source>Microbiol. Mol. Biol. Rev.</source><year>2016</year><volume>80</volume><fpage>1</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1128/MMBR.00019-15</pub-id><?supplied-pmid 26609051?><pub-id pub-id-type="pmid">26609051</pub-id></element-citation></ref><ref id="B3-antibiotics-08-00157"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garc&#x000ed;a</surname><given-names>J.C.</given-names></name><name><surname>Patr&#x000e3;o</surname><given-names>B.</given-names></name><name><surname>Almeida</surname><given-names>L.</given-names></name><name><surname>P&#x000e9;rez</surname><given-names>J.</given-names></name><name><surname>Menezes</surname><given-names>P.</given-names></name><name><surname>Dias</surname><given-names>J.</given-names></name><name><surname>Sanz</surname><given-names>P.J.</given-names></name></person-group><article-title>A natural interface for remote operation of underwater robots</article-title><source>IEEE Comput. Graph. Appl.</source><year>2015</year><volume>37</volume><fpage>34</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1109/MCG.2015.118</pub-id><?supplied-pmid 26571515?><pub-id pub-id-type="pmid">26571515</pub-id></element-citation></ref><ref id="B4-antibiotics-08-00157"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cook</surname><given-names>T.B.</given-names></name><name><surname>Pfleger</surname><given-names>B.F.</given-names></name></person-group><article-title>Leveraging synthetic biology for producing bioactive polyketides and non-ribosomal peptides in bacterial heterologous hosts</article-title><source>Medchemcomm</source><year>2019</year><volume>10</volume><fpage>668</fpage><lpage>681</lpage><pub-id pub-id-type="doi">10.1039/C9MD00055K</pub-id><?supplied-pmid 31191858?><pub-id pub-id-type="pmid">31191858</pub-id></element-citation></ref><ref id="B5-antibiotics-08-00157"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abu-Melha</surname><given-names>S.</given-names></name></person-group><article-title>Design, Synthesis and DFT/DNP Modeling Study of New 2-Amino-5-arylazothiazole Derivatives as Potential Antibacterial Agents</article-title><source>Molecules</source><year>2018</year><volume>23</volume><elocation-id>434</elocation-id><pub-id pub-id-type="doi">10.3390/molecules23020434</pub-id><?supplied-pmid 29462895?><pub-id pub-id-type="pmid">29462895</pub-id></element-citation></ref><ref id="B6-antibiotics-08-00157"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lenci</surname><given-names>E.</given-names></name><name><surname>Trabocchi</surname><given-names>A.</given-names></name></person-group><article-title>Smart Design of Small-Molecule Libraries: When Organic Synthesis Meets Cheminformatics</article-title><source>ChemBioChem</source><year>2019</year><volume>20</volume><fpage>1115</fpage><lpage>1123</lpage><pub-id pub-id-type="doi">10.1002/cbic.201800751</pub-id><?supplied-pmid 30589187?><pub-id pub-id-type="pmid">30589187</pub-id></element-citation></ref><ref id="B7-antibiotics-08-00157"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Musiol-Kroll</surname><given-names>E.</given-names></name><name><surname>Wohlleben</surname><given-names>W.</given-names></name></person-group><article-title>Acyltransferases as tools for polyketide synthase engineering</article-title><source>Antibiotics</source><year>2018</year><volume>7</volume><elocation-id>62</elocation-id><pub-id pub-id-type="doi">10.3390/antibiotics7030062</pub-id></element-citation></ref><ref id="B8-antibiotics-08-00157"><label>8.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Tong</surname><given-names>Y.</given-names></name><name><surname>Robertsen</surname><given-names>H.L.</given-names></name><name><surname>Blin</surname><given-names>K.</given-names></name><name><surname>Weber</surname><given-names>T.</given-names></name><name><surname>Lee</surname><given-names>S.Y.</given-names></name></person-group><article-title>CRISPR-Cas9 toolkit for Actinomycete genome editing</article-title><source>Synthetic Metabolic Pathways</source><publisher-name>Springer</publisher-name><publisher-loc>Berlin/Heidelberg, Germany</publisher-loc><year>2018</year><fpage>163</fpage><lpage>184</lpage></element-citation></ref><ref id="B9-antibiotics-08-00157"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blin</surname><given-names>K.</given-names></name><name><surname>Shaw</surname><given-names>S.</given-names></name><name><surname>Steinke</surname><given-names>K.</given-names></name><name><surname>Villebro</surname><given-names>R.</given-names></name><name><surname>Ziemert</surname><given-names>N.</given-names></name><name><surname>Lee</surname><given-names>S.Y.</given-names></name><name><surname>Medema</surname><given-names>M.H.</given-names></name><name><surname>Weber</surname><given-names>T.</given-names></name></person-group><article-title>antiSMASH 5.0: Updates to the secondary metabolite genome mining pipeline</article-title><source>Nucleic Acids Res.</source><year>2019</year><volume>47</volume><fpage>W81</fpage><lpage>W87</lpage><pub-id pub-id-type="doi">10.1093/nar/gkz310</pub-id><pub-id pub-id-type="pmid">31032519</pub-id></element-citation></ref><ref id="B10-antibiotics-08-00157"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Komaki</surname><given-names>H.</given-names></name><name><surname>Sakurai</surname><given-names>K.</given-names></name><name><surname>Hosoyama</surname><given-names>A.</given-names></name><name><surname>Kimura</surname><given-names>A.</given-names></name><name><surname>Igarashi</surname><given-names>Y.</given-names></name><name><surname>Tamura</surname><given-names>T.</given-names></name></person-group><article-title>Diversity of nonribosomal peptide synthetase and polyketide synthase gene clusters among taxonomically close <italic>Streptomyces</italic> strains</article-title><source>Sci. Rep.</source><year>2018</year><volume>8</volume><fpage>6888</fpage><pub-id pub-id-type="doi">10.1038/s41598-018-24921-y</pub-id><pub-id pub-id-type="pmid">29720592</pub-id></element-citation></ref><ref id="B11-antibiotics-08-00157"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nett</surname><given-names>M.</given-names></name><name><surname>Ikeda</surname><given-names>H.</given-names></name><name><surname>Moore</surname><given-names>B.S.</given-names></name></person-group><article-title>Genomic basis for natural product biosynthetic diversity in the actinomycetes</article-title><source>Nat. Prod. Rep.</source><year>2009</year><volume>26</volume><fpage>1362</fpage><lpage>1384</lpage><pub-id pub-id-type="doi">10.1039/b817069j</pub-id><pub-id pub-id-type="pmid">19844637</pub-id></element-citation></ref><ref id="B12-antibiotics-08-00157"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santos</surname><given-names>R.</given-names></name><name><surname>Ursu</surname><given-names>O.</given-names></name><name><surname>Gaulton</surname><given-names>A.</given-names></name><name><surname>Bento</surname><given-names>A.P.</given-names></name><name><surname>Donadi</surname><given-names>R.S.</given-names></name><name><surname>Bologa</surname><given-names>C.G.</given-names></name><name><surname>Karlsson</surname><given-names>A.</given-names></name><name><surname>Al-Lazikani</surname><given-names>B.</given-names></name><name><surname>Hersey</surname><given-names>A.</given-names></name><name><surname>Oprea</surname><given-names>T.I.</given-names></name><etal/></person-group><article-title>A comprehensive map of molecular drug targets</article-title><source>Nat. Rev. Drug Discov.</source><year>2017</year><volume>16</volume><fpage>19</fpage><pub-id pub-id-type="doi">10.1038/nrd.2016.230</pub-id><pub-id pub-id-type="pmid">27910877</pub-id></element-citation></ref><ref id="B13-antibiotics-08-00157"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>D.N.</given-names></name><name><surname>Harms</surname><given-names>J.M.</given-names></name><name><surname>Nierhaus</surname><given-names>K.H.</given-names></name><name><surname>Schl&#x000fc;nzen</surname><given-names>F.</given-names></name><name><surname>Fucini</surname><given-names>P.</given-names></name></person-group><article-title>Species-specific antibiotic-ribosome interactions: Implications for drug development</article-title><source>Biol. Chem.</source><year>2005</year><volume>386</volume><fpage>1239</fpage><lpage>1252</lpage><pub-id pub-id-type="doi">10.1515/BC.2005.141</pub-id><pub-id pub-id-type="pmid">16336118</pub-id></element-citation></ref><ref id="B14-antibiotics-08-00157"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koehbach</surname><given-names>J.</given-names></name><name><surname>Craik</surname><given-names>D.J.</given-names></name></person-group><article-title>The Vast Structural Diversity of Antimicrobial Peptides</article-title><source>Trends Pharmacol. Sci.</source><year>2019</year><volume>40</volume><fpage>517</fpage><lpage>528</lpage><pub-id pub-id-type="doi">10.1016/j.tips.2019.04.012</pub-id><pub-id pub-id-type="pmid">31230616</pub-id></element-citation></ref><ref id="B15-antibiotics-08-00157"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tenover</surname><given-names>F.C.</given-names></name></person-group><article-title>Mechanisms of antimicrobial resistance in bacteria</article-title><source>Am. J. Med.</source><year>2006</year><volume>119</volume><issue>Suppl. 1</issue><fpage>S3</fpage><lpage>S70</lpage><page-range>S3&#x02013;S10; discussion S62&#x02013;S70</page-range><pub-id pub-id-type="doi">10.1016/j.amjmed.2006.03.011</pub-id></element-citation></ref><ref id="B16-antibiotics-08-00157"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Du Toit</surname><given-names>A.</given-names></name></person-group><article-title>Antimicrobials: Putting antibiotic action into context</article-title><source>Nat. Rev. Microbiol.</source><year>2016</year><volume>14</volume><fpage>725</fpage><pub-id pub-id-type="doi">10.1038/nrmicro.2016.165</pub-id><pub-id pub-id-type="pmid">27795566</pub-id></element-citation></ref><ref id="B17-antibiotics-08-00157"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levy</surname><given-names>S.B.</given-names></name><name><surname>Marshall</surname><given-names>B.</given-names></name></person-group><article-title>Antibacterial resistance worldwide: Causes, challenges and responses</article-title><source>Nat. Med.</source><year>2004</year><volume>10</volume><fpage>S122</fpage><pub-id pub-id-type="doi">10.1038/nm1145</pub-id><pub-id pub-id-type="pmid">15577930</pub-id></element-citation></ref><ref id="B18-antibiotics-08-00157"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beckh</surname><given-names>W.</given-names></name><name><surname>Kulchar</surname><given-names>G.V.</given-names></name></person-group><article-title>Treatment-Resistant Syphilis: An Evaluation of the Causative Factors in Eighteen Cases</article-title><source>Arch. Derm. Syphilol.</source><year>1939</year><volume>40</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1001/archderm.1939.01490010004001</pub-id></element-citation></ref><ref id="B19-antibiotics-08-00157"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andersson</surname><given-names>D.I.</given-names></name><name><surname>Nicoloff</surname><given-names>H.</given-names></name><name><surname>Hjort</surname><given-names>K.</given-names></name></person-group><article-title>Mechanisms and clinical relevance of bacterial heteroresistance</article-title><source>Nat. Rev. Microbiol.</source><year>2019</year><volume>17</volume><fpage>479</fpage><lpage>496</lpage><pub-id pub-id-type="doi">10.1038/s41579-019-0218-1</pub-id><pub-id pub-id-type="pmid">31235888</pub-id></element-citation></ref><ref id="B20-antibiotics-08-00157"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hofer</surname><given-names>U.</given-names></name></person-group><article-title>The cost of antimicrobial resistance</article-title><source>Nat. Rev. Microbiol.</source><year>2019</year><volume>17</volume><fpage>3</fpage><pub-id pub-id-type="doi">10.1038/s41579-018-0125-x</pub-id><pub-id pub-id-type="pmid">30467331</pub-id></element-citation></ref><ref id="B21-antibiotics-08-00157"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eagle</surname><given-names>H.</given-names></name></person-group><article-title>The binding of penicillin in relation to its cytotoxic action: II. The reactivity with penicillin of resistant variants of <italic>Streptococci</italic>, <italic>Pneomocci</italic>, and <italic>Staphylococci</italic></article-title><source>J. Exp. Med.</source><year>1954</year><volume>100</volume><fpage>103</fpage><lpage>115</lpage><pub-id pub-id-type="doi">10.1084/jem.100.1.103</pub-id><pub-id pub-id-type="pmid">13163342</pub-id></element-citation></ref><ref id="B22-antibiotics-08-00157"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stekel</surname><given-names>D.</given-names></name></person-group><article-title>First report of antimicrobial resistance pre-dates penicillin</article-title><source>Nature</source><year>2018</year><volume>562</volume><fpage>192</fpage><pub-id pub-id-type="doi">10.1038/d41586-018-06983-0</pub-id></element-citation></ref><ref id="B23-antibiotics-08-00157"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frieri</surname><given-names>M.</given-names></name><name><surname>Kumar</surname><given-names>K.</given-names></name><name><surname>Boutin</surname><given-names>A.</given-names></name></person-group><article-title>Antibiotic resistance</article-title><source>J. Infect. Public Health</source><year>2017</year><volume>10</volume><fpage>369</fpage><lpage>378</lpage><pub-id pub-id-type="doi">10.1016/j.jiph.2016.08.007</pub-id><pub-id pub-id-type="pmid">27616769</pub-id></element-citation></ref><ref id="B24-antibiotics-08-00157"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turner</surname><given-names>N.A.</given-names></name><name><surname>Sharma-Kuinkel</surname><given-names>B.K.</given-names></name><name><surname>Maskarinec</surname><given-names>S.A.</given-names></name><name><surname>Eichenberger</surname><given-names>E.M.</given-names></name><name><surname>Shah</surname><given-names>P.P.</given-names></name><name><surname>Carugati</surname><given-names>M.</given-names></name><name><surname>Holland</surname><given-names>T.L.</given-names></name><name><surname>Fowler</surname><given-names>V.G.</given-names><suffix>Jr.</suffix></name></person-group><article-title>Methicillin-resistant <italic>Staphylococcus aureus</italic>: An overview of basic and clinical research</article-title><source>Nat. Rev. Microbiol.</source><year>2019</year><volume>17</volume><fpage>203</fpage><lpage>218</lpage><pub-id pub-id-type="doi">10.1038/s41579-018-0147-4</pub-id><pub-id pub-id-type="pmid">30737488</pub-id></element-citation></ref><ref id="B25-antibiotics-08-00157"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blair</surname><given-names>J.M.A.</given-names></name><name><surname>Webber</surname><given-names>M.A.</given-names></name><name><surname>Baylay</surname><given-names>A.J.</given-names></name><name><surname>Ogbolu</surname><given-names>D.O.</given-names></name><name><surname>Piddock</surname><given-names>L.J.V.</given-names></name></person-group><article-title>Molecular mechanisms of antibiotic resistance</article-title><source>Nat. Rev. Microbiol.</source><year>2015</year><volume>13</volume><fpage>42</fpage><pub-id pub-id-type="doi">10.1038/nrmicro3380</pub-id><pub-id pub-id-type="pmid">25435309</pub-id></element-citation></ref><ref id="B26-antibiotics-08-00157"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaur</surname><given-names>P.</given-names></name><name><surname>Peterson</surname><given-names>E.</given-names></name></person-group><article-title>Antibiotic resistance mechanisms in bacteria: Relationships between resistance determinants of antibiotic producers, environmental bacteria, and clinical pathogens</article-title><source>Front. Microbiol.</source><year>2018</year><volume>9</volume><fpage>2928</fpage><pub-id pub-id-type="pmid">30555448</pub-id></element-citation></ref><ref id="B27-antibiotics-08-00157"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pambos</surname><given-names>O.J.</given-names></name><name><surname>Kapanidis</surname><given-names>A.N.</given-names></name></person-group><article-title>Tracking antibiotic mechanisms</article-title><source>Nat. Rev. Microbiol.</source><year>2019</year><volume>17</volume><fpage>201</fpage><pub-id pub-id-type="doi">10.1038/s41579-019-0167-8</pub-id><pub-id pub-id-type="pmid">30804491</pub-id></element-citation></ref><ref id="B28-antibiotics-08-00157"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alanis</surname><given-names>A.J.</given-names></name></person-group><article-title>Resistance to antibiotics: Are we in the post-antibiotic era?</article-title><source>Arch. Med. Res.</source><year>2005</year><volume>36</volume><fpage>697</fpage><lpage>705</lpage><pub-id pub-id-type="doi">10.1016/j.arcmed.2005.06.009</pub-id><pub-id pub-id-type="pmid">16216651</pub-id></element-citation></ref><ref id="B29-antibiotics-08-00157"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carroll</surname><given-names>L.M.</given-names></name><name><surname>Gaballa</surname><given-names>A.</given-names></name><name><surname>Guldimann</surname><given-names>C.</given-names></name><name><surname>Sullivan</surname><given-names>G.</given-names></name><name><surname>Henderson</surname><given-names>L.O.</given-names></name><name><surname>Wiedmann</surname><given-names>M.</given-names></name></person-group><article-title>Identification of Novel Mobilized Colistin Resistance Gene <italic>mcr-9</italic> in a Multidrug-Resistant, Colistin-Susceptible <italic>Salmonella enterica</italic> Serotype <italic>Typhimurium</italic> Isolate</article-title><source>MBio</source><year>2019</year><volume>10</volume><fpage>e00853-19</fpage><pub-id pub-id-type="doi">10.1128/mBio.00853-19</pub-id><pub-id pub-id-type="pmid">31064835</pub-id></element-citation></ref><ref id="B30-antibiotics-08-00157"><label>30.</label><element-citation publication-type="web"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group><article-title>New report calls for urgent action to avert antimicrobial resistance crisis</article-title><source>Joint News Release</source><day>29</day><month>4</month><year>2019</year><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.who.int/news-room/detail/29-04-2019-new-report-calls-for-urgent-action-to-avert-antimicrobial-resistance-crisis">https://www.who.int/news-room/detail/29-04-2019-new-report-calls-for-urgent-action-to-avert-antimicrobial-resistance-crisis</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2019-08-25">(accessed on 25 August 2019)</date-in-citation></element-citation></ref><ref id="B31-antibiotics-08-00157"><label>31.</label><element-citation publication-type="web"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group><article-title>Antibiotic Resistance</article-title><year>2019</year><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.who.int/news-room/fact-sheets/detail/antibiotic-resistance">https://www.who.int/news-room/fact-sheets/detail/antibiotic-resistance</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2019-08-25">(accessed on 25 August 2019)</date-in-citation></element-citation></ref><ref id="B32-antibiotics-08-00157"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spellberg</surname><given-names>B.</given-names></name></person-group><article-title>The future of antibiotics</article-title><source>Crit. Care</source><year>2014</year><volume>18</volume><fpage>228</fpage><pub-id pub-id-type="doi">10.1186/cc13948</pub-id><pub-id pub-id-type="pmid">25043962</pub-id></element-citation></ref><ref id="B33-antibiotics-08-00157"><label>33.</label><element-citation publication-type="web"><person-group person-group-type="author"><collab>Pew Charitable Trusts</collab></person-group><article-title>Tracking the Pipeline of Antibiotics in Development</article-title><year>2019</year><comment>Available online: <ext-link ext-link-type="uri" xlink:href="http://www.pewtrusts.org/en/research-and-analysis/issue-briefs/2014/03/12/tracking-the-pipeline-of-antibiotics-in-development">http://www.pewtrusts.org/en/research-and-analysis/issue-briefs/2014/03/12/tracking-the-pipeline-of-antibiotics-in-development</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2019-08-25">(accessed on 25 August 2019)</date-in-citation></element-citation></ref><ref id="B34-antibiotics-08-00157"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Owens</surname><given-names>B.</given-names></name></person-group><article-title>Solithromycin rejection chills antibiotic sector</article-title><source>Nat. Biotechnol.</source><year>2017</year><volume>35</volume><fpage>187</fpage><lpage>188</lpage><pub-id pub-id-type="doi">10.1038/nbt0317-187</pub-id><pub-id pub-id-type="pmid">28267725</pub-id></element-citation></ref><ref id="B35-antibiotics-08-00157"><label>35.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Weissman</surname><given-names>K.</given-names></name></person-group><article-title>Chapter 1 Introduction to Polyketide Biosynthesis</article-title><source>Methods in Enzymology</source><publisher-name>Academic Press</publisher-name><publisher-loc>Cambridge, MA, USA</publisher-loc><year>2009</year><volume>Volume 459</volume><fpage>3</fpage><lpage>16</lpage></element-citation></ref><ref id="B36-antibiotics-08-00157"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>B.</given-names></name></person-group><article-title>Polyketide biosynthesis beyond the type I, II and III polyketide synthase paradigms</article-title><source>Curr. Opin. Chem. Biol.</source><year>2003</year><volume>7</volume><fpage>285</fpage><lpage>295</lpage><pub-id pub-id-type="doi">10.1016/S1367-5931(03)00020-6</pub-id><pub-id pub-id-type="pmid">12714063</pub-id></element-citation></ref><ref id="B37-antibiotics-08-00157"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hertweck</surname><given-names>C.</given-names></name></person-group><article-title>The biosynthetic logic of polyketide diversity</article-title><source>Angew. Chemie Int. Ed.</source><year>2009</year><volume>48</volume><fpage>4688</fpage><lpage>4716</lpage><pub-id pub-id-type="doi">10.1002/anie.200806121</pub-id></element-citation></ref><ref id="B38-antibiotics-08-00157"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ridley</surname><given-names>C.P.</given-names></name><name><surname>Lee</surname><given-names>H.Y.</given-names></name><name><surname>Khosla</surname><given-names>C.</given-names></name></person-group><article-title>Evolution of polyketide synthases in bacteria</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2008</year><volume>105</volume><fpage>4595</fpage><lpage>4600</lpage><pub-id pub-id-type="doi">10.1073/pnas.0710107105</pub-id><pub-id pub-id-type="pmid">18250311</pub-id></element-citation></ref><ref id="B39-antibiotics-08-00157"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>S&#x000fc;ssmuth</surname><given-names>R.D.</given-names></name><name><surname>Mainz</surname><given-names>A.</given-names></name></person-group><article-title>Nonribosomal peptide synthesis&#x02014;Principles and prospects</article-title><source>Angew. Chem. Int. Ed.</source><year>2017</year><volume>56</volume><fpage>3770</fpage><lpage>3821</lpage><pub-id pub-id-type="doi">10.1002/anie.201609079</pub-id></element-citation></ref><ref id="B40-antibiotics-08-00157"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Challis</surname><given-names>G.L.</given-names></name><name><surname>Wilkinson</surname><given-names>B.</given-names></name></person-group><article-title>Biosynthetic assembly lines themed issue</article-title><source>Nat. Prod. Rep.</source><year>2016</year><volume>33</volume><fpage>120</fpage><lpage>121</lpage><pub-id pub-id-type="doi">10.1039/C6NP90004F</pub-id><pub-id pub-id-type="pmid">26804663</pub-id></element-citation></ref><ref id="B41-antibiotics-08-00157"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Staunton</surname><given-names>J.</given-names></name><name><surname>Weissman</surname><given-names>K.J.</given-names></name></person-group><article-title>Polyketide biosynthesis: A millennium review</article-title><source>Nat. Prod. Rep.</source><year>2001</year><volume>18</volume><fpage>380</fpage><lpage>416</lpage><pub-id pub-id-type="doi">10.1039/a909079g</pub-id><pub-id pub-id-type="pmid">11548049</pub-id></element-citation></ref><ref id="B42-antibiotics-08-00157"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Helfrich</surname><given-names>E.J.N.</given-names></name><name><surname>Piel</surname><given-names>J.</given-names></name></person-group><article-title>Biosynthesis of polyketides by trans-AT polyketide synthases</article-title><source>Nat. Prod. Rep.</source><year>2016</year><volume>33</volume><fpage>231</fpage><lpage>316</lpage><pub-id pub-id-type="doi">10.1039/C5NP00125K</pub-id><pub-id pub-id-type="pmid">26689670</pub-id></element-citation></ref><ref id="B43-antibiotics-08-00157"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Musiol</surname><given-names>E.M.</given-names></name><name><surname>Weber</surname><given-names>T.</given-names></name></person-group><article-title>Discrete acyltransferases involved in polyketide biosynthesis</article-title><source>Medchemcomm</source><year>2012</year><volume>3</volume><fpage>871</fpage><lpage>886</lpage><pub-id pub-id-type="doi">10.1039/c2md20048a</pub-id></element-citation></ref><ref id="B44-antibiotics-08-00157"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meurer</surname><given-names>G.</given-names></name><name><surname>Gerlitz</surname><given-names>M.</given-names></name><name><surname>Wendt-Pienkowski</surname><given-names>E.</given-names></name><name><surname>Vining</surname><given-names>L.C.</given-names></name><name><surname>Rohr</surname><given-names>J.</given-names></name><name><surname>Hutchinson</surname><given-names>C.R.</given-names></name></person-group><article-title>Iterative type II polyketide synthases, cyclases and ketoreductases exhibit context-dependent behavior in the biosynthesis of linear and angular decapolyketides</article-title><source>Chem. Biol.</source><year>1997</year><volume>4</volume><fpage>433</fpage><lpage>443</lpage><pub-id pub-id-type="doi">10.1016/S1074-5521(97)90195-2</pub-id><pub-id pub-id-type="pmid">9224566</pub-id></element-citation></ref><ref id="B45-antibiotics-08-00157"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caffrey</surname><given-names>P.</given-names></name></person-group><article-title>Dissecting complex polyketide biosynthesis</article-title><source>Comput. Struct. Biotechnol. J.</source><year>2012</year><volume>3</volume><fpage>e201210010</fpage><pub-id pub-id-type="doi">10.5936/csbj.201210010</pub-id><pub-id pub-id-type="pmid">24688670</pub-id></element-citation></ref><ref id="B46-antibiotics-08-00157"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>A.</given-names></name><name><surname>Re</surname><given-names>R.N.</given-names></name><name><surname>Burkart</surname><given-names>M.D.</given-names></name></person-group><article-title>Type II fatty acid and polyketide synthases: Deciphering protein&#x02013;protein and protein&#x02013;substrate interactions</article-title><source>Nat. Prod. Rep.</source><year>2018</year><volume>35</volume><fpage>1029</fpage><lpage>1045</lpage><pub-id pub-id-type="doi">10.1039/C8NP00040A</pub-id><pub-id pub-id-type="pmid">30046786</pub-id></element-citation></ref><ref id="B47-antibiotics-08-00157"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herbst</surname><given-names>D.A.</given-names></name><name><surname>Townsend</surname><given-names>C.A.</given-names></name><name><surname>Maier</surname><given-names>T.</given-names></name></person-group><article-title>The architectures of iterative type I PKS and FAS</article-title><source>Nat. Prod. Rep.</source><year>2018</year><volume>35</volume><fpage>1046</fpage><lpage>1069</lpage><pub-id pub-id-type="doi">10.1039/C8NP00039E</pub-id><pub-id pub-id-type="pmid">30137093</pub-id></element-citation></ref><ref id="B48-antibiotics-08-00157"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>H.</given-names></name><name><surname>Du</surname><given-names>L.</given-names></name></person-group><article-title>Iterative polyketide biosynthesis by modular polyketide synthases in bacteria</article-title><source>Appl. Microbiol. Biotechnol.</source><year>2016</year><volume>100</volume><fpage>541</fpage><lpage>557</lpage><pub-id pub-id-type="doi">10.1007/s00253-015-7093-0</pub-id><pub-id pub-id-type="pmid">26549236</pub-id></element-citation></ref><ref id="B49-antibiotics-08-00157"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weber</surname><given-names>T.</given-names></name></person-group><article-title>Antibiotics: Biosynthesis, Generation of Novel Compounds</article-title><source>Encycl. Ind. Biotechnol.</source><year>2010</year><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1002/9780470054581.eib040</pub-id></element-citation></ref><ref id="B50-antibiotics-08-00157"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bloudoff</surname><given-names>K.</given-names></name><name><surname>Schmeing</surname><given-names>T.M.</given-names></name></person-group><article-title>Structural and functional aspects of the nonribosomal peptide synthetase condensation domain superfamily: Discovery, dissection and diversity</article-title><source>BBA Proteins Proteom.</source><year>2017</year><volume>1865</volume><fpage>1587</fpage><lpage>1604</lpage><pub-id pub-id-type="doi">10.1016/j.bbapap.2017.05.010</pub-id></element-citation></ref><ref id="B51-antibiotics-08-00157"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miyanaga</surname><given-names>A.</given-names></name><name><surname>Kudo</surname><given-names>F.</given-names></name><name><surname>Eguchi</surname><given-names>T.</given-names></name></person-group><article-title>Protein&#x02013;protein interactions in polyketide synthase&#x02013;nonribosomal peptide synthetase hybrid assembly lines</article-title><source>Nat. Prod. Rep.</source><year>2018</year><volume>35</volume><fpage>1185</fpage><lpage>1209</lpage><pub-id pub-id-type="doi">10.1039/C8NP00022K</pub-id><pub-id pub-id-type="pmid">30074030</pub-id></element-citation></ref><ref id="B52-antibiotics-08-00157"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McGuire</surname><given-names>J.M.</given-names></name><name><surname>Bunch</surname><given-names>R.L.</given-names></name><name><surname>Anderson</surname><given-names>R.C.</given-names></name><name><surname>Boaz</surname><given-names>H.E.</given-names></name><name><surname>Flynn</surname><given-names>E.H.</given-names></name><name><surname>Powell</surname><given-names>H.M.</given-names></name><name><surname>Smith</surname><given-names>J.W.</given-names></name></person-group><article-title>Ilotycin, a new antibiotic</article-title><source>Antibiot. Chemother. (Northfield, III.)</source><year>1952</year><volume>2</volume><fpage>281</fpage><lpage>283</lpage></element-citation></ref><ref id="B53-antibiotics-08-00157"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wiley</surname><given-names>P.F.</given-names></name><name><surname>Gerzon</surname><given-names>K.</given-names></name><name><surname>Flynn</surname><given-names>E.H.</given-names></name><name><surname>Sigal</surname><given-names>M.V.</given-names><suffix>Jr.</suffix></name><name><surname>Weaver</surname><given-names>O.</given-names></name><name><surname>Quarck</surname><given-names>U.C.</given-names></name><name><surname>Chauvette</surname><given-names>R.R.</given-names></name><name><surname>Monahan</surname><given-names>R.</given-names></name></person-group><article-title>Erythromycin. X. 1 Structure of Erythromycin</article-title><source>J. Am. Chem. Soc.</source><year>1957</year><volume>79</volume><fpage>6062</fpage><lpage>6070</lpage><pub-id pub-id-type="doi">10.1021/ja01579a059</pub-id></element-citation></ref><ref id="B54-antibiotics-08-00157"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harris</surname><given-names>D.R.</given-names></name><name><surname>McGeachin</surname><given-names>S.G.</given-names></name><name><surname>Mills</surname><given-names>H.H.</given-names></name></person-group><article-title>The structure and stereochemistry of erythromycin A</article-title><source>Tetrahedron Lett.</source><year>1965</year><volume>6</volume><fpage>679</fpage><lpage>685</lpage><pub-id pub-id-type="doi">10.1016/S0040-4039(00)90018-2</pub-id></element-citation></ref><ref id="B55-antibiotics-08-00157"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cortes</surname><given-names>J.</given-names></name><name><surname>Haydock</surname><given-names>S.F.</given-names></name><name><surname>Roberts</surname><given-names>G.A.</given-names></name><name><surname>Bevitt</surname><given-names>D.J.</given-names></name><name><surname>Leadlay</surname><given-names>P.F.</given-names></name></person-group><article-title>An unusually large multifunctional polypeptide in the erythromycin-producing polyketide synthase of <italic>Saccharopolyspora erythraea</italic></article-title><source>Nature</source><year>1990</year><volume>348</volume><fpage>176</fpage><pub-id pub-id-type="doi">10.1038/348176a0</pub-id><pub-id pub-id-type="pmid">2234082</pub-id></element-citation></ref><ref id="B56-antibiotics-08-00157"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Summers</surname><given-names>R.G.</given-names></name><name><surname>Donadio</surname><given-names>S.</given-names></name><name><surname>Staver</surname><given-names>M.J.</given-names></name><name><surname>Wendt-Pienkowski</surname><given-names>E.</given-names></name><name><surname>Hutchinson</surname><given-names>C.R.</given-names></name><name><surname>Katz</surname><given-names>L.</given-names></name></person-group><article-title>Sequencing and mutagenesis of genes from the erythromycin biosynthetic gene cluster of <italic>Saccharopolyspora erythraea</italic> that are involved in L-mycarose and D-desosamine production</article-title><source>Microbiology</source><year>1997</year><volume>143</volume><fpage>3251</fpage><lpage>3262</lpage><pub-id pub-id-type="doi">10.1099/00221287-143-10-3251</pub-id><pub-id pub-id-type="pmid">9353926</pub-id></element-citation></ref><ref id="B57-antibiotics-08-00157"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Donadio</surname><given-names>S.</given-names></name><name><surname>Staver</surname><given-names>M.</given-names></name><name><surname>McAlpine</surname><given-names>J.</given-names></name><name><surname>Swanson</surname><given-names>S.J.</given-names></name><name><surname>Katz</surname><given-names>L.</given-names></name></person-group><article-title>Modular Organization of Genes Required for Complex Polyketide Biosynthesis</article-title><source>Science</source><year>1991</year><volume>252</volume><fpage>675</fpage><lpage>679</lpage><pub-id pub-id-type="doi">10.1126/science.2024119</pub-id><pub-id pub-id-type="pmid">2024119</pub-id></element-citation></ref><ref id="B58-antibiotics-08-00157"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oliynyk</surname><given-names>M.</given-names></name><name><surname>Samborskyy</surname><given-names>M.</given-names></name><name><surname>Lester</surname><given-names>J.B.</given-names></name><name><surname>Mironenko</surname><given-names>T.</given-names></name><name><surname>Scott</surname><given-names>N.</given-names></name><name><surname>Dickens</surname><given-names>S.</given-names></name><name><surname>Haydock</surname><given-names>S.F.</given-names></name><name><surname>Leadlay</surname><given-names>P.F.</given-names></name></person-group><article-title>Complete genome sequence of the erythromycin-producing bacterium <italic>Saccharopolyspora erythraea</italic> NRRL23338</article-title><source>Nat. Biotechnol.</source><year>2007</year><volume>25</volume><fpage>447</fpage><pub-id pub-id-type="doi">10.1038/nbt1297</pub-id><pub-id pub-id-type="pmid">17369815</pub-id></element-citation></ref><ref id="B59-antibiotics-08-00157"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Wu</surname><given-names>J.</given-names></name><name><surname>Skalina</surname><given-names>K.</given-names></name><name><surname>Pfeifer</surname><given-names>B.A.</given-names></name></person-group><article-title>Complete biosynthesis of erythromycin A and designed analogs using <italic>E. coli</italic> as a heterologous host</article-title><source>Chem. Biol.</source><year>2010</year><volume>17</volume><fpage>1232</fpage><lpage>1240</lpage><pub-id pub-id-type="doi">10.1016/j.chembiol.2010.09.013</pub-id><pub-id pub-id-type="pmid">21095573</pub-id></element-citation></ref><ref id="B60-antibiotics-08-00157"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weissman</surname><given-names>K.J.</given-names></name></person-group><article-title>Genetic engineering of modular PKSs: From combinatorial biosynthesis to synthetic biology</article-title><source>Nat. Prod. Rep.</source><year>2016</year><volume>33</volume><fpage>203</fpage><lpage>230</lpage><pub-id pub-id-type="doi">10.1039/C5NP00109A</pub-id><pub-id pub-id-type="pmid">26555805</pub-id></element-citation></ref><ref id="B61-antibiotics-08-00157"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kibwage</surname><given-names>I.O.</given-names></name><name><surname>Hoogmartens</surname><given-names>J.</given-names></name><name><surname>Roets</surname><given-names>E.</given-names></name><name><surname>Vanderhaeghe</surname><given-names>H.</given-names></name><name><surname>Verbist</surname><given-names>L.</given-names></name><name><surname>Dubost</surname><given-names>M.</given-names></name><name><surname>Pascal</surname><given-names>C.</given-names></name><name><surname>Petitjean</surname><given-names>P.</given-names></name><name><surname>Levol</surname><given-names>G.</given-names></name></person-group><article-title>Antibacterial activities of erythromycins A, B, C, and D and some of their derivatives</article-title><source>Antimicrob. Agents Chemother.</source><year>1985</year><volume>28</volume><fpage>630</fpage><lpage>633</lpage><pub-id pub-id-type="doi">10.1128/AAC.28.5.630</pub-id><pub-id pub-id-type="pmid">4091529</pub-id></element-citation></ref><ref id="B62-antibiotics-08-00157"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amsden</surname><given-names>G.W.</given-names></name></person-group><article-title>Erythromycin, clarithromycin, and azithromycin: Are the differences real?</article-title><source>Clin. Ther.</source><year>1996</year><volume>18</volume><fpage>56</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1016/S0149-2918(96)80179-2</pub-id><pub-id pub-id-type="pmid">8851453</pub-id></element-citation></ref><ref id="B63-antibiotics-08-00157"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mazzei</surname><given-names>T.</given-names></name><name><surname>Mini</surname><given-names>E.</given-names></name><name><surname>Novelli</surname><given-names>A.</given-names></name><name><surname>Periti</surname><given-names>P.</given-names></name></person-group><article-title>Chemistry and mode of action of macrolides</article-title><source>J. Antimicrob. Chemother.</source><year>1993</year><volume>31</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1093/jac/31.suppl_C.1</pub-id></element-citation></ref><ref id="B64-antibiotics-08-00157"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vester</surname><given-names>B.</given-names></name><name><surname>Douthwaite</surname><given-names>S.</given-names></name></person-group><article-title>Macrolide resistance conferred by base substitutions in 23S rRNA</article-title><source>Antimicrob. Agents Chemother.</source><year>2001</year><volume>45</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1128/AAC.45.1.1-12.2001</pub-id><pub-id pub-id-type="pmid">11120937</pub-id></element-citation></ref><ref id="B65-antibiotics-08-00157"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tenson</surname><given-names>T.</given-names></name><name><surname>Lovmar</surname><given-names>M.</given-names></name><name><surname>Ehrenberg</surname><given-names>M.</given-names></name></person-group><article-title>The mechanism of action of macrolides, lincosamides and streptogramin B reveals the nascent peptide exit path in the ribosome</article-title><source>J. Mol. Biol.</source><year>2003</year><volume>330</volume><fpage>1005</fpage><lpage>1014</lpage><pub-id pub-id-type="doi">10.1016/S0022-2836(03)00662-4</pub-id><pub-id pub-id-type="pmid">12860123</pub-id></element-citation></ref><ref id="B66-antibiotics-08-00157"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Svetlov</surname><given-names>M.S.</given-names></name><name><surname>Plessa</surname><given-names>E.</given-names></name><name><surname>Chen</surname><given-names>C.W.</given-names></name><name><surname>Bougas</surname><given-names>A.</given-names></name><name><surname>Krokidis</surname><given-names>M.G.</given-names></name><name><surname>Dinos</surname><given-names>G.P.</given-names></name><name><surname>Polikanov</surname><given-names>Y.S.</given-names></name></person-group><article-title>High-resolution crystal structures of ribosome-bound chloramphenicol and erythromycin provide the ultimate basis for their competition</article-title><source>RNA</source><year>2019</year><volume>25</volume><fpage>600</fpage><lpage>606</lpage><pub-id pub-id-type="doi">10.1261/rna.069260.118</pub-id><pub-id pub-id-type="pmid">30733327</pub-id></element-citation></ref><ref id="B67-antibiotics-08-00157"><label>67.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Sobin</surname><given-names>B.A.</given-names></name><name><surname>English</surname><given-names>A.R.</given-names></name><name><surname>Celmer</surname><given-names>W.D.</given-names></name></person-group><article-title>PA 105, a new antibiotic</article-title><source>Antibiotics Annual</source><person-group person-group-type="editor"><name><surname>Welch</surname><given-names>H.</given-names></name><name><surname>Marti-Ibannez</surname><given-names>F.</given-names></name></person-group><publisher-name>Medical Encyclopedia Inc.</publisher-name><publisher-loc>New York, NY, USA</publisher-loc><year>1955</year><fpage>827</fpage><lpage>830</lpage></element-citation></ref><ref id="B68-antibiotics-08-00157"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>English</surname><given-names>A.R.</given-names></name><name><surname>McBride</surname><given-names>T.J.</given-names></name><name><surname>Van Halsema</surname><given-names>G.</given-names></name><name><surname>Caklozzi</surname><given-names>M.</given-names></name></person-group><article-title>Biologic studies on PA 775, a combination of tetracycline and oleandomycin with synergistic activity</article-title><source>Antibiot. Chemother.</source><year>1956</year><volume>6</volume><fpage>511</fpage><lpage>522</lpage></element-citation></ref><ref id="B69-antibiotics-08-00157"><label>69.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Podolsky</surname><given-names>S.H.</given-names></name></person-group><source>The Antibiotic Era: Reform, Resistance, and the Pursuit of a Rational Therapeutics</source><publisher-name>JHU Press</publisher-name><publisher-loc>Baltimore, MD, USA</publisher-loc><year>2015</year><fpage>1</fpage><lpage>328</lpage></element-citation></ref><ref id="B70-antibiotics-08-00157"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Albouy</surname><given-names>R.</given-names></name><name><surname>Duchesnay</surname><given-names>G.</given-names></name><name><surname>Eloy</surname><given-names>P.</given-names></name><name><surname>Pestel</surname><given-names>M.</given-names></name><name><surname>Ravina</surname><given-names>A.</given-names></name><name><surname>Rey</surname><given-names>M.</given-names></name></person-group><article-title>A new French antibiotic: Spiramycin</article-title><source>Antibiot. Annu.</source><year>1955</year><volume>3</volume><fpage>223</fpage><pub-id pub-id-type="pmid">13355270</pub-id></element-citation></ref><ref id="B71-antibiotics-08-00157"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kellow</surname><given-names>W.F.</given-names></name><name><surname>Lepper</surname><given-names>M.H.</given-names></name><name><surname>Plaut</surname><given-names>S.</given-names></name><name><surname>Rosenthal</surname><given-names>I.M.</given-names></name><name><surname>Spies</surname><given-names>H.W.</given-names></name></person-group><article-title>Spiramycin in the treatment of infection</article-title><source>Antibiot. Annu.</source><year>1955</year><volume>3</volume><fpage>658</fpage><pub-id pub-id-type="pmid">13355343</pub-id></element-citation></ref><ref id="B72-antibiotics-08-00157"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sutherland</surname><given-names>R.</given-names></name></person-group><article-title>Spiramycin: A reappraisal of its antibacterial activity</article-title><source>Br. J. Pharmacol. Chemother.</source><year>1962</year><volume>19</volume><fpage>99</fpage><lpage>110</lpage><pub-id pub-id-type="doi">10.1111/j.1476-5381.1962.tb01430.x</pub-id><pub-id pub-id-type="pmid">19108164</pub-id></element-citation></ref><ref id="B73-antibiotics-08-00157"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fernandes</surname><given-names>P.</given-names></name><name><surname>Martens</surname><given-names>E.</given-names></name><name><surname>Pereira</surname><given-names>D.</given-names></name></person-group><article-title>Nature nurtures the design of new semi-synthetic macrolide antibiotics</article-title><source>J. Antibiot. (Tokyo)</source><year>2016</year><volume>70</volume><fpage>527</fpage><pub-id pub-id-type="doi">10.1038/ja.2016.137</pub-id><pub-id pub-id-type="pmid">27899792</pub-id></element-citation></ref><ref id="B74-antibiotics-08-00157"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barry</surname><given-names>A.L.</given-names></name><name><surname>Jones</surname><given-names>R.N.</given-names></name><name><surname>Thornsberry</surname><given-names>C.</given-names></name></person-group><article-title>In vitro activities of azithromycin (CP 62,993), clarithromycin (A-56268; TE-031), erythromycin, roxithromycin, and clindamycin</article-title><source>Antimicrob. Agents Chemother.</source><year>1988</year><volume>32</volume><fpage>752</fpage><lpage>754</lpage><pub-id pub-id-type="doi">10.1128/AAC.32.5.752</pub-id><pub-id pub-id-type="pmid">2840016</pub-id></element-citation></ref><ref id="B75-antibiotics-08-00157"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watanabe</surname><given-names>Y.</given-names></name><name><surname>Moritomo</surname><given-names>S.</given-names></name><name><surname>Adachi</surname><given-names>T.</given-names></name><name><surname>Kashimure</surname><given-names>M.</given-names></name><name><surname>Asaka</surname><given-names>T.</given-names></name></person-group><article-title>Chemical modification of erythromycin. IX. 1</article-title><source>J. Antibiot. (Tokyo)</source><year>1993</year><volume>46</volume><fpage>647</fpage><lpage>660</lpage><pub-id pub-id-type="doi">10.7164/antibiotics.46.647</pub-id><pub-id pub-id-type="pmid">8501007</pub-id></element-citation></ref><ref id="B76-antibiotics-08-00157"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barlam</surname><given-names>T.</given-names></name><name><surname>Neu</surname><given-names>H.C.</given-names></name></person-group><article-title>In vitro comparison of the activity of RU 28965, a new macrolide, with that of erythromycin against aerobic and anaerobic bacteria</article-title><source>Antimicrob. Agents Chemother.</source><year>1984</year><volume>25</volume><fpage>529</fpage><lpage>531</lpage><pub-id pub-id-type="doi">10.1128/AAC.25.4.529</pub-id><pub-id pub-id-type="pmid">6732223</pub-id></element-citation></ref><ref id="B77-antibiotics-08-00157"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jorgensen</surname><given-names>J.H.</given-names></name><name><surname>Redding</surname><given-names>J.S.</given-names></name><name><surname>Howell</surname><given-names>A.W.</given-names></name></person-group><article-title>In vitro <italic>activity</italic> of the new macrolide antibiotic roxithromycin (RU 28965) against clinical isolates of <italic>Haemophilus influenzae</italic></article-title><source>Antimicrob. Agents Chemother.</source><year>1986</year><volume>29</volume><fpage>921</fpage><lpage>922</lpage><pub-id pub-id-type="doi">10.1128/AAC.29.5.921</pub-id><pub-id pub-id-type="pmid">3488019</pub-id></element-citation></ref><ref id="B78-antibiotics-08-00157"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mutak</surname><given-names>S.</given-names></name></person-group><article-title>Azalides from azithromycin to new azalide derivatives</article-title><source>J. Antibiot. (Tokyo)</source><year>2007</year><volume>60</volume><fpage>85</fpage><pub-id pub-id-type="doi">10.1038/ja.2007.10</pub-id><pub-id pub-id-type="pmid">17420561</pub-id></element-citation></ref><ref id="B79-antibiotics-08-00157"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Retsema</surname><given-names>J.</given-names></name><name><surname>Girard</surname><given-names>A.</given-names></name><name><surname>Schelkly</surname><given-names>W.</given-names></name><name><surname>Manousos</surname><given-names>M.</given-names></name><name><surname>Anderson</surname><given-names>M.</given-names></name><name><surname>Bright</surname><given-names>G.</given-names></name><name><surname>Borovoy</surname><given-names>R.</given-names></name><name><surname>Brennan</surname><given-names>L.</given-names></name><name><surname>Mason</surname><given-names>R.</given-names></name></person-group><article-title>Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms</article-title><source>Antimicrob. Agents Chemother.</source><year>1987</year><volume>31</volume><fpage>1939</fpage><lpage>1947</lpage><pub-id pub-id-type="doi">10.1128/AAC.31.12.1939</pub-id><pub-id pub-id-type="pmid">2449865</pub-id></element-citation></ref><ref id="B80-antibiotics-08-00157"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bryskier</surname><given-names>A.</given-names></name></person-group><article-title>Ketolides&#x02014;Telithromycin, an example of a new class of antibacterial agents</article-title><source>Clin. Microbiol. Infect.</source><year>2000</year><volume>6</volume><fpage>661</fpage><lpage>669</lpage><pub-id pub-id-type="doi">10.1046/j.1469-0691.2000.00185.x</pub-id><pub-id pub-id-type="pmid">11284926</pub-id></element-citation></ref><ref id="B81-antibiotics-08-00157"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ednie</surname><given-names>L.M.</given-names></name><name><surname>Jacobs</surname><given-names>M.R.</given-names></name><name><surname>Appelbaum</surname><given-names>P.C.</given-names></name></person-group><article-title>Comparative antianaerobic activities of the ketolides HMR 3647 (RU 66647) and HMR 3004 (RU 64004)</article-title><source>Antimicrob. Agents Chemother.</source><year>1997</year><volume>41</volume><fpage>2019</fpage><lpage>2022</lpage><pub-id pub-id-type="doi">10.1128/AAC.41.9.2019</pub-id><pub-id pub-id-type="pmid">9303406</pub-id></element-citation></ref><ref id="B82-antibiotics-08-00157"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ross</surname><given-names>D.B.</given-names></name></person-group><article-title>The FDA and the case of Ketek</article-title><source>N. Engl. J. Med.</source><year>2007</year><volume>356</volume><fpage>1601</fpage><lpage>1604</lpage><pub-id pub-id-type="doi">10.1056/NEJMp078032</pub-id><pub-id pub-id-type="pmid">17442902</pub-id></element-citation></ref><ref id="B83-antibiotics-08-00157"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McGhee</surname><given-names>P.</given-names></name><name><surname>Clark</surname><given-names>C.</given-names></name><name><surname>Kosowska-Shick</surname><given-names>K.M.</given-names></name><name><surname>Nagai</surname><given-names>K.</given-names></name><name><surname>Dewasse</surname><given-names>B.</given-names></name><name><surname>Beachel</surname><given-names>L.</given-names></name><name><surname>Appelbaum</surname><given-names>P.C.</given-names></name></person-group><article-title>In vitro activity of CEM-101 against <italic>Streptococcus pneumoniae</italic> and <italic>Streptococcus pyogenes</italic> with defined macrolide resistance mechanisms</article-title><source>Antimicrob. Agents Chemother.</source><year>2010</year><volume>54</volume><fpage>230</fpage><lpage>238</lpage><pub-id pub-id-type="doi">10.1128/AAC.01123-09</pub-id><pub-id pub-id-type="pmid">19884376</pub-id></element-citation></ref><ref id="B84-antibiotics-08-00157"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodvold</surname><given-names>K.A.</given-names></name><name><surname>Gotfried</surname><given-names>M.H.</given-names></name><name><surname>Chugh</surname><given-names>R.</given-names></name><name><surname>Gupta</surname><given-names>M.</given-names></name><name><surname>Friedland</surname><given-names>H.D.</given-names></name><name><surname>Bhatia</surname><given-names>A.</given-names></name></person-group><article-title>Comparison of plasma and intrapulmonary concentrations of nafithromycin (WCK 4873) in healthy adult subjects</article-title><source>Antimicrob. Agents Chemother.</source><year>2017</year><volume>61</volume><fpage>e01096-17</fpage><pub-id pub-id-type="doi">10.1128/AAC.01096-17</pub-id><pub-id pub-id-type="pmid">28696231</pub-id></element-citation></ref><ref id="B85-antibiotics-08-00157"><label>85.</label><element-citation publication-type="web"><person-group person-group-type="author"><collab>World Health Organisation</collab></person-group><article-title>Antibacterial Agents in Clinical Development</article-title><year>2018</year><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://apps.who.int/iris/handle/10665/275487">https://apps.who.int/iris/handle/10665/275487</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2019-08-25">(accessed on 25 August 2019)</date-in-citation></element-citation></ref><ref id="B86-antibiotics-08-00157"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McGuire</surname><given-names>J.M.</given-names></name><name><surname>Boniece</surname><given-names>W.S.</given-names></name><name><surname>Higgens</surname><given-names>C.E.</given-names></name><name><surname>Hoehn</surname><given-names>M.M.</given-names></name><name><surname>Stark</surname><given-names>W.M.</given-names></name><name><surname>Westhead</surname><given-names>J.</given-names></name><name><surname>Wolfe</surname><given-names>R.N.</given-names></name></person-group><article-title>Tylosin, a New Antibiotic: I. Microbiological Studies</article-title><source>Antibiot. Chemother.</source><year>1961</year><volume>11</volume><fpage>320</fpage><lpage>327</lpage></element-citation></ref><ref id="B87-antibiotics-08-00157"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cundliffe</surname><given-names>E.</given-names></name><name><surname>Bate</surname><given-names>N.</given-names></name><name><surname>Butler</surname><given-names>A.</given-names></name><name><surname>Fish</surname><given-names>S.</given-names></name><name><surname>Gandecha</surname><given-names>A.</given-names></name><name><surname>Merson-Davies</surname><given-names>L.</given-names></name></person-group><article-title>The tylosin-biosynthetic genes of <italic>Streptomyces fradiae</italic></article-title><source>Antonie Van Leeuwenhoek</source><year>2001</year><volume>79</volume><fpage>229</fpage><lpage>234</lpage><pub-id pub-id-type="doi">10.1023/A:1012065300116</pub-id><pub-id pub-id-type="pmid">11816964</pub-id></element-citation></ref><ref id="B88-antibiotics-08-00157"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baltz</surname><given-names>R.H.</given-names></name><name><surname>Seno</surname><given-names>E.T.</given-names></name></person-group><article-title>Genetics of <italic>Streptomyces fradiae</italic> and tylosin biosynthesis</article-title><source>Annu. Rev. Microbiol.</source><year>1988</year><volume>42</volume><fpage>547</fpage><lpage>574</lpage><pub-id pub-id-type="doi">10.1146/annurev.mi.42.100188.002555</pub-id><pub-id pub-id-type="pmid">3060001</pub-id></element-citation></ref><ref id="B89-antibiotics-08-00157"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tejedor</surname><given-names>F.</given-names></name><name><surname>Ballesta</surname><given-names>J.P.G.</given-names></name></person-group><article-title>Ribosome structure: Binding site of macrolides studied by photoaffinity labeling</article-title><source>Biochemistry</source><year>1985</year><volume>24</volume><fpage>467</fpage><lpage>472</lpage><pub-id pub-id-type="doi">10.1021/bi00323a033</pub-id><pub-id pub-id-type="pmid">3884043</pub-id></element-citation></ref><ref id="B90-antibiotics-08-00157"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ose</surname><given-names>E.E.</given-names></name></person-group><article-title>In vitro antibacterial properties of EL-870, a new semi-synthetic macrolide antibiotic</article-title><source>J. Antibiot. (Tokyo)</source><year>1987</year><volume>40</volume><fpage>190</fpage><lpage>194</lpage><pub-id pub-id-type="doi">10.7164/antibiotics.40.190</pub-id><pub-id pub-id-type="pmid">3570967</pub-id></element-citation></ref><ref id="B91-antibiotics-08-00157"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Debono</surname><given-names>M.</given-names></name><name><surname>Willard</surname><given-names>K.E.</given-names></name><name><surname>Kirst</surname><given-names>H.A.</given-names></name><name><surname>Wind</surname><given-names>J.A.</given-names></name><name><surname>Crouse</surname><given-names>G.D.</given-names></name><name><surname>Tao</surname><given-names>E.V.</given-names></name><name><surname>Vicenzi</surname><given-names>J.T.</given-names></name><name><surname>Counter</surname><given-names>F.T.</given-names></name><name><surname>Ott</surname><given-names>J.L.</given-names></name><name><surname>Ose</surname><given-names>E.E.</given-names></name><etal/></person-group><article-title>Synthesis and antimicrobial evaluation of 20-deoxo-20-(3,5-dimethylpiperidin-1-yl) desmycosin (tilmicosin, EL-870) and related cyclic amino derivatives</article-title><source>J. Antibiot. (Tokyo)</source><year>1989</year><volume>42</volume><fpage>1253</fpage><lpage>1267</lpage><pub-id pub-id-type="doi">10.7164/antibiotics.42.1253</pub-id><pub-id pub-id-type="pmid">2668243</pub-id></element-citation></ref><ref id="B92-antibiotics-08-00157"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Michael</surname><given-names>G.B.</given-names></name><name><surname>Eidam</surname><given-names>C.</given-names></name><name><surname>Kadlec</surname><given-names>K.</given-names></name><name><surname>Meyer</surname><given-names>K.</given-names></name><name><surname>Sweeney</surname><given-names>M.T.</given-names></name><name><surname>Murray</surname><given-names>R.W.</given-names></name><name><surname>Watts</surname><given-names>J.L.</given-names></name><name><surname>Schwarz</surname><given-names>S.</given-names></name></person-group><article-title>Increased MICs of gamithromycin and tildipirosin in the presence of the genes <italic>erm (42)</italic> and <italic>msr(E)-mph(E)</italic> for bovine <italic>Pasteurella multocida</italic> and <italic>Mannheimia haemolytica</italic></article-title><source>J. Antimicrob. Chemother.</source><year>2012</year><volume>67</volume><fpage>1555</fpage><lpage>1557</lpage><pub-id pub-id-type="doi">10.1093/jac/dks076</pub-id><pub-id pub-id-type="pmid">22398653</pub-id></element-citation></ref><ref id="B93-antibiotics-08-00157"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Menge</surname><given-names>M.</given-names></name><name><surname>Rose</surname><given-names>M.</given-names></name><name><surname>Bohland</surname><given-names>C.</given-names></name><name><surname>Zschiesche</surname><given-names>E.</given-names></name><name><surname>Kilp</surname><given-names>S.</given-names></name><name><surname>Metz</surname><given-names>W.</given-names></name><name><surname>Allan</surname><given-names>M.</given-names></name><name><surname>R&#x000f6;pke</surname><given-names>R.</given-names></name><name><surname>N&#x000fc;rnberger</surname><given-names>M.</given-names></name></person-group><article-title>Pharmacokinetics of tildipirosin in bovine plasma, lung tissue, and bronchial fluid (from live, nonanesthetized cattle)</article-title><source>J. Vet. Pharmacol. Ther.</source><year>2012</year><volume>35</volume><fpage>550</fpage><lpage>559</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2885.2011.01349.x</pub-id><pub-id pub-id-type="pmid">22188102</pub-id></element-citation></ref><ref id="B94-antibiotics-08-00157"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Evans</surname><given-names>N.A.</given-names></name></person-group><article-title>Tulathromycin: An overview of a new triamilide antimicrobial for livestock respiratory disease</article-title><source>Vet. Ther.</source><year>2005</year><volume>6</volume><fpage>83</fpage><pub-id pub-id-type="pmid">16094557</pub-id></element-citation></ref><ref id="B95-antibiotics-08-00157"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>R.A.</given-names></name><name><surname>Letendre</surname><given-names>L.T.</given-names></name><name><surname>Banav</surname><given-names>N.</given-names></name><name><surname>Fischer</surname><given-names>J.</given-names></name><name><surname>Somerville</surname><given-names>B.</given-names></name></person-group><article-title>Pharmacokinetics of gamithromycin in cattle with comparison of plasma and lung tissue concentrations and plasma antibacterial activity</article-title><source>J. Vet. Pharmacol. Ther.</source><year>2010</year><volume>33</volume><fpage>227</fpage><lpage>237</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2885.2009.01125.x</pub-id><pub-id pub-id-type="pmid">20557439</pub-id></element-citation></ref><ref id="B96-antibiotics-08-00157"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agtarap</surname><given-names>A.</given-names></name><name><surname>Chamberlin</surname><given-names>J.W.</given-names></name><name><surname>Pinkerton</surname><given-names>M.</given-names></name><name><surname>Steinrauf</surname><given-names>L.K.</given-names></name></person-group><article-title>Structure of monensic acid, a new biologically active compound</article-title><source>J. Am. Chem. Soc.</source><year>1967</year><volume>89</volume><fpage>5737</fpage><lpage>5739</lpage><pub-id pub-id-type="doi">10.1021/ja00998a062</pub-id><pub-id pub-id-type="pmid">5622366</pub-id></element-citation></ref><ref id="B97-antibiotics-08-00157"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chapman</surname><given-names>H.D.</given-names></name><name><surname>Jeffers</surname><given-names>T.K.</given-names></name><name><surname>Williams</surname><given-names>R.B.</given-names></name></person-group><article-title>Forty years of monensin for the control of coccidiosis in poultry</article-title><source>Poult. Sci.</source><year>2010</year><volume>89</volume><fpage>1788</fpage><lpage>1801</lpage><pub-id pub-id-type="doi">10.3382/ps.2010-00931</pub-id><pub-id pub-id-type="pmid">20709963</pub-id></element-citation></ref><ref id="B98-antibiotics-08-00157"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oliynyk</surname><given-names>M.</given-names></name><name><surname>Stark</surname><given-names>C.B.</given-names></name><name><surname>Bhatt</surname><given-names>A.</given-names></name><name><surname>Jones</surname><given-names>M.A.</given-names></name><name><surname>Hughes-Thomas</surname><given-names>Z.A.</given-names></name><name><surname>Wilkinson</surname><given-names>C.</given-names></name><name><surname>Oliynyk</surname><given-names>Z.</given-names></name><name><surname>Demydchuk</surname><given-names>Y.</given-names></name><name><surname>Staunton</surname><given-names>J.</given-names></name><name><surname>Leadlay</surname><given-names>P.F.</given-names></name></person-group><article-title>Analysis of the biosynthetic gene cluster for the polyether antibiotic monensin in <italic>Streptomyces cinnamonensis</italic> and evidence for the role of <italic>monB</italic> and <italic>monC</italic> genes in oxidative cyclization</article-title><source>Mol. Microbiol.</source><year>2003</year><volume>49</volume><fpage>1179</fpage><lpage>1190</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2958.2003.03571.x</pub-id><pub-id pub-id-type="pmid">12940979</pub-id></element-citation></ref><ref id="B99-antibiotics-08-00157"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goodrich</surname><given-names>R.D.</given-names></name><name><surname>Garrett</surname><given-names>J.E.</given-names></name><name><surname>Gast</surname><given-names>D.R.</given-names></name><name><surname>Kirick</surname><given-names>M.A.</given-names></name><name><surname>Larson</surname><given-names>D.A.</given-names></name><name><surname>Meiske</surname><given-names>J.C.</given-names></name></person-group><article-title>Influence of monensin on the performance of cattle</article-title><source>J. Anim. Sci.</source><year>1984</year><volume>58</volume><fpage>1484</fpage><lpage>1498</lpage><pub-id pub-id-type="doi">10.2527/jas1984.5861484x</pub-id><pub-id pub-id-type="pmid">6378865</pub-id></element-citation></ref><ref id="B100-antibiotics-08-00157"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hochlowski</surname><given-names>J.E.</given-names></name><name><surname>Swanson</surname><given-names>S.J.</given-names></name><name><surname>Ranfranz</surname><given-names>L.M.</given-names></name><name><surname>Whittern</surname><given-names>D.N.</given-names></name><name><surname>Buko</surname><given-names>A.M.</given-names></name><name><surname>McAlpine</surname><given-names>J.B.</given-names></name></person-group><article-title>Tiacumicins, A Novel Complex of 18-Membered Macrolides</article-title><source>J. Antibiot. (Tokyo)</source><year>1987</year><volume>40</volume><fpage>575</fpage><lpage>588</lpage><pub-id pub-id-type="doi">10.7164/antibiotics.40.575</pub-id><pub-id pub-id-type="pmid">3610816</pub-id></element-citation></ref><ref id="B101-antibiotics-08-00157"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>S.</given-names></name><name><surname>Niu</surname><given-names>S.</given-names></name><name><surname>Ma</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>G.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Zhang</surname><given-names>G.</given-names></name><name><surname>Ju</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>C.</given-names></name></person-group><article-title>Characterization of tiacumicin B biosynthetic gene cluster affording diversified tiacumicin analogues and revealing a tailoring dihalogenase</article-title><source>J. Am. Chem. Soc.</source><year>2011</year><volume>133</volume><fpage>1092</fpage><lpage>1105</lpage><pub-id pub-id-type="doi">10.1021/ja109445q</pub-id><pub-id pub-id-type="pmid">21186805</pub-id></element-citation></ref><ref id="B102-antibiotics-08-00157"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Swanson</surname><given-names>R.N.</given-names></name><name><surname>Hardy</surname><given-names>D.J.</given-names></name><name><surname>Shipkowitz</surname><given-names>N.L.</given-names></name><name><surname>Hanson</surname><given-names>C.W.</given-names></name><name><surname>Ramer</surname><given-names>N.C.</given-names></name><name><surname>Fernandes</surname><given-names>P.B.</given-names></name><name><surname>Clement</surname><given-names>J.J.</given-names></name></person-group><article-title>In vitro and in vivo evaluation of tiacumicins B and C against <italic>Clostridium difficile</italic></article-title><source>Antimicrob. Agents Chemother.</source><year>1991</year><volume>35</volume><fpage>1108</fpage><lpage>1111</lpage><pub-id pub-id-type="doi">10.1128/AAC.35.6.1108</pub-id><pub-id pub-id-type="pmid">1929250</pub-id></element-citation></ref><ref id="B103-antibiotics-08-00157"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>W.</given-names></name><name><surname>Das</surname><given-names>K.</given-names></name><name><surname>Degen</surname><given-names>D.</given-names></name><name><surname>Mazumder</surname><given-names>A.</given-names></name><name><surname>Duchi</surname><given-names>D.</given-names></name><name><surname>Wang</surname><given-names>D.</given-names></name><name><surname>Ebright</surname><given-names>Y.W.</given-names></name><name><surname>Ebright</surname><given-names>R.Y.</given-names></name><name><surname>Sineva</surname><given-names>E.</given-names></name><name><surname>Gigliotti</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Structural Basis of Transcription Inhibition by Fidaxomicin (Lipiarmycin A3)</article-title><source>Mol. Cell</source><year>2018</year><volume>70</volume><fpage>60</fpage><lpage>71.e15</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2018.02.026</pub-id><pub-id pub-id-type="pmid">29606590</pub-id></element-citation></ref><ref id="B104-antibiotics-08-00157"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prelog</surname><given-names>V.</given-names></name><name><surname>Oppolzer</surname><given-names>W.</given-names></name></person-group><article-title>Ansamycine, eine neuartige Klasse von mikrobiellen Stoffwechselprodukten</article-title><source>Helv. Chim. Acta</source><year>1973</year><volume>56</volume><fpage>2279</fpage><lpage>2287</lpage><pub-id pub-id-type="doi">10.1002/hlca.19730560716</pub-id></element-citation></ref><ref id="B105-antibiotics-08-00157"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Floss</surname><given-names>H.G.</given-names></name><name><surname>Yu</surname><given-names>T.W.</given-names></name></person-group><article-title>Rifamycin mode of action, resistance, and biosynthesis</article-title><source>Chem. Rev.</source><year>2005</year><volume>105</volume><fpage>621</fpage><lpage>632</lpage><pub-id pub-id-type="doi">10.1021/cr030112j</pub-id><pub-id pub-id-type="pmid">15700959</pub-id></element-citation></ref><ref id="B106-antibiotics-08-00157"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sensi</surname><given-names>P.</given-names></name><name><surname>Margalith</surname><given-names>P.</given-names></name><name><surname>Timbal</surname><given-names>M.T.</given-names></name></person-group><article-title>Rifomycin, a new antibiotic; preliminary report</article-title><source>Farm. Sci.</source><year>1959</year><volume>14</volume><fpage>146</fpage></element-citation></ref><ref id="B107-antibiotics-08-00157"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>August</surname><given-names>P.R.</given-names></name><name><surname>Tang</surname><given-names>L.</given-names></name><name><surname>Yoon</surname><given-names>Y.J.</given-names></name><name><surname>Ning</surname><given-names>S.</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>R.</given-names></name><name><surname>Yu</surname><given-names>T.W.</given-names></name><name><surname>Taylor</surname><given-names>M.</given-names></name><name><surname>Hoffmann</surname><given-names>D.</given-names></name><name><surname>Kim</surname><given-names>C.G.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Biosynthesis of the ansamycin antibiotic rifamycin: Deductions from the molecular analysis of the rif biosynthetic gene cluster of <italic>Amycolatopsis mediterranei</italic> S699</article-title><source>Chem. Biol.</source><year>1998</year><volume>5</volume><fpage>69</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.1016/S1074-5521(98)90141-7</pub-id><pub-id pub-id-type="pmid">9512878</pub-id></element-citation></ref><ref id="B108-antibiotics-08-00157"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watanabe</surname><given-names>K.</given-names></name><name><surname>Rude</surname><given-names>M.A.</given-names></name><name><surname>Walsh</surname><given-names>C.T.</given-names></name><name><surname>Khosla</surname><given-names>C.</given-names></name></person-group><article-title>Engineered biosynthesis of an ansamycin polyketide precursor in <italic>Escherichia coli</italic></article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2003</year><volume>100</volume><fpage>9774</fpage><lpage>9778</lpage><pub-id pub-id-type="doi">10.1073/pnas.1632167100</pub-id><pub-id pub-id-type="pmid">12888623</pub-id></element-citation></ref><ref id="B109-antibiotics-08-00157"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoy</surname><given-names>S.M.</given-names></name></person-group><article-title>Rifamycin SV MMX<sup>&#x000ae;</sup>: A Review in the Treatment of Traveller&#x02019;s Diarrhoea</article-title><source>Clin. Drug Investig.</source><year>2019</year><volume>39</volume><fpage>691</fpage><lpage>697</lpage><pub-id pub-id-type="doi">10.1007/s40261-019-00808-2</pub-id></element-citation></ref><ref id="B110-antibiotics-08-00157"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maggi</surname><given-names>N.</given-names></name><name><surname>Pasqualucci</surname><given-names>C.R.</given-names></name><name><surname>Ballotta</surname><given-names>R.</given-names></name><name><surname>Sensi</surname><given-names>P.</given-names></name></person-group><article-title>Rifampicin: A new orally active rifamycin</article-title><source>Chemotherapy</source><year>1966</year><volume>11</volume><fpage>285</fpage><lpage>292</lpage><pub-id pub-id-type="doi">10.1159/000220462</pub-id><pub-id pub-id-type="pmid">5958716</pub-id></element-citation></ref><ref id="B111-antibiotics-08-00157"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campbell</surname><given-names>E.A.</given-names></name><name><surname>Korzheva</surname><given-names>N.</given-names></name><name><surname>Mustaev</surname><given-names>A.</given-names></name><name><surname>Murakami</surname><given-names>K.</given-names></name><name><surname>Nair</surname><given-names>S.</given-names></name><name><surname>Goldfarb</surname><given-names>A.</given-names></name><name><surname>Darst</surname><given-names>S.A.</given-names></name></person-group><article-title>Structural mechanism for rifampicin inhibition of bacterial RNA polymerase</article-title><source>Cell</source><year>2001</year><volume>104</volume><fpage>901</fpage><lpage>912</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(01)00286-0</pub-id><pub-id pub-id-type="pmid">11290327</pub-id></element-citation></ref><ref id="B112-antibiotics-08-00157"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Della Bruna</surname><given-names>C.</given-names></name><name><surname>Schioppacassi</surname><given-names>G.</given-names></name><name><surname>Ungheri</surname><given-names>D.</given-names></name><name><surname>Jab&#x000e8;s</surname><given-names>D.</given-names></name><name><surname>Morvillo</surname><given-names>E.</given-names></name><name><surname>Sanfilippo</surname><given-names>A.</given-names></name></person-group><article-title>LM 427, a new spiropiperidylrifamycin: In vitro and in vivo studies</article-title><source>J. Antibiot. (Tokyo)</source><year>1983</year><volume>36</volume><fpage>1502</fpage><lpage>1506</lpage><pub-id pub-id-type="doi">10.7164/antibiotics.36.1502</pub-id><pub-id pub-id-type="pmid">6317622</pub-id></element-citation></ref><ref id="B113-antibiotics-08-00157"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brogden</surname><given-names>R.N.</given-names></name><name><surname>Fitton</surname><given-names>A.</given-names></name></person-group><article-title>Rifabutin</article-title><source>Drugs</source><year>1994</year><volume>47</volume><fpage>983</fpage><lpage>1009</lpage><pub-id pub-id-type="doi">10.2165/00003495-199447060-00008</pub-id><pub-id pub-id-type="pmid">7521834</pub-id></element-citation></ref><ref id="B114-antibiotics-08-00157"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kunin</surname><given-names>C.M.</given-names></name></person-group><article-title>Antimicrobial activity of rifabutin</article-title><source>Clin. Infect. Dis.</source><year>1996</year><volume>22</volume><fpage>S3</fpage><lpage>S14</lpage><pub-id pub-id-type="doi">10.1093/clinids/22.Supplement_1.S3</pub-id><pub-id pub-id-type="pmid">8785253</pub-id></element-citation></ref><ref id="B115-antibiotics-08-00157"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jarvis</surname><given-names>B.</given-names></name><name><surname>Lamb</surname><given-names>H.M.</given-names></name></person-group><article-title>Rifapentine</article-title><source>Drugs</source><year>1998</year><volume>56</volume><fpage>607</fpage><lpage>616</lpage><pub-id pub-id-type="doi">10.2165/00003495-199856040-00008</pub-id><pub-id pub-id-type="pmid">9806107</pub-id></element-citation></ref><ref id="B116-antibiotics-08-00157"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scarpignato</surname><given-names>C.</given-names></name><name><surname>Pelosini</surname><given-names>I.</given-names></name></person-group><article-title>Rifaximin, a poorly absorbed antibiotic: Pharmacology and clinical potential</article-title><source>Chemotherapy</source><year>2005</year><volume>51</volume><fpage>36</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1159/000081990</pub-id><pub-id pub-id-type="pmid">15855748</pub-id></element-citation></ref><ref id="B117-antibiotics-08-00157"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koo</surname><given-names>H.L.</given-names></name><name><surname>DuPont</surname><given-names>H.L.</given-names></name></person-group><article-title>Rifaximin: A unique gastrointestinal-selective antibiotic for enteric diseases</article-title><source>Curr. Opin. Gastroenterol.</source><year>2010</year><volume>26</volume><fpage>17</fpage><pub-id pub-id-type="doi">10.1097/MOG.0b013e328333dc8d</pub-id><pub-id pub-id-type="pmid">19881343</pub-id></element-citation></ref><ref id="B118-antibiotics-08-00157"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fodor</surname><given-names>A.A.</given-names></name><name><surname>Pimentel</surname><given-names>M.</given-names></name><name><surname>Chey</surname><given-names>W.D.</given-names></name><name><surname>Lembo</surname><given-names>A.</given-names></name><name><surname>Golden</surname><given-names>P.L.</given-names></name><name><surname>Israel</surname><given-names>R.J.</given-names></name><name><surname>Carroll</surname><given-names>I.M.</given-names></name></person-group><article-title>Rifaximin is associated with modest, transient decreases in multiple taxa in the gut microbiota of patients with diarrhoea-predominant irritable bowel syndrome</article-title><source>Gut Microbes</source><year>2019</year><volume>10</volume><fpage>22</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1080/19490976.2018.1460013</pub-id><pub-id pub-id-type="pmid">29708822</pub-id></element-citation></ref><ref id="B119-antibiotics-08-00157"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mosaei</surname><given-names>H.</given-names></name><name><surname>Molodtsov</surname><given-names>V.</given-names></name><name><surname>Kepplinger</surname><given-names>B.</given-names></name><name><surname>Harbottle</surname><given-names>J.</given-names></name><name><surname>Moon</surname><given-names>C.W.</given-names></name><name><surname>Jeeves</surname><given-names>R.E.</given-names></name><name><surname>Ceccaroni</surname><given-names>L.</given-names></name><name><surname>Shin</surname><given-names>Y.</given-names></name><name><surname>Morton-Laing</surname><given-names>S.</given-names></name><name><surname>Marrs</surname><given-names>E.C.L.</given-names></name><etal/></person-group><article-title>Mode of Action of Kanglemycin A, an Ansamycin Natural Product that Is Active against Rifampicin-Resistant <italic>Mycobacterium tuberculosis</italic></article-title><source>Mol. Cell</source><year>2018</year><volume>72</volume><fpage>263</fpage><lpage>274.e5</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2018.08.028</pub-id><pub-id pub-id-type="pmid">30244835</pub-id></element-citation></ref><ref id="B120-antibiotics-08-00157"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peek</surname><given-names>J.</given-names></name><name><surname>Lilic</surname><given-names>M.</given-names></name><name><surname>Montiel</surname><given-names>D.</given-names></name><name><surname>Milshteyn</surname><given-names>A.</given-names></name><name><surname>Woodworth</surname><given-names>I.</given-names></name><name><surname>Biggins</surname><given-names>J.B.</given-names></name><name><surname>Ternei</surname><given-names>M.A.</given-names></name><name><surname>Calle</surname><given-names>P.Y.</given-names></name><name><surname>Danziger</surname><given-names>M.</given-names></name><name><surname>Warrier</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Rifamycin congeners kanglemycins are active against rifampicin-resistant bacteria via a distinct mechanism</article-title><source>Nat. Commun.</source><year>2018</year><volume>9</volume><fpage>4147</fpage><pub-id pub-id-type="doi">10.1038/s41467-018-06587-2</pub-id><pub-id pub-id-type="pmid">30297823</pub-id></element-citation></ref><ref id="B121-antibiotics-08-00157"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Finlay</surname><given-names>A.C.</given-names></name><name><surname>Hobby</surname><given-names>G.L.</given-names></name></person-group><article-title>Terramycin, a new antibiotic</article-title><source>Science</source><year>1950</year><fpage>85</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1126/science.111.2874.85</pub-id></element-citation></ref><ref id="B122-antibiotics-08-00157"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname><given-names>R.</given-names></name><name><surname>Williams</surname><given-names>D.J.</given-names></name></person-group><article-title>Oxytetracycline biosynthesis: Origin of the carboxamide substituent</article-title><source>J. Chem. Soc. Chem. Commun.</source><year>1983</year><fpage>677</fpage><lpage>679</lpage><pub-id pub-id-type="doi">10.1039/c39830000677</pub-id></element-citation></ref><ref id="B123-antibiotics-08-00157"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chopra</surname><given-names>I.</given-names></name><name><surname>Roberts</surname><given-names>M.</given-names></name></person-group><article-title>Tetracycline antibiotics: Mode of action, applications, molecular biology, and epidemiology of bacterial resistance</article-title><source>Microbiol. Mol. Biol. Rev.</source><year>2001</year><volume>65</volume><fpage>232</fpage><lpage>260</lpage><pub-id pub-id-type="doi">10.1128/MMBR.65.2.232-260.2001</pub-id><pub-id pub-id-type="pmid">11381101</pub-id></element-citation></ref><ref id="B124-antibiotics-08-00157"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brodersen</surname><given-names>D.E.</given-names></name><name><surname>Clemons</surname><given-names>W.M.</given-names><suffix>Jr.</suffix></name><name><surname>Carter</surname><given-names>A.P.</given-names></name><name><surname>Morgan-Warren</surname><given-names>R.J.</given-names></name><name><surname>Wimberly</surname><given-names>B.T.</given-names></name><name><surname>Ramakrishnan</surname><given-names>V.</given-names></name></person-group><article-title>The structural basis for the action of the antibiotics tetracycline, pactamycin, and hygromycin B on the 30S ribosomal subunit</article-title><source>Cell</source><year>2000</year><volume>103</volume><fpage>1143</fpage><lpage>1154</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(00)00216-6</pub-id><pub-id pub-id-type="pmid">11163189</pub-id></element-citation></ref><ref id="B125-antibiotics-08-00157"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duggar</surname><given-names>B.M.</given-names></name></person-group><article-title>Aureomycin: A product of the continuing search for new antibiotics</article-title><source>Ann. N. Y. Acad. Sci.</source><year>1948</year><volume>51</volume><fpage>177</fpage><lpage>181</lpage><pub-id pub-id-type="doi">10.1111/j.1749-6632.1948.tb27262.x</pub-id><pub-id pub-id-type="pmid">18112227</pub-id></element-citation></ref><ref id="B126-antibiotics-08-00157"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>T.</given-names></name><name><surname>Cheng</surname><given-names>X.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Deng</surname><given-names>Z.</given-names></name><name><surname>You</surname><given-names>D.</given-names></name></person-group><article-title>Deciphering and engineering of the final step halogenase for improved chlortetracycline biosynthesis in industrial <italic>Streptomyces aureofaciens</italic></article-title><source>Metab. Eng.</source><year>2013</year><volume>19</volume><fpage>69</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1016/j.ymben.2013.06.003</pub-id><pub-id pub-id-type="pmid">23800859</pub-id></element-citation></ref><ref id="B127-antibiotics-08-00157"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>F.</given-names></name><name><surname>Starosta</surname><given-names>A.L.</given-names></name><name><surname>Arenz</surname><given-names>S.</given-names></name><name><surname>Sohmen</surname><given-names>D.</given-names></name><name><surname>D&#x000f6;nh&#x000f6;fer</surname><given-names>A.</given-names></name><name><surname>Wilson</surname><given-names>D.N.</given-names></name></person-group><article-title>Tetracycline antibiotics and resistance mechanisms</article-title><source>Biol. Chem.</source><year>2014</year><volume>395</volume><fpage>559</fpage><lpage>575</lpage><pub-id pub-id-type="doi">10.1515/hsz-2013-0292</pub-id><pub-id pub-id-type="pmid">24497223</pub-id></element-citation></ref><ref id="B128-antibiotics-08-00157"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stephens</surname><given-names>C.R.</given-names></name><name><surname>Beereboom</surname><given-names>J.J.</given-names></name><name><surname>Rennhard</surname><given-names>H.H.</given-names></name><name><surname>Gordon</surname><given-names>P.N.</given-names></name><name><surname>Murai</surname><given-names>K.</given-names></name><name><surname>Blackwood</surname><given-names>R.K.</given-names></name><name><surname>von Wittenau</surname><given-names>M.S.</given-names></name></person-group><article-title>6-Deoxytetracyclines. IV.1,2 Preparation, C-6 Stereochemistry, and Reactions</article-title><source>J. Am. Chem. Soc.</source><year>1963</year><volume>85</volume><fpage>2643</fpage><lpage>2652</lpage><pub-id pub-id-type="doi">10.1021/ja00900a027</pub-id></element-citation></ref><ref id="B129-antibiotics-08-00157"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCormick</surname><given-names>J.R.D.</given-names></name><name><surname>Sjolander</surname><given-names>N.O.</given-names></name><name><surname>Hirsch</surname><given-names>U.</given-names></name><name><surname>Jensen</surname><given-names>E.R.</given-names></name><name><surname>Doerschuk</surname><given-names>A.P.</given-names></name></person-group><article-title>A new family of antibiotics: The demethyltetracyclines</article-title><source>J. Am. Chem. Soc.</source><year>1957</year><volume>79</volume><fpage>4561</fpage><lpage>4563</lpage><pub-id pub-id-type="doi">10.1021/ja01573a089</pub-id></element-citation></ref><ref id="B130-antibiotics-08-00157"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCormick</surname><given-names>J.R.D.</given-names></name><name><surname>Hirsch</surname><given-names>U.</given-names></name><name><surname>Sjolander</surname><given-names>N.O.</given-names></name><name><surname>Doerschuk</surname><given-names>A.P.</given-names></name></person-group><article-title>Cosynthesis of tetracyclines by pairs of <italic>Streptomyces aureofaciens</italic> mutants</article-title><source>J. Am. Chem. Soc.</source><year>1960</year><volume>82</volume><fpage>5006</fpage><lpage>5007</lpage><pub-id pub-id-type="doi">10.1021/ja01503a066</pub-id></element-citation></ref><ref id="B131-antibiotics-08-00157"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martell</surname><given-names>M.J.</given-names></name><name><surname>Boothe</surname><given-names>J.H.</given-names></name></person-group><article-title>The 6-deoxytetracyclines. VII. Alkylated aminotetracyclines possessing unique antibacterial activity</article-title><source>J. Med. Chem.</source><year>1967</year><volume>10</volume><fpage>44</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1021/jm00313a009</pub-id><pub-id pub-id-type="pmid">6031702</pub-id></element-citation></ref><ref id="B132-antibiotics-08-00157"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zakeri</surname><given-names>B.</given-names></name><name><surname>Wright</surname><given-names>G.D.</given-names></name></person-group><article-title>Chemical biology of tetracycline antibiotics</article-title><source>Biochem. Cell Biol.</source><year>2008</year><volume>86</volume><fpage>124</fpage><lpage>136</lpage><pub-id pub-id-type="doi">10.1139/O08-002</pub-id><pub-id pub-id-type="pmid">18443626</pub-id></element-citation></ref><ref id="B133-antibiotics-08-00157"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sum</surname><given-names>P.E.</given-names></name><name><surname>Lee</surname><given-names>V.J.</given-names></name><name><surname>Testa</surname><given-names>R.T.</given-names></name><name><surname>Hlavka</surname><given-names>J.J.</given-names></name><name><surname>Ellestad</surname><given-names>G.A.</given-names></name><name><surname>Bloom</surname><given-names>J.D.</given-names></name><name><surname>Gluzman</surname><given-names>Y.</given-names></name><name><surname>Tally</surname><given-names>F.P.</given-names></name></person-group><article-title>Glycylcyclines. 1. A new generation of potent antibacterial agents through modification of 9-aminotetracyclines</article-title><source>J. Med. Chem.</source><year>1994</year><volume>37</volume><fpage>184</fpage><lpage>188</lpage><pub-id pub-id-type="doi">10.1021/jm00027a023</pub-id><pub-id pub-id-type="pmid">8289194</pub-id></element-citation></ref><ref id="B134-antibiotics-08-00157"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petersen</surname><given-names>P.J.</given-names></name><name><surname>Jacobus</surname><given-names>N.V.</given-names></name><name><surname>Weiss</surname><given-names>W.J.</given-names></name><name><surname>Sum</surname><given-names>P.E.</given-names></name><name><surname>Testa</surname><given-names>R.T.</given-names></name></person-group><article-title>In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936)</article-title><source>Antimicrob. Agents Chemother.</source><year>1999</year><volume>43</volume><fpage>738</fpage><lpage>744</lpage><pub-id pub-id-type="doi">10.1128/AAC.43.4.738</pub-id><pub-id pub-id-type="pmid">10103174</pub-id></element-citation></ref><ref id="B135-antibiotics-08-00157"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bergeron</surname><given-names>J.</given-names></name><name><surname>Ammirati</surname><given-names>M.</given-names></name><name><surname>Danley</surname><given-names>D.</given-names></name><name><surname>James</surname><given-names>L.</given-names></name><name><surname>Norcia</surname><given-names>M.</given-names></name><name><surname>Retsema</surname><given-names>J.</given-names></name><name><surname>Strick</surname><given-names>C.A.</given-names></name><name><surname>Su</surname><given-names>W.G.</given-names></name><name><surname>Sutcliffe</surname><given-names>J.</given-names></name><name><surname>Wondrack</surname><given-names>L.</given-names></name></person-group><article-title>Glycylcyclines bind to the high-affinity tetracycline ribosomal binding site and evade Tet(M)-and Tet(O)-mediated ribosomal protection</article-title><source>Antimicrob. Agents Chemother.</source><year>1996</year><volume>40</volume><fpage>2226</fpage><lpage>2228</lpage><pub-id pub-id-type="doi">10.1128/AAC.40.9.2226</pub-id><pub-id pub-id-type="pmid">8878615</pub-id></element-citation></ref><ref id="B136-antibiotics-08-00157"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nelson</surname><given-names>M.L.</given-names></name><name><surname>Ismail</surname><given-names>M.Y.</given-names></name><name><surname>McIntyre</surname><given-names>L.</given-names></name><name><surname>Bhatia</surname><given-names>B.</given-names></name><name><surname>Viski</surname><given-names>P.</given-names></name><name><surname>Hawkins</surname><given-names>P.</given-names></name><name><surname>Rennie</surname><given-names>G.</given-names></name><name><surname>Andorsky</surname><given-names>D.</given-names></name><name><surname>Messersmith</surname><given-names>D.</given-names></name><name><surname>Stapleton</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Versatile and facile synthesis of diverse semisynthetic tetracycline derivatives via Pd-catalyzed reactions</article-title><source>J. Org. Chem.</source><year>2003</year><volume>68</volume><fpage>5838</fpage><lpage>5851</lpage><pub-id pub-id-type="doi">10.1021/jo030047d</pub-id><pub-id pub-id-type="pmid">12868916</pub-id></element-citation></ref><ref id="B137-antibiotics-08-00157"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Draper</surname><given-names>M.P.</given-names></name><name><surname>Weir</surname><given-names>S.</given-names></name><name><surname>Macone</surname><given-names>A.</given-names></name><name><surname>Donatelli</surname><given-names>J.</given-names></name><name><surname>Trieber</surname><given-names>C.A.</given-names></name><name><surname>Tanaka</surname><given-names>S.K.</given-names></name><name><surname>Levy</surname><given-names>S.B.</given-names></name></person-group><article-title>Mechanism of action of the novel aminomethylcycline antibiotic omadacycline</article-title><source>Antimicrob. Agents Chemother.</source><year>2014</year><volume>58</volume><fpage>1279</fpage><lpage>1283</lpage><pub-id pub-id-type="doi">10.1128/AAC.01066-13</pub-id><pub-id pub-id-type="pmid">24041885</pub-id></element-citation></ref><ref id="B138-antibiotics-08-00157"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dougherty</surname><given-names>J.A.</given-names></name><name><surname>Sucher</surname><given-names>A.J.</given-names></name><name><surname>Chahine</surname><given-names>E.B.</given-names></name><name><surname>Shihadeh</surname><given-names>K.C.</given-names></name></person-group><article-title>Omadacycline: A New Tetracycline Antibiotic</article-title><source>Ann. Pharmacother.</source><year>2019</year><volume>53</volume><fpage>486</fpage><lpage>500</lpage><pub-id pub-id-type="doi">10.1177/1060028018818094</pub-id><pub-id pub-id-type="pmid">30917674</pub-id></element-citation></ref><ref id="B139-antibiotics-08-00157"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>C.</given-names></name><name><surname>Wang</surname><given-names>Q.</given-names></name><name><surname>Brubaker</surname><given-names>J.D.</given-names></name><name><surname>Wright</surname><given-names>P.M.</given-names></name><name><surname>Lerner</surname><given-names>C.D.</given-names></name><name><surname>Noson</surname><given-names>K.</given-names></name><name><surname>Charest</surname><given-names>M.</given-names></name><name><surname>Siegel</surname><given-names>D.R.</given-names></name><name><surname>Wang</surname><given-names>Y.M.</given-names></name><name><surname>Myers</surname><given-names>A.G.</given-names></name><etal/></person-group><article-title>A robust platform for the synthesis of new tetracycline antibiotics</article-title><source>J. Am. Chem. Soc.</source><year>2008</year><volume>130</volume><fpage>17913</fpage><lpage>17927</lpage><pub-id pub-id-type="doi">10.1021/ja806629e</pub-id><pub-id pub-id-type="pmid">19053822</pub-id></element-citation></ref><ref id="B140-antibiotics-08-00157"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grossman</surname><given-names>T.H.</given-names></name><name><surname>Starosta</surname><given-names>A.L.</given-names></name><name><surname>Fyfe</surname><given-names>C.</given-names></name><name><surname>O&#x02019;Brien</surname><given-names>W.</given-names></name><name><surname>Rothstein</surname><given-names>D.M.</given-names></name><name><surname>Mikolajka</surname><given-names>A.</given-names></name><name><surname>Wilson</surname><given-names>D.N.</given-names></name><name><surname>Sutcliffe</surname><given-names>J.A.</given-names></name></person-group><article-title>Target-and resistance-based mechanistic studies with TP-434, a novel fluorocycline antibiotic</article-title><source>Antimicrob. Agents Chemother.</source><year>2012</year><volume>56</volume><fpage>2559</fpage><lpage>2564</lpage><pub-id pub-id-type="doi">10.1128/AAC.06187-11</pub-id><pub-id pub-id-type="pmid">22354310</pub-id></element-citation></ref><ref id="B141-antibiotics-08-00157"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>Y.R.</given-names></name><name><surname>Burton</surname><given-names>C.E.</given-names></name></person-group><article-title>Eravacycline, a newly approved fluorocycline</article-title><source>Eur. J. Clin. Microbiol. Infect. Dis.</source><year>2019</year><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1007/s10096-019-03590-3</pub-id></element-citation></ref><ref id="B142-antibiotics-08-00157"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhanel</surname><given-names>G.</given-names></name><name><surname>Critchley</surname><given-names>I.</given-names></name><name><surname>Lin</surname><given-names>L.Y.</given-names></name><name><surname>Alvandi</surname><given-names>N.</given-names></name></person-group><article-title>Microbiological profile of sarecycline, a novel targeted spectrum tetracycline for the treatment of acne vulgaris</article-title><source>Antimicrob. Agents Chemother.</source><year>2019</year><volume>63</volume><fpage>e01297-18</fpage><pub-id pub-id-type="doi">10.1128/AAC.01297-18</pub-id><pub-id pub-id-type="pmid">30397052</pub-id></element-citation></ref><ref id="B143-antibiotics-08-00157"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grossman</surname><given-names>T.H.</given-names></name><name><surname>Fyfe</surname><given-names>C.</given-names></name><name><surname>O&#x02019;Brien</surname><given-names>W.</given-names></name><name><surname>Hackel</surname><given-names>M.</given-names></name><name><surname>Minyard</surname><given-names>M.B.</given-names></name><name><surname>Waites</surname><given-names>K.B.</given-names></name><name><surname>Dubois</surname><given-names>J.</given-names></name><name><surname>Murphy</surname><given-names>T.M.</given-names></name><name><surname>Slee</surname><given-names>A.M.</given-names></name><name><surname>Weiss</surname><given-names>W.J.</given-names></name><etal/></person-group><article-title>Fluorocycline TP-271 Is Potent against Complicated Community-Acquired Bacterial Pneumonia Pathogens</article-title><source>mSphere</source><year>2017</year><volume>2</volume><fpage>e00004-17</fpage><pub-id pub-id-type="doi">10.1128/mSphere.00004-17</pub-id><pub-id pub-id-type="pmid">28251179</pub-id></element-citation></ref><ref id="B144-antibiotics-08-00157"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>F.</given-names></name><name><surname>Myers</surname><given-names>A.G.</given-names></name></person-group><article-title>Development of a platform for the discovery and practical synthesis of new tetracycline antibiotics</article-title><source>Curr. Opin. Chem. Biol.</source><year>2016</year><volume>32</volume><fpage>48</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1016/j.cbpa.2016.03.011</pub-id><pub-id pub-id-type="pmid">27043373</pub-id></element-citation></ref><ref id="B145-antibiotics-08-00157"><label>145.</label><element-citation publication-type="web"><person-group person-group-type="author"><collab>Tetraphase-Pharmaceuticals</collab></person-group><article-title>Pipeline</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.tphase.com/products/pipeline/">https://www.tphase.com/products/pipeline/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2019-08-25">(accessed on 25 August 2019)</date-in-citation></element-citation></ref><ref id="B146-antibiotics-08-00157"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Preud&#x02019;homme</surname><given-names>J.</given-names></name><name><surname>Tarridec</surname><given-names>P.</given-names></name><name><surname>Belloc</surname><given-names>A.</given-names></name></person-group><article-title>90. Isolation, characterization and identification of the components of pristinamycin</article-title><source>Bull. Soc. Chim. Fr.</source><year>1968</year><volume>2</volume><fpage>585</fpage><lpage>591</lpage><pub-id pub-id-type="pmid">5650822</pub-id></element-citation></ref><ref id="B147-antibiotics-08-00157"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Celmer</surname><given-names>W.D.</given-names></name><name><surname>Sobin</surname><given-names>B.A.</given-names></name></person-group><article-title>The isolation of two synergistic antibiotics from a single fermentation source</article-title><source>Antibiot. Annu.</source><year>1955</year><volume>3</volume><fpage>437</fpage><lpage>441</lpage><pub-id pub-id-type="pmid">13355307</pub-id></element-citation></ref><ref id="B148-antibiotics-08-00157"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mast</surname><given-names>Y.</given-names></name><name><surname>Weber</surname><given-names>T.</given-names></name><name><surname>G&#x000f6;lz</surname><given-names>M.</given-names></name><name><surname>Ort-Winklbauer</surname><given-names>R.</given-names></name><name><surname>Gondran</surname><given-names>A.</given-names></name><name><surname>Wohlleben</surname><given-names>W.</given-names></name><name><surname>Schinko</surname><given-names>E.</given-names></name></person-group><article-title>Characterization of the &#x02018;pristinamycin supercluster&#x02019;of <italic>Streptomyces pristinaespiralis</italic></article-title><source>Microb. Biotechnol.</source><year>2011</year><volume>4</volume><fpage>192</fpage><lpage>206</lpage><pub-id pub-id-type="doi">10.1111/j.1751-7915.2010.00213.x</pub-id><pub-id pub-id-type="pmid">21342465</pub-id></element-citation></ref><ref id="B149-antibiotics-08-00157"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cocito</surname><given-names>C.</given-names></name><name><surname>Di Giambattista</surname><given-names>M.</given-names></name><name><surname>Nyssen</surname><given-names>E.</given-names></name><name><surname>Vannuffel</surname><given-names>P.</given-names></name></person-group><article-title>Inhibition of protein synthesis by streptogramins and related antibiotics</article-title><source>J. Antimicrob. Chemother.</source><year>1997</year><volume>39</volume><issue>Suppl. A</issue><fpage>7</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1093/jac/39.suppl_1.7</pub-id><pub-id pub-id-type="pmid">9511056</pub-id></element-citation></ref><ref id="B150-antibiotics-08-00157"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bouanchaud</surname><given-names>D.H.</given-names></name></person-group><article-title>In vitro and in vivo antibacterial activity of quinupristin/dalfopristin</article-title><source>J. Antimicrob. Chemother.</source><year>1997</year><volume>39</volume><fpage>15</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1093/jac/39.suppl_1.15</pub-id></element-citation></ref><ref id="B151-antibiotics-08-00157"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harms</surname><given-names>J.M.</given-names></name><name><surname>Schl&#x000fc;nzen</surname><given-names>F.</given-names></name><name><surname>Fucini</surname><given-names>P.</given-names></name><name><surname>Bartels</surname><given-names>H.</given-names></name><name><surname>Yonath</surname><given-names>A.</given-names></name></person-group><article-title>Alterations at the peptidyl transferase centre of the ribosome induced by the synergistic action of the streptogramins dalfopristin and quinupristin</article-title><source>BMC Biol.</source><year>2004</year><volume>2</volume><elocation-id>4</elocation-id><pub-id pub-id-type="doi">10.1186/1741-7007-2-4</pub-id><?supplied-pmid 15059283?><pub-id pub-id-type="pmid">15059283</pub-id></element-citation></ref><ref id="B152-antibiotics-08-00157"><label>152.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barriere</surname><given-names>J.C.</given-names></name><name><surname>Bouanchaud</surname><given-names>D.H.</given-names></name><name><surname>Paris</surname><given-names>J.M.</given-names></name><name><surname>Rolin</surname><given-names>O.</given-names></name><name><surname>Harris</surname><given-names>N.V.</given-names></name><name><surname>Smith</surname><given-names>C.</given-names></name></person-group><article-title>Antimicrobial activity against <italic>Staphylococcus aureus</italic> of semisynthetic injectable streptogramins: RP 59500 and related compounds</article-title><source>J. Antimicrob. Chemother.</source><year>1992</year><volume>30</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1093/jac/30.suppl_A.1</pub-id><?supplied-pmid 1399940?><pub-id pub-id-type="pmid">1399940</pub-id></element-citation></ref><ref id="B153-antibiotics-08-00157"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Finch</surname><given-names>R.G.</given-names></name></person-group><article-title>Antibacterial Activity of Quinupristin/Dalfopristin</article-title><source>Drugs</source><year>1996</year><volume>51</volume><fpage>31</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.2165/00003495-199600511-00007</pub-id><?supplied-pmid 8724814?><pub-id pub-id-type="pmid">8724814</pub-id></element-citation></ref><ref id="B154-antibiotics-08-00157"><label>154.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Politano</surname><given-names>A.D.</given-names></name><name><surname>Sawyer</surname><given-names>R.G.</given-names></name></person-group><article-title>NXL-103, a combination of flopristin and linopristin, for the potential treatment of bacterial infections including community-acquired pneumonia and MRSA</article-title><source>Curr. Opin. Investig. Drugs (Lond. UK 2000)</source><year>2010</year><volume>11</volume><fpage>225</fpage></element-citation></ref><ref id="B155-antibiotics-08-00157"><label>155.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Noeske</surname><given-names>J.</given-names></name><name><surname>Huang</surname><given-names>J.</given-names></name><name><surname>Olivier</surname><given-names>N.B.</given-names></name><name><surname>Giacobbe</surname><given-names>R.A.</given-names></name><name><surname>Zambrowski</surname><given-names>M.</given-names></name><name><surname>Cate</surname><given-names>J.H.D.</given-names></name></person-group><article-title>Synergy of streptogramin antibiotics occurs independently of their effects on translation</article-title><source>Antimicrob. Agents Chemother.</source><year>2014</year><volume>58</volume><fpage>5269</fpage><lpage>5279</lpage><pub-id pub-id-type="doi">10.1128/AAC.03389-14</pub-id><pub-id pub-id-type="pmid">24957822</pub-id></element-citation></ref><ref id="B156-antibiotics-08-00157"><label>156.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hazen</surname><given-names>E.L.</given-names></name><name><surname>Brown</surname><given-names>R.</given-names></name></person-group><article-title>Fungicidin, an Antibiotic Produced by a Soil Actinomycete</article-title><source>Proc. Soc. Exp. Biol. Med.</source><year>1951</year><volume>76</volume><fpage>93</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.3181/00379727-76-18397</pub-id><?supplied-pmid 14816400?><pub-id pub-id-type="pmid">14816400</pub-id></element-citation></ref><ref id="B157-antibiotics-08-00157"><label>157.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hazen</surname><given-names>E.L.</given-names></name><name><surname>Brown</surname><given-names>R.</given-names></name><name><surname>Mason</surname><given-names>A.</given-names></name></person-group><article-title>Protective action of fungicidin (nystatin) in mice against virulence enhancing activity of oxytetracycline on <italic>Candida albicans</italic></article-title><source>Antibiot. Chemother. (Northfield, III.)</source><year>1953</year><volume>3</volume><fpage>1125</fpage></element-citation></ref><ref id="B158-antibiotics-08-00157"><label>158.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brautaset</surname><given-names>T.</given-names></name><name><surname>Sekurova</surname><given-names>O.N.</given-names></name><name><surname>Sletta</surname><given-names>H.</given-names></name><name><surname>Ellingsen</surname><given-names>T.E.</given-names></name><name><surname>Str&#x000f8;m</surname><given-names>A.R.</given-names></name><name><surname>Valla</surname><given-names>S.</given-names></name><name><surname>Zotchev</surname><given-names>S.B.</given-names></name></person-group><article-title>Biosynthesis of the polyene antifungal antibiotic nystatin in <italic>Streptomyces noursei</italic> ATCC 11455: Analysis of the gene cluster and deduction of the biosynthetic pathway</article-title><source>Chem. Biol.</source><year>2000</year><volume>7</volume><fpage>395</fpage><lpage>403</lpage><pub-id pub-id-type="doi">10.1016/S1074-5521(00)00120-4</pub-id><pub-id pub-id-type="pmid">10873841</pub-id></element-citation></ref><ref id="B159-antibiotics-08-00157"><label>159.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bolard</surname><given-names>J.</given-names></name></person-group><article-title>How do the polyene macrolide antibiotics affect the cellular membrane properties?</article-title><source>BBA Rev. Biomembr.</source><year>1986</year><volume>864</volume><fpage>257</fpage><lpage>304</lpage><pub-id pub-id-type="doi">10.1016/0304-4157(86)90002-X</pub-id></element-citation></ref><ref id="B160-antibiotics-08-00157"><label>160.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brautaset</surname><given-names>T.</given-names></name><name><surname>Sletta</surname><given-names>H.</given-names></name><name><surname>Nedal</surname><given-names>A.</given-names></name><name><surname>Borgos</surname><given-names>S.E.</given-names></name><name><surname>Degnes</surname><given-names>K.F.</given-names></name><name><surname>Bakke</surname><given-names>I.</given-names></name><name><surname>Volokhan</surname><given-names>O.</given-names></name><name><surname>Sekurova</surname><given-names>O.N.</given-names></name><name><surname>Treshalin</surname><given-names>I.D.</given-names></name><name><surname>Mirchink</surname><given-names>E.P.</given-names></name><etal/></person-group><article-title>Improved antifungal polyene macrolides via engineering of the nystatin biosynthetic genes in <italic>Streptomyces noursei</italic></article-title><source>Chem. Biol.</source><year>2008</year><volume>15</volume><fpage>1198</fpage><lpage>1206</lpage><pub-id pub-id-type="doi">10.1016/j.chembiol.2008.08.009</pub-id><pub-id pub-id-type="pmid">19022180</pub-id></element-citation></ref><ref id="B161-antibiotics-08-00157"><label>161.</label><element-citation publication-type="web"><person-group person-group-type="author"><collab>Biosergen</collab></person-group><article-title>BSG005 for Systemic Fungal Infections</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="http://biosergen.se/products-pipeline/bsg005-for-systemic-fungal-infections/">http://biosergen.se/products-pipeline/bsg005-for-systemic-fungal-infections/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2019-08-25">(accessed on 25 August 2019)</date-in-citation></element-citation></ref><ref id="B162-antibiotics-08-00157"><label>162.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dutcher</surname><given-names>J.D.</given-names></name></person-group><article-title>The Discovery and Development of Amphotericin B</article-title><source>Dis. Chest</source><year>1968</year><volume>54</volume><fpage>296</fpage><lpage>298</lpage><pub-id pub-id-type="doi">10.1378/chest.54.Supplement_1.296</pub-id><?supplied-pmid 4877964?><pub-id pub-id-type="pmid">4877964</pub-id></element-citation></ref><ref id="B163-antibiotics-08-00157"><label>163.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McNamara</surname><given-names>C.</given-names></name><name><surname>Crawforth</surname><given-names>J.</given-names></name><name><surname>Hickman</surname><given-names>B.</given-names></name><name><surname>Norwood</surname><given-names>T.</given-names></name><name><surname>Rawlings</surname><given-names>B.</given-names></name></person-group><article-title>Biosynthesis of amphotericin B</article-title><source>J. Chem. Soc. Perkin Trans. 1</source><year>1998</year><fpage>83</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1039/a704545j</pub-id></element-citation></ref><ref id="B164-antibiotics-08-00157"><label>164.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brajtburg</surname><given-names>J.</given-names></name><name><surname>Powderly</surname><given-names>W.G.</given-names></name><name><surname>Kobayashi</surname><given-names>G.S.</given-names></name><name><surname>Medoff</surname><given-names>G.</given-names></name></person-group><article-title>Amphotericin B: Current understanding of mechanisms of action</article-title><source>Antimicrob. Agents Chemother.</source><year>1990</year><volume>34</volume><fpage>183</fpage><pub-id pub-id-type="doi">10.1128/AAC.34.2.183</pub-id><?supplied-pmid 2183713?><pub-id pub-id-type="pmid">2183713</pub-id></element-citation></ref><ref id="B165-antibiotics-08-00157"><label>165.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clemons</surname><given-names>K.V.</given-names></name><name><surname>Stevens</surname><given-names>D.A.</given-names></name></person-group><article-title>Comparative Efficacies of Four Amphotericin B Formulations&#x02014;Fungizone, Amphotec (Amphocil), AmBisome, and Abelcet&#x02014;Against Systemic Murine Aspergillosis</article-title><source>Antimicrob. Agents Chemother.</source><year>2004</year><volume>48</volume><fpage>1047</fpage><lpage>1050</lpage><pub-id pub-id-type="doi">10.1128/AAC.48.3.1047-1050.2004</pub-id><?supplied-pmid 14982807?><pub-id pub-id-type="pmid">14982807</pub-id></element-citation></ref><ref id="B166-antibiotics-08-00157"><label>166.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Struyk</surname><given-names>A.P.</given-names></name><name><surname>Drost</surname><given-names>G.</given-names></name><name><surname>Haisvisz</surname><given-names>J.M.</given-names></name><name><surname>van Eek</surname><given-names>T.</given-names></name><name><surname>Hoogerheide</surname><given-names>J.C.</given-names></name></person-group><article-title>Pimaricin, a new antifungal antibiotic</article-title><source>Antibiotics Annual 1957&#x02013;1958</source><person-group person-group-type="editor"><name><surname>Welch</surname><given-names>H.</given-names></name><name><surname>Marti-Ibanez</surname><given-names>F.</given-names></name></person-group><publisher-name>Medical Encylopedia, Inc.</publisher-name><publisher-loc>New York, NY, USA</publisher-loc><year>1958</year><fpage>878</fpage><lpage>885</lpage></element-citation></ref><ref id="B167-antibiotics-08-00157"><label>167.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aparicio</surname><given-names>J.F.</given-names></name><name><surname>Fouces</surname><given-names>R.</given-names></name><name><surname>Mendes</surname><given-names>M.V.</given-names></name><name><surname>Olivera</surname><given-names>N.</given-names></name><name><surname>Mart&#x000ed;n</surname><given-names>J.F.</given-names></name></person-group><article-title>A complex multienzyme system encoded by five polyketide synthase genes is involved in the biosynthesis of the 26-membered polyene macrolide pimaricin in <italic>Streptomyces natalensis</italic></article-title><source>Chem. Biol.</source><year>2000</year><volume>7</volume><fpage>895</fpage><lpage>905</lpage><pub-id pub-id-type="doi">10.1016/S1074-5521(00)00038-7</pub-id><pub-id pub-id-type="pmid">11094342</pub-id></element-citation></ref><ref id="B168-antibiotics-08-00157"><label>168.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ansari</surname><given-names>Z.</given-names></name><name><surname>Miller</surname><given-names>D.</given-names></name><name><surname>Galor</surname><given-names>A.</given-names></name></person-group><article-title>Current thoughts in fungal keratitis: Diagnosis and treatment</article-title><source>Curr. Fungal Infect. Rep.</source><year>2013</year><volume>7</volume><fpage>209</fpage><lpage>218</lpage><pub-id pub-id-type="doi">10.1007/s12281-013-0150-1</pub-id><?supplied-pmid 24040467?><pub-id pub-id-type="pmid">24040467</pub-id></element-citation></ref><ref id="B169-antibiotics-08-00157"><label>169.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Te Welscher</surname><given-names>Y.M.</given-names></name><name><surname>van Leeuwen</surname><given-names>M.R.</given-names></name><name><surname>de Kruijff</surname><given-names>B.</given-names></name><name><surname>Dijksterhuis</surname><given-names>J.</given-names></name><name><surname>Breukink</surname><given-names>E.</given-names></name></person-group><article-title>Polyene antibiotic that inhibits membrane transport proteins</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2012</year><volume>109</volume><fpage>11156</fpage><lpage>11159</lpage><pub-id pub-id-type="doi">10.1073/pnas.1203375109</pub-id><pub-id pub-id-type="pmid">22733749</pub-id></element-citation></ref><ref id="B170-antibiotics-08-00157"><label>170.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>C.X.</given-names></name><name><surname>Lv</surname><given-names>W.</given-names></name><name><surname>Li</surname><given-names>Y.X.</given-names></name><name><surname>Fan</surname><given-names>B.Z.</given-names></name><name><surname>Han</surname><given-names>X.</given-names></name><name><surname>Kong</surname><given-names>F.S.</given-names></name><name><surname>Tian</surname><given-names>J.C.</given-names></name><name><surname>Cushman</surname><given-names>M.</given-names></name><name><surname>Liang</surname><given-names>J.H.</given-names></name></person-group><article-title>Design, synthesis and structure-activity relationships of novel macrolones: Hybrids of 2-fluoro 9-oxime ketolides and carbamoyl quinolones with highly improved activity against resistant pathogens</article-title><source>Eur. J. Med. Chem.</source><year>2019</year><volume>169</volume><fpage>1</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2019.02.073</pub-id><pub-id pub-id-type="pmid">30852383</pub-id></element-citation></ref><ref id="B171-antibiotics-08-00157"><label>171.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>C.</given-names></name><name><surname>Ma</surname><given-names>S.</given-names></name></person-group><article-title>Various novel erythromycin derivatives obtained by different modifications: Recent advance in macrolide antibiotics</article-title><source>Mini Rev. Med. Chem.</source><year>2010</year><volume>10</volume><fpage>272</fpage><lpage>286</lpage><pub-id pub-id-type="doi">10.2174/138955710791331025</pub-id><pub-id pub-id-type="pmid">20470243</pub-id></element-citation></ref><ref id="B172-antibiotics-08-00157"><label>172.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jeli&#x00107;</surname><given-names>D.</given-names></name><name><surname>Antolovi&#x00107;</surname><given-names>R.</given-names></name></person-group><article-title>From erythromycin to azithromycin and new potential ribosome-binding antimicrobials</article-title><source>Antibiotics</source><year>2016</year><volume>5</volume><elocation-id>29</elocation-id><pub-id pub-id-type="doi">10.3390/antibiotics5030029</pub-id></element-citation></ref><ref id="B173-antibiotics-08-00157"><label>173.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aronoff</surname><given-names>S.C.</given-names></name><name><surname>Laurent</surname><given-names>C.</given-names></name><name><surname>Jacobs</surname><given-names>M.R.</given-names></name></person-group><article-title>In vitro activity of erythromycin, roxithromycin and CP 62993 against common paediatric pathogens</article-title><source>J. Antimicrob. Chemother.</source><year>1987</year><volume>19</volume><fpage>275</fpage><lpage>276</lpage><pub-id pub-id-type="doi">10.1093/jac/19.2.275</pub-id><?supplied-pmid 3032883?><pub-id pub-id-type="pmid">3032883</pub-id></element-citation></ref><ref id="B174-antibiotics-08-00157"><label>174.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schl&#x000fc;nzen</surname><given-names>F.</given-names></name><name><surname>Harms</surname><given-names>J.M.</given-names></name><name><surname>Franceschi</surname><given-names>F.</given-names></name><name><surname>Hansen</surname><given-names>H.A.S.</given-names></name><name><surname>Bartels</surname><given-names>H.</given-names></name><name><surname>Zarivach</surname><given-names>R.</given-names></name><name><surname>Yonath</surname><given-names>A.</given-names></name></person-group><article-title>Structural basis for the antibiotic activity of ketolides and azalides</article-title><source>Structure</source><year>2003</year><volume>11</volume><fpage>329</fpage><lpage>338</lpage><pub-id pub-id-type="doi">10.1016/S0969-2126(03)00022-4</pub-id><pub-id pub-id-type="pmid">12623020</pub-id></element-citation></ref><ref id="B175-antibiotics-08-00157"><label>175.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ackermann</surname><given-names>G.</given-names></name><name><surname>Rodloff</surname><given-names>A.C.</given-names></name></person-group><article-title>Drugs of the 21st century: Telithromycin (HMR 3647)&#x02014;The first ketolide</article-title><source>J. Antimicrob. Chemother.</source><year>2003</year><volume>51</volume><fpage>497</fpage><lpage>511</lpage><pub-id pub-id-type="doi">10.1093/jac/dkg123</pub-id><?supplied-pmid 12615850?><pub-id pub-id-type="pmid">12615850</pub-id></element-citation></ref><ref id="B176-antibiotics-08-00157"><label>176.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonnefoy</surname><given-names>A.</given-names></name><name><surname>Girard</surname><given-names>A.M.</given-names></name><name><surname>Agouridas</surname><given-names>C.</given-names></name><name><surname>Chantot</surname><given-names>J.F.</given-names></name></person-group><article-title>Ketolides lack inducibility properties of MLS (B) resistance phenotype</article-title><source>J. Antimicrob. Chemother.</source><year>1997</year><volume>40</volume><fpage>85</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1093/jac/40.1.85</pub-id><?supplied-pmid 9249208?><pub-id pub-id-type="pmid">9249208</pub-id></element-citation></ref><ref id="B177-antibiotics-08-00157"><label>177.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Douthwaite</surname><given-names>S.</given-names></name></person-group><article-title>Structure-activity relationships of ketolides vs. macrolides</article-title><source>Clin. Microbiol. Infect.</source><year>2001</year><volume>7</volume><fpage>11</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1046/j.1469-0691.2001.00049.x</pub-id><?supplied-pmid 11523556?><pub-id pub-id-type="pmid">11523556</pub-id></element-citation></ref><ref id="B178-antibiotics-08-00157"><label>178.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brockmann</surname><given-names>H.</given-names></name><name><surname>Henkel</surname><given-names>W.</given-names></name></person-group><article-title>Pikromycin, ein bitter schmeckendes Antibioticum aus Actinomyceten (Antibiotica aus Actinomyceten, VI. Mitteil</article-title><source>Chem. Ber.</source><year>1951</year><volume>84</volume><fpage>284</fpage><lpage>288</lpage><pub-id pub-id-type="doi">10.1002/cber.19510840306</pub-id></element-citation></ref><ref id="B179-antibiotics-08-00157"><label>179.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weinstein</surname><given-names>M.J.</given-names></name><name><surname>Wagman</surname><given-names>G.H.</given-names></name><name><surname>Marquez</surname><given-names>J.A.</given-names></name><name><surname>Testa</surname><given-names>R.T.</given-names></name><name><surname>Oden</surname><given-names>E.</given-names></name><name><surname>Waitz</surname><given-names>J.A.</given-names></name></person-group><article-title>Megalomicin, a new macrolide antibiotic complex produced by <italic>Micromonospora</italic></article-title><source>J. Antibiot. (Tokyo)</source><year>1969</year><volume>22</volume><fpage>253</fpage><lpage>258</lpage><pub-id pub-id-type="doi">10.7164/antibiotics.22.253</pub-id><?supplied-pmid 5810991?><pub-id pub-id-type="pmid">5810991</pub-id></element-citation></ref><ref id="B180-antibiotics-08-00157"><label>180.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garrod</surname><given-names>L.P.</given-names></name></person-group><article-title>The erythromycin group of antibiotics</article-title><source>Br. Med. J.</source><year>1957</year><volume>2</volume><fpage>57</fpage><pub-id pub-id-type="doi">10.1136/bmj.2.5036.57</pub-id><?supplied-pmid 13436854?><pub-id pub-id-type="pmid">13436854</pub-id></element-citation></ref><ref id="B181-antibiotics-08-00157"><label>181.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pinnerts-Indico</surname><given-names>S.</given-names></name></person-group><article-title>Une nouvelle esp&#x000e8;ce de <italic>Streptomyces</italic> productrice d&#x02019;antibiotiques: <italic>Streptomyces ambofaciens</italic> n. sp.</article-title><source>Ann. L Inst. Pasteur</source><year>1954</year><volume>87</volume><fpage>702</fpage><lpage>707</lpage></element-citation></ref><ref id="B182-antibiotics-08-00157"><label>182.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rubinstein</surname><given-names>E.</given-names></name><name><surname>Keller</surname><given-names>N.</given-names></name></person-group><article-title>Spiramycin renaissance</article-title><source>J. Antimicrob. Chemother.</source><year>1998</year><volume>42</volume><fpage>572</fpage><lpage>576</lpage><pub-id pub-id-type="doi">10.1093/jac/42.5.572</pub-id><pub-id pub-id-type="pmid">9848439</pub-id></element-citation></ref><ref id="B183-antibiotics-08-00157"><label>183.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanfer</surname><given-names>I.</given-names></name><name><surname>Skinner</surname><given-names>M.F.</given-names></name><name><surname>Walker</surname><given-names>R.B.</given-names></name></person-group><article-title>Analysis of macrolide antibiotics</article-title><source>J. Chromatogr. A</source><year>1998</year><volume>812</volume><fpage>255</fpage><lpage>286</lpage><pub-id pub-id-type="doi">10.1016/S0021-9673(98)00276-3</pub-id><pub-id pub-id-type="pmid">9691324</pub-id></element-citation></ref><ref id="B184-antibiotics-08-00157"><label>184.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Washington</surname><given-names>J.A.</given-names></name><name><surname>Wilson</surname><given-names>W.R.</given-names></name></person-group><article-title>Erythromycin: A Microbial and Clinical Perspective after 30 Years of Clinical Use (Second of Two Parts)</article-title><source>Mayo Clin. Proc.</source><year>1985</year><volume>60</volume><fpage>271</fpage><lpage>278</lpage><pub-id pub-id-type="doi">10.1016/S0025-6196(12)60322-X</pub-id><pub-id pub-id-type="pmid">3884913</pub-id></element-citation></ref><ref id="B185-antibiotics-08-00157"><label>185.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Papich</surname><given-names>M.G.</given-names></name></person-group><article-title>Tylosin</article-title><source>Saunders Handbook of Veterinary Drugs-E-Book: Small and Large Animal</source><publisher-name>Elsevier Health Sciences</publisher-name><publisher-loc>St. Louis, MO, USA</publisher-loc><year>2015</year><fpage>826</fpage><lpage>827</lpage></element-citation></ref><ref id="B186-antibiotics-08-00157"><label>186.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Denny</surname><given-names>C.B.</given-names></name><name><surname>Sharpe</surname><given-names>L.E.</given-names></name><name><surname>Bohrer</surname><given-names>C.W.</given-names></name></person-group><article-title>Effects of tylosin and nisin on canned food spoilage bacteria</article-title><source>Appl. Microbiol.</source><year>1961</year><volume>9</volume><fpage>108</fpage><?supplied-pmid 13721908?><pub-id pub-id-type="pmid">13721908</pub-id></element-citation></ref><ref id="B187-antibiotics-08-00157"><label>187.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Denny</surname><given-names>C.B.</given-names></name><name><surname>Bohrer</surname><given-names>C.W.</given-names></name></person-group><article-title>Effect of antibiotics on the thermal death rate of spores of food spoilage organisms</article-title><source>J. Food Sci.</source><year>1959</year><volume>24</volume><fpage>247</fpage><lpage>252</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2621.1959.tb17269.x</pub-id></element-citation></ref><ref id="B188-antibiotics-08-00157"><label>188.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamill</surname><given-names>R.L.</given-names></name><name><surname>Haney</surname><given-names>M.E.</given-names><suffix>Jr.</suffix></name><name><surname>Stamper</surname><given-names>M.</given-names></name><name><surname>Wlley</surname><given-names>P.F.</given-names></name></person-group><article-title>Tylosin, a New Antibiotic: II. Isolation, Properties, and Preparation of Pesmycosin, a Microbiologically Active Degradation Product</article-title><source>Antibiot. Chemother.</source><year>1961</year><volume>11</volume><fpage>328</fpage><lpage>334</lpage></element-citation></ref><ref id="B189-antibiotics-08-00157"><label>189.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stark</surname><given-names>W.M.</given-names></name><name><surname>Daily</surname><given-names>W.A.</given-names></name><name><surname>McGuire</surname><given-names>J.M.</given-names></name></person-group><article-title>A fermentation study of the biosynthesis of tylosin in synthetic media</article-title><source>Sci. Rep. Ist. Super. Sanita</source><year>1961</year><volume>1</volume><fpage>340</fpage><lpage>354</lpage><?supplied-pmid 13916323?><pub-id pub-id-type="pmid">13916323</pub-id></element-citation></ref><ref id="B190-antibiotics-08-00157"><label>190.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pape</surname><given-names>H.</given-names></name><name><surname>Brillinger</surname><given-names>G.U.</given-names></name></person-group><article-title>Metabolic products of microorganisms. 113. Biosynthesis of thymidine diphospho mycarose in a cell-free system from <italic>Streptomyces rimosus</italic></article-title><source>Arch. Mikrobiol.</source><year>1973</year><volume>88</volume><fpage>25</fpage><pub-id pub-id-type="doi">10.1007/BF00408838</pub-id><pub-id pub-id-type="pmid">4405313</pub-id></element-citation></ref><ref id="B191-antibiotics-08-00157"><label>191.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jensen</surname><given-names>A.L.</given-names></name><name><surname>Darken</surname><given-names>M.A.</given-names></name><name><surname>Schultz</surname><given-names>J.S.</given-names></name><name><surname>Shay</surname><given-names>A.J.</given-names></name></person-group><article-title>Relomycin: Flask and Tank Fermentation Studies</article-title><source>Antimicrob. Agents Chemother.</source><year>1963</year><volume>161</volume><fpage>49</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">14274950</pub-id></element-citation></ref><ref id="B192-antibiotics-08-00157"><label>192.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamill</surname><given-names>R.L.</given-names></name><name><surname>Stark</surname><given-names>W.M.</given-names></name></person-group><article-title>Macromicin, a new antibiotic, and Lactenocin, an active degradation product</article-title><source>J. Antibiot. (Tokyo)</source><year>1964</year><volume>17</volume><fpage>133</fpage><lpage>139</lpage><pub-id pub-id-type="pmid">14196285</pub-id></element-citation></ref><ref id="B193-antibiotics-08-00157"><label>193.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whaley</surname><given-names>H.A.</given-names></name><name><surname>Patterson</surname><given-names>E.L.</given-names></name><name><surname>Dornbush</surname><given-names>A.C.</given-names></name><name><surname>Backus</surname><given-names>E.J.</given-names></name><name><surname>Bohonos</surname><given-names>N.</given-names></name></person-group><article-title>Isolation and characterization of relomycin, a new antibiotic</article-title><source>Antimicrob. Agents Chemother.</source><year>1963</year><volume>161</volume><fpage>45</fpage><pub-id pub-id-type="pmid">14274943</pub-id></element-citation></ref><ref id="B194-antibiotics-08-00157"><label>194.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roets</surname><given-names>E.</given-names></name><name><surname>Beirinckx</surname><given-names>P.</given-names></name><name><surname>Quintens</surname><given-names>I.</given-names></name><name><surname>Hoogmartens</surname><given-names>J.</given-names></name></person-group><article-title>Quantitative analysis of tylosin by column liquid chromatography</article-title><source>J. Chromatogr. A</source><year>1993</year><volume>630</volume><fpage>159</fpage><lpage>166</lpage><pub-id pub-id-type="doi">10.1016/0021-9673(93)80452-E</pub-id></element-citation></ref><ref id="B195-antibiotics-08-00157"><label>195.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loke</surname><given-names>M.L.</given-names></name><name><surname>Ingerslev</surname><given-names>F.</given-names></name><name><surname>Halling-S&#x000f8;rensen</surname><given-names>B.</given-names></name><name><surname>Tj&#x000f8;rnelund</surname><given-names>J.</given-names></name></person-group><article-title>Stability of tylosin A in manure containing test systems determined by high performance liquid chromatography</article-title><source>Chemosphere</source><year>2000</year><volume>40</volume><fpage>759</fpage><lpage>765</lpage><pub-id pub-id-type="doi">10.1016/S0045-6535(99)00450-6</pub-id><pub-id pub-id-type="pmid">10705554</pub-id></element-citation></ref><ref id="B196-antibiotics-08-00157"><label>196.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cox</surname><given-names>K.L.</given-names></name><name><surname>Fishman</surname><given-names>S.E.</given-names></name><name><surname>Larson</surname><given-names>J.L.</given-names></name><name><surname>Stanzak</surname><given-names>R.</given-names></name><name><surname>Reynolds</surname><given-names>P.A.</given-names></name><name><surname>Yeh</surname><given-names>W.K.</given-names></name><name><surname>van Frank</surname><given-names>R.M.</given-names></name><name><surname>Birmingham</surname><given-names>V.A.</given-names></name><name><surname>Hershberger</surname><given-names>C.L.</given-names></name><name><surname>Seno</surname><given-names>E.T.</given-names></name></person-group><article-title>The use of recombinant DNA techniques to study tylosin biosynthesis and resistance in <italic>Streptomyces fradiae</italic></article-title><source>J. Nat. Prod.</source><year>1986</year><volume>49</volume><fpage>971</fpage><lpage>980</lpage><pub-id pub-id-type="doi">10.1021/np50048a002</pub-id><pub-id pub-id-type="pmid">3572425</pub-id></element-citation></ref><ref id="B197-antibiotics-08-00157"><label>197.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Merson-Davies</surname><given-names>L.A.</given-names></name><name><surname>Cundiiffe</surname><given-names>E.</given-names></name></person-group><article-title>Analysis of five tylosin biosynthetic genes from the <italic>tyllBA</italic> region of the <italic>Streptomyces fradiae</italic> genome</article-title><source>Mol. Microbiol.</source><year>1994</year><volume>13</volume><fpage>349</fpage><lpage>355</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2958.1994.tb00428.x</pub-id><?supplied-pmid 7984112?><pub-id pub-id-type="pmid">7984112</pub-id></element-citation></ref><ref id="B198-antibiotics-08-00157"><label>198.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gandecha</surname><given-names>A.R.</given-names></name><name><surname>Large</surname><given-names>S.L.</given-names></name><name><surname>Cundliffe</surname><given-names>E.</given-names></name></person-group><article-title>Analysis of four tylosin biosynthetic genes from the <italic>tylLM</italic> region of the <italic>Streptomyces fradiae</italic> genome</article-title><source>Gene</source><year>1997</year><volume>184</volume><fpage>197</fpage><lpage>203</lpage><pub-id pub-id-type="doi">10.1016/S0378-1119(96)00595-1</pub-id><pub-id pub-id-type="pmid">9031628</pub-id></element-citation></ref><ref id="B199-antibiotics-08-00157"><label>199.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fouces</surname><given-names>R.</given-names></name><name><surname>Mellado</surname><given-names>E.</given-names></name><name><surname>Diez</surname><given-names>B.</given-names></name><name><surname>Barredo</surname><given-names>J.L.</given-names></name></person-group><article-title>The tylosin biosynthetic cluster from <italic>Streptomyces fradiae</italic>: Genetic organization of the left region</article-title><source>Microbiology</source><year>1999</year><volume>145</volume><fpage>855</fpage><lpage>868</lpage><pub-id pub-id-type="doi">10.1099/13500872-145-4-855</pub-id><?supplied-pmid 10220165?><pub-id pub-id-type="pmid">10220165</pub-id></element-citation></ref><ref id="B200-antibiotics-08-00157"><label>200.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stratigopoulos</surname><given-names>G.</given-names></name><name><surname>Cundliffe</surname><given-names>E.</given-names></name></person-group><article-title>Expression Analysis of the Tylosin-Biosynthetic Gene Cluster: Pivotal Regulatory Role of the <italic>tylQ</italic> Product</article-title><source>Chem. Biol.</source><year>2002</year><volume>9</volume><fpage>71</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1016/S1074-5521(01)00095-3</pub-id><pub-id pub-id-type="pmid">11841940</pub-id></element-citation></ref><ref id="B201-antibiotics-08-00157"><label>201.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baltz</surname><given-names>R.H.</given-names></name><name><surname>Seno</surname><given-names>E.T.</given-names></name></person-group><article-title>Properties of <italic>Streptomyces fradiae</italic> mutants blocked in biosynthesis of the macrolide antibiotic tylosin</article-title><source>Antimicrob. Agents Chemother.</source><year>1981</year><volume>20</volume><fpage>214</fpage><lpage>225</lpage><pub-id pub-id-type="doi">10.1128/AAC.20.2.214</pub-id><pub-id pub-id-type="pmid">7283418</pub-id></element-citation></ref><ref id="B202-antibiotics-08-00157"><label>202.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodriguez</surname><given-names>E.</given-names></name><name><surname>Ward</surname><given-names>S.</given-names></name><name><surname>Fu</surname><given-names>H.</given-names></name><name><surname>Revill</surname><given-names>W.P.</given-names></name><name><surname>McDaniel</surname><given-names>R.</given-names></name><name><surname>Katz</surname><given-names>L.</given-names></name></person-group><article-title>Engineered biosynthesis of 16-membered macrolides that require methoxymalonyl-ACP precursors in <italic>Streptomyces fradiae</italic></article-title><source>Appl. Microbiol. Biotechnol.</source><year>2004</year><volume>66</volume><fpage>85</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1007/s00253-004-1658-7</pub-id><pub-id pub-id-type="pmid">15179529</pub-id></element-citation></ref><ref id="B203-antibiotics-08-00157"><label>203.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castonguay</surname><given-names>R.</given-names></name><name><surname>Valenzano</surname><given-names>C.R.</given-names></name><name><surname>Chen</surname><given-names>A.Y.</given-names></name><name><surname>Keatinge-Clay</surname><given-names>A.</given-names></name><name><surname>Khosla</surname><given-names>C.</given-names></name><name><surname>Cane</surname><given-names>D.E.</given-names></name></person-group><article-title>Stereospecificity of ketoreductase domains 1 and 2 of the tylactone modular polyketide synthase</article-title><source>J. Am. Chem. Soc.</source><year>2008</year><volume>130</volume><fpage>11598</fpage><lpage>11599</lpage><pub-id pub-id-type="doi">10.1021/ja804453p</pub-id><pub-id pub-id-type="pmid">18693734</pub-id></element-citation></ref><ref id="B204-antibiotics-08-00157"><label>204.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Butler</surname><given-names>A.R.</given-names></name><name><surname>Bate</surname><given-names>N.</given-names></name><name><surname>Cundliffe</surname><given-names>E.</given-names></name></person-group><article-title>Impact of thioesterase activity on tylosin biosynthesis in <italic>Streptomyces fradiae</italic></article-title><source>Chem. Biol.</source><year>1999</year><volume>6</volume><fpage>287</fpage><lpage>292</lpage><pub-id pub-id-type="doi">10.1016/S1074-5521(99)80074-X</pub-id><pub-id pub-id-type="pmid">10322123</pub-id></element-citation></ref><ref id="B205-antibiotics-08-00157"><label>205.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Butler</surname><given-names>A.R.</given-names></name><name><surname>Flint</surname><given-names>S.A.</given-names></name><name><surname>Cundliffe</surname><given-names>E.</given-names></name></person-group><article-title>Feedback control of polyketide metabolism during tylosin production</article-title><source>Microbiology</source><year>2001</year><volume>147</volume><fpage>795</fpage><lpage>801</lpage><pub-id pub-id-type="doi">10.1099/00221287-147-4-795</pub-id><?supplied-pmid 11283275?><pub-id pub-id-type="pmid">11283275</pub-id></element-citation></ref><ref id="B206-antibiotics-08-00157"><label>206.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poulsen</surname><given-names>S.M.</given-names></name><name><surname>Kofoed</surname><given-names>C.</given-names></name><name><surname>Vester</surname><given-names>B.</given-names></name></person-group><article-title>Inhibition of the ribosomal peptidyl transferase reaction by the mycarose moiety of the antibiotics carbomycin, spiramycin and tylosin</article-title><source>J. Mol. Biol.</source><year>2000</year><volume>304</volume><fpage>471</fpage><lpage>481</lpage><pub-id pub-id-type="doi">10.1006/jmbi.2000.4229</pub-id><?supplied-pmid 11090288?><pub-id pub-id-type="pmid">11090288</pub-id></element-citation></ref><ref id="B207-antibiotics-08-00157"><label>207.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hansen</surname><given-names>J.L.</given-names></name><name><surname>Ippolito</surname><given-names>J.A.</given-names></name><name><surname>Ban</surname><given-names>N.</given-names></name><name><surname>Nissen</surname><given-names>P.</given-names></name><name><surname>Moore</surname><given-names>P.B.</given-names></name><name><surname>Steitz</surname><given-names>T.A.</given-names></name></person-group><article-title>The structures of four macrolide antibiotics bound to the large ribosomal subunit</article-title><source>Mol. Cell</source><year>2002</year><volume>10</volume><fpage>117</fpage><lpage>128</lpage><pub-id pub-id-type="doi">10.1016/S1097-2765(02)00570-1</pub-id><pub-id pub-id-type="pmid">12150912</pub-id></element-citation></ref><ref id="B208-antibiotics-08-00157"><label>208.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lyutskanova</surname><given-names>D.G.</given-names></name><name><surname>Stoilova-Disheva</surname><given-names>M.M.</given-names></name><name><surname>Peltekova</surname><given-names>V.T.</given-names></name></person-group><article-title>Increase in tylosin production by a commercial strain of <italic>Streptomyces fradiae</italic></article-title><source>Appl. Biochem. Microbiol.</source><year>2005</year><volume>41</volume><fpage>165</fpage><lpage>168</lpage><pub-id pub-id-type="doi">10.1007/s10438-005-0028-2</pub-id></element-citation></ref><ref id="B209-antibiotics-08-00157"><label>209.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haney</surname><given-names>M.E.J.</given-names></name><name><surname>Hoehn</surname><given-names>M.M.</given-names></name></person-group><article-title>Monensin, a new biologically active compound. I. Discovery and isolation</article-title><source>Antimicrob. Agents Chemother.</source><year>1967</year><volume>7</volume><fpage>349</fpage><lpage>352</lpage><?supplied-pmid 5596158?><pub-id pub-id-type="pmid">5596158</pub-id></element-citation></ref><ref id="B210-antibiotics-08-00157"><label>210.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>&#x00141;owicki</surname><given-names>D.</given-names></name><name><surname>Huczy&#x00144;ski</surname><given-names>A.</given-names></name></person-group><article-title>Structure and antimicrobial properties of monensin A and its derivatives: Summary of the achievements</article-title><source>BioMed Res. Int.</source><year>2013</year><fpage>742149</fpage><pub-id pub-id-type="doi">10.1155/2013/742149</pub-id><pub-id pub-id-type="pmid">23509771</pub-id></element-citation></ref><ref id="B211-antibiotics-08-00157"><label>211.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duax</surname><given-names>W.L.</given-names></name><name><surname>Smith</surname><given-names>G.D.</given-names></name><name><surname>Strong</surname><given-names>P.D.</given-names></name></person-group><article-title>Complexation of metal ions by monensin. Crystal and molecular structure of hydrated and anhydrous crystal forms of sodium monensin</article-title><source>J. Am. Chem. Soc.</source><year>1980</year><volume>102</volume><fpage>6725</fpage><lpage>6729</lpage><pub-id pub-id-type="doi">10.1021/ja00542a010</pub-id></element-citation></ref><ref id="B212-antibiotics-08-00157"><label>212.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barrans</surname><given-names>Y.</given-names></name><name><surname>Alleaume</surname><given-names>M.</given-names></name><name><surname>Jeminet</surname><given-names>G.</given-names></name></person-group><article-title>Complexe de sodium de l&#x02019;ionophore monensine B monohydrate</article-title><source>Acta Crystallogr. Sect. B Struct. Sci. Cryst. Eng. Mater.</source><year>1982</year><volume>38</volume><fpage>1144</fpage><lpage>1149</lpage><pub-id pub-id-type="doi">10.1107/S0567740882005172</pub-id></element-citation></ref><ref id="B213-antibiotics-08-00157"><label>213.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riddell</surname><given-names>F.G.</given-names></name><name><surname>Arumugam</surname><given-names>S.</given-names></name><name><surname>Cox</surname><given-names>B.G.</given-names></name></person-group><article-title>The monesin-mediated transport of Na+ and K+ through phospholipid bilayers studied by 23Na-and 39K-NMR</article-title><source>BBA Biomembr.</source><year>1988</year><volume>944</volume><fpage>279</fpage><lpage>284</lpage><pub-id pub-id-type="doi">10.1016/0005-2736(88)90442-7</pub-id></element-citation></ref><ref id="B214-antibiotics-08-00157"><label>214.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakazato</surname><given-names>K.</given-names></name><name><surname>Hatano</surname><given-names>Y.</given-names></name></person-group><article-title>Monensin-mediated antiport of Na+ and H+ across liposome membrane</article-title><source>BBA Biomembr.</source><year>1991</year><volume>1064</volume><fpage>103</fpage><lpage>110</lpage><pub-id pub-id-type="doi">10.1016/0005-2736(91)90416-6</pub-id></element-citation></ref><ref id="B215-antibiotics-08-00157"><label>215.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sandeaux</surname><given-names>R.</given-names></name><name><surname>Seta</surname><given-names>P.</given-names></name><name><surname>Jeminet</surname><given-names>G.</given-names></name><name><surname>Alleaume</surname><given-names>M.</given-names></name><name><surname>Gavach</surname><given-names>C.</given-names></name></person-group><article-title>The influence of pH on the conductance of lipid bimolecular membranes in relation to the alkaline ion transport induced by carboxylic carriers grisorixin, alborixin and monensin</article-title><source>BBA Biomembr.</source><year>1978</year><volume>511</volume><fpage>499</fpage><lpage>508</lpage><pub-id pub-id-type="doi">10.1016/0005-2736(78)90284-5</pub-id></element-citation></ref><ref id="B216-antibiotics-08-00157"><label>216.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Antonenko</surname><given-names>Y.N.</given-names></name><name><surname>Yaguzhinsky</surname><given-names>L.S.</given-names></name></person-group><article-title>The ion selectivity of nonelectrogenic ionophores measured on a bilayer lipid membrane: Nigericin, monensin, A23187 and lasalocid A</article-title><source>BBA Biomembr.</source><year>1988</year><volume>938</volume><fpage>125</fpage><lpage>130</lpage><pub-id pub-id-type="doi">10.1016/0005-2736(88)90151-4</pub-id></element-citation></ref><ref id="B217-antibiotics-08-00157"><label>217.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Lin</surname><given-names>C.Y.</given-names></name><name><surname>Li</surname><given-names>X.M.</given-names></name><name><surname>Tang</surname><given-names>Z.K.</given-names></name><name><surname>Qiao</surname><given-names>J.</given-names></name><name><surname>Zhao</surname><given-names>G.R.</given-names></name></person-group><article-title>DasR positively controls monensin production at two-level regulation in <italic>Streptomyces cinnamonensis</italic></article-title><source>J. Ind. Microbiol. Biotechnol.</source><year>2016</year><volume>43</volume><fpage>1681</fpage><lpage>1692</lpage><pub-id pub-id-type="doi">10.1007/s10295-016-1845-4</pub-id><?supplied-pmid 27718094?><pub-id pub-id-type="pmid">27718094</pub-id></element-citation></ref><ref id="B218-antibiotics-08-00157"><label>218.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harvey</surname><given-names>B.M.</given-names></name><name><surname>Hong</surname><given-names>H.</given-names></name><name><surname>Jones</surname><given-names>M.A.</given-names></name><name><surname>Hughes-Thomas</surname><given-names>Z.A.</given-names></name><name><surname>Goss</surname><given-names>R.M.</given-names></name><name><surname>Heathcote</surname><given-names>M.L.</given-names></name><name><surname>Bolanos-Garcia</surname><given-names>V.M.</given-names></name><name><surname>Kroutil</surname><given-names>W.</given-names></name><name><surname>Staunton</surname><given-names>J.</given-names></name><name><surname>Leadlay</surname><given-names>P.F.</given-names></name><etal/></person-group><article-title>Evidence that a Novel Thioesterase is Responsible for Polyketide Chain Release during Biosynthesis of the Polyether Ionophore Monensin</article-title><source>ChemBioChem</source><year>2006</year><volume>7</volume><fpage>1435</fpage><lpage>1442</lpage><pub-id pub-id-type="doi">10.1002/cbic.200500474</pub-id><?supplied-pmid 16897798?><pub-id pub-id-type="pmid">16897798</pub-id></element-citation></ref><ref id="B219-antibiotics-08-00157"><label>219.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>H&#x000fc;ttel</surname><given-names>W.</given-names></name><name><surname>Spencer</surname><given-names>J.B.</given-names></name><name><surname>Leadlay</surname><given-names>P.F.</given-names></name></person-group><article-title>Intermediates in monensin biosynthesis: A late step in biosynthesis of the polyether ionophore monensin is crucial for the integrity of cation binding</article-title><source>Beilstein J. Org. Chem.</source><year>2014</year><volume>10</volume><fpage>361</fpage><lpage>368</lpage><pub-id pub-id-type="doi">10.3762/bjoc.10.34</pub-id><?supplied-pmid 24605157?><pub-id pub-id-type="pmid">24605157</pub-id></element-citation></ref><ref id="B220-antibiotics-08-00157"><label>220.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>F.</given-names></name><name><surname>Hou</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Chu</surname><given-names>Y.</given-names></name><name><surname>Xia</surname><given-names>H.</given-names></name><name><surname>Tian</surname><given-names>Y.</given-names></name></person-group><article-title>Regulatory genes and their roles for improvement of antibiotic biosynthesis in <italic>Streptomyces</italic></article-title><source>3 Biotech</source><year>2017</year><volume>7</volume><fpage>250</fpage><pub-id pub-id-type="doi">10.1007/s13205-017-0875-6</pub-id><?supplied-pmid 28718097?><pub-id pub-id-type="pmid">28718097</pub-id></element-citation></ref><ref id="B221-antibiotics-08-00157"><label>221.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>Z.K.</given-names></name><name><surname>Li</surname><given-names>X.M.</given-names></name><name><surname>Pang</surname><given-names>A.P.</given-names></name><name><surname>Lin</surname><given-names>C.Y.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Qiao</surname><given-names>J.</given-names></name><name><surname>Zhao</surname><given-names>G.R.</given-names></name></person-group><article-title>Characterization of three pathway-specific regulators for high production of monensin in <italic>Streptomyces cinnamonensis</italic></article-title><source>Appl. Microbiol. Biotechnol.</source><year>2017</year><volume>101</volume><fpage>6083</fpage><lpage>6097</lpage><pub-id pub-id-type="doi">10.1007/s00253-017-8353-y</pub-id><?supplied-pmid 28685195?><pub-id pub-id-type="pmid">28685195</pub-id></element-citation></ref><ref id="B222-antibiotics-08-00157"><label>222.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>C.</given-names></name><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Kang</surname><given-names>Q.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Bai</surname><given-names>L.</given-names></name></person-group><article-title>Cloning and Characterization of the Polyether Salinomycin Biosynthesis Gene Cluster of <italic>Streptomyces albus</italic> XM211</article-title><source>Appl. Environ. Microbiol.</source><year>2012</year><volume>78</volume><fpage>994</fpage><lpage>1003</lpage><pub-id pub-id-type="doi">10.1128/AEM.06701-11</pub-id><?supplied-pmid 22156425?><pub-id pub-id-type="pmid">22156425</pub-id></element-citation></ref><ref id="B223-antibiotics-08-00157"><label>223.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Migita</surname><given-names>A.</given-names></name><name><surname>Watanabe</surname><given-names>M.</given-names></name><name><surname>Hirose</surname><given-names>Y.</given-names></name><name><surname>Watanabe</surname><given-names>K.</given-names></name><name><surname>Tokiwano</surname><given-names>T.</given-names></name><name><surname>Kinashi</surname><given-names>H.</given-names></name><name><surname>Oikawa</surname><given-names>H.</given-names></name></person-group><article-title>Identification of a gene cluster of polyether antibiotic lasalocid from <italic>Streptomyces lasaliensis</italic></article-title><source>Biosci. Biotechnol. Biochem.</source><year>2009</year><volume>73</volume><fpage>169</fpage><lpage>176</lpage><pub-id pub-id-type="doi">10.1271/bbb.80631</pub-id><pub-id pub-id-type="pmid">19129623</pub-id></element-citation></ref><ref id="B224-antibiotics-08-00157"><label>224.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roder</surname><given-names>J.D.</given-names></name></person-group><article-title>Ionophore Toxicity and Tolerance</article-title><source>Vet. Clin. N. Am. Food Anim. Pract.</source><year>2011</year><volume>27</volume><fpage>305</fpage><lpage>314</lpage><pub-id pub-id-type="doi">10.1016/j.cvfa.2011.02.012</pub-id><?supplied-pmid 21575772?><pub-id pub-id-type="pmid">21575772</pub-id></element-citation></ref><ref id="B225-antibiotics-08-00157"><label>225.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Russell</surname><given-names>J.B.</given-names></name><name><surname>Houlihan</surname><given-names>A.J.</given-names></name></person-group><article-title>Ionophore resistance of ruminal bacteria and its potential impact on human health</article-title><source>FEMS Microbiol. Rev.</source><year>2003</year><volume>27</volume><fpage>65</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1016/S0168-6445(03)00019-6</pub-id><pub-id pub-id-type="pmid">12697342</pub-id></element-citation></ref><ref id="B226-antibiotics-08-00157"><label>226.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bergen</surname><given-names>W.G.</given-names></name><name><surname>Bates</surname><given-names>D.B.</given-names></name></person-group><article-title>Ionophores: Their effect on production efficiency and mode of action</article-title><source>J. Anim. Sci.</source><year>1984</year><volume>58</volume><fpage>1465</fpage><lpage>1483</lpage><pub-id pub-id-type="doi">10.2527/jas1984.5861465x</pub-id><?supplied-pmid 6378864?><pub-id pub-id-type="pmid">6378864</pub-id></element-citation></ref><ref id="B227-antibiotics-08-00157"><label>227.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>M.</given-names></name><name><surname>Wolin</surname><given-names>M.J.</given-names></name></person-group><article-title>Effect of monensin and lasalocid-sodium on the growth of methanogenic and rumen saccharolytic bacteria</article-title><source>Appl. Environ. Microbiol.</source><year>1979</year><volume>38</volume><fpage>72</fpage><lpage>77</lpage><?supplied-pmid 16345418?><pub-id pub-id-type="pmid">16345418</pub-id></element-citation></ref><ref id="B228-antibiotics-08-00157"><label>228.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Newbold</surname><given-names>C.J.</given-names></name><name><surname>Wallace</surname><given-names>R.J.</given-names></name><name><surname>Watt</surname><given-names>N.D.</given-names></name></person-group><article-title>Properties of ionophore-resistant <italic>Bacteroides rurninicola</italic> enriched by cultivation in the presence of tetronasin</article-title><source>J. Appl. Bacteriol.</source><year>1992</year><volume>72</volume><fpage>65</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2672.1992.tb05188.x</pub-id><?supplied-pmid 1541602?><pub-id pub-id-type="pmid">1541602</pub-id></element-citation></ref><ref id="B229-antibiotics-08-00157"><label>229.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Callaway</surname><given-names>T.R.</given-names></name><name><surname>Adams</surname><given-names>K.A.</given-names></name><name><surname>Russell</surname><given-names>J.B.</given-names></name></person-group><article-title>The ability of &#x0201c;low G+C gram-positive&#x0201d; ruminal bacteria to resist monensin and counteract potassium depletion</article-title><source>Curr. Microbiol.</source><year>1999</year><volume>39</volume><fpage>226</fpage><lpage>230</lpage><pub-id pub-id-type="doi">10.1007/s002849900449</pub-id><?supplied-pmid 10486059?><pub-id pub-id-type="pmid">10486059</pub-id></element-citation></ref><ref id="B230-antibiotics-08-00157"><label>230.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Callaway</surname><given-names>T.R.</given-names></name><name><surname>Russell</surname><given-names>J.B.</given-names></name></person-group><article-title>Variations in the ability of ruminal gram-negative <italic>Prevotella</italic> species to resist monensin</article-title><source>Curr. Microbiol.</source><year>2000</year><volume>40</volume><fpage>185</fpage><lpage>189</lpage><pub-id pub-id-type="doi">10.1007/s002849910037</pub-id><pub-id pub-id-type="pmid">10679051</pub-id></element-citation></ref><ref id="B231-antibiotics-08-00157"><label>231.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McAlpine</surname><given-names>J.B.</given-names></name></person-group><article-title>The ups and downs of drug discovery: The early history of Fidaxomicin</article-title><source>J. Antibiot. (Tokyo)</source><year>2017</year><volume>70</volume><fpage>492</fpage><pub-id pub-id-type="doi">10.1038/ja.2016.157</pub-id><pub-id pub-id-type="pmid">28096550</pub-id></element-citation></ref><ref id="B232-antibiotics-08-00157"><label>232.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niu</surname><given-names>S.</given-names></name><name><surname>Hu</surname><given-names>T.</given-names></name><name><surname>Li</surname><given-names>S.</given-names></name><name><surname>Xiao</surname><given-names>Y.</given-names></name><name><surname>Ma</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>G.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Yang</surname><given-names>X.</given-names></name><name><surname>Ju</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>C.</given-names></name></person-group><article-title>Characterization of a Sugar-O-methyltransferase TiaS5 Affords New Tiacumicin Analogues with Improved Antibacterial Properties and Reveals Substrate Promiscuity</article-title><source>ChemBioChem</source><year>2011</year><volume>12</volume><fpage>1740</fpage><lpage>1748</lpage><pub-id pub-id-type="doi">10.1002/cbic.201100129</pub-id><pub-id pub-id-type="pmid">21633995</pub-id></element-citation></ref><ref id="B233-antibiotics-08-00157"><label>233.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Erb</surname><given-names>W.</given-names></name><name><surname>Zhu</surname><given-names>J.</given-names></name></person-group><article-title>From natural product to marketed drug: The tiacumicin odyssey</article-title><source>Nat. Prod. Rep.</source><year>2013</year><volume>30</volume><fpage>161</fpage><lpage>174</lpage><pub-id pub-id-type="doi">10.1039/C2NP20080E</pub-id><pub-id pub-id-type="pmid">23111588</pub-id></element-citation></ref><ref id="B234-antibiotics-08-00157"><label>234.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koglin</surname><given-names>A.</given-names></name><name><surname>L&#x000f6;hr</surname><given-names>F.</given-names></name><name><surname>Bernhard</surname><given-names>F.</given-names></name><name><surname>Rogov</surname><given-names>V.V.</given-names></name><name><surname>Frueh</surname><given-names>D.P.</given-names></name><name><surname>Strieter</surname><given-names>E.R.</given-names></name><name><surname>Mofid</surname><given-names>M.R.</given-names></name><name><surname>G&#x000fc;ntert</surname><given-names>P.</given-names></name><name><surname>Wagner</surname><given-names>G.</given-names></name><name><surname>Walsh</surname><given-names>C.T.</given-names></name><etal/></person-group><article-title>Structural basis for the selectivity of the external thioesterase of the surfactin synthetase</article-title><source>Nature</source><year>2008</year><volume>454</volume><fpage>907</fpage><lpage>911</lpage><pub-id pub-id-type="doi">10.1038/nature07161</pub-id><?supplied-pmid 18704089?><pub-id pub-id-type="pmid">18704089</pub-id></element-citation></ref><ref id="B235-antibiotics-08-00157"><label>235.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>&#x0014c;mura</surname><given-names>S.</given-names></name><name><surname>Imamura</surname><given-names>N.</given-names></name><name><surname>Oiwa</surname><given-names>R.</given-names></name><name><surname>Kuga</surname><given-names>H.</given-names></name><name><surname>Iwata</surname><given-names>R.</given-names></name><name><surname>Masuma</surname><given-names>R.</given-names></name><name><surname>Iwai</surname><given-names>Y.</given-names></name></person-group><article-title>Clostomicins, new antibiotics produced by <italic>Micromonospora echinospora</italic> subsp. armenica subsp. Nov. I Production, isolation and physico-chemical and biological properties</article-title><source>J. Antibiot.</source><year>1986</year><volume>39</volume><fpage>1407</fpage><lpage>1412</lpage><pub-id pub-id-type="pmid">3781911</pub-id></element-citation></ref><ref id="B236-antibiotics-08-00157"><label>236.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coronelli</surname><given-names>C.</given-names></name><name><surname>White</surname><given-names>R.J.</given-names></name><name><surname>Lancini</surname><given-names>G.C.</given-names></name><name><surname>Parenti</surname><given-names>F.</given-names></name></person-group><article-title>Lipiarmycin, a new antibiotic from <italic>Actinoplanes</italic>. II. Isolation, chemical, biological and biochemical characterization</article-title><source>J. Antibiot. (Tokyo)</source><year>1975</year><volume>28</volume><fpage>253</fpage><lpage>259</lpage><pub-id pub-id-type="doi">10.7164/antibiotics.28.253</pub-id><?supplied-pmid 807545?><pub-id pub-id-type="pmid">807545</pub-id></element-citation></ref><ref id="B237-antibiotics-08-00157"><label>237.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Louie</surname><given-names>T.J.</given-names></name><name><surname>Emery</surname><given-names>J.</given-names></name><name><surname>Krulicki</surname><given-names>W.</given-names></name><name><surname>Byrne</surname><given-names>B.</given-names></name><name><surname>Mah</surname><given-names>M.</given-names></name></person-group><article-title>OPT-80 Eliminates <italic>Clostridium Difficile</italic> and Is Sparing of <italic>Bacteroides</italic> Species during Treatment of <italic>C. Difficile</italic> Infection</article-title><source>Antimicrob. Agents Chemother.</source><year>2009</year><volume>53</volume><fpage>261</fpage><lpage>263</lpage><pub-id pub-id-type="doi">10.1128/AAC.01443-07</pub-id><?supplied-pmid 18955523?><pub-id pub-id-type="pmid">18955523</pub-id></element-citation></ref><ref id="B238-antibiotics-08-00157"><label>238.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thorpe</surname><given-names>C.M.</given-names></name><name><surname>McDermott</surname><given-names>L.A.</given-names></name><name><surname>Tran</surname><given-names>M.K.</given-names></name><name><surname>Chang</surname><given-names>J.</given-names></name><name><surname>Jenkins</surname><given-names>S.G.</given-names></name><name><surname>Goldstein</surname><given-names>E.J.C.</given-names></name><name><surname>Patel</surname><given-names>R.</given-names></name><name><surname>Forbes</surname><given-names>B.A.</given-names></name><name><surname>Johnson</surname><given-names>S.</given-names></name><name><surname>Gerding</surname><given-names>D.N.</given-names></name><etal/></person-group><article-title>US-based National Surveillance for Fidaxomicin Susceptibility of <italic>Clostridioides difficile</italic> (formerly <italic>Clostridium</italic>) Associated Diarrheal Isolates from 2013&#x02013;2016</article-title><source>Antimicrob. Agents Chemother.</source><year>2019</year><volume>63</volume><fpage>e00391-19</fpage><pub-id pub-id-type="doi">10.1128/AAC.00391-19</pub-id><?supplied-pmid 31085514?><pub-id pub-id-type="pmid">31085514</pub-id></element-citation></ref><ref id="B239-antibiotics-08-00157"><label>239.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Talpaert</surname><given-names>M.</given-names></name><name><surname>Campagnari</surname><given-names>F.</given-names></name><name><surname>Clerici</surname><given-names>L.</given-names></name></person-group><article-title>Lipiarmycin: An antibiotic inhibiting nucleic acid polymerases</article-title><source>Biochem. Biophys. Res. Commun.</source><year>1975</year><volume>63</volume><fpage>328</fpage><lpage>334</lpage><pub-id pub-id-type="doi">10.1016/S0006-291X(75)80047-7</pub-id><pub-id pub-id-type="pmid">1092299</pub-id></element-citation></ref><ref id="B240-antibiotics-08-00157"><label>240.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Tian</surname><given-names>X.</given-names></name><name><surname>Pu</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>Q.</given-names></name><name><surname>Zhang</surname><given-names>W.</given-names></name><name><surname>Zhang</surname><given-names>C.</given-names></name></person-group><article-title>Tiacumicin Congeners with Improved Antibacterial Activity from a Halogenase-Inactivated Mutant</article-title><source>J. Nat. Prod.</source><year>2018</year><volume>81</volume><fpage>1219</fpage><lpage>1224</lpage><pub-id pub-id-type="doi">10.1021/acs.jnatprod.7b00990</pub-id><?supplied-pmid 29676573?><pub-id pub-id-type="pmid">29676573</pub-id></element-citation></ref><ref id="B241-antibiotics-08-00157"><label>241.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bartsch</surname><given-names>S.M.</given-names></name><name><surname>Umscheid</surname><given-names>C.A.</given-names></name><name><surname>Fishman</surname><given-names>N.</given-names></name><name><surname>Lee</surname><given-names>B.Y.</given-names></name></person-group><article-title>Is fidaxomicin worth the cost? An economic analysis</article-title><source>Clin. Infect. Dis.</source><year>2013</year><volume>57</volume><fpage>555</fpage><lpage>561</lpage><pub-id pub-id-type="doi">10.1093/cid/cit346</pub-id><pub-id pub-id-type="pmid">23704121</pub-id></element-citation></ref><ref id="B242-antibiotics-08-00157"><label>242.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lechevalier</surname><given-names>M.P.</given-names></name><name><surname>Prauser</surname><given-names>H.</given-names></name><name><surname>Labeda</surname><given-names>D.P.</given-names></name><name><surname>Ruan</surname><given-names>J.S.</given-names></name></person-group><article-title>Two new genera of nocardioform actinomycetes: <italic>Amycolata</italic> gen. nov. and <italic>Amycolatopsis</italic> gen. nov</article-title><source>Int. J. Syst. Evol. Microbiol.</source><year>1986</year><volume>36</volume><fpage>29</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1099/00207713-36-1-29</pub-id></element-citation></ref><ref id="B243-antibiotics-08-00157"><label>243.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mariani</surname><given-names>R.</given-names></name><name><surname>Maffioli</surname><given-names>S.I.</given-names></name></person-group><article-title>Bacterial RNA polymerase inhibitors: An organized overview of their structure, derivatives, biological activity and current clinical development status</article-title><source>Curr. Med. Chem.</source><year>2009</year><volume>16</volume><fpage>430</fpage><lpage>454</lpage><pub-id pub-id-type="doi">10.2174/092986709787315559</pub-id><pub-id pub-id-type="pmid">19199915</pub-id></element-citation></ref><ref id="B244-antibiotics-08-00157"><label>244.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sensi</surname><given-names>P.</given-names></name></person-group><article-title>History of the Development of Rifampin</article-title><source>Clin. Infect. Dis.</source><year>1983</year><volume>5</volume><fpage>S402</fpage><lpage>S406</lpage><pub-id pub-id-type="doi">10.1093/clinids/5.Supplement_3.S402</pub-id><?supplied-pmid 6635432?><pub-id pub-id-type="pmid">6635432</pub-id></element-citation></ref><ref id="B245-antibiotics-08-00157"><label>245.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oppolzer</surname><given-names>W.</given-names></name><name><surname>Prelog</surname><given-names>V.</given-names></name><name><surname>Sensi</surname><given-names>P.</given-names></name></person-group><article-title>Konstitution des Rifamycins B und verwandter Rifamycine</article-title><source>Experientia</source><year>1964</year><volume>20</volume><fpage>336</fpage><lpage>339</lpage><pub-id pub-id-type="doi">10.1007/BF02171084</pub-id><?supplied-pmid 5855864?><pub-id pub-id-type="pmid">5855864</pub-id></element-citation></ref><ref id="B246-antibiotics-08-00157"><label>246.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lancini</surname><given-names>G.G.</given-names></name><name><surname>Gallo</surname><given-names>G.G.</given-names></name><name><surname>Sartori</surname><given-names>G.</given-names></name><name><surname>Sensi</surname><given-names>P.</given-names></name></person-group><article-title>Isolation and structure of rifamycin L and its biogenetic relationship with other rifamycins</article-title><source>J. Antibiot. (Tokyo)</source><year>1969</year><volume>22</volume><fpage>369</fpage><lpage>377</lpage><pub-id pub-id-type="doi">10.7164/antibiotics.22.369</pub-id><?supplied-pmid 5345679?><pub-id pub-id-type="pmid">5345679</pub-id></element-citation></ref><ref id="B247-antibiotics-08-00157"><label>247.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Admiraal</surname><given-names>S.J.</given-names></name><name><surname>Walsh</surname><given-names>C.T.</given-names></name><name><surname>Khosla</surname><given-names>C.</given-names></name></person-group><article-title>The Loading Module of Rifamycin Synthetase Is an Adenylation&#x02212;Thiolation Didomain with Substrate Tolerance for Substituted Benzoates</article-title><source>Biochemistry</source><year>2001</year><volume>40</volume><fpage>6116</fpage><lpage>6123</lpage><pub-id pub-id-type="doi">10.1021/bi010080z</pub-id><?supplied-pmid 11352749?><pub-id pub-id-type="pmid">11352749</pub-id></element-citation></ref><ref id="B248-antibiotics-08-00157"><label>248.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>T.W.</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>R.</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>M.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Draeger</surname><given-names>G.</given-names></name><name><surname>Kim</surname><given-names>C.G.</given-names></name><name><surname>Leistner</surname><given-names>E.</given-names></name><name><surname>Floss</surname><given-names>H.G.</given-names></name></person-group><article-title>Mutational analysis and reconstituted expression of the biosynthetic genes involved in the formation of 3-amino-5-hydroxybenzoic acid, the starter unit of rifamycin biosynthesis in <italic>Amycolatopsis mediterranei</italic> S699</article-title><source>J. Biol. Chem.</source><year>2001</year><volume>276</volume><fpage>12546</fpage><lpage>12555</lpage><pub-id pub-id-type="doi">10.1074/jbc.M009667200</pub-id><pub-id pub-id-type="pmid">11278540</pub-id></element-citation></ref><ref id="B249-antibiotics-08-00157"><label>249.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>T.W.</given-names></name><name><surname>Shen</surname><given-names>Y.</given-names></name><name><surname>Doi-Katayama</surname><given-names>Y.</given-names></name><name><surname>Tang</surname><given-names>L.</given-names></name><name><surname>Park</surname><given-names>C.</given-names></name><name><surname>Moore</surname><given-names>B.S.</given-names></name><name><surname>Hutchinson</surname><given-names>C.R.</given-names></name><name><surname>Floss</surname><given-names>H.G.</given-names></name></person-group><article-title>Direct evidence that the rifamycin polyketide synthase assembles polyketide chains processively</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>1999</year><volume>96</volume><fpage>9051</fpage><lpage>9056</lpage><pub-id pub-id-type="doi">10.1073/pnas.96.16.9051</pub-id><?supplied-pmid 10430893?><pub-id pub-id-type="pmid">10430893</pub-id></element-citation></ref><ref id="B250-antibiotics-08-00157"><label>250.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doi-Katayama</surname><given-names>Y.</given-names></name><name><surname>Yoon</surname><given-names>Y.J.</given-names></name><name><surname>Choi</surname><given-names>C.Y.</given-names></name><name><surname>Yu</surname><given-names>T.W.</given-names></name><name><surname>Floss</surname><given-names>H.G.</given-names></name><name><surname>Hutchinson</surname><given-names>C.R.</given-names></name></person-group><article-title>Thioesterases and the premature termination of polyketide chain elongation in rifamycin B biosynthesis by <italic>Amycolatopsis mediterranei</italic> S699</article-title><source>J. Antibiot. (Tokyo)</source><year>2000</year><volume>53</volume><fpage>484</fpage><lpage>495</lpage><pub-id pub-id-type="doi">10.7164/antibiotics.53.484</pub-id><pub-id pub-id-type="pmid">10908112</pub-id></element-citation></ref><ref id="B251-antibiotics-08-00157"><label>251.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Floss</surname><given-names>H.G.</given-names></name><name><surname>Yu</surname><given-names>T.W.</given-names></name></person-group><article-title>Lessons from the rifamycin biosynthetic gene cluster</article-title><source>Curr. Opin. Chem. Biol.</source><year>1999</year><volume>3</volume><fpage>592</fpage><lpage>597</lpage><pub-id pub-id-type="doi">10.1016/S1367-5931(99)00014-9</pub-id><pub-id pub-id-type="pmid">10508670</pub-id></element-citation></ref><ref id="B252-antibiotics-08-00157"><label>252.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>J.</given-names></name><name><surname>Wan</surname><given-names>E.</given-names></name><name><surname>Kim</surname><given-names>C.J.</given-names></name><name><surname>Floss</surname><given-names>H.G.</given-names></name><name><surname>Mahmud</surname><given-names>T.</given-names></name></person-group><article-title>Identification of tailoring genes involved in the modification of the polyketide backbone of rifamycin B by <italic>Amycolatopsis mediterranei</italic> S699</article-title><source>Microbiology</source><year>2005</year><volume>151</volume><fpage>2515</fpage><lpage>2528</lpage><pub-id pub-id-type="doi">10.1099/mic.0.28138-0</pub-id><pub-id pub-id-type="pmid">16079331</pub-id></element-citation></ref><ref id="B253-antibiotics-08-00157"><label>253.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>White</surname><given-names>R.J.</given-names></name><name><surname>Martinelli</surname><given-names>E.</given-names></name><name><surname>Lancini</surname><given-names>G.</given-names></name></person-group><article-title>Ansamycin biogenesis: Studies on a novel rifamycin isolated from a mutant strain of <italic>Nocardia mediterranei</italic></article-title><source>Proc. Natl. Acad. Sci. USA</source><year>1974</year><volume>71</volume><fpage>3260</fpage><lpage>3264</lpage><pub-id pub-id-type="doi">10.1073/pnas.71.8.3260</pub-id><pub-id pub-id-type="pmid">4528428</pub-id></element-citation></ref><ref id="B254-antibiotics-08-00157"><label>254.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qi</surname><given-names>F.</given-names></name><name><surname>Lei</surname><given-names>C.</given-names></name><name><surname>Li</surname><given-names>F.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>W.</given-names></name><name><surname>Fan</surname><given-names>Z.</given-names></name><name><surname>Li</surname><given-names>W.</given-names></name><name><surname>Tang</surname><given-names>G.</given-names></name><name><surname>Xiao</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Deciphering the late steps of rifamycin biosynthesis</article-title><source>Nat. Commun.</source><year>2018</year><volume>9</volume><fpage>2342</fpage><pub-id pub-id-type="doi">10.1038/s41467-018-04772-x</pub-id><?supplied-pmid 29904078?><pub-id pub-id-type="pmid">29904078</pub-id></element-citation></ref><ref id="B255-antibiotics-08-00157"><label>255.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>C.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Lei</surname><given-names>C.</given-names></name><name><surname>Yan</surname><given-names>H.</given-names></name><name><surname>Shao</surname><given-names>Z.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Zhao</surname><given-names>G.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Ding</surname><given-names>X.</given-names></name></person-group><article-title>RifZ (AMED_0655) is a pathway-specific regulator for rifamycin biosynthesis in <italic>Amycolatopsis mediterranei</italic></article-title><source>Appl. Environ. Microbiol.</source><year>2017</year><volume>83</volume><fpage>e03201-16</fpage><pub-id pub-id-type="doi">10.1128/AEM.03201-16</pub-id><?supplied-pmid 28159794?><pub-id pub-id-type="pmid">28159794</pub-id></element-citation></ref><ref id="B256-antibiotics-08-00157"><label>256.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lei</surname><given-names>C.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Zhao</surname><given-names>G.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name></person-group><article-title>A feedback regulatory model for RifQ-mediated repression of rifamycin export in <italic>Amycolatopsis mediterranei</italic></article-title><source>Microb. Cell Fact.</source><year>2018</year><volume>17</volume><fpage>14</fpage><pub-id pub-id-type="doi">10.1186/s12934-018-0863-5</pub-id><?supplied-pmid 29375035?><pub-id pub-id-type="pmid">29375035</pub-id></element-citation></ref><ref id="B257-antibiotics-08-00157"><label>257.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Absalon</surname><given-names>A.E.</given-names></name><name><surname>Fern&#x000e1;ndez</surname><given-names>F.J.</given-names></name><name><surname>Olivares</surname><given-names>P.X.</given-names></name><name><surname>Barrios-Gonz&#x000e1;lez</surname><given-names>J.</given-names></name><name><surname>Campos</surname><given-names>C.</given-names></name><name><surname>Mej&#x000ed;a</surname><given-names>A.</given-names></name></person-group><article-title>RifP; a membrane protein involved in rifamycin export in <italic>Amycolatopsis mediterranei</italic></article-title><source>Biotechnol. Lett.</source><year>2007</year><volume>29</volume><fpage>951</fpage><lpage>958</lpage><pub-id pub-id-type="doi">10.1007/s10529-007-9340-7</pub-id><?supplied-pmid 17351715?><pub-id pub-id-type="pmid">17351715</pub-id></element-citation></ref><ref id="B258-antibiotics-08-00157"><label>258.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wehrli</surname><given-names>W.</given-names></name></person-group><article-title>Rifampin: Mechanisms of action and resistance</article-title><source>Rev. Infect. Dis.</source><year>1983</year><volume>5</volume><fpage>S407</fpage><lpage>S411</lpage><pub-id pub-id-type="doi">10.1093/clinids/5.Supplement_3.S407</pub-id><?supplied-pmid 6356275?><pub-id pub-id-type="pmid">6356275</pub-id></element-citation></ref><ref id="B259-antibiotics-08-00157"><label>259.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boucher</surname><given-names>H.W.</given-names></name><name><surname>Talbot</surname><given-names>G.H.</given-names></name><name><surname>Benjamin</surname><given-names>D.K.</given-names><suffix>Jr.</suffix></name><name><surname>Bradley</surname><given-names>J.</given-names></name><name><surname>Guidos</surname><given-names>R.J.</given-names></name><name><surname>Jones</surname><given-names>R.N.</given-names></name><name><surname>Murray</surname><given-names>B.E.</given-names></name><name><surname>Bonomo</surname><given-names>R.A.</given-names></name><name><surname>Gilbert</surname><given-names>D.</given-names></name><collab>The Infectious Diseases Society of America</collab></person-group><article-title>10&#x000d7;&#x02019;20 progress&#x02014;Development of new drugs active against gram-negative bacilli: An update from the Infectious Diseases Society of America</article-title><source>Clin. Infect. Dis.</source><year>2013</year><volume>56</volume><fpage>1685</fpage><lpage>1694</lpage><pub-id pub-id-type="doi">10.1093/cid/cit152</pub-id><?supplied-pmid 23599308?><pub-id pub-id-type="pmid">23599308</pub-id></element-citation></ref><ref id="B260-antibiotics-08-00157"><label>260.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ponziani</surname><given-names>F.R.</given-names></name><name><surname>Scaldaferri</surname><given-names>F.</given-names></name><name><surname>Petito</surname><given-names>V.</given-names></name><name><surname>Paroni Sterbini</surname><given-names>F.</given-names></name><name><surname>Pecere</surname><given-names>S.</given-names></name><name><surname>Lopetuso</surname><given-names>L.R.</given-names></name><name><surname>Palladini</surname><given-names>A.</given-names></name><name><surname>Gerardi</surname><given-names>V.</given-names></name><name><surname>Masucci</surname><given-names>L.</given-names></name><name><surname>Pompili</surname><given-names>M.</given-names></name><etal/></person-group><article-title>The role of antibiotics in gut microbiota modulation: The eubiotic effects of rifaximin</article-title><source>Dig. Dis.</source><year>2016</year><volume>34</volume><fpage>269</fpage><lpage>278</lpage><pub-id pub-id-type="doi">10.1159/000443361</pub-id><pub-id pub-id-type="pmid">27027301</pub-id></element-citation></ref><ref id="B261-antibiotics-08-00157"><label>261.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weber</surname><given-names>D.</given-names></name><name><surname>Oefner</surname><given-names>P.J.</given-names></name><name><surname>Dettmer</surname><given-names>K.</given-names></name><name><surname>Hiergeist</surname><given-names>A.</given-names></name><name><surname>Koestler</surname><given-names>J.</given-names></name><name><surname>Gessner</surname><given-names>A.</given-names></name><name><surname>Weber</surname><given-names>M.</given-names></name><name><surname>St&#x000e4;mmler</surname><given-names>F.</given-names></name><name><surname>Hahn</surname><given-names>J.</given-names></name><name><surname>Wolff</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Rifaximin preserves intestinal microbiota balance in patients undergoing allogeneic stem cell transplantation</article-title><source>Bone Marrow Transplant.</source><year>2016</year><volume>51</volume><fpage>1087</fpage><pub-id pub-id-type="doi">10.1038/bmt.2016.66</pub-id><?supplied-pmid 26999466?><pub-id pub-id-type="pmid">26999466</pub-id></element-citation></ref><ref id="B262-antibiotics-08-00157"><label>262.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aristoff</surname><given-names>P.A.</given-names></name><name><surname>Garcia</surname><given-names>G.A.</given-names></name><name><surname>Kirchhoff</surname><given-names>P.D.</given-names></name><name><surname>Showalter</surname><given-names>H.D.</given-names></name></person-group><article-title>Rifamycins-obstacles and opportunities</article-title><source>Tuberculosis (Edinb.)</source><year>2010</year><volume>90</volume><fpage>94</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.1016/j.tube.2010.02.001</pub-id><pub-id pub-id-type="pmid">20236863</pub-id></element-citation></ref><ref id="B263-antibiotics-08-00157"><label>263.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Conover</surname><given-names>L.H.</given-names></name><name><surname>Moreland</surname><given-names>W.T.</given-names></name><name><surname>English</surname><given-names>A.R.</given-names></name><name><surname>Stephens</surname><given-names>C.R.</given-names></name><name><surname>Pilgrim</surname><given-names>F.J.</given-names></name><name><surname>Terramycin</surname><given-names>X.I.</given-names></name></person-group><article-title>Tetracycline</article-title><source>J. Am. Chem. Soc.</source><year>1953</year><volume>75</volume><fpage>4622</fpage><lpage>4623</lpage><pub-id pub-id-type="doi">10.1021/ja01114a537</pub-id></element-citation></ref><ref id="B264-antibiotics-08-00157"><label>264.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nelson</surname><given-names>M.L.</given-names></name><name><surname>Levy</surname><given-names>S.B.</given-names></name></person-group><article-title>The history of the tetracyclines</article-title><source>Ann. N. Y. Acad. Sci.</source><year>2011</year><volume>1241</volume><fpage>17</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1111/j.1749-6632.2011.06354.x</pub-id><?supplied-pmid 22191524?><pub-id pub-id-type="pmid">22191524</pub-id></element-citation></ref><ref id="B265-antibiotics-08-00157"><label>265.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>W.</given-names></name><name><surname>Ames</surname><given-names>B.D.</given-names></name><name><surname>Tsai</surname><given-names>S.C.</given-names></name><name><surname>Tang</surname><given-names>Y.</given-names></name></person-group><article-title>Engineered biosynthesis of a novel amidated polyketide, using the malonamyl-specific initiation module from the oxytetracycline polyketide synthase</article-title><source>Appl. Environ. Microbiol.</source><year>2006</year><volume>72</volume><fpage>2573</fpage><lpage>2580</lpage><pub-id pub-id-type="doi">10.1128/AEM.72.4.2573-2580.2006</pub-id><?supplied-pmid 16597959?><pub-id pub-id-type="pmid">16597959</pub-id></element-citation></ref><ref id="B266-antibiotics-08-00157"><label>266.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>P.</given-names></name><name><surname>Gao</surname><given-names>X.</given-names></name><name><surname>Chooi</surname><given-names>Y.H.</given-names></name><name><surname>Deng</surname><given-names>Z.</given-names></name><name><surname>Tang</surname><given-names>Y.</given-names></name></person-group><article-title>Genetic characterization of enzymes involved in the priming steps of oxytetracycline biosynthesis in <italic>Streptomyces rimosus</italic></article-title><source>Microbiology</source><year>2011</year><volume>157</volume><fpage>2401</fpage><lpage>2409</lpage><pub-id pub-id-type="doi">10.1099/mic.0.048439-0</pub-id><?supplied-pmid 21622525?><pub-id pub-id-type="pmid">21622525</pub-id></element-citation></ref><ref id="B267-antibiotics-08-00157"><label>267.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>W.</given-names></name><name><surname>Watanabe</surname><given-names>K.</given-names></name><name><surname>Wang</surname><given-names>C.C.C.</given-names></name><name><surname>Tang</surname><given-names>Y.</given-names></name></person-group><article-title>Heterologous biosynthesis of amidated polyketides with novel cyclization regioselectivity from oxytetracycline polyketide synthase</article-title><source>J. Nat. Prod.</source><year>2006</year><volume>69</volume><fpage>1633</fpage><lpage>1636</lpage><pub-id pub-id-type="doi">10.1021/np060290i</pub-id><?supplied-pmid 17125237?><pub-id pub-id-type="pmid">17125237</pub-id></element-citation></ref><ref id="B268-antibiotics-08-00157"><label>268.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pickens</surname><given-names>L.B.</given-names></name><name><surname>Tang</surname><given-names>Y.</given-names></name></person-group><article-title>Oxytetracycline biosynthesis</article-title><source>J. Biol. Chem.</source><year>2010</year><volume>285</volume><fpage>27509</fpage><lpage>27515</lpage><pub-id pub-id-type="doi">10.1074/jbc.R110.130419</pub-id><?supplied-pmid 20522541?><pub-id pub-id-type="pmid">20522541</pub-id></element-citation></ref><ref id="B269-antibiotics-08-00157"><label>269.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petkovi&#x00107;</surname><given-names>H.</given-names></name><name><surname>Luke&#x0017e;i&#x0010d;</surname><given-names>T.</given-names></name><name><surname>&#x00160;u&#x00161;kovi&#x00107;</surname><given-names>J.</given-names></name></person-group><article-title>Biosynthesis of oxytetracycline by <italic>Streptomyces rimosus</italic>: Past, present and future directions in the development of tetracycline antibiotics</article-title><source>Food Technol. Biotechnol.</source><year>2017</year><volume>55</volume><fpage>3</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.17113/ftb.55.01.17.4617</pub-id><pub-id pub-id-type="pmid">28559729</pub-id></element-citation></ref><ref id="B270-antibiotics-08-00157"><label>270.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>P.</given-names></name><name><surname>Bashiri</surname><given-names>G.</given-names></name><name><surname>Gao</surname><given-names>X.</given-names></name><name><surname>Sawaya</surname><given-names>M.R.</given-names></name><name><surname>Tang</surname><given-names>Y.</given-names></name></person-group><article-title>Uncovering the enzymes that catalyze the final steps in oxytetracycline biosynthesis</article-title><source>J. Am. Chem. Soc.</source><year>2013</year><volume>135</volume><fpage>7138</fpage><lpage>7141</lpage><pub-id pub-id-type="doi">10.1021/ja403516u</pub-id><pub-id pub-id-type="pmid">23621493</pub-id></element-citation></ref><ref id="B271-antibiotics-08-00157"><label>271.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohnuki</surname><given-names>T.</given-names></name><name><surname>Katoh</surname><given-names>T.</given-names></name><name><surname>Imanaka</surname><given-names>T.</given-names></name><name><surname>Aiba</surname><given-names>S.</given-names></name></person-group><article-title>Molecular cloning of tetracycline resistance genes from <italic>Streptomyces rimosus</italic> in <italic>Streptomyces griseus</italic> and characterization of the cloned genes</article-title><source>J. Bacteriol.</source><year>1985</year><volume>161</volume><fpage>1010</fpage><lpage>1016</lpage><pub-id pub-id-type="pmid">2982781</pub-id></element-citation></ref><ref id="B272-antibiotics-08-00157"><label>272.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le&#x00161;nik</surname><given-names>U.</given-names></name><name><surname>Gormand</surname><given-names>A.</given-names></name><name><surname>Magdevska</surname><given-names>V.</given-names></name><name><surname>Fujs</surname><given-names>&#x00160;.</given-names></name><name><surname>Raspor</surname><given-names>P.</given-names></name><name><surname>Hunter</surname><given-names>I.</given-names></name><name><surname>Petkovi&#x00107;</surname><given-names>H.</given-names></name></person-group><article-title>Regulatory elements in tetracycline-encoding gene clusters: The <italic>otcG</italic> gene positively regulates the production of oxytetracycline in <italic>Streptomyces rimosus</italic></article-title><source>Food Technol. Biotechnol.</source><year>2009</year><volume>47</volume><fpage>323</fpage><lpage>330</lpage></element-citation></ref><ref id="B273-antibiotics-08-00157"><label>273.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yin</surname><given-names>S.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Zhu</surname><given-names>Y.</given-names></name><name><surname>Jia</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>S.</given-names></name><name><surname>Yuan</surname><given-names>F.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Yang</surname><given-names>K.</given-names></name></person-group><article-title>Identification of a cluster-situated activator of oxytetracycline biosynthesis and manipulation of its expression for improved oxytetracycline production in <italic>Streptomyces rimosus</italic></article-title><source>Microb. Cell Fact.</source><year>2015</year><volume>14</volume><fpage>46</fpage><pub-id pub-id-type="doi">10.1186/s12934-015-0231-7</pub-id><pub-id pub-id-type="pmid">25886456</pub-id></element-citation></ref><ref id="B274-antibiotics-08-00157"><label>274.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jenner</surname><given-names>L.</given-names></name><name><surname>Starosta</surname><given-names>A.L.</given-names></name><name><surname>Terry</surname><given-names>D.S.</given-names></name><name><surname>Mikolajka</surname><given-names>A.</given-names></name><name><surname>Filonava</surname><given-names>L.</given-names></name><name><surname>Yusupov</surname><given-names>M.</given-names></name><name><surname>Blanchard</surname><given-names>S.C.</given-names></name><name><surname>Wilson</surname><given-names>D.N.</given-names></name><name><surname>Yusupova</surname><given-names>G.</given-names></name></person-group><article-title>Structural basis for potent inhibitory activity of the antibiotic tigecycline during protein synthesis</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2013</year><volume>110</volume><fpage>3812</fpage><lpage>3816</lpage><pub-id pub-id-type="doi">10.1073/pnas.1216691110</pub-id><?supplied-pmid 23431179?><pub-id pub-id-type="pmid">23431179</pub-id></element-citation></ref><ref id="B275-antibiotics-08-00157"><label>275.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nelson</surname><given-names>M.L.</given-names></name><name><surname>Park</surname><given-names>B.H.</given-names></name><name><surname>Levy</surname><given-names>S.B.</given-names></name></person-group><article-title>Molecular requirements for the inhibition of the tetracycline antiport protein and the effect of potent inhibitors on the growth of tetracycline-resistant bacteria</article-title><source>J. Med. Chem.</source><year>1994</year><volume>37</volume><fpage>1355</fpage><lpage>1361</lpage><pub-id pub-id-type="doi">10.1021/jm00035a016</pub-id><?supplied-pmid 8176712?><pub-id pub-id-type="pmid">8176712</pub-id></element-citation></ref><ref id="B276-antibiotics-08-00157"><label>276.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Villano</surname><given-names>S.</given-names></name><name><surname>Steenbergen</surname><given-names>J.</given-names></name><name><surname>Loh</surname><given-names>E.</given-names></name></person-group><article-title>Omadacycline: Development of a novel aminomethylcycline antibiotic for treating drug-resistant bacterial infections</article-title><source>Future Microbiol.</source><year>2016</year><volume>11</volume><fpage>1421</fpage><lpage>1434</lpage><pub-id pub-id-type="doi">10.2217/fmb-2016-0100</pub-id><?supplied-pmid 27539442?><pub-id pub-id-type="pmid">27539442</pub-id></element-citation></ref><ref id="B277-antibiotics-08-00157"><label>277.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barriere</surname><given-names>J.C.</given-names></name><name><surname>Berthaud</surname><given-names>N.</given-names></name><name><surname>Beyer</surname><given-names>D.</given-names></name><name><surname>Dutka-Malen</surname><given-names>S.</given-names></name><name><surname>Paris</surname><given-names>J.M.</given-names></name><name><surname>Desnottes</surname><given-names>J.F.</given-names></name></person-group><article-title>Recent developments in streptogramin research</article-title><source>Curr. Pharm. Des.</source><year>1998</year><volume>4</volume><fpage>155</fpage><?supplied-pmid 10197038?><pub-id pub-id-type="pmid">10197038</pub-id></element-citation></ref><ref id="B278-antibiotics-08-00157"><label>278.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mast</surname><given-names>Y.</given-names></name><name><surname>Wohlleben</surname><given-names>W.</given-names></name></person-group><article-title>Streptogramins&#x02014;Two are better than one!</article-title><source>Int. J. Med. Microbiol.</source><year>2014</year><volume>304</volume><fpage>44</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1016/j.ijmm.2013.08.008</pub-id><?supplied-pmid 24119565?><pub-id pub-id-type="pmid">24119565</pub-id></element-citation></ref><ref id="B279-antibiotics-08-00157"><label>279.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Charney</surname><given-names>J.</given-names></name><name><surname>Fisher</surname><given-names>W.P.</given-names></name><name><surname>Curran</surname><given-names>C.</given-names></name><name><surname>Machlowitz</surname><given-names>R.A.</given-names></name><name><surname>Tytell</surname><given-names>A.A.</given-names></name></person-group><article-title>Streptogramin, a new antibiotic</article-title><source>Antibiot. Chemother. (Northfield, III.)</source><year>1953</year><volume>3</volume><fpage>1283</fpage><lpage>1286</lpage></element-citation></ref><ref id="B280-antibiotics-08-00157"><label>280.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arai</surname><given-names>M.</given-names></name><name><surname>Karasawa</surname><given-names>K.</given-names></name><name><surname>Nakamura</surname><given-names>S.</given-names></name><name><surname>Yonehara</surname><given-names>H.</given-names></name><name><surname>Umezawa</surname><given-names>H.</given-names></name></person-group><article-title>Studies on mikamycin. I</article-title><source>J. Antibiot. (Tokyo)</source><year>1958</year><volume>11</volume><fpage>14</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">13525248</pub-id></element-citation></ref><ref id="B281-antibiotics-08-00157"><label>281.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watanabe</surname><given-names>K.</given-names></name></person-group><article-title>Studies on mikamycin. VII. Structure of mikamycin B</article-title><source>J. Antibiot. Ser. A</source><year>1961</year><volume>14</volume><fpage>14</fpage><lpage>17</lpage></element-citation></ref><ref id="B282-antibiotics-08-00157"><label>282.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Bartz</surname><given-names>Q.R.</given-names></name><name><surname>Standiford</surname><given-names>J.</given-names></name><name><surname>Mold</surname><given-names>J.D.</given-names></name><name><surname>Johannessen</surname><given-names>D.W.</given-names></name><name><surname>Ryder</surname><given-names>A.</given-names></name><name><surname>Maretski</surname><given-names>A.</given-names></name><name><surname>Haskell</surname><given-names>T.H.</given-names></name></person-group><source>Antibiotics Annual (1954&#x02013;1955)</source><publisher-name>Medical Encyclopedia Inc.</publisher-name><publisher-loc>New York, NY, USA</publisher-loc><year>1954</year><fpage>777</fpage><lpage>783</lpage></element-citation></ref><ref id="B283-antibiotics-08-00157"><label>283.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Somer</surname><given-names>P.</given-names></name><name><surname>Van Dijck</surname><given-names>P.</given-names></name></person-group><article-title>A preliminary report on antibiotic number 899, a streptogramin-like substance</article-title><source>Antibiot. Chemother. (Northfield, III.)</source><year>1955</year><volume>5</volume><fpage>632</fpage><lpage>639</lpage></element-citation></ref><ref id="B284-antibiotics-08-00157"><label>284.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Casewell</surname><given-names>M.</given-names></name><name><surname>Friis</surname><given-names>C.</given-names></name><name><surname>Marco</surname><given-names>E.</given-names></name><name><surname>McMullin</surname><given-names>P.</given-names></name><name><surname>Phillips</surname><given-names>I.</given-names></name></person-group><article-title>The European ban on growth-promoting antibiotics and emerging consequences for human and animal health</article-title><source>J. Antimicrob. Chemother.</source><year>2003</year><volume>52</volume><fpage>159</fpage><lpage>161</lpage><pub-id pub-id-type="doi">10.1093/jac/dkg313</pub-id><pub-id pub-id-type="pmid">12837737</pub-id></element-citation></ref><ref id="B285-antibiotics-08-00157"><label>285.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Musiol</surname><given-names>E.M.</given-names></name><name><surname>Greule</surname><given-names>A.</given-names></name><name><surname>H&#x000e4;rtner</surname><given-names>T.</given-names></name><name><surname>Kulik</surname><given-names>A.</given-names></name><name><surname>Wohlleben</surname><given-names>W.</given-names></name><name><surname>Weber</surname><given-names>T.</given-names></name></person-group><article-title>The AT2 domain of KirCI loads malonyl extender units to the ACPs of the kirromycin PKS</article-title><source>ChemBioChem</source><year>2013</year><volume>14</volume><fpage>1343</fpage><lpage>1352</lpage><pub-id pub-id-type="doi">10.1002/cbic.201300211</pub-id><pub-id pub-id-type="pmid">23828654</pub-id></element-citation></ref><ref id="B286-antibiotics-08-00157"><label>286.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weber</surname><given-names>T.</given-names></name><name><surname>Laiple</surname><given-names>K.J.</given-names></name><name><surname>Pross</surname><given-names>E.K.</given-names></name><name><surname>Textor</surname><given-names>A.</given-names></name><name><surname>Grond</surname><given-names>S.</given-names></name><name><surname>Welzel</surname><given-names>K.</given-names></name><name><surname>Pelzer</surname><given-names>S.</given-names></name><name><surname>Vente</surname><given-names>A.</given-names></name><name><surname>Wohlleben</surname><given-names>W.</given-names></name></person-group><article-title>Molecular analysis of the kirromycin biosynthetic gene cluster revealed &#x003b2;-alanine as precursor of the pyridone moiety</article-title><source>Chem. Biol.</source><year>2008</year><volume>15</volume><fpage>175</fpage><lpage>188</lpage><pub-id pub-id-type="doi">10.1016/j.chembiol.2007.12.009</pub-id><?supplied-pmid 18291322?><pub-id pub-id-type="pmid">18291322</pub-id></element-citation></ref><ref id="B287-antibiotics-08-00157"><label>287.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mast</surname><given-names>Y.</given-names></name><name><surname>Guezguez</surname><given-names>J.</given-names></name><name><surname>Handel</surname><given-names>F.</given-names></name><name><surname>Schinko</surname><given-names>E.</given-names></name></person-group><article-title>A complex signaling cascade governs pristinamycin biosynthesis in <italic>Streptomyces pristinaespiralis</italic></article-title><source>Appl. Environ. Microbiol.</source><year>2015</year><volume>81</volume><fpage>6621</fpage><lpage>6636</lpage><pub-id pub-id-type="doi">10.1128/AEM.00728-15</pub-id><?supplied-pmid 26187956?><pub-id pub-id-type="pmid">26187956</pub-id></element-citation></ref><ref id="B288-antibiotics-08-00157"><label>288.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Tian</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Ge</surname><given-names>M.</given-names></name><name><surname>Zhu</surname><given-names>H.</given-names></name><name><surname>Zheng</surname><given-names>G.</given-names></name><name><surname>Huang</surname><given-names>H.</given-names></name><name><surname>Ruan</surname><given-names>L.</given-names></name><name><surname>Jiang</surname><given-names>W.</given-names></name><name><surname>Lu</surname><given-names>Y.</given-names></name></person-group><article-title>Identification of two novel regulatory genes involved in pristinamycin biosynthesis and elucidation of the mechanism for AtrA-p-mediated regulation in <italic>Streptomyces pristinaespiralis</italic></article-title><source>Appl. Microbiol. Biotechnol.</source><year>2015</year><volume>99</volume><fpage>7151</fpage><lpage>7164</lpage><pub-id pub-id-type="doi">10.1007/s00253-015-6638-6</pub-id><?supplied-pmid 25957493?><pub-id pub-id-type="pmid">25957493</pub-id></element-citation></ref><ref id="B289-antibiotics-08-00157"><label>289.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meng</surname><given-names>J.</given-names></name><name><surname>Feng</surname><given-names>R.</given-names></name><name><surname>Zheng</surname><given-names>G.</given-names></name><name><surname>Ge</surname><given-names>M.</given-names></name><name><surname>Mast</surname><given-names>Y.</given-names></name><name><surname>Wohlleben</surname><given-names>W.</given-names></name><name><surname>Gao</surname><given-names>J.</given-names></name><name><surname>Jiang</surname><given-names>W.</given-names></name><name><surname>Lu</surname><given-names>Y.</given-names></name></person-group><article-title>Improvement of pristinamycin I (PI) production in <italic>Streptomyces pristinaespiralis</italic> by metabolic engineering approaches</article-title><source>Synth. Syst. Biotechnol.</source><year>2017</year><volume>2</volume><fpage>130</fpage><lpage>136</lpage><pub-id pub-id-type="doi">10.1016/j.synbio.2017.06.001</pub-id><?supplied-pmid 29062970?><pub-id pub-id-type="pmid">29062970</pub-id></element-citation></ref><ref id="B290-antibiotics-08-00157"><label>290.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Zhao</surname><given-names>Y.</given-names></name><name><surname>Ruan</surname><given-names>L.</given-names></name><name><surname>Yang</surname><given-names>S.</given-names></name><name><surname>Ge</surname><given-names>M.</given-names></name><name><surname>Jiang</surname><given-names>W.</given-names></name><name><surname>Lu</surname><given-names>Y.</given-names></name></person-group><article-title>A stepwise increase in pristinamycin II biosynthesis by <italic>Streptomyces pristinaespiralis</italic> through combinatorial metabolic engineering</article-title><source>Metab. Eng.</source><year>2015</year><volume>29</volume><fpage>12</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1016/j.ymben.2015.02.001</pub-id><pub-id pub-id-type="pmid">25708513</pub-id></element-citation></ref><ref id="B291-antibiotics-08-00157"><label>291.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nyssen</surname><given-names>E.</given-names></name><name><surname>Di Giambattista</surname><given-names>M.</given-names></name><name><surname>Cocito</surname><given-names>C.</given-names></name></person-group><article-title>Analysis of the reversible binding of virginiamycin M to ribosome and particle functions after removal of the antibiotic</article-title><source>Biochim. Biophys. Acta Gene Struct. Expr.</source><year>1989</year><volume>1009</volume><fpage>39</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1016/0167-4781(89)90076-6</pub-id></element-citation></ref><ref id="B292-antibiotics-08-00157"><label>292.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnston</surname><given-names>N.J.</given-names></name><name><surname>Mukhtar</surname><given-names>T.A.</given-names></name><name><surname>Wright</surname><given-names>G.D.</given-names></name></person-group><article-title>Streptogramin antibiotics: Mode of action and resistance</article-title><source>Curr. Drug Targets</source><year>2002</year><volume>3</volume><fpage>335</fpage><lpage>344</lpage><pub-id pub-id-type="doi">10.2174/1389450023347678</pub-id><?supplied-pmid 12102603?><pub-id pub-id-type="pmid">12102603</pub-id></element-citation></ref><ref id="B293-antibiotics-08-00157"><label>293.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roberts</surname><given-names>M.C.</given-names></name></person-group><article-title>Environmental macrolide&#x02013;lincosamide&#x02013;streptogramin and tetracycline resistant bacteria</article-title><source>Front. Microbiol.</source><year>2011</year><volume>2</volume><fpage>40</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2011.00040</pub-id><?supplied-pmid 21833302?><pub-id pub-id-type="pmid">21833302</pub-id></element-citation></ref><ref id="B294-antibiotics-08-00157"><label>294.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roberts</surname><given-names>M.C.</given-names></name></person-group><article-title>Resistance to macrolide, lincosamide, streptogramin, ketolide, and oxazolidinone antibiotics</article-title><source>Mol. Biotechnol.</source><year>2004</year><volume>28</volume><fpage>47</fpage><pub-id pub-id-type="doi">10.1385/MB:28:1:47</pub-id><pub-id pub-id-type="pmid">15456963</pub-id></element-citation></ref><ref id="B295-antibiotics-08-00157"><label>295.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poehlsgaard</surname><given-names>J.</given-names></name><name><surname>Douthwaite</surname><given-names>S.</given-names></name></person-group><article-title>The bacterial ribosome as a target for antibiotics</article-title><source>Nat. Rev. Microbiol.</source><year>2005</year><volume>3</volume><fpage>870</fpage><pub-id pub-id-type="doi">10.1038/nrmicro1265</pub-id><?supplied-pmid 16261170?><pub-id pub-id-type="pmid">16261170</pub-id></element-citation></ref><ref id="B296-antibiotics-08-00157"><label>296.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allignet</surname><given-names>J.</given-names></name><name><surname>Loncle</surname><given-names>V.</given-names></name><name><surname>Mazodier</surname><given-names>P.</given-names></name><name><surname>El Solh</surname><given-names>N.</given-names></name></person-group><article-title>Nucleotide sequence of a staphylococcal plasmid gene, <italic>vgb</italic>, encoding a hydrolase inactivating the B components of virginiamycin-like antibiotics</article-title><source>Plasmid</source><year>1988</year><volume>20</volume><fpage>271</fpage><lpage>275</lpage><pub-id pub-id-type="doi">10.1016/0147-619X(88)90034-0</pub-id><pub-id pub-id-type="pmid">3149758</pub-id></element-citation></ref><ref id="B297-antibiotics-08-00157"><label>297.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allignet</surname><given-names>J.</given-names></name><name><surname>Loncle</surname><given-names>V.</given-names></name><name><surname>El Solh</surname><given-names>N.</given-names></name></person-group><article-title>Sequence of a staphylococcal plasmid gene, <italic>vga</italic>, encoding a putative ATP-binding protein involved in resistance to virginiamycin A-like antibiotics</article-title><source>Gene</source><year>1992</year><volume>117</volume><fpage>45</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1016/0378-1119(92)90488-B</pub-id><pub-id pub-id-type="pmid">1644314</pub-id></element-citation></ref><ref id="B298-antibiotics-08-00157"><label>298.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aparicio</surname><given-names>J.F.</given-names></name><name><surname>Caffrey</surname><given-names>P.</given-names></name><name><surname>Gil</surname><given-names>J.A.</given-names></name><name><surname>Zotchev</surname><given-names>S.B.</given-names></name></person-group><article-title>Polyene antibiotic biosynthesis gene clusters</article-title><source>Appl. Microbiol. Biotechnol.</source><year>2003</year><volume>61</volume><fpage>179</fpage><lpage>188</lpage><pub-id pub-id-type="doi">10.1007/s00253-002-1183-5</pub-id><?supplied-pmid 12698274?><pub-id pub-id-type="pmid">12698274</pub-id></element-citation></ref><ref id="B299-antibiotics-08-00157"><label>299.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fj&#x000e6;rvik</surname><given-names>E.</given-names></name><name><surname>Zotchev</surname><given-names>S.B.</given-names></name></person-group><article-title>Biosynthesis of the polyene macrolide antibiotic nystatin in <italic>Streptomyces noursei</italic></article-title><source>Appl. Microbiol. Biotechnol.</source><year>2005</year><volume>67</volume><fpage>436</fpage><lpage>443</lpage><pub-id pub-id-type="doi">10.1007/s00253-004-1802-4</pub-id><?supplied-pmid 15700127?><pub-id pub-id-type="pmid">15700127</pub-id></element-citation></ref><ref id="B300-antibiotics-08-00157"><label>300.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hazen</surname><given-names>E.L.</given-names></name><name><surname>Brown</surname><given-names>R.</given-names></name></person-group><article-title>Two antifungal agents produced by a soil actinomycete</article-title><source>Science</source><year>1950</year><volume>112</volume><fpage>423</fpage><?supplied-pmid 14781786?><pub-id pub-id-type="pmid">14781786</pub-id></element-citation></ref><ref id="B301-antibiotics-08-00157"><label>301.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mechlinski</surname><given-names>W.</given-names></name><name><surname>Schaffner</surname><given-names>C.P.</given-names></name></person-group><article-title>Separation of polyene antifungal antibiotics by high-speed liquid chromatography</article-title><source>J. Chromatogr. A</source><year>1974</year><volume>99</volume><fpage>619</fpage><lpage>633</lpage><pub-id pub-id-type="doi">10.1016/S0021-9673(00)90890-2</pub-id></element-citation></ref><ref id="B302-antibiotics-08-00157"><label>302.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsuoka</surname><given-names>M.</given-names></name></person-group><article-title>Biological studies on antifungal substances produced by <italic>Streptomyces fungicidicus</italic></article-title><source>J. Antibiot. (Tokyo)</source><year>1960</year><volume>13</volume><fpage>121</fpage><lpage>124</lpage><pub-id pub-id-type="pmid">13853855</pub-id></element-citation></ref><ref id="B303-antibiotics-08-00157"><label>303.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Veiga</surname><given-names>M.</given-names></name><name><surname>Fabregas</surname><given-names>J.</given-names></name></person-group><article-title>Tetrafungin, a new polyene macrolide antibiotic. I. Fermentation, isolation, characterization, and biological properties</article-title><source>J. Antibiot. (Tokyo)</source><year>1983</year><volume>36</volume><fpage>770</fpage><lpage>775</lpage><pub-id pub-id-type="doi">10.7164/antibiotics.36.770</pub-id><pub-id pub-id-type="pmid">6885632</pub-id></element-citation></ref><ref id="B304-antibiotics-08-00157"><label>304.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chong</surname><given-names>C.N.</given-names></name><name><surname>Rickards</surname><given-names>R.W.</given-names></name></person-group><article-title>Macrolide antibiotic studies. XVI. The structure of nystatin</article-title><source>Tetrahedron Lett.</source><year>1970</year><volume>11</volume><fpage>5145</fpage><lpage>5148</lpage><pub-id pub-id-type="doi">10.1016/S0040-4039(00)96962-4</pub-id></element-citation></ref><ref id="B305-antibiotics-08-00157"><label>305.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sletta</surname><given-names>H.</given-names></name><name><surname>Borgos</surname><given-names>S.E.F.</given-names></name><name><surname>Bruheim</surname><given-names>P.</given-names></name><name><surname>Sekurova</surname><given-names>O.N.</given-names></name><name><surname>Grasdalen</surname><given-names>H.</given-names></name><name><surname>Aune</surname><given-names>R.</given-names></name><name><surname>Ellingsen</surname><given-names>T.E.</given-names></name><name><surname>Zotchev</surname><given-names>S.B.</given-names></name></person-group><article-title>Nystatin biosynthesis and transport: <italic>nysH</italic> and <italic>nysG</italic> genes encoding a putative ABC transporter system in <italic>Streptomyces noursei</italic> ATCC 11455 are required for efficient conversion of 10-deoxynystatin to nystatin</article-title><source>Antimicrob. Agents Chemother.</source><year>2005</year><volume>49</volume><fpage>4576</fpage><lpage>4583</lpage><pub-id pub-id-type="doi">10.1128/AAC.49.11.4576-4583.2005</pub-id><?supplied-pmid 16251298?><pub-id pub-id-type="pmid">16251298</pub-id></element-citation></ref><ref id="B306-antibiotics-08-00157"><label>306.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sekurova</surname><given-names>O.N.</given-names></name><name><surname>Brautaset</surname><given-names>T.</given-names></name><name><surname>Sletta</surname><given-names>H.</given-names></name><name><surname>Borgos</surname><given-names>S.E.F.</given-names></name><name><surname>Jakobsen</surname><given-names>&#x000d8;.M.</given-names></name><name><surname>Ellingsen</surname><given-names>T.E.</given-names></name><name><surname>Str&#x000f8;m</surname><given-names>A.R.</given-names></name><name><surname>Valla</surname><given-names>S.</given-names></name><name><surname>Zotchev</surname><given-names>S.B.</given-names></name></person-group><article-title>In vivo analysis of the regulatory genes in the nystatin biosynthetic gene cluster of <italic>Streptomyces noursei</italic> ATCC 11455 reveals their differential control over antibiotic biosynthesis</article-title><source>J. Bacteriol.</source><year>2004</year><volume>186</volume><fpage>1345</fpage><lpage>1354</lpage><pub-id pub-id-type="doi">10.1128/JB.186.5.1345-1354.2004</pub-id><?supplied-pmid 14973031?><pub-id pub-id-type="pmid">14973031</pub-id></element-citation></ref><ref id="B307-antibiotics-08-00157"><label>307.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupte</surname><given-names>M.</given-names></name><name><surname>Kulkarni</surname><given-names>P.</given-names></name><name><surname>Ganguli</surname><given-names>B.</given-names></name></person-group><article-title>Antifungal antibiotics</article-title><source>Appl. Microbiol. Biotechnol.</source><year>2002</year><volume>58</volume><fpage>46</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1007/s002530100822</pub-id><?supplied-pmid 11831475?><pub-id pub-id-type="pmid">11831475</pub-id></element-citation></ref><ref id="B308-antibiotics-08-00157"><label>308.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamilton-Miller</surname><given-names>J.M.</given-names></name></person-group><article-title>Chemistry and biology of the polyene macrolide antibiotics</article-title><source>Bacteriol. Rev.</source><year>1973</year><volume>37</volume><fpage>166</fpage><?supplied-pmid 4202146?><pub-id pub-id-type="pmid">4202146</pub-id></element-citation></ref><ref id="B309-antibiotics-08-00157"><label>309.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>M.Y.</given-names></name><name><surname>Myeong</surname><given-names>J.S.</given-names></name><name><surname>Park</surname><given-names>H.J.</given-names></name><name><surname>Han</surname><given-names>K.</given-names></name><name><surname>Kim</surname><given-names>E.S.</given-names></name></person-group><article-title>Isolation and partial characterization of a cryptic polyene gene cluster in <italic>Pseudonocardia autotrophica</italic></article-title><source>J. Ind. Microbiol. Biotechnol.</source><year>2006</year><volume>33</volume><fpage>84</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1007/s10295-005-0018-7</pub-id><?supplied-pmid 16096834?><pub-id pub-id-type="pmid">16096834</pub-id></element-citation></ref><ref id="B310-antibiotics-08-00157"><label>310.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>B.G.</given-names></name><name><surname>Lee</surname><given-names>M.J.</given-names></name><name><surname>Seo</surname><given-names>J.</given-names></name><name><surname>Hwang</surname><given-names>Y.B.</given-names></name><name><surname>Lee</surname><given-names>M.Y.</given-names></name><name><surname>Han</surname><given-names>K.</given-names></name><name><surname>Sherman</surname><given-names>D.H.</given-names></name><name><surname>Kim</surname><given-names>E.S.</given-names></name></person-group><article-title>Identification of functionally clustered nystatin-like biosynthetic genes in a rare actinomycetes, <italic>Pseudonocardia autotrophica</italic></article-title><source>J. Ind. Microbiol. Biotechnol.</source><year>2009</year><volume>36</volume><fpage>1425</fpage><pub-id pub-id-type="doi">10.1007/s10295-009-0629-5</pub-id><?supplied-pmid 19697072?><pub-id pub-id-type="pmid">19697072</pub-id></element-citation></ref><ref id="B311-antibiotics-08-00157"><label>311.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>M.J.</given-names></name><name><surname>Kong</surname><given-names>D.</given-names></name><name><surname>Han</surname><given-names>K.</given-names></name><name><surname>Sherman</surname><given-names>D.H.</given-names></name><name><surname>Bai</surname><given-names>L.</given-names></name><name><surname>Deng</surname><given-names>Z.</given-names></name><name><surname>Lin</surname><given-names>S.</given-names></name><name><surname>Kim</surname><given-names>E.S.</given-names></name></person-group><article-title>Structural analysis and biosynthetic engineering of a solubility-improved and less-hemolytic nystatin-like polyene in <italic>Pseudonocardia autotrophica</italic></article-title><source>Appl. Microbiol. Biotechnol.</source><year>2012</year><volume>95</volume><fpage>157</fpage><lpage>168</lpage><pub-id pub-id-type="doi">10.1007/s00253-012-3955-x</pub-id><?supplied-pmid 22382166?><pub-id pub-id-type="pmid">22382166</pub-id></element-citation></ref><ref id="B312-antibiotics-08-00157"><label>312.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>H.J.</given-names></name><name><surname>Han</surname><given-names>C.Y.</given-names></name><name><surname>Park</surname><given-names>J.S.</given-names></name><name><surname>Oh</surname><given-names>S.H.</given-names></name><name><surname>Kang</surname><given-names>S.H.</given-names></name><name><surname>Choi</surname><given-names>S.S.</given-names></name><name><surname>Kim</surname><given-names>J.M.</given-names></name><name><surname>Kwak</surname><given-names>J.H.</given-names></name><name><surname>Kim</surname><given-names>E.S.</given-names></name></person-group><article-title>Nystatin-like <italic>Pseudonocardia</italic> polyene B1, a novel disaccharide-containing antifungal heptaene antibiotic</article-title><source>Sci. Rep.</source><year>2018</year><volume>8</volume><fpage>13584</fpage><pub-id pub-id-type="doi">10.1038/s41598-018-31801-y</pub-id><?supplied-pmid 30206268?><pub-id pub-id-type="pmid">30206268</pub-id></element-citation></ref><ref id="B313-antibiotics-08-00157"><label>313.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caffrey</surname><given-names>P.</given-names></name><name><surname>Lynch</surname><given-names>S.</given-names></name><name><surname>Flood</surname><given-names>E.</given-names></name><name><surname>Finnan</surname><given-names>S.</given-names></name><name><surname>Oliynyk</surname><given-names>M.</given-names></name></person-group><article-title>Amphotericin biosynthesis in <italic>Streptomyces nodosus</italic>: Deductions from analysis of polyketide synthase and late genes</article-title><source>Chem. Biol.</source><year>2001</year><volume>8</volume><fpage>713</fpage><lpage>723</lpage><pub-id pub-id-type="doi">10.1016/S1074-5521(01)00046-1</pub-id><pub-id pub-id-type="pmid">11451671</pub-id></element-citation></ref><ref id="B314-antibiotics-08-00157"><label>314.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carmody</surname><given-names>M.</given-names></name><name><surname>Murphy</surname><given-names>B.</given-names></name><name><surname>Byrne</surname><given-names>B.</given-names></name><name><surname>Power</surname><given-names>P.</given-names></name><name><surname>Rai</surname><given-names>D.</given-names></name><name><surname>Rawlings</surname><given-names>B.</given-names></name><name><surname>Caffrey</surname><given-names>P.</given-names></name></person-group><article-title>Biosynthesis of amphotericin derivatives lacking exocyclic carboxyl groups</article-title><source>J. Biol. Chem.</source><year>2005</year><volume>280</volume><fpage>34420</fpage><lpage>34426</lpage><pub-id pub-id-type="doi">10.1074/jbc.M506689200</pub-id><pub-id pub-id-type="pmid">16079135</pub-id></element-citation></ref><ref id="B315-antibiotics-08-00157"><label>315.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carmody</surname><given-names>M.</given-names></name><name><surname>Byrne</surname><given-names>B.</given-names></name><name><surname>Murphy</surname><given-names>B.</given-names></name><name><surname>Breen</surname><given-names>C.</given-names></name><name><surname>Lynch</surname><given-names>S.</given-names></name><name><surname>Flood</surname><given-names>E.</given-names></name><name><surname>Finnan</surname><given-names>S.</given-names></name><name><surname>Caffrey</surname><given-names>P.</given-names></name></person-group><article-title>Analysis and manipulation of amphotericin biosynthetic genes by means of modified phage KC515 transduction techniques</article-title><source>Gene</source><year>2004</year><volume>343</volume><fpage>107</fpage><lpage>115</lpage><pub-id pub-id-type="doi">10.1016/j.gene.2004.08.006</pub-id><?supplied-pmid 15563836?><pub-id pub-id-type="pmid">15563836</pub-id></element-citation></ref><ref id="B316-antibiotics-08-00157"><label>316.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ellis</surname><given-names>D.</given-names></name></person-group><article-title>Amphotericin B: Spectrum and resistance</article-title><source>J. Antimicrob. Chemother.</source><year>2002</year><volume>49</volume><fpage>7</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1093/jac/49.suppl_1.7</pub-id><?supplied-pmid 11801575?><pub-id pub-id-type="pmid">11801575</pub-id></element-citation></ref><ref id="B317-antibiotics-08-00157"><label>317.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldman</surname><given-names>C.</given-names></name><name><surname>Akiyama</surname><given-names>M.J.</given-names></name><name><surname>Torres</surname><given-names>J.</given-names></name><name><surname>Louie</surname><given-names>E.</given-names></name><name><surname>Meehan</surname><given-names>S.A.</given-names></name></person-group><article-title><italic>Scedosporium apiospermum</italic> infections and the role of combination antifungal therapy and GM-CSF: A case report and review of the literature</article-title><source>Med. Mycol. Case Rep.</source><year>2016</year><volume>11</volume><fpage>40</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1016/j.mmcr.2016.04.005</pub-id><?supplied-pmid 27182483?><pub-id pub-id-type="pmid">27182483</pub-id></element-citation></ref><ref id="B318-antibiotics-08-00157"><label>318.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Volmer</surname><given-names>A.A.</given-names></name><name><surname>Szpilman</surname><given-names>A.M.</given-names></name><name><surname>Carreira</surname><given-names>E.M.</given-names></name></person-group><article-title>Synthesis and biological evaluation of amphotericin B derivatives</article-title><source>Nat. Prod. Rep.</source><year>2010</year><volume>27</volume><fpage>1329</fpage><lpage>1349</lpage><pub-id pub-id-type="doi">10.1039/b820743g</pub-id><?supplied-pmid 20556271?><pub-id pub-id-type="pmid">20556271</pub-id></element-citation></ref><ref id="B319-antibiotics-08-00157"><label>319.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>B.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Zhou</surname><given-names>Y.</given-names></name><name><surname>Huang</surname><given-names>K.</given-names></name><name><surname>Liu</surname><given-names>Z.</given-names></name><name><surname>Zheng</surname><given-names>Y.</given-names></name></person-group><article-title>Improvement of amphotericin B production by a newly isolated <italic>Streptomyces nodosus</italic> mutant</article-title><source>Biotechnol. Appl. Biochem.</source><year>2018</year><volume>65</volume><fpage>188</fpage><lpage>194</lpage><pub-id pub-id-type="doi">10.1002/bab.1579</pub-id><?supplied-pmid 28762559?><pub-id pub-id-type="pmid">28762559</pub-id></element-citation></ref><ref id="B320-antibiotics-08-00157"><label>320.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aparicio</surname><given-names>J.F.</given-names></name><name><surname>Barreales</surname><given-names>E.G.</given-names></name><name><surname>Payero</surname><given-names>T.D.</given-names></name><name><surname>Vicente</surname><given-names>C.M.</given-names></name><name><surname>de Pedro</surname><given-names>A.</given-names></name><name><surname>Santos-Aberturas</surname><given-names>J.</given-names></name></person-group><article-title>Biotechnological production and application of the antibiotic pimaricin: Biosynthesis and its regulation</article-title><source>Appl. Microbiol. Biotechnol.</source><year>2016</year><volume>100</volume><fpage>61</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1007/s00253-015-7077-0</pub-id><pub-id pub-id-type="pmid">26512010</pub-id></element-citation></ref><ref id="B321-antibiotics-08-00157"><label>321.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Divekar</surname><given-names>P.V.</given-names></name><name><surname>Bloomer</surname><given-names>J.L.</given-names></name><name><surname>Eastham</surname><given-names>J.F.</given-names></name><name><surname>Holtman</surname><given-names>D.F.</given-names></name><name><surname>Shirley</surname><given-names>D.A.</given-names></name></person-group><article-title>The isolation of crystalline tennecetin and the comparison of this antibiotic with pimaricin</article-title><source>Antibiot. Chemother. (Northfield, III.)</source><year>1961</year><volume>11</volume><fpage>377</fpage></element-citation></ref><ref id="B322-antibiotics-08-00157"><label>322.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burns</surname><given-names>J.</given-names></name></person-group><article-title>Tennecetin: A new antifungal antibiotic</article-title><source>Antibiot. Chemother.</source><year>1959</year><volume>9</volume><fpage>398</fpage><lpage>405</lpage></element-citation></ref><ref id="B323-antibiotics-08-00157"><label>323.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sui</surname><given-names>Q.</given-names></name><name><surname>Liu</surname><given-names>W.</given-names></name><name><surname>Lu</surname><given-names>C.</given-names></name><name><surname>Liu</surname><given-names>T.</given-names></name><name><surname>Qiu</surname><given-names>J.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name></person-group><article-title>Extraction and structural identification of the antifungal metabolite of <italic>Streptomyces lydicus</italic> A02</article-title><source>Chin. J. Biotechnol.</source><year>2009</year><volume>25</volume><fpage>840</fpage><lpage>846</lpage></element-citation></ref><ref id="B324-antibiotics-08-00157"><label>324.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>T.J.</given-names></name><name><surname>Shan</surname><given-names>Y.M.</given-names></name><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Dou</surname><given-names>W.W.</given-names></name><name><surname>Jiang</surname><given-names>X.H.</given-names></name><name><surname>Mao</surname><given-names>X.M.</given-names></name><name><surname>Liu</surname><given-names>S.P.</given-names></name><name><surname>Guan</surname><given-names>W.J.</given-names></name><name><surname>Li</surname><given-names>Y.Q.</given-names></name></person-group><article-title>Multiple transporters are involved in natamycin efflux in <italic>Streptomyces chattanoogensis</italic> L10</article-title><source>Mol. Microbiol.</source><year>2017</year><volume>103</volume><fpage>713</fpage><lpage>728</lpage><pub-id pub-id-type="doi">10.1111/mmi.13583</pub-id><pub-id pub-id-type="pmid">27874224</pub-id></element-citation></ref><ref id="B325-antibiotics-08-00157"><label>325.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anton</surname><given-names>N.</given-names></name><name><surname>Santos-Aberturas</surname><given-names>J.</given-names></name><name><surname>Mendes</surname><given-names>M.V.</given-names></name><name><surname>Guerra</surname><given-names>S.M.</given-names></name><name><surname>Martin</surname><given-names>J.F.</given-names></name><name><surname>Aparicio</surname><given-names>J.F.</given-names></name></person-group><article-title>PimM, a PAS domain positive regulator of pimaricin biosynthesis in <italic>Streptomyces natalensis</italic></article-title><source>Microbiology</source><year>2007</year><volume>153</volume><fpage>3174</fpage><lpage>3183</lpage><pub-id pub-id-type="doi">10.1099/mic.0.2007/009126-0</pub-id><?supplied-pmid 17768260?><pub-id pub-id-type="pmid">17768260</pub-id></element-citation></ref><ref id="B326-antibiotics-08-00157"><label>326.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anton</surname><given-names>N.</given-names></name><name><surname>Mendes</surname><given-names>M.V.</given-names></name><name><surname>Martin</surname><given-names>J.F.</given-names></name><name><surname>Aparicio</surname><given-names>J.F.</given-names></name></person-group><article-title>Identification of PimR as a positive regulator of pimaricin biosynthesis in <italic>Streptomyces natalensis</italic></article-title><source>J. Bacteriol.</source><year>2004</year><volume>186</volume><fpage>2567</fpage><lpage>2575</lpage><pub-id pub-id-type="doi">10.1128/JB.186.9.2567-2575.2004</pub-id><?supplied-pmid 15090496?><pub-id pub-id-type="pmid">15090496</pub-id></element-citation></ref><ref id="B327-antibiotics-08-00157"><label>327.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vicente</surname><given-names>C.M.</given-names></name><name><surname>Santos-Aberturas</surname><given-names>J.</given-names></name><name><surname>Guerra</surname><given-names>S.M.</given-names></name><name><surname>Payero</surname><given-names>T.D.</given-names></name><name><surname>Martin</surname><given-names>J.F.</given-names></name><name><surname>Aparicio</surname><given-names>J.F.</given-names></name></person-group><article-title>PimT, an amino acid exporter controls polyene production via secretion of the quorum sensing pimaricin-inducer PI-factor in <italic>Streptomyces natalensis</italic></article-title><source>Microb. Cell Fact.</source><year>2009</year><volume>8</volume><fpage>33</fpage><pub-id pub-id-type="doi">10.1186/1475-2859-8-33</pub-id><?supplied-pmid 19505319?><pub-id pub-id-type="pmid">19505319</pub-id></element-citation></ref><ref id="B328-antibiotics-08-00157"><label>328.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mendes</surname><given-names>M.V.</given-names></name><name><surname>Recio</surname><given-names>E.</given-names></name><name><surname>Ant&#x000f3;n</surname><given-names>N.</given-names></name><name><surname>Guerra</surname><given-names>S.M.</given-names></name><name><surname>Santos-Aberturas</surname><given-names>J.</given-names></name><name><surname>Mart&#x000ed;n</surname><given-names>J.F.</given-names></name><name><surname>Aparicio</surname><given-names>J.F.</given-names></name></person-group><article-title>Cholesterol oxidases act as signaling proteins for the biosynthesis of the polyene macrolide pimaricin</article-title><source>Chem. Biol.</source><year>2007</year><volume>14</volume><fpage>279</fpage><lpage>290</lpage><pub-id pub-id-type="doi">10.1016/j.chembiol.2007.01.010</pub-id><?supplied-pmid 17379143?><pub-id pub-id-type="pmid">17379143</pub-id></element-citation></ref><ref id="B329-antibiotics-08-00157"><label>329.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aparicio</surname><given-names>J.F.</given-names></name><name><surname>Mart&#x000ed;n</surname><given-names>J.F.</given-names></name></person-group><article-title>Microbial cholesterol oxidases: Bioconversion enzymes or signal proteins?</article-title><source>Mol. Biosyst.</source><year>2008</year><volume>4</volume><fpage>804</fpage><lpage>809</lpage><pub-id pub-id-type="doi">10.1039/b717500k</pub-id><?supplied-pmid 18633481?><pub-id pub-id-type="pmid">18633481</pub-id></element-citation></ref><ref id="B330-antibiotics-08-00157"><label>330.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Du</surname><given-names>Y.L.</given-names></name><name><surname>Chen</surname><given-names>S.F.</given-names></name><name><surname>Cheng</surname><given-names>L.Y.</given-names></name><name><surname>Shen</surname><given-names>X.L.</given-names></name><name><surname>Tian</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>Y.Q.</given-names></name></person-group><article-title>Identification of a novel <italic>Streptomyces chattanoogensis</italic> L10 and enhancing its natamycin production by overexpressing positive regulator ScnRII</article-title><source>J. Microbiol.</source><year>2009</year><volume>47</volume><fpage>506</fpage><lpage>513</lpage><pub-id pub-id-type="doi">10.1007/s12275-009-0014-0</pub-id><?supplied-pmid 19763427?><pub-id pub-id-type="pmid">19763427</pub-id></element-citation></ref><ref id="B331-antibiotics-08-00157"><label>331.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>S.</given-names></name><name><surname>Liu</surname><given-names>F.</given-names></name><name><surname>Hou</surname><given-names>Z.</given-names></name><name><surname>Zong</surname><given-names>G.</given-names></name><name><surname>Zhu</surname><given-names>X.</given-names></name><name><surname>Ling</surname><given-names>P.</given-names></name></person-group><article-title>Enhancement of natamycin production on <italic>Streptomyces gilvosporeus</italic> by chromosomal integration of the <italic>Vitreoscilla</italic> hemoglobin gene (vgb)</article-title><source>World J. Microbiol. Biotechnol.</source><year>2014</year><volume>30</volume><fpage>1369</fpage><lpage>1376</lpage><pub-id pub-id-type="doi">10.1007/s11274-013-1561-4</pub-id><pub-id pub-id-type="pmid">24272774</pub-id></element-citation></ref><ref id="B332-antibiotics-08-00157"><label>332.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>K.M.</given-names></name><name><surname>Lee</surname><given-names>C.K.</given-names></name><name><surname>Choi</surname><given-names>S.U.</given-names></name><name><surname>Park</surname><given-names>H.R.</given-names></name><name><surname>Kitani</surname><given-names>S.</given-names></name><name><surname>Nihira</surname><given-names>T.</given-names></name><name><surname>Hwang</surname><given-names>Y.I.</given-names></name></person-group><article-title>Cloning and in vivo functional analysis by disruption of a gene encoding the &#x003b3;-butyrolactone autoregulator receptor from <italic>Streptomyces natalensis</italic></article-title><source>Arch. Microbiol.</source><year>2005</year><volume>184</volume><fpage>249</fpage><lpage>257</lpage><pub-id pub-id-type="doi">10.1007/s00203-005-0047-7</pub-id><pub-id pub-id-type="pmid">16228193</pub-id></element-citation></ref><ref id="B333-antibiotics-08-00157"><label>333.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qi</surname><given-names>Z.</given-names></name><name><surname>Kang</surname><given-names>Q.</given-names></name><name><surname>Jiang</surname><given-names>C.</given-names></name><name><surname>Han</surname><given-names>M.</given-names></name><name><surname>Bai</surname><given-names>L.</given-names></name></person-group><article-title>Engineered biosynthesis of pimaricin derivatives with improved antifungal activity and reduced cytotoxicity</article-title><source>Appl. Microbiol. Biotechnol.</source><year>2015</year><volume>99</volume><fpage>6745</fpage><lpage>6752</lpage><pub-id pub-id-type="doi">10.1007/s00253-015-6635-9</pub-id><pub-id pub-id-type="pmid">25952111</pub-id></element-citation></ref><ref id="B334-antibiotics-08-00157"><label>334.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>X.Z.</given-names></name><name><surname>Pl&#x000e9;siat</surname><given-names>P.</given-names></name><name><surname>Nikaido</surname><given-names>H.</given-names></name></person-group><article-title>The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria</article-title><source>Clin. Microbiol. Rev.</source><year>2015</year><volume>28</volume><fpage>337</fpage><lpage>418</lpage><pub-id pub-id-type="doi">10.1128/CMR.00117-14</pub-id><pub-id pub-id-type="pmid">25788514</pub-id></element-citation></ref><ref id="B335-antibiotics-08-00157"><label>335.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coates</surname><given-names>A.R.M.</given-names></name><name><surname>Halls</surname><given-names>G.</given-names></name><name><surname>Hu</surname><given-names>Y.</given-names></name></person-group><article-title>Novel classes of antibiotics or more of the same?</article-title><source>Br. J. Pharmacol.</source><year>2011</year><volume>163</volume><fpage>184</fpage><lpage>194</lpage><pub-id pub-id-type="doi">10.1111/j.1476-5381.2011.01250.x</pub-id><?supplied-pmid 21323894?><pub-id pub-id-type="pmid">21323894</pub-id></element-citation></ref><ref id="B336-antibiotics-08-00157"><label>336.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spellberg</surname><given-names>B.</given-names></name><name><surname>Bartlett</surname><given-names>J.G.</given-names></name><name><surname>Gilbert</surname><given-names>D.N.</given-names></name></person-group><article-title>The future of antibiotics and resistance</article-title><source>N. Engl. J. Med.</source><year>2013</year><volume>368</volume><fpage>299</fpage><lpage>302</lpage><pub-id pub-id-type="doi">10.1056/NEJMp1215093</pub-id><?supplied-pmid 23343059?><pub-id pub-id-type="pmid">23343059</pub-id></element-citation></ref><ref id="B337-antibiotics-08-00157"><label>337.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blunt</surname><given-names>J.W.</given-names></name><name><surname>Copp</surname><given-names>B.R.</given-names></name><name><surname>Munro</surname><given-names>M.H.G.</given-names></name><name><surname>Northcote</surname><given-names>P.T.</given-names></name><name><surname>Prinsep</surname><given-names>M.R.</given-names></name></person-group><article-title>Marine natural products</article-title><source>Nat. Prod. Rep.</source><year>2011</year><volume>28</volume><fpage>196</fpage><lpage>268</lpage><pub-id pub-id-type="doi">10.1039/C005001F</pub-id><?supplied-pmid 21152619?><pub-id pub-id-type="pmid">21152619</pub-id></element-citation></ref><ref id="B338-antibiotics-08-00157"><label>338.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katz</surname><given-names>L.</given-names></name><name><surname>Baltz</surname><given-names>R.H.</given-names></name></person-group><article-title>Natural product discovery: Past, present, and future</article-title><source>J. Ind. Microbiol. Biotechnol.</source><year>2016</year><volume>43</volume><fpage>155</fpage><lpage>176</lpage><pub-id pub-id-type="doi">10.1007/s10295-015-1723-5</pub-id><?supplied-pmid 26739136?><pub-id pub-id-type="pmid">26739136</pub-id></element-citation></ref><ref id="B339-antibiotics-08-00157"><label>339.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kealey</surname><given-names>C.</given-names></name><name><surname>Creaven</surname><given-names>C.A.</given-names></name><name><surname>Murphy</surname><given-names>C.D.</given-names></name><name><surname>Brady</surname><given-names>C.B.</given-names></name></person-group><article-title>New approaches to antibiotic discovery</article-title><source>Biotechnol. Lett.</source><year>2017</year><volume>39</volume><fpage>805</fpage><lpage>817</lpage><pub-id pub-id-type="doi">10.1007/s10529-017-2311-8</pub-id><?supplied-pmid 28275884?><pub-id pub-id-type="pmid">28275884</pub-id></element-citation></ref><ref id="B340-antibiotics-08-00157"><label>340.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iorio</surname><given-names>M.</given-names></name><name><surname>Tocchetti</surname><given-names>A.</given-names></name><name><surname>Cruz</surname><given-names>J.</given-names></name><name><surname>Del Gatto</surname><given-names>G.</given-names></name><name><surname>Brunati</surname><given-names>C.</given-names></name><name><surname>Maffioli</surname><given-names>S.</given-names></name><name><surname>Sosio</surname><given-names>M.</given-names></name><name><surname>Donadio</surname><given-names>S.</given-names></name></person-group><article-title>Novel Polyethers from Screening <italic>Actinoallomurus</italic> spp.</article-title><source>Antibiotics</source><year>2018</year><volume>7</volume><elocation-id>47</elocation-id><pub-id pub-id-type="doi">10.3390/antibiotics7020047</pub-id><?supplied-pmid 29904034?><pub-id pub-id-type="pmid">29904034</pub-id></element-citation></ref><ref id="B341-antibiotics-08-00157"><label>341.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hug</surname><given-names>J.</given-names></name><name><surname>Bader</surname><given-names>C.</given-names></name><name><surname>Rem&#x00161;kar</surname><given-names>M.</given-names></name><name><surname>Cirnski</surname><given-names>K.</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>R.</given-names></name></person-group><article-title>Concepts and methods to access novel antibiotics from actinomycetes</article-title><source>Antibiotics</source><year>2018</year><volume>7</volume><elocation-id>44</elocation-id><pub-id pub-id-type="doi">10.3390/antibiotics7020044</pub-id><?supplied-pmid 29789481?><pub-id pub-id-type="pmid">29789481</pub-id></element-citation></ref><ref id="B342-antibiotics-08-00157"><label>342.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Genilloud</surname><given-names>O.</given-names></name></person-group><article-title>Mining actinomycetes for novel antibiotics in the omics era: Are we ready to exploit this new paradigm?</article-title><source>Antibiotics</source><year>2018</year><volume>7</volume><elocation-id>85</elocation-id><pub-id pub-id-type="doi">10.3390/antibiotics7040085</pub-id></element-citation></ref><ref id="B343-antibiotics-08-00157"><label>343.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amoutzias</surname><given-names>G.</given-names></name><name><surname>Chaliotis</surname><given-names>A.</given-names></name><name><surname>Mossialos</surname><given-names>D.</given-names></name></person-group><article-title>Discovery strategies of bioactive compounds synthesized by nonribosomal peptide synthetases and type-I polyketide synthases derived from marine microbiomes</article-title><source>Mar. Drugs</source><year>2016</year><volume>14</volume><elocation-id>80</elocation-id><pub-id pub-id-type="doi">10.3390/md14040080</pub-id></element-citation></ref><ref id="B344-antibiotics-08-00157"><label>344.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adnani</surname><given-names>N.</given-names></name><name><surname>Chevrette</surname><given-names>M.</given-names></name><name><surname>Adibhatla</surname><given-names>S.N.</given-names></name><name><surname>Zhang</surname><given-names>F.</given-names></name><name><surname>Yu</surname><given-names>Q.</given-names></name><name><surname>Braun</surname><given-names>D.R.</given-names></name><name><surname>Nelson</surname><given-names>J.</given-names></name><name><surname>Simpkins</surname><given-names>S.W.</given-names></name><name><surname>McDonald</surname><given-names>B.R.</given-names></name><name><surname>Myers</surname><given-names>C.L.</given-names></name><etal/></person-group><article-title>Coculture of marine invertebrate-associated bacteria and interdisciplinary technologies enable biosynthesis and discovery of a new antibiotic, keyicin</article-title><source>ACS Chem. Biol.</source><year>2017</year><volume>12</volume><fpage>3093</fpage><lpage>3102</lpage><pub-id pub-id-type="doi">10.1021/acschembio.7b00688</pub-id><pub-id pub-id-type="pmid">29121465</pub-id></element-citation></ref><ref id="B345-antibiotics-08-00157"><label>345.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goers</surname><given-names>L.</given-names></name><name><surname>Freemont</surname><given-names>P.</given-names></name><name><surname>Polizzi</surname><given-names>K.M.</given-names></name></person-group><article-title>Co-culture systems and technologies: Taking synthetic biology to the next level</article-title><source>J. R. Soc. Interface</source><year>2014</year><volume>11</volume><fpage>20140065</fpage><pub-id pub-id-type="doi">10.1098/rsif.2014.0065</pub-id><pub-id pub-id-type="pmid">24829281</pub-id></element-citation></ref><ref id="B346-antibiotics-08-00157"><label>346.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dashti</surname><given-names>Y.</given-names></name><name><surname>Grkovic</surname><given-names>T.</given-names></name><name><surname>Abdelmohsen</surname><given-names>U.</given-names></name><name><surname>Hentschel</surname><given-names>U.</given-names></name><name><surname>Quinn</surname><given-names>R.</given-names></name></person-group><article-title>Production of induced secondary metabolites by a co-culture of sponge-associated actinomycetes, <italic>Actinokineospora</italic> sp. EG49 and <italic>Nocardiopsis</italic> sp. RV163</article-title><source>Mar. Drugs</source><year>2014</year><volume>12</volume><fpage>3046</fpage><lpage>3059</lpage><pub-id pub-id-type="doi">10.3390/md12053046</pub-id><pub-id pub-id-type="pmid">24857962</pub-id></element-citation></ref><ref id="B347-antibiotics-08-00157"><label>347.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piel</surname><given-names>J.</given-names></name></person-group><article-title>Metabolites from symbiotic bacteria</article-title><source>Nat. Prod. Rep.</source><year>2009</year><volume>26</volume><fpage>338</fpage><lpage>362</lpage><pub-id pub-id-type="doi">10.1039/B703499G</pub-id><pub-id pub-id-type="pmid">19240945</pub-id></element-citation></ref><ref id="B348-antibiotics-08-00157"><label>348.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ling</surname><given-names>L.L.</given-names></name><name><surname>Schneider</surname><given-names>T.</given-names></name><name><surname>Peoples</surname><given-names>A.J.</given-names></name><name><surname>Spoering</surname><given-names>A.L.</given-names></name><name><surname>Engels</surname><given-names>I.</given-names></name><name><surname>Conlon</surname><given-names>B.P.</given-names></name><name><surname>Mueller</surname><given-names>A.</given-names></name><name><surname>Sch&#x000e4;berle</surname><given-names>T.F.</given-names></name><name><surname>Hughes</surname><given-names>D.E.</given-names></name><name><surname>Epstein</surname><given-names>S.</given-names></name><etal/></person-group><article-title>A new antibiotic kills pathogens without detectable resistance</article-title><source>Nature</source><year>2015</year><volume>517</volume><fpage>455</fpage><pub-id pub-id-type="doi">10.1038/nature14098</pub-id><pub-id pub-id-type="pmid">25561178</pub-id></element-citation></ref><ref id="B349-antibiotics-08-00157"><label>349.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nichols</surname><given-names>D.</given-names></name><name><surname>Cahoon</surname><given-names>N.</given-names></name><name><surname>Trakhtenberg</surname><given-names>E.M.</given-names></name><name><surname>Pham</surname><given-names>L.</given-names></name><name><surname>Mehta</surname><given-names>A.</given-names></name><name><surname>Belanger</surname><given-names>A.</given-names></name><name><surname>Kanigan</surname><given-names>T.</given-names></name><name><surname>Lewis</surname><given-names>K.</given-names></name><name><surname>Epstein</surname><given-names>S.S.</given-names></name></person-group><article-title>Use of ichip for high-throughput in situ cultivation of &#x0201c;uncultivable&#x0201d; microbial species</article-title><source>Appl. Environ. Microbiol.</source><year>2010</year><volume>76</volume><fpage>2445</fpage><lpage>2450</lpage><pub-id pub-id-type="doi">10.1128/AEM.01754-09</pub-id><pub-id pub-id-type="pmid">20173072</pub-id></element-citation></ref><ref id="B350-antibiotics-08-00157"><label>350.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piddock</surname><given-names>L.J.V.</given-names></name></person-group><article-title>Teixobactin, the first of a new class of antibiotics discovered by iChip technology?</article-title><source>J. Antimicrob. Chemother.</source><year>2015</year><volume>70</volume><fpage>2679</fpage><lpage>2680</lpage><pub-id pub-id-type="doi">10.1093/jac/dkv175</pub-id><pub-id pub-id-type="pmid">26089440</pub-id></element-citation></ref><ref id="B351-antibiotics-08-00157"><label>351.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sherpa</surname><given-names>R.T.</given-names></name><name><surname>Reese</surname><given-names>C.J.</given-names></name><name><surname>Aliabadi</surname><given-names>H.M.</given-names></name></person-group><article-title>Application of iChip to grow &#x0201c;uncultivable&#x0201d; microorganisms and its impact on antibiotic discovery</article-title><source>J. Pharm. Pharm. Sci.</source><year>2015</year><volume>18</volume><fpage>303</fpage><lpage>315</lpage><pub-id pub-id-type="doi">10.18433/J30894</pub-id><pub-id pub-id-type="pmid">26517134</pub-id></element-citation></ref><ref id="B352-antibiotics-08-00157"><label>352.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alessi</surname><given-names>A.M.</given-names></name><name><surname>Redeker</surname><given-names>K.R.</given-names></name><name><surname>Chong</surname><given-names>J.P.J.</given-names></name></person-group><article-title>A practical introduction to microbial molecular ecology through the use of isolation chips</article-title><source>Ecol. Evol.</source><year>2018</year><volume>8</volume><fpage>12286</fpage><lpage>12298</lpage><pub-id pub-id-type="doi">10.1002/ece3.4748</pub-id><pub-id pub-id-type="pmid">30619545</pub-id></element-citation></ref><ref id="B353-antibiotics-08-00157"><label>353.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lodhi</surname><given-names>A.F.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Adil</surname><given-names>M.</given-names></name><name><surname>Deng</surname><given-names>Y.</given-names></name></person-group><article-title>Antibiotic discovery: Combining isolation chip (iChip) technology and co-culture technique</article-title><source>Appl. Microbiol. Biotechnol.</source><year>2018</year><volume>102</volume><fpage>7333</fpage><lpage>7341</lpage><pub-id pub-id-type="doi">10.1007/s00253-018-9193-0</pub-id><pub-id pub-id-type="pmid">29974183</pub-id></element-citation></ref><ref id="B354-antibiotics-08-00157"><label>354.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mohana</surname><given-names>N.C.</given-names></name><name><surname>Rao</surname><given-names>H.C.Y.</given-names></name><name><surname>Rakshith</surname><given-names>D.</given-names></name><name><surname>Mithun</surname><given-names>P.R.</given-names></name><name><surname>Nuthan</surname><given-names>B.R.</given-names></name><name><surname>Satish</surname><given-names>S.</given-names></name></person-group><article-title>Omics based approach for biodiscovery of microbial natural products in antibiotic resistance era</article-title><source>J. Genet. Eng. Biotechnol.</source><year>2018</year><volume>16</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.jgeb.2018.01.006</pub-id><pub-id pub-id-type="pmid">30647697</pub-id></element-citation></ref><ref id="B355-antibiotics-08-00157"><label>355.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Vijayakumar</surname><given-names>S.</given-names></name><name><surname>Conway</surname><given-names>M.</given-names></name><name><surname>Li&#x000f3;</surname><given-names>P.</given-names></name><name><surname>Angione</surname><given-names>C.</given-names></name></person-group><article-title>Optimization of multi-omic genome-scale models: Methodologies, hands-on tutorial, and perspectives</article-title><source>Metabolic Network Reconstruction and Modeling</source><publisher-name>Springer</publisher-name><publisher-loc>Berlin/Heidelberg, Germany</publisher-loc><year>2018</year><fpage>389</fpage><lpage>408</lpage></element-citation></ref><ref id="B356-antibiotics-08-00157"><label>356.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Franzosa</surname><given-names>E.A.</given-names></name><name><surname>Hsu</surname><given-names>T.</given-names></name><name><surname>Sirota-Madi</surname><given-names>A.</given-names></name><name><surname>Shafquat</surname><given-names>A.</given-names></name><name><surname>Abu-Ali</surname><given-names>G.</given-names></name><name><surname>Morgan</surname><given-names>X.C.</given-names></name><name><surname>Huttenhower</surname><given-names>C.</given-names></name></person-group><article-title>Sequencing and beyond: Integrating molecular&#x02019;omics&#x02019; for microbial community profiling</article-title><source>Nat. Rev. Microbiol.</source><year>2015</year><volume>13</volume><fpage>360</fpage><pub-id pub-id-type="doi">10.1038/nrmicro3451</pub-id><pub-id pub-id-type="pmid">25915636</pub-id></element-citation></ref><ref id="B357-antibiotics-08-00157"><label>357.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palazzotto</surname><given-names>E.</given-names></name><name><surname>Weber</surname><given-names>T.</given-names></name></person-group><article-title>Omics and multi-omics approaches to study the biosynthesis of secondary metabolites in microorganisms</article-title><source>Curr. Opin. Microbiol.</source><year>2018</year><volume>45</volume><fpage>109</fpage><lpage>116</lpage><pub-id pub-id-type="doi">10.1016/j.mib.2018.03.004</pub-id><pub-id pub-id-type="pmid">29656009</pub-id></element-citation></ref><ref id="B358-antibiotics-08-00157"><label>358.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nikolouli</surname><given-names>K.</given-names></name><name><surname>Mossialos</surname><given-names>D.</given-names></name></person-group><article-title>Bioactive compounds synthesized by non-ribosomal peptide synthetases and type-I polyketide synthases discovered through genome-mining and metagenomics</article-title><source>Biotechnol. Lett.</source><year>2012</year><volume>34</volume><fpage>1393</fpage><lpage>1403</lpage><pub-id pub-id-type="doi">10.1007/s10529-012-0919-2</pub-id><pub-id pub-id-type="pmid">22481301</pub-id></element-citation></ref><ref id="B359-antibiotics-08-00157"><label>359.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Medema</surname><given-names>M.H.</given-names></name><name><surname>Fischbach</surname><given-names>M.A.</given-names></name></person-group><article-title>Computational approaches to natural product discovery</article-title><source>Nat. Chem. Biol.</source><year>2015</year><volume>11</volume><fpage>639</fpage><pub-id pub-id-type="doi">10.1038/nchembio.1884</pub-id><pub-id pub-id-type="pmid">26284671</pub-id></element-citation></ref><ref id="B360-antibiotics-08-00157"><label>360.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carbonell</surname><given-names>P.</given-names></name><name><surname>Currin</surname><given-names>A.</given-names></name><name><surname>Jervis</surname><given-names>A.J.</given-names></name><name><surname>Rattray</surname><given-names>N.J.W.</given-names></name><name><surname>Swainston</surname><given-names>N.</given-names></name><name><surname>Yan</surname><given-names>C.</given-names></name><name><surname>Takano</surname><given-names>E.</given-names></name><name><surname>Breitling</surname><given-names>R.</given-names></name></person-group><article-title>Bioinformatics for the synthetic biology of natural products: Integrating across the Design-Build-Test cycle</article-title><source>Nat. Prod. Rep.</source><year>2016</year><volume>33</volume><fpage>925</fpage><lpage>932</lpage><pub-id pub-id-type="doi">10.1039/C6NP00018E</pub-id><pub-id pub-id-type="pmid">27185383</pub-id></element-citation></ref><ref id="B361-antibiotics-08-00157"><label>361.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ito</surname><given-names>T.</given-names></name><name><surname>Masubuchi</surname><given-names>M.</given-names></name></person-group><article-title>Dereplication of microbial extracts and related analytical technologies</article-title><source>J. Antibiot. (Tokyo)</source><year>2014</year><volume>67</volume><fpage>353</fpage><lpage>360</lpage><pub-id pub-id-type="doi">10.1038/ja.2014.12</pub-id><pub-id pub-id-type="pmid">24569671</pub-id></element-citation></ref><ref id="B362-antibiotics-08-00157"><label>362.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seger</surname><given-names>C.</given-names></name><name><surname>Sturm</surname><given-names>S.</given-names></name><name><surname>Stuppner</surname><given-names>H.</given-names></name></person-group><article-title>Mass spectrometry and NMR spectroscopy: Modern high-end detectors for high resolution separation techniques--state of the art in natural product HPLC-MS, HPLC-NMR, and CE-MS hyphenations</article-title><source>Nat. Prod. Rep.</source><year>2013</year><volume>30</volume><fpage>970</fpage><lpage>987</lpage><pub-id pub-id-type="doi">10.1039/c3np70015a</pub-id><pub-id pub-id-type="pmid">23739842</pub-id></element-citation></ref><ref id="B363-antibiotics-08-00157"><label>363.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perez-Victoria</surname><given-names>I.</given-names></name><name><surname>Martin</surname><given-names>J.</given-names></name><name><surname>Reyes</surname><given-names>F.</given-names></name></person-group><article-title>Combined LC/UV/MS and NMR Strategies for the Dereplication of Marine Natural Products</article-title><source>Planta Med.</source><year>2016</year><volume>82</volume><fpage>857</fpage><lpage>871</lpage><pub-id pub-id-type="doi">10.1055/s-0042-101763</pub-id><pub-id pub-id-type="pmid">27002401</pub-id></element-citation></ref><ref id="B364-antibiotics-08-00157"><label>364.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spraker</surname><given-names>J.E.</given-names></name><name><surname>Luu</surname><given-names>G.T.</given-names></name><name><surname>Sanchez</surname><given-names>L.M.</given-names></name></person-group><article-title>Imaging mass spectrometry for natural products discovery: A review of ionization methods</article-title><source>Nat. Prod. Rep.</source><year>2019</year><pub-id pub-id-type="doi">10.1039/C9NP00038K</pub-id></element-citation></ref><ref id="B365-antibiotics-08-00157"><label>365.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>H.</given-names></name><name><surname>Sandiford</surname><given-names>S.K.</given-names></name><name><surname>van Wezel</surname><given-names>G.P.</given-names></name></person-group><article-title>Triggers and cues that activate antibiotic production by actinomycetes</article-title><source>J. Ind. Microbiol. Biotechnol.</source><year>2014</year><volume>41</volume><fpage>371</fpage><lpage>386</lpage><pub-id pub-id-type="doi">10.1007/s10295-013-1309-z</pub-id><pub-id pub-id-type="pmid">23907251</pub-id></element-citation></ref><ref id="B366-antibiotics-08-00157"><label>366.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rutledge</surname><given-names>P.J.</given-names></name><name><surname>Challis</surname><given-names>G.L.</given-names></name></person-group><article-title>Discovery of microbial natural products by activation of silent biosynthetic gene clusters</article-title><source>Nat. Rev. Microbiol.</source><year>2015</year><volume>13</volume><fpage>509</fpage><lpage>523</lpage><pub-id pub-id-type="doi">10.1038/nrmicro3496</pub-id><pub-id pub-id-type="pmid">26119570</pub-id></element-citation></ref><ref id="B367-antibiotics-08-00157"><label>367.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seyedsayamdost</surname><given-names>M.R.</given-names></name></person-group><article-title>High-throughput platform for the discovery of elicitors of silent bacterial gene clusters</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2014</year><volume>111</volume><fpage>7266</fpage><lpage>7271</lpage><pub-id pub-id-type="doi">10.1073/pnas.1400019111</pub-id><pub-id pub-id-type="pmid">24808135</pub-id></element-citation></ref><ref id="B368-antibiotics-08-00157"><label>368.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosen</surname><given-names>P.C.</given-names></name><name><surname>Seyedsayamdost</surname><given-names>M.R.</given-names></name></person-group><article-title>Though Much Is Taken, Much Abides: Finding New Antibiotics Using Old Ones</article-title><source>Biochemistry</source><year>2017</year><volume>56</volume><fpage>4925</fpage><lpage>4926</lpage><pub-id pub-id-type="doi">10.1021/acs.biochem.7b00782</pub-id><pub-id pub-id-type="pmid">28862834</pub-id></element-citation></ref><ref id="B369-antibiotics-08-00157"><label>369.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okada</surname><given-names>B.K.</given-names></name><name><surname>Seyedsayamdost</surname><given-names>M.R.</given-names></name></person-group><article-title>Antibiotic dialogues: Induction of silent biosynthetic gene clusters by exogenous small molecules</article-title><source>FEMS Microbiol. Rev.</source><year>2017</year><volume>41</volume><fpage>19</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1093/femsre/fuw035</pub-id><pub-id pub-id-type="pmid">27576366</pub-id></element-citation></ref><ref id="B370-antibiotics-08-00157"><label>370.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Altaee</surname><given-names>N.</given-names></name><name><surname>Kadhim</surname><given-names>M.J.</given-names></name><name><surname>Hameed</surname><given-names>I.H.</given-names></name></person-group><article-title>Characterization of metabolites produced by <italic>E. coli</italic> and analysis of its chemical compounds using GC-MS</article-title><source>Int. J. Curr. Pharm. Rev. Res.</source><year>2017</year><volume>7</volume><fpage>13</fpage><lpage>19</lpage></element-citation></ref><ref id="B371-antibiotics-08-00157"><label>371.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wexler</surname><given-names>M.</given-names></name><name><surname>Johnston</surname><given-names>A.W.B.</given-names></name></person-group><article-title>Wide host-range cloning for functional metagenomics</article-title><source>Methods Mol. Biol.</source><year>2010</year><volume>668</volume><fpage>77</fpage><lpage>96</lpage><pub-id pub-id-type="pmid">20830557</pub-id></element-citation></ref><ref id="B372-antibiotics-08-00157"><label>372.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ongley</surname><given-names>S.E.</given-names></name><name><surname>Bian</surname><given-names>X.</given-names></name><name><surname>Neilan</surname><given-names>B.A.</given-names></name><name><surname>Muller</surname><given-names>R.</given-names></name></person-group><article-title>Recent advances in the heterologous expression of microbial natural product biosynthetic pathways</article-title><source>Nat. Prod. Rep.</source><year>2013</year><volume>30</volume><fpage>1121</fpage><lpage>1138</lpage><pub-id pub-id-type="doi">10.1039/c3np70034h</pub-id><pub-id pub-id-type="pmid">23832108</pub-id></element-citation></ref><ref id="B373-antibiotics-08-00157"><label>373.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kallifidas</surname><given-names>D.</given-names></name><name><surname>Jiang</surname><given-names>G.</given-names></name><name><surname>Ding</surname><given-names>Y.</given-names></name><name><surname>Luesch</surname><given-names>H.</given-names></name></person-group><article-title>Rational engineering of <italic>Streptomyces albus</italic> J1074 for the overexpression of secondary metabolite gene clusters</article-title><source>Microb. Cell Fact.</source><year>2018</year><volume>17</volume><fpage>25</fpage><pub-id pub-id-type="doi">10.1186/s12934-018-0874-2</pub-id><pub-id pub-id-type="pmid">29454348</pub-id></element-citation></ref><ref id="B374-antibiotics-08-00157"><label>374.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gomez-Escribano</surname><given-names>J.P.</given-names></name><name><surname>Bibb</surname><given-names>M.J.</given-names></name></person-group><article-title>Engineering <italic>Streptomyces coelicolor</italic> for heterologous expression of secondary metabolite gene clusters</article-title><source>Microb. Biotechnol.</source><year>2011</year><volume>4</volume><fpage>207</fpage><lpage>215</lpage><pub-id pub-id-type="doi">10.1111/j.1751-7915.2010.00219.x</pub-id><pub-id pub-id-type="pmid">21342466</pub-id></element-citation></ref><ref id="B375-antibiotics-08-00157"><label>375.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonet</surname><given-names>B.</given-names></name><name><surname>Teufel</surname><given-names>R.</given-names></name><name><surname>Crusemann</surname><given-names>M.</given-names></name><name><surname>Ziemert</surname><given-names>N.</given-names></name><name><surname>Moore</surname><given-names>B.S.</given-names></name></person-group><article-title>Direct capture and heterologous expression of <italic>Salinispora</italic> natural product genes for the biosynthesis of enterocin</article-title><source>J. Nat. Prod.</source><year>2015</year><volume>78</volume><fpage>539</fpage><lpage>542</lpage><pub-id pub-id-type="doi">10.1021/np500664q</pub-id><pub-id pub-id-type="pmid">25382643</pub-id></element-citation></ref><ref id="B376-antibiotics-08-00157"><label>376.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deng</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name></person-group><article-title>Recent advances in genetic modification systems for Actinobacteria</article-title><source>Appl. Microbiol. Biotechnol.</source><year>2017</year><volume>101</volume><fpage>2217</fpage><lpage>2226</lpage><pub-id pub-id-type="doi">10.1007/s00253-017-8156-1</pub-id><pub-id pub-id-type="pmid">28184986</pub-id></element-citation></ref><ref id="B377-antibiotics-08-00157"><label>377.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dhakal</surname><given-names>D.</given-names></name><name><surname>Sohng</surname><given-names>J.K.</given-names></name><name><surname>Pandey</surname><given-names>R.P.</given-names></name></person-group><article-title>Engineering actinomycetes for biosynthesis of macrolactone polyketides</article-title><source>Microb. Cell Fact.</source><year>2019</year><volume>18</volume><fpage>137</fpage><pub-id pub-id-type="doi">10.1186/s12934-019-1184-z</pub-id><pub-id pub-id-type="pmid">31409353</pub-id></element-citation></ref><ref id="B378-antibiotics-08-00157"><label>378.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baltz</surname><given-names>R.H.</given-names></name></person-group><article-title>Genetic manipulation of secondary metabolite biosynthesis for improved production in <italic>Streptomyces</italic> and other actinomycetes</article-title><source>J. Ind. Microbiol. Biotechnol.</source><year>2016</year><volume>43</volume><fpage>343</fpage><lpage>370</lpage><pub-id pub-id-type="doi">10.1007/s10295-015-1682-x</pub-id><pub-id pub-id-type="pmid">26364200</pub-id></element-citation></ref><ref id="B379-antibiotics-08-00157"><label>379.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>N.</given-names></name><name><surname>Hwang</surname><given-names>S.</given-names></name><name><surname>Lee</surname><given-names>Y.</given-names></name><name><surname>Cho</surname><given-names>S.</given-names></name><name><surname>Palsson</surname><given-names>B.</given-names></name><name><surname>Cho</surname><given-names>B.K.</given-names></name></person-group><article-title>Synthetic Biology Tools for Novel Secondary Metabolite Discovery in <italic>Streptomyces</italic></article-title><source>J. Microbiol. Biotechnol.</source><year>2019</year><volume>29</volume><fpage>667</fpage><lpage>686</lpage><pub-id pub-id-type="doi">10.4014/jmb.1904.04015</pub-id><pub-id pub-id-type="pmid">31091862</pub-id></element-citation></ref><ref id="B380-antibiotics-08-00157"><label>380.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palazzotto</surname><given-names>E.</given-names></name><name><surname>Tong</surname><given-names>Y.</given-names></name><name><surname>Lee</surname><given-names>S.Y.</given-names></name><name><surname>Weber</surname><given-names>T.</given-names></name></person-group><article-title>Synthetic biology and metabolic engineering of actinomycetes for natural product discovery</article-title><source>Biotechnol. Adv.</source><year>2019</year><volume>37</volume><fpage>107366</fpage><pub-id pub-id-type="doi">10.1016/j.biotechadv.2019.03.005</pub-id><pub-id pub-id-type="pmid">30853630</pub-id></element-citation></ref><ref id="B381-antibiotics-08-00157"><label>381.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Genilloud</surname><given-names>O.</given-names></name></person-group><article-title>Actinomycetes: Still a source of novel antibiotics</article-title><source>Nat. Prod. Rep.</source><year>2017</year><volume>34</volume><fpage>1203</fpage><lpage>1232</lpage><pub-id pub-id-type="doi">10.1039/C7NP00026J</pub-id><pub-id pub-id-type="pmid">28820533</pub-id></element-citation></ref><ref id="B382-antibiotics-08-00157"><label>382.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mazzetti</surname><given-names>C.</given-names></name><name><surname>Ornaghi</surname><given-names>M.</given-names></name><name><surname>Gaspari</surname><given-names>E.</given-names></name><name><surname>Parapini</surname><given-names>S.</given-names></name><name><surname>Maffioli</surname><given-names>S.</given-names></name><name><surname>Sosio</surname><given-names>M.</given-names></name><name><surname>Donadio</surname><given-names>S.</given-names></name></person-group><article-title>Halogenated spirotetronates from <italic>Actinoallomurus</italic></article-title><source>J. Nat. Prod.</source><year>2012</year><volume>75</volume><fpage>1044</fpage><lpage>1050</lpage><pub-id pub-id-type="doi">10.1021/np300003n</pub-id><pub-id pub-id-type="pmid">22616554</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="antibiotics-08-00157-f001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>The process of drug development.</p></caption><graphic xlink:href="antibiotics-08-00157-g001"/></fig><fig id="antibiotics-08-00157-f002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Structures of the two natural substances erythromycin A and spiramycin, and the semi-synthetic derivatives of erythromycin, including clarithromycin, azithromycin, roxithromycin, telithromycin (Ketek), solithromycin, and nafithromycin.</p></caption><graphic xlink:href="antibiotics-08-00157-g002"/></fig><fig id="antibiotics-08-00157-f003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Structures of tylosin A and the four semi-synthetic derivatives tilmicosin, tildipirosin, tulathromycin, and gamithromycin.</p></caption><graphic xlink:href="antibiotics-08-00157-g003"/></fig><fig id="antibiotics-08-00157-f004" orientation="portrait" position="float"><label>Figure 4</label><caption><p>The structures of monensin A and monensin A in complex with sodium (Na<sup>+</sup>) ion.</p></caption><graphic xlink:href="antibiotics-08-00157-g004"/></fig><fig id="antibiotics-08-00157-f005" orientation="portrait" position="float"><label>Figure 5</label><caption><p>Structure of tiacumicin B.</p></caption><graphic xlink:href="antibiotics-08-00157-g005"/></fig><fig id="antibiotics-08-00157-f006" orientation="portrait" position="float"><label>Figure 6</label><caption><p>Structures of the two naturally derived substances rifamycin B and rifamycin SV and the semi-synthetic derivatives rifampicin, rifabutin, rifapentin, and rifamixin. Additionally, the structure of the natural substance kanglemycin A isolated from <italic>Nocardia mediterranei</italic> var. <italic>kanglensis</italic> 1741-64 is included.</p></caption><graphic xlink:href="antibiotics-08-00157-g006"/></fig><fig id="antibiotics-08-00157-f007" orientation="portrait" position="float"><label>Figure 7</label><caption><p>Structures of the naturally derived chlortetracycline and oxytetracycline and their semi-synthetic derivatives doxytetracycline, minocycline, tigecycline, omadacycline, and sarecycline. Eravacycline and TP-271 are fully synthetic tetracycline analogues.</p></caption><graphic xlink:href="antibiotics-08-00157-g007"/></fig><fig id="antibiotics-08-00157-f008" orientation="portrait" position="float"><label>Figure 8</label><caption><p>Structures of the two naturally derived antibiotics pristinamycin I<sub>A</sub> and pristinamycin II<sub>A</sub> and their two respective semi-synthetic analogues quinupristin and dalfopristin.</p></caption><graphic xlink:href="antibiotics-08-00157-g008"/></fig><fig id="antibiotics-08-00157-f009" orientation="portrait" position="float"><label>Figure 9</label><caption><p>Structures of the three antifungal compounds nystatin A1, amphotericin B, and pimaricin (also referred to as natamycin).</p></caption><graphic xlink:href="antibiotics-08-00157-g009"/></fig><table-wrap id="antibiotics-08-00157-t001" orientation="portrait" position="float"><object-id pub-id-type="pii">antibiotics-08-00157-t001_Table 1</object-id><label>Table 1</label><caption><p>Examples of actinomycetes-derived antimicrobial polyketide drugs.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Compound Class</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Natural Product (NP) or Synthetic (S)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Compound Name</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Trade Names</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Original Producer Strain/Origin</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Target/MOA</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Most Relevant References</th></tr></thead><tbody><tr><td rowspan="9" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>Erythromycin and related compounds</bold>
</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">NP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Erythromycin A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ilosone</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>Saccharopolyspora erythraea</italic>
</td><td rowspan="9" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Prokaryotic 50S ribosomal subunit</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B52-antibiotics-08-00157" ref-type="bibr">52</xref>,<xref rid="B55-antibiotics-08-00157" ref-type="bibr">55</xref>,<xref rid="B58-antibiotics-08-00157" ref-type="bibr">58</xref>,<xref rid="B61-antibiotics-08-00157" ref-type="bibr">61</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oleandomycin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sigmamycin (with tetracycline)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>Streptomyces antibioticus</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B67-antibiotics-08-00157" ref-type="bibr">67</xref>,<xref rid="B68-antibiotics-08-00157" ref-type="bibr">68</xref>,<xref rid="B69-antibiotics-08-00157" ref-type="bibr">69</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Spiramycin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rovamycine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>Streptomyces ambofaciens</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B70-antibiotics-08-00157" ref-type="bibr">70</xref>,<xref rid="B71-antibiotics-08-00157" ref-type="bibr">71</xref>,<xref rid="B72-antibiotics-08-00157" ref-type="bibr">72</xref>]</td></tr><tr><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">S</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Clarithromycin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Biaxin</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Erythromycin A derivative</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B62-antibiotics-08-00157" ref-type="bibr">62</xref>,<xref rid="B73-antibiotics-08-00157" ref-type="bibr">73</xref>,<xref rid="B74-antibiotics-08-00157" ref-type="bibr">74</xref>,<xref rid="B75-antibiotics-08-00157" ref-type="bibr">75</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Roxithromycin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02013;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B76-antibiotics-08-00157" ref-type="bibr">76</xref>,<xref rid="B77-antibiotics-08-00157" ref-type="bibr">77</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Azithromycin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Zithromax</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Erythromycin A (azalide)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B62-antibiotics-08-00157" ref-type="bibr">62</xref>,<xref rid="B78-antibiotics-08-00157" ref-type="bibr">78</xref>,<xref rid="B79-antibiotics-08-00157" ref-type="bibr">79</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Telithromycin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ketek</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Erythromycin A (ketolide)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B80-antibiotics-08-00157" ref-type="bibr">80</xref>,<xref rid="B81-antibiotics-08-00157" ref-type="bibr">81</xref>,<xref rid="B82-antibiotics-08-00157" ref-type="bibr">82</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Solithromycin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Solithera, CEM&#x02013;101, T&#x02013;4288</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B83-antibiotics-08-00157" ref-type="bibr">83</xref>,<xref rid="B84-antibiotics-08-00157" ref-type="bibr">84</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nafithromycin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">WCK 4873</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B83-antibiotics-08-00157" ref-type="bibr">83</xref>,<xref rid="B84-antibiotics-08-00157" ref-type="bibr">84</xref>,<xref rid="B85-antibiotics-08-00157" ref-type="bibr">85</xref>]</td></tr><tr><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>Tylosin and derivatives</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tylosin A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tylocine, Tylan</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>Streptomyces fradiae</italic>
</td><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Prokaryotic 50S ribosomal subunit</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B86-antibiotics-08-00157" ref-type="bibr">86</xref>,<xref rid="B87-antibiotics-08-00157" ref-type="bibr">87</xref>,<xref rid="B88-antibiotics-08-00157" ref-type="bibr">88</xref>,<xref rid="B89-antibiotics-08-00157" ref-type="bibr">89</xref>]</td></tr><tr><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">S</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tilmicosin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pulmotil, Micotil, Tilmovet</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Tylosin A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B90-antibiotics-08-00157" ref-type="bibr">90</xref>,<xref rid="B91-antibiotics-08-00157" ref-type="bibr">91</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tildipirosin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Zuprevo</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B92-antibiotics-08-00157" ref-type="bibr">92</xref>,<xref rid="B93-antibiotics-08-00157" ref-type="bibr">93</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tulathromycin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Draxxin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B94-antibiotics-08-00157" ref-type="bibr">94</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gamithromycin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Zactran</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B95-antibiotics-08-00157" ref-type="bibr">95</xref>,<xref rid="B96-antibiotics-08-00157" ref-type="bibr">96</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Monensin A</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Monensin A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Coban, Rumensin, Monensin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>Streptomyces cinnamonensis</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ionophore (transport of Na<sup>+</sup> ions)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B97-antibiotics-08-00157" ref-type="bibr">97</xref>,<xref rid="B98-antibiotics-08-00157" ref-type="bibr">98</xref>,<xref rid="B99-antibiotics-08-00157" ref-type="bibr">99</xref>,<xref rid="B100-antibiotics-08-00157" ref-type="bibr">100</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Tiacumicin B</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tiacumicin B</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dificid</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>Dactylosporangium aurantiacum</italic> subsp. <italic>hamdenensis</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RNA polymerase &#x003c3; factor</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B101-antibiotics-08-00157" ref-type="bibr">101</xref>,<xref rid="B102-antibiotics-08-00157" ref-type="bibr">102</xref>,<xref rid="B103-antibiotics-08-00157" ref-type="bibr">103</xref>,<xref rid="B104-antibiotics-08-00157" ref-type="bibr">104</xref>]</td></tr><tr><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>Rifamycin and derivatives</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rifamycin SV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Aemcolo, Relafalk</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>Amycolatopsis mediterranei</italic>
</td><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Bacterial DNA&#x02013;dependent RNA synthesis</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B105-antibiotics-08-00157" ref-type="bibr">105</xref>,<xref rid="B106-antibiotics-08-00157" ref-type="bibr">106</xref>,<xref rid="B107-antibiotics-08-00157" ref-type="bibr">107</xref>,<xref rid="B108-antibiotics-08-00157" ref-type="bibr">108</xref>,<xref rid="B109-antibiotics-08-00157" ref-type="bibr">109</xref>]</td></tr><tr><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">S</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rifampicin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rifadin, Rimactane</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Rifamycin SV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B106-antibiotics-08-00157" ref-type="bibr">106</xref>,<xref rid="B110-antibiotics-08-00157" ref-type="bibr">110</xref>,<xref rid="B111-antibiotics-08-00157" ref-type="bibr">111</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rifabutin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mycobutin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B112-antibiotics-08-00157" ref-type="bibr">112</xref>,<xref rid="B113-antibiotics-08-00157" ref-type="bibr">113</xref>,<xref rid="B114-antibiotics-08-00157" ref-type="bibr">114</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rifapentine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Priftin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B115-antibiotics-08-00157" ref-type="bibr">115</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rifamixin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Normix, Rifacol, Xifacan</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B116-antibiotics-08-00157" ref-type="bibr">116</xref>,<xref rid="B117-antibiotics-08-00157" ref-type="bibr">117</xref>,<xref rid="B118-antibiotics-08-00157" ref-type="bibr">118</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Kanglemycin A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02013; </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>Nocardia mediterranei</italic> var. <italic>kanglensis</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B119-antibiotics-08-00157" ref-type="bibr">119</xref>,<xref rid="B120-antibiotics-08-00157" ref-type="bibr">120</xref>]</td></tr><tr><td rowspan="9" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>Tetracyclines</bold>
</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">NP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oxytetracycline</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Terracycline</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>Streptomyces rimosus</italic>
</td><td rowspan="9" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Prokaryotic 30S ribosomal subunit</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B121-antibiotics-08-00157" ref-type="bibr">121</xref>,<xref rid="B122-antibiotics-08-00157" ref-type="bibr">122</xref>,<xref rid="B123-antibiotics-08-00157" ref-type="bibr">123</xref>,<xref rid="B124-antibiotics-08-00157" ref-type="bibr">124</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chlortetracycline</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Aureomycin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>Streptomyces aureofaciens</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B123-antibiotics-08-00157" ref-type="bibr">123</xref>,<xref rid="B124-antibiotics-08-00157" ref-type="bibr">124</xref>,<xref rid="B125-antibiotics-08-00157" ref-type="bibr">125</xref>,<xref rid="B126-antibiotics-08-00157" ref-type="bibr">126</xref>]</td></tr><tr><td rowspan="7" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">S</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Doxycycline</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vibramycin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chlortetracycline</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B123-antibiotics-08-00157" ref-type="bibr">123</xref>,<xref rid="B127-antibiotics-08-00157" ref-type="bibr">127</xref>,<xref rid="B128-antibiotics-08-00157" ref-type="bibr">128</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Minocycline</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Minocin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oxytetracycline</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B129-antibiotics-08-00157" ref-type="bibr">129</xref>,<xref rid="B130-antibiotics-08-00157" ref-type="bibr">130</xref>,<xref rid="B131-antibiotics-08-00157" ref-type="bibr">131</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tigecycline</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tygacil</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Minocycline</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B132-antibiotics-08-00157" ref-type="bibr">132</xref>,<xref rid="B133-antibiotics-08-00157" ref-type="bibr">133</xref>,<xref rid="B134-antibiotics-08-00157" ref-type="bibr">134</xref>,<xref rid="B135-antibiotics-08-00157" ref-type="bibr">135</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Omadacycline</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nuzyra</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Minocycline</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B133-antibiotics-08-00157" ref-type="bibr">133</xref>,<xref rid="B136-antibiotics-08-00157" ref-type="bibr">136</xref>,<xref rid="B137-antibiotics-08-00157" ref-type="bibr">137</xref>,<xref rid="B138-antibiotics-08-00157" ref-type="bibr">138</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Eravacycline</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Xerava</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fully synthetic</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B139-antibiotics-08-00157" ref-type="bibr">139</xref>,<xref rid="B140-antibiotics-08-00157" ref-type="bibr">140</xref>,<xref rid="B141-antibiotics-08-00157" ref-type="bibr">141</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sarecycline</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Seysara</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tetracycline</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B127-antibiotics-08-00157" ref-type="bibr">127</xref>,<xref rid="B133-antibiotics-08-00157" ref-type="bibr">133</xref>,<xref rid="B142-antibiotics-08-00157" ref-type="bibr">142</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TP&#x02013;271</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TP&#x02013;271</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fully synthetic</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B143-antibiotics-08-00157" ref-type="bibr">143</xref>,<xref rid="B144-antibiotics-08-00157" ref-type="bibr">144</xref>,<xref rid="B145-antibiotics-08-00157" ref-type="bibr">145</xref>]</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>Pristinamycins and derivatives</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pristinamycin I<sub>A</sub>/II<sub>A</sub> (PI<sub>A</sub> and PII<sub>A</sub>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pyostacine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>Streptomyces pristinaespiralis</italic>
</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Prokaryotic 50S ribosomal subunit</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B146-antibiotics-08-00157" ref-type="bibr">146</xref>,<xref rid="B147-antibiotics-08-00157" ref-type="bibr">147</xref>,<xref rid="B148-antibiotics-08-00157" ref-type="bibr">148</xref>,<xref rid="B149-antibiotics-08-00157" ref-type="bibr">149</xref>]</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">S</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Quinupristin (30%)/Dalfopristin (70%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Synercid</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PI<sub>A</sub> and PII<sub>A</sub> derivatives</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B150-antibiotics-08-00157" ref-type="bibr">150</xref>,<xref rid="B151-antibiotics-08-00157" ref-type="bibr">151</xref>,<xref rid="B152-antibiotics-08-00157" ref-type="bibr">152</xref>,<xref rid="B153-antibiotics-08-00157" ref-type="bibr">153</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Linopristin (30%)/Flopristin (70%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NXL&#x02013;103</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PI<sub>A</sub> and PII<sub>A</sub> derivatives</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B154-antibiotics-08-00157" ref-type="bibr">154</xref>,<xref rid="B155-antibiotics-08-00157" ref-type="bibr">155</xref>]</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>Nystatin and derivative</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nystatin A1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mycostatin, Nystop</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>Streptomyces noursei</italic>
</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Lipid receptor (ergosterol)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B156-antibiotics-08-00157" ref-type="bibr">156</xref>,<xref rid="B157-antibiotics-08-00157" ref-type="bibr">157</xref>,<xref rid="B158-antibiotics-08-00157" ref-type="bibr">158</xref>,<xref rid="B159-antibiotics-08-00157" ref-type="bibr">159</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BSG005</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02013;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>Streptomyces noursei</italic> GG5073SP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B160-antibiotics-08-00157" ref-type="bibr">160</xref>,<xref rid="B161-antibiotics-08-00157" ref-type="bibr">161</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Amphotericin</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Amphotericin B</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fungizone, Amphocin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>Streptomyces nodosus</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B162-antibiotics-08-00157" ref-type="bibr">162</xref>,<xref rid="B163-antibiotics-08-00157" ref-type="bibr">163</xref>,<xref rid="B164-antibiotics-08-00157" ref-type="bibr">164</xref>,<xref rid="B165-antibiotics-08-00157" ref-type="bibr">165</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Pimaricin/Natamycin</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Natamycin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Natacyn, E235</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>Streptomyces natalensis</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B166-antibiotics-08-00157" ref-type="bibr">166</xref>,<xref rid="B167-antibiotics-08-00157" ref-type="bibr">167</xref>,<xref rid="B168-antibiotics-08-00157" ref-type="bibr">168</xref>,<xref rid="B169-antibiotics-08-00157" ref-type="bibr">169</xref>]</td></tr></tbody></table></table-wrap></floats-group></article>